datetime,title,source,link,sentiment_class,sentiment_score
1/13/2005 7:27:00 PM,Sod-Turning Ceremony Marks Start of Construction of First Pediatric HI,PR Newswire,/news/stocks/sod-turning-ceremony-marks-start-of-construction-of-first-pediatric-hi-1009438132,neutral,0.9007321000099182
12/13/2005 8:32:00 PM,PLAVIX(R) (clopidogrel bisulfate) Recommended as Effective Cardiovascular Risk Reduction Treatment for Patients With Established Peripheral Arterial Disease (P.A.D.),PR Newswire,/news/stocks/plavixr-clopidogrel-bisulfate-recommended-as-effective-cardiovascular-risk-reduction-treatment-for-patients-with-established-peripheral-arterial-disease-p-a-d--1000053026,positive,0.8947616815567017
1/18/2006 2:42:00 PM,FDA Grants Priority Review to PLAVIX(R) (Clopidogrel Bisulfate) Supplemental New Drug Application (sNDA) for Additional Type of Heart Attack,PR Newswire,/news/stocks/fda-grants-priority-review-to-plavix-r-clopidogrel-bisulfate-supplemental-new-drug-application-snda-for-additional-type-of-heart-attack-1028241630,positive,0.8210455179214478
1/23/2006 3:12:00 PM,Crohn's Patient Robert Hill Reaches Peak of Antarctica's Tallest Mountain,PR Newswire,/news/stocks/crohns-patient-robert-hill-reaches-peak-of-antarcticas-tallest-mountain-866939,neutral,0.753421425819397
1/25/2006 1:02:00 PM,Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006,PR Newswire,/news/stocks/bristol-myers-squibb-company-reports-financial-results-for-the-fourth-quarter-and-twelve-months-of-2005-and-announces-eps-guidance-for-2006-1012388763,neutral,0.9183541536331177
9/28/2006 2:12:00 PM,Crohn's & Colitis Foundation of America and ConvaTec Announce 2006 Great Comebacks Regional Awards Recipients,PR Newswire,/news/stocks/crohns-&-colitis-foundation-of-america-and-convatec-announce-2006-great-comebacks-regional-awards-recipients-1000124648,neutral,0.6399334669113159
11/13/2006 9:32:00 PM,ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria,PR Newswire,/news/stocks/orencia-r-abatacept-data-demonstrated-improvement-in-children-and-adolescents-with-juvenile-idiopathic-arthritis-as-measured-by-the-validated-acr-pediatric-criteria-1005290630,positive,0.9553226828575134
11/20/2006 6:27:00 PM,Crohn's and Colitis Foundation of America and ConvaTec Recognize Young Patients With Inflammatory Bowel Disease,PR Newswire,/news/stocks/crohn-s-and-colitis-foundation-of-america-and-convatec-recognize-young-patients-with-inflammatory-bowel-disease-1027845523,neutral,0.6664834022521973
4/13/2007 12:10:00 PM,BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment,PR Newswire,/news/stocks/baraclude-r-entecavir-therapy-resulted-in-undetectable-levels-of-hepatitis-b-virus-in-cohort-of-patients-who-re-started-treatment-1012353856,positive,0.7428292036056519
11/12/2007 5:55:00 PM,"Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)",PR Newswire,/news/stocks/post-hoc-data-show-daily-activity-participation-independence-and-sleep-quality-improved-in-adults-with-moderate-to-severe-rheumatoid-arthritis-after-treatment-with-orencia-r-abatacept-1027498817,positive,0.9574458003044128
9/27/2016 3:40:24 PM,"BRIEF-Bristol-Myers Squibb and Nektar Therapeutics announce Oncology clinical collaboration (BMY, NKTR)",Reuters,/news/stocks/brief-bristol-myers-squibb-and-nektar-therapeutics-announce-oncology-clinical-collaboration-bmy-nktr-1001420874,neutral,0.6068368554115295
9/27/2016 4:20:23 PM,"Bristol-Myers to test Opdivo with Nektar drug for several cancers (BMY, NKTR)",Reuters,/news/stocks/bristol-myers-to-test-opdivo-with-nektar-drug-for-several-cancers-bmy-nktr-1001420897,neutral,0.5885056853294373
10/5/2016 11:30:22 AM,"BRIEF-U.S. FDA warns about the risk of Hepatitis B (BMY, GILD, JNJ, MRK)",Reuters,/news/stocks/brief-u-s-fda-warns-about-the-risk-of-hepatitis-b-bmy-gild-jnj-mrk-1001436685,negative,0.5751611590385437
10/10/2016 11:20:20 AM,"Roche lung cancer drug success adds to pressure on Bristol (MRK, BMY)",Reuters,/news/stocks/roche-lung-cancer-drug-success-adds-to-pressure-on-bristol-mrk-bmy-1001445153,negative,0.7881217002868652
10/10/2016 11:30:24 AM,"Merck drug shines in lung cancer and also works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/merck-drug-shines-in-lung-cancer-and-also-works-with-chemo-mrk-bmy-azn-1001445152,neutral,0.8784257769584656
10/10/2016 12:10:24 PM,"UPDATE 1-'New day' in lung cancer as Merck drug shines, works with chemo (MRK, BMY, AZN)",Reuters,/news/stocks/update-1-new-day-in-lung-cancer-as-merck-drug-shines-works-with-chemo-mrk-bmy-azn-1001445165,positive,0.7416434288024902
10/10/2016 1:10:24 PM,"No silver lining in failed Bristol cancer drug trial (BMY, MRK)",Reuters,/news/stocks/no-silver-lining-in-failed-bristol-cancer-drug-trial-bmy-mrk-1001445520,neutral,0.8390213847160339
10/10/2016 2:40:22 PM,"UK Stocks-Factors to watch on Oct. 10 (RDSA, WMH, BA., BLT, BHP, RRS, BMY, AZN, SVI, WTM, VED)",Reuters,/news/stocks/uk-stocks-factors-to-watch-on-oct-10-rdsa-wmh-ba-blt-bhp-rrs-bmy-azn-svi-wtm-ved-1001445819,neutral,0.9423686861991882
10/10/2016 2:50:22 PM,"BRIEF-Innate Pharma announced data for two Phase I studies for lirilumab and nivolumab (IPH, BMY)",Reuters,/news/stocks/brief-innate-pharma-announced-data-for-two-phase-i-studies-for-lirilumab-and-nivolumab-iph-bmy-1001446002,positive,0.5366402268409729
10/10/2016 3:10:22 PM,"UPDATE 1-UK Stocks-Factors to watch on Oct. 10 (RDSA, WMH, BA., BLT, BHP, RRS, BMY, AZN, SVI, VED, MTO)",Reuters,/news/stocks/update-1-uk-stocks-factors-to-watch-on-oct-10-rdsa-wmh-ba-blt-bhp-rrs-bmy-azn-svi-ved-mto-1001446131,neutral,0.9381389617919922
10/10/2016 11:30:20 PM,"INSIGHT-Doctors grapple with best use of potent new cancer drugs (MRK, BMY, AZN)",Reuters,/news/stocks/insight-doctors-grapple-with-best-use-of-potent-new-cancer-drugs-mrk-bmy-azn-1001447119,positive,0.5750654339790344
10/12/2016 7:40:53 PM,"A new kind of drug is working better than chemotherapy in some lung cancer patients (BMY, MRK)",Business Insider,/news/stocks/a-new-kind-of-drug-is-working-better-than-chemotherapy-in-some-lung-cancer-patients-bmy-mrk,positive,0.8869583606719971
10/14/2016 3:40:22 PM,BRIEF-Bristol-Myers receives positive CHMP opinion for Opdivo (BMY),Reuters,/news/stocks/brief-bristol-myers-receives-positive-chmp-opinion-for-opdivo-bmy-1001456913,positive,0.9275833964347839
10/19/2016 12:20:24 PM,"Roche's lung cancer drug wins U.S. approval (MRK, BMY)",Reuters,/news/stocks/roches-lung-cancer-drug-wins-u-s-approval-mrk-bmy-1001463837,positive,0.9151583909988403
10/21/2016 3:46:22 PM,"Merck's immunotherapy drug succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-drug-succeeds-in-key-bladder-cancer-trial-2016-10,positive,0.9444848299026489
10/21/2016 4:32:24 PM,"UPDATE 1-Merck's Keytruda succeeds in key bladder cancer trial (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-mercks-keytruda-succeeds-in-key-bladder-cancer-trial-2016-10,positive,0.8114346861839294
10/21/2016 11:30:20 PM,BRIEF-Bristol-Myers Squibb says U.S. FDA accepts for priority review the sBLA for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-us-fda-accepts-for-priority-review-the-sbla-for-opdivo-2016-10,neutral,0.8956634998321533
10/25/2016 1:10:19 PM,"UPDATE 1-Merck wins early U.S. approval for Keytruda in untreated lung cancer (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-merck-wins-early-us-approval-for-keytruda-in-untreated-lung-cancer-2016-10,positive,0.9381353259086609
10/25/2016 2:18:21 PM,BRIEF-Bristol-Myers presents new results for opdivo (nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-presents-new-results-for-opdivo-nivolumab-2016-10,neutral,0.8232860565185547
10/27/2016 1:28:20 PM,Bristol hikes 2016 forecast after top drugs deliver (BMY),Reuters,http://www.businessinsider.com/r-bristol-hikes-2016-forecast-after-top-drugs-deliver-2016-10,positive,0.5109304189682007
10/27/2016 2:44:18 PM,"UPDATE 1-Bristol hikes 2016 profit forecast after top drugs deliver (PFE, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-hikes-2016-profit-forecast-after-top-drugs-deliver-2016-10,negative,0.7187318801879883
10/27/2016 10:10:18 PM,BRIEF-Bristol says expects Opdivo to face pressure from Roche lung cancer drug (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-says-expects-opdivo-to-face-pressure-from-roche-lung-cancer-drug-2016-10,negative,0.8655228614807129
10/27/2016 11:06:30 PM,"Biotech's election-year political cloud threatens to linger (VRX, LLY, BMY, ARIA, VRX)",Reuters,http://www.businessinsider.com/r-biotechs-election-year-political-cloud-threatens-to-linger-2016-10,neutral,0.5415087342262268
11/3/2016 4:36:18 PM,BRIEF-Blackline announces pricing of IPO of 8.60 mln shares at $17/shr (BLN),Reuters,http://www.businessinsider.com/r-brief-blackline-announces-pricing-of-ipo-of-860-mln-shares-at-17/shr-2016-10,neutral,0.9254159927368164
11/9/2016 3:20:18 PM,"BRIEF-Bristol-Myers, Infinity Pharma to evaluate Opdivo with IPI-549 in advanced solid tumors (BMY, INFI)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-infinity-pharma-to-evaluate-opdivo-with-ipi-549-in-advanced-solid-tumors-2016-11,positive,0.562933087348938
11/10/2016 12:46:18 PM,"AstraZeneca drops early head and neck cancer drug plans (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-drops-early-head-and-neck-cancer-drug-plans-2016-11,neutral,0.6714643239974976
11/10/2016 1:44:18 PM,"Bristol-Myers' deepens focus on fibrosis with Nitto deal (6988, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-deepens-focus-on-fibrosis-with-nitto-deal-2016-11,neutral,0.5977364778518677
11/10/2016 1:48:20 PM,"Bristol-Myers' Opdivo immunotherapy succeeds in key stomach cancer study (4528, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-opdivo-immunotherapy-succeeds-in-key-stomach-cancer-study-2016-11,positive,0.6716595888137817
11/10/2016 2:36:18 PM,"UPDATE 1-Bristol-Myers' Opdivo succeeds in key stomach cancer study (4528, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-opdivo-succeeds-in-key-stomach-cancer-study-2016-11,neutral,0.5067538022994995
11/10/2016 3:40:18 PM,"BRIEF-Bristol-Myers Squibb and Pfizer to deliver 12 new Eliquis (apixaban) presentations at American Heart Association (AHA) scientific sessions 2016 (BMY, PFE)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-pfizer-to-deliver-12-new-eliquis-apixaban-presentations-at-american-heart-association-aha-scientific-sessions-2016-2016-11,neutral,0.719663143157959
11/10/2016 3:40:18 PM,"BRIEF-Opdivo (nivolumab) demonstrates overall survival benefit in patients with unresectable advanced or recurrent gastric cancer in phase 3 study (BMY, 4528)",Reuters,http://www.businessinsider.com/r-brief-opdivo-nivolumab-demonstrates-overall-survival-benefit-in-patients-with-unresectable-advanced-or-recurrent-gastric-cancer-in-phase-3-study-2016-11,positive,0.9523391723632812
11/10/2016 5:16:12 PM,A pharma giant just made a $100 million move into a disease that's been called 'one of the next epidemic-level chronic diseases' (BMY),Business Insider,http://www.businessinsider.com/bristol-myers-squibb-picks-up-nash-drug-for-100-million-2016-11,positive,0.5003324747085571
11/16/2016 1:12:18 PM,"BRIEF-Bristol-Myers Squibb and Enterome announce immuno-oncology collaboration (BMY, ETRM)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-enterome-announce-immuno-oncology-collaboration-2016-11,neutral,0.7826680541038513
11/17/2016 8:34:20 AM,"Roche, Bristol-Myers cut cancer drug prices to win UK approval (PFE, BMY)",Reuters,http://www.businessinsider.com/r-roche-bristol-myers-cut-cancer-drug-prices-to-win-uk-approval-2016-11,positive,0.8597098588943481
11/17/2016 10:54:20 AM,"Japan sets 50 pct price cut for Opdivo cancer drug: Ono Pharma (4528, BMY)",Reuters,http://www.businessinsider.com/r-japan-sets-50-pct-price-cut-for-opdivo-cancer-drug-ono-pharma-2016-11,positive,0.4979662001132965
11/17/2016 11:42:18 AM,"UPDATE 1-Japan sets 50 pct price cut for Bristol Myers' Opdivo cancer drug (4528, BMY)",Reuters,http://www.businessinsider.com/r-update-1-japan-sets-50-pct-price-cut-for-bristol-myers-opdivo-cancer-drug-2016-11,negative,0.7790194749832153
11/21/2016 12:18:19 PM,"Swiss stocks - Factors to watch on Nov. 21 (BMY, MRK, LECN, 300068, ODHN)",Reuters,http://www.businessinsider.com/r-swiss-stocks---factors-to-watch-on-nov-21-2016-11,neutral,0.9382715225219727
11/22/2016 12:48:20 PM,"UPDATE 1-AstraZeneca cleared to resume enrolment in cancer drug trials (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-cleared-to-resume-enrolment-in-cancer-drug-trials-2016-11,positive,0.8660773038864136
11/22/2016 10:54:21 PM,BRIEF-Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-opdivo-gets-european-commission-approval-for-relapsed-or-refractory-chl-treatment-2016-11,positive,0.935821533203125
11/25/2016 11:28:18 AM,"Costly leukaemia pill wins UK green light after price cut (JNJ, PFE, BMY, 4523)",Reuters,http://www.businessinsider.com/r-costly-leukaemia-pill-wins-uk-green-light-after-price-cut-2016-11,positive,0.9057518243789673
12/2/2016 6:26:05 PM,"BRIEF-EMA says patients treated with direct-acting antivirals for hepatitis C may be at risk of hepatitis B re-activation (BMY, GILD)",Reuters,http://www.businessinsider.com/r-brief-ema-says-patients-treated-with-direct-acting-antivirals-for-hepatitis-c-may-be-at-risk-of-hepatitis-b-re-activation-2016-12,negative,0.7200148701667786
12/2/2016 6:34:06 PM,EU health regulator warns some hep C drugs could reactivate hep B,Reuters,http://www.businessinsider.com/r-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12,negative,0.942558765411377
12/2/2016 7:16:03 PM,"UPDATE 1-EU health regulator warns some hep C drugs could reactivate hep B (JNJ, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-eu-health-regulator-warns-some-hep-c-drugs-could-reactivate-hep-b-2016-12,negative,0.9269317388534546
12/5/2016 3:24:03 PM,BRIEF-CytomX says Bristol-Myers will pay company $15 mln (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-says-bristol-myers-will-pay-company-15-mln-2016-12,neutral,0.916634202003479
12/6/2016 12:00:07 PM,"DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,negative,0.8780304193496704
12/6/2016 2:02:03 PM,"RPT-DEALTALK-Trump's corporate tax holiday could spur pharma M&A (JNJ, AGN, MSFT, ACAD, MRK, LLY, PFE, AMGN, AAPL, BMY, INCY, GILD)",Reuters,http://www.businessinsider.com/r-rpt-dealtalk-trumps-corporate-tax-holiday-could-spur-pharma-ma-2016-12,negative,0.9314920902252197
12/6/2016 3:28:05 PM,BRIEF-Heat Biologics presents topline results from lung cancer drug study (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-presents-topline-results-from-lung-cancer-drug-study-2016-12,neutral,0.9188583493232727
12/6/2016 4:56:03 PM,BRIEF-Bristol-Myers provides positive results from Phase 1/2 study Checkmate-032 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-provides-positive-results-from-phase-1/2-study-checkmate-032-2016-12,positive,0.881509006023407
12/7/2016 8:02:03 AM,EU clears Bristol-Myers immunotherapy drug for blood cancer (BMY),Reuters,http://www.businessinsider.com/r-eu-clears-bristol-myers-immunotherapy-drug-for-blood-cancer-2016-12,neutral,0.8081404566764832
12/7/2016 2:00:08 PM,Japan PM's advisers urge annual review of drug prices,Reuters,http://www.businessinsider.com/r-japan-pms-advisers-urge-annual-review-of-drug-prices-2016-12,neutral,0.8687899112701416
12/7/2016 8:24:03 PM,"BRIEF-Transgene says UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo (BMY, TNG)",Reuters,http://www.businessinsider.com/r-brief-transgene-says-uc-davis-to-conduct-phase-2-trial-of-the-combination-of-tg4010-with-opdivo-2016-12,positive,0.5309819579124451
12/7/2016 8:50:03 PM,"BRIEF-Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer (TNG, BMY)",Reuters,http://www.businessinsider.com/r-brief-transgene-announces-phase-2-trial-with-bristol-myers-squibb-for-2nd-line-treatment-of-metastatic-non-small-cell-lung-cancer-2016-12,positive,0.7782943248748779
12/8/2016 8:50:07 PM,Bristol-Meyers Squibb to pay $19.5 mln to settle off-label promotion case (BMY),Reuters,http://www.businessinsider.com/r-bristol-meyers-squibb-to-pay-195-mln-to-settle-off-label-promotion-case-2016-12,neutral,0.4834810495376587
12/8/2016 9:50:04 PM,REFILE-Bristol-Myers Squibb to pay $19.5 mln to settle off-label promotion case (BMY),Reuters,http://www.businessinsider.com/r-refile-bristol-myers-squibb-to-pay-195-mln-to-settle-off-label-promotion-case-2016-12,neutral,0.6514347195625305
12/8/2016 11:22:03 PM,BRIEF-Bristol-Myers Squibb reports dividend increase (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-reports-dividend-increase-2016-12,positive,0.936476469039917
12/13/2016 3:36:05 PM,BRIEF-CytomX says clinical candidate probody from Bristol-Myers Squibb collaboration selected (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-says-clinical-candidate-probody-from-bristol-myers-squibb-collaboration-selected-2016-12,neutral,0.6303858160972595
12/19/2016 4:16:05 PM,"UPDATE 1-Japan to review drug prices annually rather than every two years -sources (4528, BMY, GILD)",Reuters,http://www.businessinsider.com/r-update-1-japan-to-review-drug-prices-annually-rather-than-every-two-years--sources-2016-12,neutral,0.9321296811103821
12/29/2016 1:18:03 PM,"BRIEF-Bavarian Nordic starts trial of CV301 in combination with Nivolumab (BAVA, BMY)",Reuters,http://www.businessinsider.com/r-brief-bavarian-nordic-starts-trial-of-cv301-in-combination-with-nivolumab-2016-12,neutral,0.6947036981582642
1/6/2017 1:28:03 PM,BRIEF-Bristol-Myers Squibb and genecentric diagnostics announces exploratory biomarker research collaboration (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-genecentric-diagnostics-announces-exploratory-biomarker-research-collaboration-2017-1,neutral,0.8113065361976624
1/6/2017 5:00:06 PM,"BRIEF-Bristol-Myers' Nivolumab study reaches limit, suspends recruitment - Clinicaltrials.gov (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-nivolumab-study-reaches-limit-suspends-recruitment---clinicaltrialsgov-2017-1,negative,0.49592846632003784
1/10/2017 7:20:06 PM,BRIEF-Bristol-Myers sees operating expenses flat through 2020 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-sees-operating-expenses-flat-through-2020-2017-1,negative,0.6433205008506775
1/19/2017 3:46:07 PM,BRIEF-Opdivo demonstrated efficacy in patients gastric cancer in a Phase 3 study (BMY),Reuters,http://www.businessinsider.com/r-brief-opdivo-demonstrated-efficacy-in-patients-gastric-cancer-in-a-phase-3-study-2017-1,positive,0.9147651791572571
1/19/2017 9:30:04 PM,U.S. top court to hear Bristol-Myers out-of-state injury appeal (BMY),Reuters,http://www.businessinsider.com/r-us-top-court-to-hear-bristol-myers-out-of-state-injury-appeal-2017-1,neutral,0.819054901599884
1/20/2017 12:56:09 AM,BRIEF-Bristol-Myers decides not to pursue accelerated regulatory pathway for combination of Opdivo plus Yervoy (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-decides-not-to-pursue-accelerated-regulatory-pathway-for-combination-of-opdivo-plus-yervoy-2017-1,neutral,0.8747692108154297
1/20/2017 1:26:04 AM,"Bristol-Myers won't seek accelerated Opdivo lung cancer approval (MRK, BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-wont-seek-accelerated-opdivo-lung-cancer-approval-2017-1,neutral,0.7845621705055237
1/20/2017 5:06:54 PM,"Bristol-Myers shares are sliding after some bad news on its lung cancer drug (BMY, MRK)",Reuters,http://www.businessinsider.com/bristol-opdivo-yervoy-lung-cancer-no-fast-approval-2017-1,negative,0.9732322692871094
1/20/2017 10:16:07 PM,"BRIEF-Merck announces license agreement resolving Keytruda patent litigation (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-merck-announces-license-agreement-resolving-keytruda-patent-litigation-2017-1,positive,0.8731755614280701
1/20/2017 10:24:06 PM,"BRIEF-Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-ono-pharmaceutical-enters-license-agreement-with-merck-2017-1,positive,0.8483484983444214
1/21/2017 12:06:09 AM,"UPDATE 1-Merck, Bristol-Myers agree to settle Keytruda patent suit (4528, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1,positive,0.4937172830104828
1/21/2017 12:14:12 AM,"Merck, Bristol-Myers agree to settle Keytruda patent suit",Reuters,http://www.businessinsider.com/r-merck-bristol-myers-agree-to-settle-keytruda-patent-suit-2017-1,positive,0.5158829092979431
1/26/2017 5:56:05 PM,"BRIEF-Bristol-Myers cites forex, oncology competition for outlook cut (MRK, BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-cites-forex-oncology-competition-for-outlook-cut-2017-1,negative,0.5960447788238525
1/26/2017 7:10:05 PM,"UPDATE 1-Bristol-Myers cuts 2017 outlook amid Opdivo competition (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-cuts-2017-outlook-amid-opdivo-competition-2017-1,negative,0.968569815158844
1/27/2017 12:30:06 PM,"Roche cancer drug taking bite out of Bristol's Opdivo (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-cancer-drug-taking-bite-out-of-bristols-opdivo-2017-1,neutral,0.8549368381500244
2/1/2017 6:54:08 PM,BRIEF-Bristol-Myers squibb announces European Patent Office decision on Sprycel (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-european-patent-office-decision-on-sprycel-2017-2,neutral,0.8651823997497559
2/2/2017 9:02:07 PM,"BRIEF-FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab (BMY, MRK)",Reuters,http://www.businessinsider.com/r-brief-fda-grants-accelerated-approval-to-bristol-myers-squibbs-nivolumab-2017-2,positive,0.9157432913780212
2/2/2017 9:34:07 PM,U.S. FDA approves Bristol-Myers' Opdivo for bladder cancer,Reuters,http://www.businessinsider.com/r-us-fda-approves-bristol-myers-opdivo-for-bladder-cancer-2017-2,positive,0.7095035314559937
2/3/2017 1:02:08 AM,BRIEF-Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-fda-approval-for-opdivo-nivolumab-2017-2,positive,0.8717412352561951
2/10/2017 2:34:10 PM,BRIEF-Bristol-Myers Squibb Canada reached an agreement with Pan-Canadian Pharmaceutical Alliance (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-canada-reached-an-agreement-with-pan-canadian-pharmaceutical-alliance-2017-2,positive,0.9409183859825134
2/14/2017 10:16:13 PM,"BRIEF-Jana Partners takes sole share stake in Bristol-Myers, Cognizant (BMY, CTSH, CRM, GPK)",Reuters,http://www.businessinsider.com/r-brief-jana-partners-takes-sole-share-stake-in-bristol-myers-cognizant-2017-2,neutral,0.9481045603752136
2/21/2017 1:13:42 PM,Bristol-Myers Plans $2 Bln Accelerated Share Buyback; Names 3 New Directors ,RTTNews,/news/stocks/bristol-myers-plans-2-bln-accelerated-share-buyback-names-3-new-directors-1001767464,neutral,0.8218466639518738
2/21/2017 2:06:14 PM,Bristol-Myers adds three directors in deal with Jana Partners (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-adds-three-directors-in-deal-with-jana-partners-2017-2,neutral,0.8730934858322144
2/21/2017 5:30:11 PM,"UPDATE 1-Bristol-Myers adds 3 directors in agreement with JANA Partners (BMY, MRK, VRTX, SHP)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-adds-3-directors-in-agreement-with-jana-partners-2017-2,positive,0.5899607539176941
2/21/2017 6:36:14 PM,BRIEF-Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-sees-restructuring-charges-between-15-20-bln-through-2020-2017-2,negative,0.8658700585365295
2/22/2017 3:43:04 AM,Icahn Takes Stake In Bristol-Myers ,RTTNews,/news/stocks/icahn-takes-stake-in-bristol-myers-1001770437,neutral,0.9495301246643066
2/22/2017 10:10:52 AM,Carl Icahn has reportedly taken a stake in Bristol-Myers and its shares are jumping (BMY),Business Insider,http://www.businessinsider.com/carl-icahn-stake-bristol-myers-2017-2,neutral,0.8876558542251587
2/22/2017 4:10:12 PM,"US STOCKS-Wall St slips on weak oil prices; Fed minutes in focus (XOM, GRMN, BMY, UPS, TSLA, HPQ)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slips-on-weak-oil-prices-fed-minutes-in-focus-2017-2,negative,0.9564036726951599
2/22/2017 6:22:12 PM,"US STOCKS-Wall St slightly lower ahead of Fed minutes (DD, DOW, GRMN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-slightly-lower-ahead-of-fed-minutes-2017-2,negative,0.9512373208999634
2/22/2017 6:29:15 PM,"Carl Icahn just jumped into a $90 billion drug maker, and people are betting it'll be a takeover target (BMY)",Business Insider,http://www.businessinsider.com/carl-icahn-invests-in-bristol-myers-squibb-heres-why-2017-2,neutral,0.8609607219696045
2/22/2017 7:36:13 PM,"US STOCKS-S&P, Nasdaq dip ahead of Fed minutes; Dow hits record high (DD, DOW, GRMN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-sp-nasdaq-dip-ahead-of-fed-minutes-dow-hits-record-high-2017-2,positive,0.5157692432403564
2/23/2017 12:20:12 AM,BRIEF-Bristol-Myers squibb files pricing term sheet (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-files-pricing-term-sheet-2017-2,neutral,0.9456900358200073
2/23/2017 12:58:12 AM,BRIEF-Bristol-Myers Squibb prices $1.5 billion of senior notes (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-prices-15-billion-of-senior-notes-2017-2,neutral,0.8825632929801941
2/27/2017 1:28:13 PM,BRIEF-Bristol-Myers Squibb expands international immuno-oncology network (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-expands-international-immuno-oncology-network-2017-2,positive,0.8642364144325256
2/28/2017 11:58:14 AM,"Deals of the day-Mergers and acquisitions (ISP, 9437, FRO, DHT, BLND, WOR)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-2,neutral,0.9435482025146484
3/1/2017 2:26:19 PM,BRIEF-Bristol-Myers announces equity investment in GRAIL Inc (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-equity-investment-in-grail-inc-2017-3,neutral,0.9263265132904053
3/2/2017 11:16:19 PM,BRIEF-Bristol-Myers Squibb declared a qtrly div of $0.39 per share (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-declared-a-qtrly-div-of-039-per-share-2017-3,neutral,0.8629570603370667
3/8/2017 7:00:22 PM,BRIEF-Bristol-Myers Squibb appoints Thomas Lynch as Chief Scientific Officer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-appoints-thomas-lynch-as-chief-scientific-officer-2017-3,neutral,0.9297695755958557
3/9/2017 6:56:22 AM,"PRESS DIGEST - Wall Street Journal - March 9 (AMZN, MSFT, 005930, BMY, S)",Reuters,http://www.businessinsider.com/r-press-digest---wall-street-journal---march-9-2017-3,neutral,0.9329018592834473
3/13/2017 4:10:24 PM,BRIEF-Heat Biologics Meets Efficacy Endpoint in Phase 1B Lung Cancer Trial (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-meets-efficacy-endpoint-in-phase-1b-lung-cancer-trial-2017-3,positive,0.8882246017456055
3/13/2017 6:52:26 PM,"US STOCKS-Wall St dips as drug stocks drag; Fed meeting in focus (MRK, BMY, INTC, NVDA, WYNN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-as-drug-stocks-drag-fed-meeting-in-focus-2017-3,negative,0.9373961091041565
3/13/2017 7:46:23 PM,"BRIEF-Transgene SA says first results from Phase 2 trial could be expected from end of 2017 (TNG, BMY)",Reuters,http://www.businessinsider.com/r-brief-transgene-sa-says-first-results-from-phase-2-trial-could-be-expected-from-end-of-2017-2017-3,neutral,0.905993640422821
3/17/2017 12:10:00 PM,"Technical Reports on Drug Makers Stocks -- Bristol-Myers Squibb, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/technical-reports-on-drug-makers-stocks-bristol-myers-squibb-astrazeneca-eli-lilly-and-immune-pharma-1001845502,neutral,0.9368956089019775
3/20/2017 12:20:22 PM,"Bristol-Myers, CytomX Extend Deal To Find Probody Therapeutics To Treat Cancer ",RTTNews,/news/stocks/bristol-myers-cytomx-extend-deal-to-find-probody-therapeutics-to-treat-cancer-1001849534,positive,0.8331161141395569
3/20/2017 12:24:44 PM,"BRIEF-Bristol-Myers Squibb, Cytomx Therapeutics extend worldwide collaboration (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-cytomx-therapeutics-extend-worldwide-collaboration-2017-3,neutral,0.7912711501121521
3/20/2017 4:28:56 PM,"A small drug company that's trying to make cancer treatments safer just received a $3.8 billion endorsement (CTMX, BMY)",Business Insider,http://www.businessinsider.com/cytomx-partners-with-bristol-myers-squibb-for-200-million-2017-3,positive,0.7461712956428528
3/21/2017 12:30:45 PM,BRIEF-Heat Biologics reports positive results from mid-stage lung cancer trial (BMY),Reuters,http://www.businessinsider.com/r-brief-heat-biologics-reports-positive-results-from-mid-stage-lung-cancer-trial-2017-3,positive,0.9124113917350769
3/23/2017 8:26:45 PM,"FDA approves Pfizer, German Merck immunotherapy for skin cancer",Reuters,http://www.businessinsider.com/r-fda-approves-pfizer-german-merck-immunotherapy-for-skin-cancer-2017-3,positive,0.7539388537406921
3/23/2017 10:40:47 PM,BRIEF-Bristol-Myers' CEO Caforio's 2016 total compensation $16.9 mln (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-ceo-caforios-2016-total-compensation-169-mln-2017-3,neutral,0.9113245010375977
3/24/2017 2:34:49 PM,BRIEF-Bristol-Myers Squibb receives positive CHMP opinion recommending opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-opdivo-2017-3,positive,0.8938047885894775
3/24/2017 4:42:45 PM,"LPC: Top US firms raise loans on tax reform hopes (LLY, BMY, CSCO)",Reuters,http://www.businessinsider.com/r-lpc-top-us-firms-raise-loans-on-tax-reform-hopes-2017-3,positive,0.9026652574539185
3/27/2017 5:03:34 AM,"XENE Loses Face As Acne Trial Flops, NBRV Awaits LEAP Data, Opdivo Scores A Nod ",RTTNews,/news/stocks/xene-loses-face-as-acne-trial-flops-nbrv-awaits-leap-data-opdivo-scores-a-nod-1001868165,neutral,0.4511517286300659
3/27/2017 10:00:47 PM,"Senators press Icahn on White House influence, business conflicts (CVI, HLF, BMY, BWSA)",Reuters,http://www.businessinsider.com/r-senators-press-icahn-on-white-house-influence-business-conflicts-2017-3,neutral,0.9403237104415894
3/28/2017 1:30:20 PM,"PICI, Bristol-Myers, CRI Collaborate To Accelerate Immuno-Oncology Research ",RTTNews,/news/stocks/pici-bristol-myers-cri-collaborate-to-accelerate-immuno-oncology-research-1001873382,positive,0.7568468451499939
3/29/2017 6:34:47 PM,U.S. FDA nominee moves to untangle potential conflicts of interest,Reuters,http://www.businessinsider.com/r-us-fda-nominee-moves-to-untangle-potential-conflicts-of-interest-2017-3,negative,0.6755934953689575
3/29/2017 11:14:50 PM,"UPDATE 1-U.S. FDA nominee moves to untangle potential conflicts of interest (GSK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-nominee-moves-to-untangle-potential-conflicts-of-interest-2017-3,neutral,0.48614028096199036
3/30/2017 1:24:48 PM,"BRIEF-Bristol-Myers enters collaboration to identify predictive biomarkers across multiple tumor types, immunotherapy agents (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-enters-collaboration-to-identify-predictive-biomarkers-across-multiple-tumor-types-immunotherapy-agents-2017-3,positive,0.7015173435211182
4/3/2017 6:05:53 AM,"Setback For ACOR In Ampyra Suit, EARS Put On Notice, STDY On Steady Rise ",RTTNews,/news/stocks/setback-for-acor-in-ampyra-suit-ears-put-on-notice-stdy-on-steady-rise-1001888420,positive,0.8297256827354431
4/3/2017 1:10:51 PM,"RPT-The cost of cancer: new drugs show success at a steep price (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-rpt-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4,positive,0.8700268864631653
4/3/2017 3:22:53 PM,BRIEF-Bristol-Myers says Opdivo in combination with Yervoy and Opdivo Monotherapy significantly improved overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-opdivo-in-combination-with-yervoy-and-opdivo-monotherapy-significantly-improved-overall-survival-2017-4,positive,0.9558054208755493
4/3/2017 3:56:23 PM,"New cancer drugs can cost more than $250,000 a year (BMY, MRK, ESRX, PFE, AZN)",Reuters,http://www.businessinsider.com/r-the-cost-of-cancer-new-drugs-show-success-at-a-steep-price-2017-4,neutral,0.9377228617668152
4/3/2017 4:46:09 PM,"A combination of cancer drugs work better together than on their own — but there's a catch (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-immunotherapy-combination-extends-survival-in-melanoma-2017-4,neutral,0.7886539697647095
4/3/2017 5:00:00 PM,Bristol-Myers Says CheckMate -143 Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-says-checkmate-143-fails-to-meet-primary-endpoint-1001891098,negative,0.9654613733291626
4/4/2017 5:03:37 AM,"FDA Nod For TEVA, Cheers For PRTK, SRNE Hits Goal, SNY Launches Kids Toothpaste ",RTTNews,/news/stocks/fda-nod-for-teva-cheers-for-prtk-srne-hits-goal-sny-launches-kids-toothpaste-1001892460,positive,0.4879663586616516
4/4/2017 10:40:50 PM,BRIEF-FDA accepts for priority review Bristol-Myers' application for Opdivo in previously treated metastatic colorectal cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-for-priority-review-bristol-myers-application-for-opdivo-in-previously-treated-metastatic-colorectal-cancer-2017-4,neutral,0.7033641934394836
4/5/2017 8:28:48 AM,"INNL To Be Acquired, ELGX Seeks Funds, Opdivo At FDA Altar Again, NLNK Abuzz ",RTTNews,/news/stocks/innl-to-be-acquired-elgx-seeks-funds-opdivo-at-fda-altar-again-nlnk-abuzz-1001896978,neutral,0.7651054263114929
4/6/2017 2:25:00 PM,"Global Oncology Market Gains Ground, Driven by Innovative Cancer Treatment Therapies",PR Newswire,/news/stocks/global-oncology-market-gains-ground-driven-by-innovative-cancer-treatment-therapies-1001902626,positive,0.9531072974205017
4/11/2017 1:40:54 AM,UK cost agency turns down Bristol drug for head and neck cancer,Reuters,http://www.businessinsider.com/r-uk-cost-agency-turns-down-bristol-drug-for-head-and-neck-cancer-2017-4,negative,0.8210610747337341
4/11/2017 1:16:57 PM,BRIEF-Bristol-Myers and Apexigen announce clinical collaboration to evaluate Opdivo in combination with APX005M in advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-apexigen-announce-clinical-collaboration-to-evaluate-opdivo-in-combination-with-apx005m-in-advanced-solid-tumors-2017-4,positive,0.904350221157074
4/13/2017 1:21:00 PM,"Bristol-Myers To Get $470 Mln Upfront From Licensing Deals With Biogen, Roche ",RTTNews,/news/stocks/bristol-myers-to-get-470-mln-upfront-from-licensing-deals-with-biogen-roche-1001920351,positive,0.9083372354507446
4/13/2017 1:23:07 PM,"BRIEF-Bristol-Myers Squibb enters into separate agreements with Biogen and Roche (BMY, BIIB)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-enters-into-separate-agreements-with-biogen-and-roche-2017-4,positive,0.5764212608337402
4/13/2017 1:45:07 PM,"Bristol-Myers to license two of its drugs to Biogen, Roche",Reuters,http://www.businessinsider.com/r-bristol-myers-to-license-two-of-its-drugs-to-biogen-roche-2017-4,neutral,0.7247767448425293
4/13/2017 2:07:04 PM,"BRIEF-Biogen licenses Phase 2 Anti-Tau antibody from Bristol-Myers Squibb (BIIB, BMY)",Reuters,http://www.businessinsider.com/r-brief-biogen-licenses-phase-2-anti-tau-antibody-from-bristol-myers-squibb-2017-4,neutral,0.6860154867172241
4/13/2017 2:11:12 PM,"UPDATE 1-Bristol-Myers to license two drugs to Biogen, Roche (BMY, BIIB, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-to-license-two-drugs-to-biogen-roche-2017-4,positive,0.5787065029144287
4/17/2017 1:08:19 PM,"Bristol-Myers, Nordic Bioscience To Develop Fibrosis Biomarker Technology ",RTTNews,/news/stocks/bristol-myers-nordic-bioscience-to-develop-fibrosis-biomarker-technology-1001923803,neutral,0.8073248863220215
4/17/2017 5:01:07 PM,"BRIEF-Bristol-Myers,Nordic Bioscience announce collaboration for fibrosis biomarker technology (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myersnordic-bioscience-announce-collaboration-for-fibrosis-biomarker-technology-2017-4,positive,0.5835232138633728
4/18/2017 11:31:03 AM,Novartis advances with push on cancer and liver disease,Reuters,http://www.businessinsider.com/r-novartis-advances-with-push-on-cancer-and-liver-disease-2017-4,positive,0.8682873845100403
4/21/2017 3:55:06 PM,Only one person has used the Western world's first gene therapy so its maker is pulling it off the market (QURE),Reuters,http://www.businessinsider.com/r-biotech-firm-pulls-pioneering-gene-therapy-due-to-no-demand-2017-4,neutral,0.801278293132782
4/21/2017 9:37:05 PM,BRIEF-Bristol-Myers gets positive CHMP opinion recommending approval of Opdivo for treatment of a type of bladder cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-opdivo-for-treatment-of-a-type-of-bladder-cancer-2017-4,positive,0.9312087893486023
4/23/2017 8:53:05 PM,Bristol-Myers NASH drug reduces liver fat in midstage study (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-nash-drug-reduces-liver-fat-in-midstage-study-2017-4,neutral,0.6002413630485535
4/24/2017 12:25:00 PM,"Drug Makers Stocks Under Scanner -- Bristol-Myers, AstraZeneca, Eli Lilly, and Immune Pharma",PR Newswire,/news/stocks/drug-makers-stocks-under-scanner-bristol-myers-astrazeneca-eli-lilly-and-immune-pharma-1001941450,neutral,0.6895373463630676
4/24/2017 1:11:08 PM,"RPT-INSIGHT-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-rpt-insight-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,neutral,0.8234216570854187
4/24/2017 8:17:06 PM,"UPDATE 1-NASH: The next untapped pharma market gives investors many options (PFE, BMY, GILD, AGN, MRK, JNJ, DRRX)",Reuters,http://www.businessinsider.com/r-update-1-nash-the-next-untapped-pharma-market-gives-investors-many-options-2017-4,neutral,0.7897850275039673
4/25/2017 6:43:08 PM,"U.S. Supreme Court may limit where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-us-supreme-court-may-limit-where-companies-can-be-sued-2017-4,neutral,0.8574921488761902
4/25/2017 9:45:06 PM,"UPDATE 1-U.S. Supreme Court may limit where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-may-limit-where-companies-can-be-sued-2017-4,neutral,0.8318422436714172
4/27/2017 10:01:11 AM,"UPDATE 1-Strong pharma unit drives Bayer earnings beat (BAYN, MON, JNJ, PFE, BMY)",Reuters,http://www.businessinsider.com/r-update-1-strong-pharma-unit-drives-bayer-earnings-beat-2017-4,positive,0.9419052600860596
4/27/2017 1:20:56 PM,Bristol-Myers Squibb Q1 Profit Rises; Lifts 2017 Profit View ,RTTNews,/news/stocks/bristol-myers-squibb-q1-profit-rises-lifts-2017-profit-view-1001956263,positive,0.8954622745513916
4/27/2017 1:33:33 PM,Bristol-Myers Squibb Co. Reveals 13% Rise In Q1 Bottom Line,RTTNews,/news/stocks/bristol-myers-squibb-co-reveals-13-rise-in-q1-bottom-line-1001956363,positive,0.9313188791275024
4/27/2017 3:09:06 PM,"US STOCKS-Wall St set to open higher with earnings in focus (BMY, RTN, MSFT, AMZN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-set-to-open-higher-with-earnings-in-focus-2017-4,positive,0.9385248422622681
4/27/2017 4:21:11 PM,"US STOCKS-Wall St little changed with eyes on earnings (CMCSA, BMY, DAL, UAL, MSFT, AMZN)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-little-changed-with-eyes-on-earnings-2017-4,neutral,0.7589772343635559
4/27/2017 4:27:47 PM,"AstraZeneca wants to escape from its falling drug sales in the second half of 2017 (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-hopes-to-escape-drug-sales-trough-in-second-half-2017-4,negative,0.9427145719528198
4/27/2017 4:55:06 PM,"UPDATE 1-Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-beats-wall-st-estimates-helped-by-cancer-drug-opdivo-2017-4,positive,0.9376236796379089
4/27/2017 6:11:13 PM,BRIEF-Bristol-Myers CFO: potential for 2017 U.S. growth for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-cfo-potential-for-2017-us-growth-for-opdivo-2017-4,positive,0.5657451748847961
4/27/2017 6:17:09 PM,BRIEF-Bristol-Myers says discontinued development of drug to treat breast and gastric cancer in Q1 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-discontinued-development-of-drug-to-treat-breast-and-gastric-cancer-in-q1-2017-4,negative,0.8849306702613831
4/28/2017 1:53:22 PM,"Bristol-Myers: China FDA Oks Daklinza, Sunvepra Combination For HCV ",RTTNews,/news/stocks/bristol-myers-china-fda-oks-daklinza-sunvepra-combination-for-hcv-1001961578,neutral,0.6694258451461792
4/28/2017 2:09:09 PM,BRIEF-China FDA approves country's first all-oral regimen for chronic Hepatitis C (BMY),Reuters,http://www.businessinsider.com/r-brief-china-fda-approves-countrys-first-all-oral-regimen-for-chronic-hepatitis-c-2017-4,positive,0.659383237361908
5/1/2017 10:20:05 PM,"UPDATE 2-AstraZeneca immunotherapy wins first approval in bladder cancer (AZN, BMY, MRK, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-2-astrazeneca-immunotherapy-wins-first-approval-in-bladder-cancer-2017-5,positive,0.9408506155014038
5/3/2017 11:10:05 PM,"UPDATE 1-Bayer, J&J win first trial over Xarelto bleeding risks (BAYN, JNJ, BMY)",Reuters,http://www.businessinsider.com/r-update-1-bayer-jj-win-first-trial-over-xarelto-bleeding-risks-2017-5,positive,0.9144780039787292
5/10/2017 1:16:08 PM,"BRIEF-Bristol-Myers Squibb, Calithera Biosciences expand collaboration (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-calithera-biosciences-expand-collaboration-2017-5,neutral,0.7697113752365112
5/11/2017 12:00:05 AM,"UPDATE 1-U.S. FDA approves Merck immunotherapy/chemo combo for lung cancer (MRK, LLY, BMY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-us-fda-approves-merck-immunotherapy-chemo-combo-for-lung-cancer-2017-5,positive,0.843059241771698
5/15/2017 10:30:51 AM,Agilent Announces Expanded Use For PD-L1 IHC 28-8 PharmDx Diagnostic In Europe ,RTTNews,/news/stocks/agilent-announces-expanded-use-for-pd-l1-ihc-28-8-pharmdx-diagnostic-in-europe-1002011377,positive,0.9036492109298706
5/16/2017 12:06:02 AM,BRIEF-Jana Partners cuts sole share stake in Bristol-Myers Squibb (BMY),Reuters,http://www.businessinsider.com/r-brief-jana-partners-cuts-sole-share-stake-in-bristol-myers-squibb-2017-5,negative,0.5196757912635803
5/17/2017 2:42:03 PM,BRIEF-Health Canada approves Bristol-Myers' opdivo(nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-health-canada-approves-bristol-myers-opdivonivolumab-2017-5,positive,0.6893087029457092
5/17/2017 11:12:03 PM,"Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE)",Reuters,http://www.businessinsider.com/r-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5,positive,0.9524326920509338
5/18/2017 1:56:03 AM,"UPDATE 1-Merck says test shows Keytruda improves survival for bladder cancer patients (MRK, AZN, BMY, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-merck-says-test-shows-keytruda-improves-survival-for-bladder-cancer-patients-2017-5,positive,0.9497457146644592
5/18/2017 9:06:03 AM,"UK Stocks-Factors to watch on May 18 (UKX, BHP, BLT, BP., SKT, VOD, BIR, HSBA, TATASTEEL, TKA, CPG, ITRK, RDSA, ERM, BOK, HL., RNK, LAND, BBY, BRBY, TCG, DCG, NG., III, BMY, MARS, INVP)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-may-18-2017-5,neutral,0.9455063343048096
5/18/2017 10:16:10 AM,"UPDATE 1-UK Stocks-Factors to watch on May 18 (UKX, TCG, HL., BRBY, BHP, BLT, BP., SKT, VOD, BIR, HSBA, TATASTEEL, TKA, CPG, ITRK, RDSA, ERM, BOK, RNK, LAND, BBY, DCG, BMY, INVP, III, NG., MARS)",Reuters,http://www.businessinsider.com/r-update-1-uk-stocks-factors-to-watch-on-may-18-2017-5,neutral,0.9440799355506897
5/19/2017 2:30:05 AM,"For millions of Chinese with rare diseases, some relief in sight (CELG, BMY, JNJ, SHP, SAN, PFE, MRK, SAPL, ALXN)",Reuters,http://www.businessinsider.com/r-for-millions-of-chinese-with-rare-diseases-some-relief-in-sight-2017-5,positive,0.8676333427429199
5/19/2017 2:19:02 PM,EMA Validates Application For Bristol-Myers' Sprycel In Children With CML ,RTTNews,/news/stocks/ema-validates-application-for-bristol-myers-sprycel-in-children-with-cml-1002028867,positive,0.6599410772323608
5/30/2017 11:30:07 AM,"Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5,negative,0.7272356748580933
5/30/2017 11:30:07 AM,"RPT-Novartis has assets to sell, investors wary of what it might buy (GSK, MRK, BMY, AZN, JNJ)",Reuters,http://www.businessinsider.com/r-rpt-novartis-has-assets-to-sell-investors-wary-of-what-it-might-buy-2017-5,negative,0.5483756065368652
5/30/2017 12:59:00 PM,Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration,PR Newswire,/news/stocks/array-biopharma-and-bristol-myers-squibb-announce-strategic-collaboration-1002050073,neutral,0.9142920970916748
5/30/2017 1:15:24 PM,"Array BioPharma, Bristol-Myers Squibb Announce Strategic Collaboration ",RTTNews,/news/stocks/array-biopharma-bristol-myers-squibb-announce-strategic-collaboration-1002050158,neutral,0.892777144908905
5/30/2017 1:18:02 PM,"BRIEF-Array BioPharma and Bristol-Myers Squibb announce strategic collaboration (ARRY, BMY)",Reuters,http://www.businessinsider.com/r-brief-array-biopharma-and-bristol-myers-squibb-announce-strategic-collaboration-2017-5,neutral,0.7078173756599426
5/30/2017 1:18:02 PM,BRIEF-Advaxis and Bristol-Myers Squibb announce clinical collaboration to evaluate ADXS-DUAL and Opdivo in metastatic cervical cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-advaxis-and-bristol-myers-squibb-announce-clinical-collaboration-to-evaluate-adxs-dual-and-opdivo-in-metastatic-cervical-cancer-2017-5,positive,0.8717886209487915
5/30/2017 4:58:03 PM,"U.S. top court tightens rules on where companies can be sued (BRK., BMY)",Reuters,http://www.businessinsider.com/r-us-top-court-tightens-rules-on-where-companies-can-be-sued-2017-5,negative,0.772825300693512
5/30/2017 5:18:05 PM,"UPDATE 1-U.S. top court tightens rules on where companies can be sued (BRK., BMY)",Reuters,http://www.businessinsider.com/r-update-1-us-top-court-tightens-rules-on-where-companies-can-be-sued-2017-5,negative,0.8579300045967102
6/1/2017 12:20:00 PM,"Drug Makers Stocks on Investors' Radar -- AstraZeneca, Bristol-Myers Squibb, Eli Lilly, and Sanofi",PR Newswire,/news/stocks/drug-makers-stocks-on-investors-radar-astrazeneca-bristol-myers-squibb-eli-lilly-and-sanofi-1002058233,neutral,0.9125478267669678
6/2/2017 12:15:03 PM,Bristol-Myers & Seattle Genetics To Evaluate Combination Of Opdivo And ADCETRIS ,RTTNews,/news/stocks/bristol-myers-seattle-genetics-to-evaluate-combination-of-opdivo-and-adcetris-1002062780,neutral,0.8469250798225403
6/2/2017 12:36:07 PM,"BRIEF-Bristol-Myers Squibb and Seattle Genetics expand collaboration to evaluate combination of opdivo and adcetris (BMY, SGEN)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-seattle-genetics-expand-collaboration-to-evaluate-combination-of-opdivo-and-adcetris-2017-6,positive,0.8944385051727295
6/2/2017 1:21:08 PM,"Bristol-Myers Reports Opdivo Data, Shows Overall Response Rate Of 26.3% ",RTTNews,/news/stocks/bristol-myers-reports-opdivo-data-shows-overall-response-rate-of-26-3-1002063031,positive,0.5623155236244202
6/2/2017 1:28:03 PM,BRIEF-Bristol-Myers announces first disclosure of data from a cohort of phase 1/2 CheckMate-358 study (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-first-disclosure-of-data-from-a-cohort-of-phase-1-2-checkmate-358-study-2017-6,neutral,0.9171303510665894
6/2/2017 11:22:05 PM,BRIEF-European commission approves Bristol-Myers Squibb’s opdivo (nivolumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-european-commission-approves-bristol-myers-squibbs-opdivo-nivolumab-2017-6,positive,0.5579176545143127
6/3/2017 7:00:00 PM,Bristol-Myers Squibb and QIAGEN Sign Agreement for Use of NGS Technology to Develop Gene Expression Profiles for Immuno-Oncology Therapies,PR Newswire,/news/stocks/bristol-myers-squibb-and-qiagen-sign-agreement-for-use-of-ngs-technology-to-develop-gene-expression-profiles-for-immuno-oncology-therapies-1002065369,positive,0.9258031845092773
6/5/2017 1:28:05 PM,BRIEF-Bristol-Myers Squibb says early responses seen with Sprycel in first and second line treatment of pediatric patients with chronic myeloid leukemia in chronic phase (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-early-responses-seen-with-sprycel-in-first-and-second-line-treatment-of-pediatric-patients-with-chronic-myeloid-leukemia-in-chronic-phase-2017-6,positive,0.8778425455093384
6/5/2017 1:48:05 PM,"BRIEF-Incyte says epacadostat, Bristol-Myers' Opdivo combo data positive in head and neck cancer patients (INCY, BMY)",Reuters,http://www.businessinsider.com/r-brief-incyte-says-epacadostat-bristol-myers-opdivo-combo-data-positive-in-head-and-neck-cancer-patients-2017-6,positive,0.6345503926277161
6/5/2017 10:22:06 PM,"US STOCKS-Wall St dips; 2017's laggards tick up, Apple slips (AAPL, BMY, HLF)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-dips-2017s-laggards-tick-up-apple-slips-2017-6,negative,0.9523115754127502
6/5/2017 10:28:06 PM,BRIEF-Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-new-collaboration-to-evaluate-combination-therapy-in-colorectal-cancer-2017-6,positive,0.7992326021194458
6/6/2017 3:05:40 AM,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer ",RTTNews,/news/stocks/novartis-bristol-myers-to-evaluate-treatments-in-metastatic-colorectal-cancer-1002068811,neutral,0.7891083359718323
6/8/2017 1:42:06 PM,BRIEF-Bristol-Myers announces availability of Orencia subcutaneous administration option for patients above 2 yrs of age with moderately to severely active polyarticular JIA (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-availability-of-orencia-subcutaneous-administration-option-for-patients-above-2-yrs-of-age-with-moderately-to-severely-active-polyarticular-jia-2017-6,positive,0.9111655950546265
6/13/2017 10:12:08 PM,BRIEF-Bristol-Myers Squibb declares quarterly dividend of $0.39/shr (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-declares-quarterly-dividend-of-039-shr-2017-6,negative,0.5468937754631042
6/14/2017 3:28:05 PM,BRIEF-Bristol-Myers Squibb announces cash tender offer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-cash-tender-offer-2017-6,neutral,0.9108942151069641
6/16/2017 11:18:28 AM,"Bristol-Myers To Sell Manufacturing Facility In Swords, Ireland - Quick Facts ",RTTNews,/news/stocks/bristol-myers-to-sell-manufacturing-facility-in-swords-ireland-quick-facts-1002098897,neutral,0.7981665134429932
6/16/2017 12:02:05 PM,"BRIEF-Bristol-Myers Squibb to sell manufacturing facility to SK Biotek Co (BMY, 034730)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-to-sell-manufacturing-facility-to-sk-biotek-co-2017-6,neutral,0.9187574982643127
6/16/2017 1:11:48 PM,Bristol-Myers Reports Opdivo Follow-Up Data - Quick Facts ,RTTNews,/news/stocks/bristol-myers-reports-opdivo-follow-up-data-quick-facts-1002099243,neutral,0.9457032084465027
6/19/2017 4:52:06 PM,"U.S. Supreme Court limits where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-us-supreme-court-limits-where-companies-can-be-sued-2017-6,neutral,0.8893726468086243
6/19/2017 6:18:05 PM,"UPDATE 1-U.S. Supreme Court again limits where companies can be sued (BMY, BRK.)",Reuters,http://www.businessinsider.com/r-update-1-us-supreme-court-again-limits-where-companies-can-be-sued-2017-6,neutral,0.8382997512817383
6/21/2017 1:18:03 AM,"U.S. Supreme Court ruling threatens massive talc litigation against J&J (JNJ, BMY, BAYN, GSK, MCK)",Reuters,http://www.businessinsider.com/r-us-supreme-court-ruling-threatens-massive-talc-litigation-against-jj-2017-6,negative,0.9487156271934509
6/21/2017 1:10:06 PM,BRIEF-Bristol-Myers Squibb announces expiration of cash tender offer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-expiration-of-cash-tender-offer-2017-6,neutral,0.5566613078117371
6/21/2017 1:10:09 PM,"RPT-U.S. Supreme Court ruling threatens massive talc litigation against J&J (JNJ, BMY, BAYN, GSK, MCK)",Reuters,http://www.businessinsider.com/r-rpt-us-supreme-court-ruling-threatens-massive-talc-litigation-against-jj-2017-6,negative,0.9463071823120117
6/21/2017 4:00:00 PM,S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017,PR Newswire,/news/stocks/s-p-500-buybacks-fall-17-5-year-over-year-to-133-1-billion-for-q1-2017-1002112472,negative,0.9629759788513184
6/26/2017 1:12:03 PM,"Seattle Genetics, Takeda lymphoma drug succeeds late-stage trial (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-seattle-genetics-takeda-lymphoma-drug-succeeds-late-stage-trial-2017-6,neutral,0.6685408353805542
6/26/2017 3:58:03 PM,"UPDATE 1-Seattle Genetics, Takeda lymphoma drug success fails (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-update-1-seattle-genetics-takeda-lymphoma-drug-success-fails-2017-6,neutral,0.5062691569328308
6/26/2017 6:40:18 PM,"UPDATE 2-Seattle Genetics slumps as cancer drug data fails to impress (SGEN, 4502, BMY)",Reuters,http://www.businessinsider.com/r-update-2-seattle-genetics-slumps-as-cancer-drug-data-fails-to-impress-2017-6,negative,0.9717447757720947
6/27/2017 7:08:03 PM,"AstraZeneca cancer drug trial prompts investors to take options cover (AZN, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-cancer-drug-trial-prompts-investors-to-take-options-cover-2017-6,neutral,0.8400912880897522
7/5/2017 12:34:00 PM,Bristol-Myers Phase 3 Study Of Opdivo Vs Yervoy Meets Primary Goal ,RTTNews,/news/stocks/bristol-myers-phase-3-study-of-opdivo-vs-yervoy-meets-primary-goal-1002148519,neutral,0.9208788871765137
7/5/2017 12:38:04 PM,BRIEF-Bristol-Myers Squibb says phase 3 study evaluating the safety and efficacy of adjuvant Opdivo in resected high-risk melanoma patients meets main goal (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-phase-3-study-evaluatingthe-safety-and-efficacy-of-adjuvant-opdivoin-resected-high-risk-melanoma-patients-meets-main-goal-2017-7,neutral,0.7807918787002563
7/5/2017 7:02:05 PM,"New cancer treatments that are programmed to treat a person's specific tumor just passed 2 early tests (MRK, BMY, SAN, LLY)",Reuters,http://www.businessinsider.com/r-personalised-vaccines-hold-cancer-at-bay-in-two-early-trials-2017-7,neutral,0.6401915550231934
7/5/2017 11:42:05 PM,"UPDATE 1-FDA puts hold on Merck multiple myeloma trials after deaths (MRK, BMY, CELG)",Reuters,http://www.businessinsider.com/r-update-1-fda-puts-hold-on-merck-multiple-myeloma-trials-after-deaths-2017-7,negative,0.848567545413971
7/6/2017 1:48:03 PM,BRIEF-Bristol-Myers Squibb's Orencia receives FDA approval (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibbs-orencia-receives-fda-approval-2017-7,positive,0.8531537652015686
7/7/2017 7:36:45 AM,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track ",RTTNews,/news/stocks/bmy-s-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-1002154681,neutral,0.850072979927063
7/10/2017 1:22:37 PM,FDA Accepts For Priority Review Bristol-Myers' SNDA For Sprycel For Children ,RTTNews,/news/stocks/fda-accepts-for-priority-review-bristol-myers-snda-for-sprycel-for-children-1002159701,neutral,0.8113067150115967
7/10/2017 1:30:06 PM,BRIEF-FDA accepts for priority review Bristol-Myers Squibb's application for sprycel (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-for-priority-review-bristol-myers-squibbs-application-for-sprycel-2017-7,neutral,0.853513777256012
7/10/2017 3:06:03 PM,"BRIEF-Exelixis, Bristol-Myers Squibb initiate phase 3 trial (BMY, EXEL, IPN)",Reuters,http://www.businessinsider.com/r-brief-exelixis-bristol-myers-squibb-initiate-phase-3-trial-2017-7,neutral,0.8726809620857239
7/11/2017 7:59:29 AM,"ARNA Heartened By Phase II Trial, BMY To Face FDA In Nov., Concert Back In Play ",RTTNews,/news/stocks/arna-heartened-by-phase-ii-trial-bmy-to-face-fda-in-nov-concert-back-in-play-1002161941,positive,0.7407658100128174
7/13/2017 12:02:03 PM,"T-cell cancer therapy holds promise, longer-term results await (MRK, BMY, AET)",Reuters,http://www.businessinsider.com/r-t-cell-cancer-therapy-holds-promise-longer-term-results-await-2017-7,positive,0.8325119018554688
7/14/2017 10:34:08 PM,BRIEF-Bristol-Myers Squibb Co says Laurie Glimcher notified co that she will retire from board (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-co-says-laurie-glimcher-notified-co-that-she-will-retire-from-board-2017-7,neutral,0.7354662418365479
7/24/2017 1:38:42 PM,Bristol-Myers Squibb Reports Expanded Approval For Yervoy - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-expanded-approval-for-yervoy-quick-facts-1002198278,positive,0.9262861013412476
7/24/2017 2:22:05 PM,BRIEF-Bristol-Myers Squibb says Yervoy showed a consistent safety profile and comparable drug levels across pediatric and adult patients​ (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-yervoy-showed-a-consistent-safety-profile-and-comparable-drug-levels-across-pediatric-and-adult-patients-2017-7,positive,0.9419978857040405
7/24/2017 10:38:05 PM,BRIEF-FDA accepts Bristol-Myers Squibb's applications for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-bristol-myers-squibbs-applications-for-opdivo-2017-7,positive,0.5006648302078247
7/26/2017 2:20:13 PM,BRIEF-Bristol-Myers Squibb’s Orencia receives second European Commission approval (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibbs-orencia-receives-second-european-commission-approval-2017-7,positive,0.8803396821022034
7/27/2017 1:06:04 PM,"Bristol-Myers quarterly sales meet Wall Street estimates (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-quarterly-sales-meet-wall-street-estimates-2017-7,neutral,0.6415177583694458
7/27/2017 2:38:05 PM,"UPDATE 1-Bristol-Myers shares fall after failed AstraZeneca drug trial (BMY, AZN, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-shares-fall-after-failed-astrazeneca-drug-trial-2017-7,negative,0.9680455923080444
7/27/2017 5:02:03 PM,"Hepatitis drugs more affordable but disease still deadly - WHO (MYL, BMY)",Reuters,http://www.businessinsider.com/r-hepatitis-drugs-more-affordable-but-disease-still-deadly---who-2017-7,neutral,0.8475713133811951
7/27/2017 10:28:03 PM,"US STOCKS-Tech, transports drag on Wall Street; Dow hits record (UPS, FDX, AMZN, BMY, AZN, VZ, T)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-transports-drag-on-wall-street-dow-hits-record-2017-7,negative,0.4473652243614197
7/31/2017 7:47:51 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1002217371,neutral,0.6419673562049866
8/1/2017 11:12:04 PM,"BRIEF-Seattle Genetics to buy Bothell plant from Bristol-Myers Squibb (BMY, SGEN)",Reuters,http://www.businessinsider.com/r-brief-seattle-genetics-to-buy-bothell-plant-from-bristol-myers-squibb-2017-8,neutral,0.8721346855163574
8/2/2017 8:28:58 AM,"FDA Nod For AGIO's IDHIFA, BMY Expands Opdivo Use, OCUL Reduces Headcount ",RTTNews,/news/stocks/fda-nod-for-agio-s-idhifa-bmy-expands-opdivo-use-ocul-reduces-headcount-1002224912,positive,0.9267181158065796
8/3/2017 10:03:05 PM,Pharma giant Bristol-Myers Squibb just made another big bet on cancer immunotherapy (BMY),Business Insider,http://www.businessinsider.com/bristol-myers-squibb-acquires-ifm-therapeutics-for-up-to-232-billion-2017-8,positive,0.817042887210846
8/3/2017 10:17:03 PM,BRIEF-Bristol-Myers Squibb to acquire IFM Therapeutics to strengthen oncology pipeline focus on innate immunity (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-to-acquire-ifm-therapeutics-to-strengthen-oncology-pipeline-focus-on-innate-immunity-2017-8,positive,0.8524182438850403
8/3/2017 10:19:36 PM,Bristol-Myers Squibb To Acquire IFM Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-ifm-therapeutics-quick-facts-1002231883,neutral,0.9393984079360962
8/3/2017 11:17:03 PM,"Bristol-Myers to buy IFM Therapeutics to strengthen cancer pipeline (BMY, MRK)",Reuters,http://www.businessinsider.com/r-bristol-myers-to-buy-ifm-therapeutics-to-strengthen-cancer-pipeline-2017-8,positive,0.6997410655021667
8/4/2017 12:07:03 PM,"Deals of the day-Mergers and acquisitions (GAS, BMY, MRK, 7261, BX, 2914, VNM)",Reuters,http://www.businessinsider.com/r-deals-of-the-day-mergers-and-acquisitions-2017-8,neutral,0.9484180808067322
8/10/2017 12:15:00 PM,"Technical Snapshots for These Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/technical-snapshots-for-these-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002247897,neutral,0.9072645306587219
8/14/2017 4:47:05 PM,"BRIEF-Jana Partners dissolves sole share stake in Snap Inc, Shire Plc (BMY, SHP, NUVA, CRM, UHS)",Reuters,http://www.businessinsider.com/r-brief-jana-partners-dissolves-sole-share-stake-in-snap-inc-shire-plc-2017-8,neutral,0.8493162393569946
8/15/2017 10:42:14 PM,BRIEF-Bristol-Myers Squibb announces topline results (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-topline-results-2017-8,neutral,0.9010427594184875
8/15/2017 10:57:14 PM,Bristol-Myers kidney cancer drug fails late-stage trial (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-kidney-cancer-drug-fails-late-stage-trial-2017-8,neutral,0.6753196120262146
8/16/2017 8:01:41 AM,"ALXN's Strengthening Patents, FOLD's Fabry Drug Approved In OZ, VBIV Surges ",RTTNews,/news/stocks/alxn-s-strengthening-patents-fold-s-fabry-drug-approved-in-oz-vbiv-surges-1002260660,positive,0.8968322277069092
8/16/2017 1:37:03 PM,"US STOCKS-Futures higher ahead of Fed minutes (TGT, URBN, AMZN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-futures-higher-ahead-of-fed-minutes-2017-8,positive,0.8846075534820557
8/16/2017 3:07:03 PM,"US STOCKS-U.S. stocks set to open higher ahead of Fed minutes (TGT, URBN, AMZN, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-us-stocks-set-to-open-higher-ahead-of-fed-minutes-2017-8,positive,0.9126654267311096
8/27/2017 11:27:08 AM,"Bayer, J&J in frame for bigger anti-clotting market opportunity (BAYN, JNJ, PFE, BMY)",Reuters,http://www.businessinsider.com/r-bayer-jj-in-frame-for-bigger-anti-clotting-market-opportunity-2017-8,positive,0.757800281047821
8/28/2017 8:47:13 AM,Bristol-Myers: Eliquis Shows Lower Risk Of Stroke In NVAF Patient Subgroups ,RTTNews,/news/stocks/bristol-myers-eliquis-shows-lower-risk-of-stroke-in-nvaf-patient-subgroups-1002287443,positive,0.6588336825370789
8/28/2017 11:26:34 AM,"Bristol-Myers, Pfizer Report Investigational Eliquis Data - Quick Facts ",RTTNews,/news/stocks/bristol-myers-pfizer-report-investigational-eliquis-data-quick-facts-1002287826,neutral,0.9458391070365906
8/28/2017 10:17:03 PM,"BRIEF-Bristol-Myers Squibb and Daiichi Sankyo collaborate to evaluate Opdivo (Nivolumab) and DS-8201 (4568, BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-daiichi-sankyo-collaborate-to-evaluate-opdivo-nivolumab-and-ds-8201-2017-8,neutral,0.5405148863792419
8/28/2017 10:47:07 PM,"Bristol-Myers, Daiichi Sankyo to test combo therapy for breast, bladder cancers (BMY, 4568)",Reuters,http://www.businessinsider.com/r-bristol-myers-daiichi-sankyo-to-test-combo-therapy-for-breast-bladder-cancers-2017-8,neutral,0.887721598148346
8/28/2017 11:12:03 PM,"UPDATE 1-Bristol-Myers, Daiichi Sankyo to test Opdivo combo for cancers (BMY, 4568, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-daiichi-sankyo-to-test-opdivo-combo-for-cancers-2017-8,neutral,0.8390173316001892
8/29/2017 10:56:50 AM,"KMDA Slips On AAT Therapy Concerns, ETRM Gains Weight, LJPC On Watch ",RTTNews,/news/stocks/kmda-slips-on-aat-therapy-concerns-etrm-gains-weight-ljpc-on-watch-1002290567,negative,0.7280263304710388
8/29/2017 2:23:52 PM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1002291346,neutral,0.6874346733093262
8/31/2017 2:52:03 PM,"AstraZeneca aims to offset drug setback at big cancer congress (AZN, LLY, PFE, BMY, MRK, INCY)",Reuters,http://www.businessinsider.com/r-astrazeneca-aims-to-offset-drug-setback-at-big-cancer-congress-2017-8,positive,0.9372472763061523
9/6/2017 4:07:03 PM,"Merck & Co snaps up 3 yr-old German biotech firm for up to $550 mln (MRK, BMY)",Reuters,http://www.businessinsider.com/r-merck--co-snaps-up-3-yr-old-german-biotech-firm-for-up-to-550-mln-2017-9,positive,0.8173832297325134
9/7/2017 12:22:13 AM,"Bristol-Myers says FDA places partial hold on Opdivo myeloma trials (BMY, MRK, CELG)",Reuters,http://www.businessinsider.com/r-bristol-myers-says-fda-places-partial-hold-on-opdivo-myeloma-trials-2017-9,negative,0.8835951089859009
9/7/2017 1:27:07 PM,Bristol-Myers kidney cancer drug meets main goal of late-stage trial (BMY),Reuters,http://www.businessinsider.com/r-bristol-myers-kidney-cancer-drug-meets-main-goal-of-late-stage-trial-2017-9,neutral,0.7831133008003235
9/7/2017 1:41:15 PM,Bristol-Myers: Phase 3 Study Of Opdivo Plus Yervoy Met Co-primary Endpoint ,RTTNews,/news/stocks/bristol-myers-phase-3-study-of-opdivo-plus-yervoy-met-co-primary-endpoint-1002349426,neutral,0.547947347164154
9/7/2017 1:57:06 PM,BRIEF-‍Bristol-Myers Squibb says Opdivo plus Yervoy showed superior overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-opdivo-plus-yervoy-showed-superior-overall-survival-2017-9,positive,0.9579119086265564
9/7/2017 1:57:06 PM,"UPDATE 1-Bristol-Myers kidney cancer drug meets main goal of late-stage trial (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-kidney-cancer-drug-meets-main-goal-of-late-stage-trial-2017-9,positive,0.6243601441383362
9/7/2017 10:32:09 PM,"US STOCKS-Wall St ends flat as media stocks slump, healthcare gains (CMCSA, BMY, MSFT, AMZN, GE, AAPL, LLY, CBS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ends-flat-as-media-stocks-slump-healthcare-gains-2017-9,negative,0.9583507776260376
9/7/2017 11:02:18 PM,BRIEF-Bristol-Myers Squibb completes acquisition of IFM Therapeutics (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-completes-acquisition-of-ifm-therapeutics-2017-9,neutral,0.8985984325408936
9/8/2017 12:07:09 AM,"Roche blood test could help 'personalize' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-blood-test-could-help-personalize-cancer-immunotherapy-2017-9,neutral,0.729407012462616
9/8/2017 12:07:10 AM,"Merck's immunotherapy, chemo mix shows extended lung cancer gains (MRK, BMY, AZN)",Reuters,http://www.businessinsider.com/r-mercks-immunotherapy-chemo-mix-shows-extended-lung-cancer-gains-2017-9,positive,0.8237944841384888
9/8/2017 9:02:03 AM,"UPDATE 1-Roche blood test could help 'personalise' cancer immunotherapy (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-blood-test-could-help-personalise-cancer-immunotherapy-2017-9,positive,0.5246525406837463
9/8/2017 11:51:28 AM,Bristol-Myers: Phase 3 Data Reinforce Sustained Survival Benefit Of Opdivo ,RTTNews,/news/stocks/bristol-myers-phase-3-data-reinforce-sustained-survival-benefit-of-opdivo-1002353010,positive,0.9558454751968384
9/9/2017 12:07:13 AM,"AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.93507319688797
9/9/2017 11:02:03 AM,"UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.9298104047775269
9/10/2017 5:57:04 PM,"Bristol kidney cancer drug cut death risk 37 pct in key patients (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-bristol-kidney-cancer-drug-cut-death-risk-37-pct-in-key-patients-2017-9,positive,0.9072890877723694
9/10/2017 6:39:55 PM,Bristol-Myers Announces Results From The Phase 3 CheckMate ,RTTNews,/news/stocks/bristol-myers-announces-results-from-the-phase-3-checkmate-1002356021,neutral,0.8761695623397827
9/10/2017 7:02:03 PM,"UPDATE 1-Bristol's drug cocktail cuts kidney cancer death risk 37 pct (BMY, AZN, PFE, MRK)",Reuters,http://www.businessinsider.com/r-update-1-bristols-drug-cocktail-cuts-kidney-cancer-death-risk-37-pct-2017-9,positive,0.9252809286117554
9/11/2017 12:17:08 AM,"After melanoma surgery, Bristol's Opdivo offers new care standard (BMY)",Reuters,http://www.businessinsider.com/r-after-melanoma-surgery-bristols-opdivo-offers-new-care-standard-2017-9,positive,0.76885586977005
9/11/2017 12:17:09 AM,"Novartis posts a win, Roche a flop in skin cancer trials (BMY, GSK)",Reuters,http://www.businessinsider.com/r-novartis-posts-a-win-roche-a-flop-in-skin-cancer-trials-2017-9,positive,0.775973916053772
9/11/2017 6:58:22 AM,"New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch ",RTTNews,/news/stocks/new-hope-for-azn-s-old-drug-more-about-bmy-s-opdivo-imdz-on-watch-1002356354,neutral,0.8646789789199829
9/11/2017 8:17:03 AM,"RPT-UPDATE 1-AstraZeneca rebuilds cancer drug hopes with new lung data (AZN, BMY, MRK)",Reuters,http://www.businessinsider.com/r-rpt-update-1-astrazeneca-rebuilds-cancer-drug-hopes-with-new-lung-data-2017-9,positive,0.9237905144691467
9/11/2017 12:07:03 PM,"Cancer immunotherapy proves itself in earlier-stage disease (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-cancer-immunotherapy-proves-itself-in-earlier-stage-disease-2017-9,positive,0.8216858506202698
9/13/2017 12:25:00 PM,"Breakfast Technical Briefing on Drug Makers Stocks -- AbbVie, AstraZeneca, Bristol Myers Squibb, and Johnson & Johnson",PR Newswire,/news/stocks/breakfast-technical-briefing-on-drug-makers-stocks-abbvie-astrazeneca-bristol-myers-squibb-and-johnson-johnson-1002365439,neutral,0.9458073973655701
9/13/2017 10:37:14 PM,BRIEF-Bristol-Myers Squibb Co says ‍declared a quarterly dividend (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-co-says-declared-a-quarterly-dividend-2017-9,negative,0.9158344864845276
9/13/2017 10:42:16 PM,BRIEF-Bristol-Myers Squibb says Karen Vousden elected as member of board (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-says-karen-vousden-elected-as-member-of-board-2017-9,neutral,0.9240821599960327
9/14/2017 1:08:34 PM,Bristol-Myers Partners With Halozyme; Gains Access To ENHANZE Technology ,RTTNews,/news/stocks/bristol-myers-partners-with-halozyme-gains-access-to-enhanze-technology-1002369805,positive,0.9302984476089478
9/14/2017 1:17:04 PM,"BRIEF-Bristol-Myers Squibb and Halozyme enter global collaboration and license agreement for enhanze technology (BMY, HALO)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-and-halozyme-enter-global-collaboration-and-license-agreement-for-enhanze-technology-2017-9,positive,0.9114565849304199
9/14/2017 2:02:03 PM,"Halozyme to license drug delivery tech to Roche, Bristol-Myers (HALO, BMY)",Reuters,http://www.businessinsider.com/r-halozyme-to-license-drug-delivery-tech-to-roche-bristol-myers-2017-9,neutral,0.7361684441566467
9/14/2017 3:31:00 PM,"Stock Score Reports for Bristol-Myers Squibb, Cliffs Natural Resources, Hertz Global Holdings, Nordstrom and Oclaro Inc.",PR Newswire,/news/stocks/stock-score-reports-for-bristol-myers-squibb-cliffs-natural-resources-hertz-global-holdings-nordstrom-and-oclaro-inc--671790,neutral,0.9479849338531494
9/22/2017 11:12:00 AM,Bristol-Myers Reports Approval Of Opdivo For Recurrent Gastric Cancer In Japan ,RTTNews,/news/stocks/bristol-myers-reports-approval-of-opdivo-for-recurrent-gastric-cancer-in-japan-1002419060,positive,0.9196597933769226
9/22/2017 1:00:00 PM,AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors,PR Newswire,/news/stocks/abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-therapeutic-regimen-in-advanced-solid-tumors-1002421197,positive,0.8202074766159058
9/22/2017 1:17:03 PM,BRIEF-AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-abbvie-and-bristol-myers-squibb-announce-clinical-research-collaboration-to-evaluate-a-therapeutic-regimen-in-advanced-solid-tumors-2017-9,positive,0.8401444554328918
9/23/2017 12:17:15 AM,BRIEF-Bristol-Myers says ‍FDA approves Opdivo(Nivolumab) injection for intravenous use in certain patients (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-fda-approves-opdivonivolumab-injection-for-intravenous-use-in-certain-patients-2017-9,positive,0.8468965888023376
9/25/2017 4:36:05 AM,"Opdivo, Keytruda Back In The News, FDA Snubs AGN, EARS Catches Eyes ",RTTNews,/news/stocks/opdivo-keytruda-back-in-the-news-fda-snubs-agn-ears-catches-eyes-1002503240,neutral,0.6159443259239197
9/25/2017 2:12:08 PM,"BRIEF-Infinity Pharmaceuticals and Bristol-Myers Squibb expand clinical collaboration (BMY, INFI)",Reuters,http://www.businessinsider.com/r-brief-infinity-pharmaceuticals-and-bristol-myers-squibb-expand-clinical-collaboration-2017-9,positive,0.9198089838027954
9/25/2017 2:21:45 PM,"Infinity Pharma, Bristol-Myers Collaborate; Expands IPI-549 Study ",RTTNews,/news/stocks/infinity-pharma-bristol-myers-collaborate-expands-ipi-549-study-1002518792,positive,0.7447835803031921
9/29/2017 5:27:05 PM,"Puerto Rico power outage set to hurt global reinsurers (MAP, QBE, AIG, BMY, LLY, PFE, AMGN, AZN, MMC)",Reuters,http://www.businessinsider.com/r-puerto-rico-power-outage-set-to-hurt-global-reinsurers-2017-9,negative,0.960808515548706
10/5/2017 11:42:17 PM,"BRIEF-Aveo Pharmaceuticals- Tivo-3 study will continue as planned without modification (AVEO, BMY)",Reuters,http://www.businessinsider.com/r-brief-aveo-pharmaceuticals--tivo-3-study-will-continue-as-planned-without-modification-2017-10,neutral,0.9426422119140625
10/9/2017 1:32:04 PM,BRIEF-Bristol-Myers Squibb names Saurabh Saha as senior vice president (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-names-saurabh-saha-as-senior-vice-president-2017-10,neutral,0.9361658692359924
10/12/2017 3:00:00 PM,Bristol-Myers Squibb (BMY) Extends Strategic Partnership with TARGET PharmaSolutions for TARGET-NASH,PR Newswire,/news/stocks/bristol-myers-squibb-bmy-extends-strategic-partnership-with-target-pharmasolutions-for-target-nash-1003980998,positive,0.9173660278320312
10/12/2017 3:22:25 PM,BRIEF-Bristol-Myers Squibb extends strategic partnership with Target Pharmasolutions (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-extends-strategic-partnership-with-target-pharmasolutions-2017-10,positive,0.9102016687393188
10/12/2017 4:12:03 PM,"NIH partners 11 drugmakers to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-nih-partners-11-drugmakers-to-accelerate-cancer-therapy-research-2017-10,positive,0.7635127902030945
10/12/2017 6:27:06 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,positive,0.8402750492095947
10/12/2017 10:12:15 PM,"UPDATE 1-US NIH, 11 drugmakers partner to accelerate cancer therapy research (BMY, MRK, PFE, JNJ, AMGN, CELG, GILD, GSK)",Reuters,http://www.businessinsider.com/r-update-1-us-nih-11-drugmakers-partner-to-accelerate-cancer-therapy-research-2017-10,positive,0.8402750492095947
10/16/2017 9:42:11 AM,BRIEF-Bristol-Myers ‍announces data for Opdivo and Opdivo plus Yervoy in previously treated small cell lung cancer​ (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-announces-data-for-opdivo-and-opdivo-plus-yervoy-in-previously-treated-small-cell-lung-cancer-2017-10,neutral,0.7044661045074463
10/16/2017 9:45:48 AM,"Bristol-Myers: Opdivo Shows Encouraging Response, Survival Rates - Quick Facts ",RTTNews,/news/stocks/bristol-myers-opdivo-shows-encouraging-response-survival-rates-quick-facts-1004461009,positive,0.9252005219459534
10/16/2017 7:22:12 PM,"US STOCKS-Wall St higher as bank stocks rebound, Apple gains (JPM, BAC, AAPL, BMY, ADBE, FCX, NFLX, GS, MS)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-higher-as-bank-stocks-rebound-apple-gains-2017-10,positive,0.9310608506202698
10/16/2017 10:27:09 PM,BRIEF-FDA accepts Bristol-Myers Squibb’s application for Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-fda-accepts-bristol-myers-squibbs-application-for-opdivo-2017-10,neutral,0.563418447971344
10/17/2017 7:46:16 AM,"ANIK Expands Horizons, FENC Hits Study Goals, IMDZ Abuzz, One More For Opdivo ",RTTNews,/news/stocks/anik-expands-horizons-fenc-hits-study-goals-imdz-abuzz-one-more-for-opdivo-1004579305,positive,0.8043040633201599
10/20/2017 2:01:28 PM,Bristol-Myers To Present Data Across Serious Liver Diseases - Quick Facts ,RTTNews,/news/stocks/bristol-myers-to-present-data-across-serious-liver-diseases-quick-facts-1005028356,neutral,0.871954083442688
10/24/2017 8:07:14 AM,"UK Stocks-Factors to watch on Oct 24 (UKX, RBS, BARC, LLOY, RIO, RIO, GKN, WTB, BNZL, AAL, BMY, STJ, IPF)",Reuters,http://www.businessinsider.com/r-uk-stocks-factors-to-watch-on-oct-24-2017-10,neutral,0.9405462741851807
10/25/2017 2:37:12 PM,"UPDATE 1-Baxter expects $70 mln hit to 4th-qtr sales from Hurricane Maria (BAX, MRK, JNJ, PFE, GSK, MDT, DEPO, AMGN, BMY, LLY, AZN)",Reuters,http://www.businessinsider.com/r-update-1-baxter-expects-70-mln-hit-to-4th-qtr-sales-from-hurricane-maria-2017-10,positive,0.805812418460846
10/26/2017 1:07:08 PM,"Bristol Myers posts in-line sales, but profit margins worsen (BMY)",Reuters,http://www.businessinsider.com/r-bristol-myers-posts-in-line-sales-but-profit-margins-worsen-2017-10,negative,0.9308827519416809
10/26/2017 1:21:38 PM,Bristol-Myers Squibb Co. Reports 8% Decline In Q3 Bottom Line,RTTNews,/news/stocks/bristol-myers-squibb-co-reports-8-decline-in-q3-bottom-line-1005694605,negative,0.9723514318466187
10/26/2017 1:21:56 PM,Bristol-Myers Squibb Increases 2017 Non-GAAP EPS Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-increases-2017-non-gaap-eps-guidance-quick-facts-1005694603,neutral,0.8177919983863831
10/26/2017 4:12:03 PM,"US STOCKS-Dow advances at open; Celgene holds back S&P, Nasdaq (AMZN, MSFT, INTC, CELG, BMY, F)",Reuters,http://www.businessinsider.com/r-us-stocks-dow-advances-at-open-celgene-holds-back-sp-nasdaq-2017-10,neutral,0.36478477716445923
10/26/2017 5:27:03 PM,"UPDATE 1-Bristol-Myers sales in line, but profit margins worsen (BMY, MRK, PFE)",Reuters,http://www.businessinsider.com/r-update-1-bristol-myers-sales-in-line-but-profit-margins-worsen-2017-10,negative,0.9019615054130554
10/26/2017 5:42:05 PM,"US STOCKS-Financial, tech stocks drive Wall St higher (CELG, BMY, MSFT, INTC, JPM, BAC)",Reuters,http://www.businessinsider.com/r-us-stocks-financial-tech-stocks-drive-wall-st-higher-2017-10,positive,0.9125258326530457
10/26/2017 6:45:00 PM,M2Gen® Announces Bristol-Myers Squibb's Participation in ORIEN Avatar™ Research Program,PR Newswire,/news/stocks/m2gen-announces-bristol-myers-squibb-s-participation-in-orien-avatar-research-program-1005725025,neutral,0.669708788394928
10/26/2017 7:07:03 PM,"US STOCKS-Upbeat earnings keep Wall St on firm footing (CELG, JPM, BAC, BMY, NKE)",Reuters,http://www.businessinsider.com/r-us-stocks-upbeat-earnings-keep-wall-st-on-firm-footing-2017-10,positive,0.9256995916366577
10/26/2017 8:42:14 PM,"US STOCKS-Wall St advances on earnings but healthcare lags (CELG, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-advances-on-earnings-but-healthcare-lags-2017-10,negative,0.8379631638526917
10/27/2017 11:04:05 AM,Biotech Stocks Facing FDA Decision In November ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-1005814640,neutral,0.6474880576133728
10/30/2017 12:17:08 PM,BRIEF-EMA validates Bristol-Myers' type II variation application for Opdivo for treatment of patients with resected high-risk advanced melanoma (BMY),Reuters,http://www.businessinsider.com/r-brief-ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-for-treatment-of-patients-with-resected-high-risk-advanced-melanoma-2017-10,positive,0.8640727400779724
10/30/2017 12:34:05 PM,EMA Validates Bristol-Myers' Type II Variation Application For Opdivo ,RTTNews,/news/stocks/ema-validates-bristol-myers-type-ii-variation-application-for-opdivo-1006167862,positive,0.4968530833721161
10/31/2017 9:37:06 AM,"AstraZeneca plans new pivotal lung cancer trial with Incyte (AZN, INCY, MRK, BMY)",Reuters,http://www.businessinsider.com/r-astrazeneca-plans-new-pivotal-lung-cancer-trial-with-incyte-2017-10,neutral,0.7332110404968262
10/31/2017 1:32:13 PM,"MSF charity secures generic hepatitis C drugs for $1.40 a day (GILD, BMY)",Reuters,http://www.businessinsider.com/r-msf-charity-secures-generic-hepatitis-c-drugs-for-140-a-day-2017-10,neutral,0.853745698928833
11/6/2017 10:42:03 AM,"Bayer in bid to broaden use of anti-clotting drug Xarelto (BAYN, JNJ, MON, PFE, BMY)",Reuters,http://www.businessinsider.com/r-bayer-in-bid-to-broaden-use-of-anti-clotting-drug-xarelto-2017-11,positive,0.8729289174079895
11/6/2017 1:27:06 PM,BRIEF-Opdivo demonstrates superior 3-yr survival benefit for patients with previously treated advanced RCC (BMY),Reuters,http://www.businessinsider.com/r-brief-opdivo-demonstrates-superior-3-yr-survival-benefit-for-patients-with-previously-treated-advanced-rcc-2017-11,positive,0.9542164206504822
11/6/2017 1:46:26 PM,Bristol-Myers Reports Overall Survival Update From Phase 3 CheckMate -025 Study ,RTTNews,/news/stocks/bristol-myers-reports-overall-survival-update-from-phase-3-checkmate-025-study-1007054167,positive,0.8425881862640381
11/9/2017 2:32:03 PM,BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-five-prime-present-early-stage-data-evaluating-cabiralizumab-with-opdivo-in-patients-with-advanced-solid-tumors-2017-11,positive,0.6875851154327393
11/10/2017 12:45:43 PM,Bristol-Myers Says FDA Expands Approval Of Sprycel ,RTTNews,/news/stocks/bristol-myers-says-fda-expands-approval-of-sprycel-1007544696,positive,0.5972764492034912
11/10/2017 12:52:04 PM,BRIEF-U.S. Food and Drug Administration expands approval of Sprycel (dasatinib) (BMY),Reuters,http://www.businessinsider.com/r-brief-us-food-and-drug-administration-expands-approval-of-sprycel-dasatinib-2017-11,positive,0.6746917366981506
11/10/2017 1:17:03 PM,"BRIEF-Bristol-Myers says encouraging response observed with Opdivo plus BMS-986205, in heavily pre-treated patients with advanced cancers in early-stage study (BMY)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-encouraging-response-observed-with-opdivo-plus-bms-986205-in-heavily-pre-treated-patients-with-advanced-cancers-in-early-stage-study-2017-11,positive,0.9512013792991638
11/10/2017 1:25:51 PM,Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor ,RTTNews,/news/stocks/bistol-myers-encouraging-response-observed-with-opdivo-plus-ido1-inhibitor-1007548045,positive,0.9534375071525574
11/11/2017 11:54:00 PM,"First Data for NKTR-214 in Combination with OPDIVO® (nivolumab) for Patients with Stage IV Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancers, Including Patients with PD-L1 Negative...",PR Newswire,/news/stocks/first-data-for-nktr-214-in-combination-with-opdivo-nivolumab-for-patients-with-stage-iv-melanoma-renal-cell-carcinoma-and-non-small-cell-lung-cancers-including-patients-with-pd-l1-negative-1007713046,neutral,0.5372434854507446
11/13/2017 3:58:00 AM,"FDA Nod For BMY's Sprycel, ARNA To Report Data In Q1, MYL Delists From TASE ",RTTNews,/news/stocks/fda-nod-for-bmy-s-sprycel-arna-to-report-data-in-q1-myl-delists-from-tase-1007827172,negative,0.6471301913261414
11/14/2017 4:17:03 AM,BRIEF-Syngene International ‍expands collaboration with Bristol-Myers Squibb​ (BMY),Reuters,http://www.businessinsider.com/r-brief-syngene-international-expands-collaboration-with-bristol-myers-squibb-2017-11,positive,0.8930423855781555
11/14/2017 3:57:05 PM,BRIEF-Bristol-Myers and Syngene expand ongoing research collaboration (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-and-syngene-expand-ongoing-research-collaboration-2017-11,positive,0.9296472668647766
11/15/2017 3:22:04 PM,"BRIEF-Labcorp announces new expanded use for PD-L1 test with Bristol-Myers Squibb's Opdivo (LH, BMY)",Reuters,http://www.businessinsider.com/r-brief-labcorp-announces-new-expanded-use-for-pd-l1-test-with-bristol-myers-squibbs-opdivo-2017-11,positive,0.8877180218696594
11/20/2017 8:17:03 AM,"UPDATE 1-Roche says Tecentriq combination cuts lung cancer risk (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-says-tecentriq-combination-cuts-lung-cancer-risk-2017-11,positive,0.9479862451553345
11/20/2017 3:22:03 PM,"Roche win boosts case for adding chemo to cancer immunotherapy (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-roche-win-boosts-case-for-adding-chemo-to-cancer-immunotherapy-2017-11,positive,0.8871214389801025
11/20/2017 5:37:03 PM,"US STOCKS-Tech stocks help Wall Street higher (VZ, CSCO, IBM, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-tech-stocks-help-wall-street-higher-2017-11,positive,0.9138022661209106
11/20/2017 7:02:03 PM,"US STOCKS-Industrials, techs lift Wall St, health stocks limit gains (VZ, CAVM, MRVL, MRK, BMY, WMT)",Reuters,http://www.businessinsider.com/r-us-stocks-industrials-techs-lift-wall-st-health-stocks-limit-gains-2017-11,positive,0.8869585394859314
11/20/2017 9:47:03 PM,"US STOCKS-Telecoms rise, buoy Wall St as quiet week kicks off (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-telecoms-rise-buoy-wall-st-as-quiet-week-kicks-off-2017-11,positive,0.9105930328369141
11/20/2017 10:27:09 PM,"US STOCKS-Wall St ticks up, lifted by Verizon, chipmakers (VZ, CAVM, MRVL, TWX, T, MRK, BMY)",Reuters,http://www.businessinsider.com/r-us-stocks-wall-st-ticks-up-lifted-by-verizon-chipmakers-2017-11,positive,0.9360113739967346
11/28/2017 12:53:10 PM,Bristol-Myers: EMA To Review Opdivo Plus Yervoy In Expanded Indications ,RTTNews,/news/stocks/bristol-myers-ema-to-review-opdivo-plus-yervoy-in-expanded-indications-1009779212,neutral,0.8938456177711487
11/28/2017 1:27:04 PM,BRIEF-European Medicines Agency Validates Bristol-Myers's Type II Variation Application For Opdivo (BMY),Reuters,http://www.businessinsider.com/r-brief-european-medicines-agency-validates-bristol-myerss-type-ii-variation-application-for-opdivo-2017-11,neutral,0.5529981255531311
11/28/2017 2:42:04 PM,BRIEF-Cytomx Therapeutics Says FDA Accepts IND For CTLA-4 Probody Therapeutic (BMY),Reuters,http://www.businessinsider.com/r-brief-cytomx-therapeutics-says-fda-accepts-ind-for-ctla-4-probody-therapeutic-2017-11,positive,0.7759436368942261
11/28/2017 3:42:03 PM,"UPDATE 1-Merck KGaA, Pfizer's immunotherapy fails in gastric cancer trial (MRK, PFE, MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-merck-kgaa-pfizers-immunotherapy-fails-in-gastric-cancer-trial-2017-11,negative,0.9397372603416443
12/1/2017 1:47:04 AM,BRIEF-Bristol-Myers says Checkmate -078 trial stopped early for demonstrating superior overall survival (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-says-checkmate--078-trial-stopped-early-for-demonstrating-superior-overall-survival-2017-11,positive,0.5878629088401794
12/6/2017 4:02:03 PM,BRIEF-Ayala Enters Exclusive Worldwide License Agreement With Bristol-Myers Squibb (BMY),Reuters,http://www.businessinsider.com/r-brief-ayala-enters-exclusive-worldwide-license-agreement-with-bristol-myers-squibb-2017-12,positive,0.9280470609664917
12/6/2017 7:37:03 PM,"UPDATE 1-Roche to seize leap-frog opportunity in lung cancer (MRK, AZN, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-to-seize-leap-frog-opportunity-in-lung-cancer-2017-12,positive,0.8292357921600342
12/7/2017 7:02:04 AM,"Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12,neutral,0.7651478052139282
12/7/2017 8:27:03 AM,"UPDATE 1-Roche drug cocktail doubles chance of holding lung cancer at bay (MRK, BMY)",Reuters,http://www.businessinsider.com/r-update-1-roche-drug-cocktail-doubles-chance-of-holding-lung-cancer-at-bay-2017-12,positive,0.8763296604156494
12/7/2017 10:27:08 PM,BRIEF-Bristol-Myers Squibb Announces 2.6 Pct Increase In Quarterly Dividend Beginning Q1 2018 (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-announces-26-pct-increase-in-quarterly-dividend-beginning-q1-2018-2017-12,positive,0.9235844612121582
12/8/2017 4:48:10 AM,New Drugs Approved In November ,RTTNews,/news/stocks/new-drugs-approved-in-november-1010552162,neutral,0.6200432777404785
12/9/2017 12:32:03 AM,"UPDATE 1-Lilly's stomach cancer drug meets main goal, but fails to improve survival rate (LLY, BMY)",Reuters,http://www.businessinsider.com/r-update-1-lillys-stomach-cancer-drug-meets-main-goal-but-fails-to-improve-survival-rate-2017-12,positive,0.835602343082428
12/11/2017 8:02:03 AM,"UPDATE 1-Roche: Tecentriq cocktail slows kidney cancer progression (BMY, MRK)",Reuters,http://www.businessinsider.com/r-update-1-roche-tecentriq-cocktail-slows-kidney-cancer-progression-2017-12,neutral,0.6993885040283203
12/14/2017 12:47:04 AM,"BRIEF-Bristol-Myers Squibb Granted Exclusive License By Ono Pharmaceutical For Multiple Programs Targeting Immuno-Suppressive Factors In The Tumor Microenvironment (BMY, 4528)",Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-granted-exclusive-license-by-ono-pharmaceutical-for-multiple-programs-targeting-immuno-suppressive-factors-in-the-tumor-microenvironment-2017-12,positive,0.8753372430801392
12/14/2017 1:02:03 AM,"Bumper crop of new drugs fails to lift big pharma R&D returns (BION, NOVO , PFE, SAN, GSK, JNJ, AZN, MRK, LLY, BMY, 4502, AMGN, BIIB, CELG, GILD)",Reuters,http://www.businessinsider.com/r-bumper-crop-of-new-drugs-fails-to-lift-big-pharma-rd-returns-2017-12,negative,0.7240304350852966
12/18/2017 1:15:30 PM,Bristol-Myers Gets Positive CHMP Opinion Recommending Approval Of Yervoy ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-yervoy-1011615898,positive,0.9342751502990723
12/18/2017 3:52:03 PM,BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Yervoy (ipilimumab) (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-yervoy-ipilimumab-2017-12,positive,0.9070383310317993
12/20/2017 1:04:37 PM,TARIS And Bristol-Myers Enter Into Clinical Trial Collaboration ,RTTNews,/news/stocks/taris-and-bristol-myers-enter-into-clinical-trial-collaboration-1011680090,positive,0.7305356860160828
12/20/2017 9:42:03 PM,BRIEF-Bristol-Myers Squibb Receives FDA Approval For Opdivo As Treatment For Patients With A Type Of Skin Cancer (BMY),Reuters,http://www.businessinsider.com/r-brief-bristol-myers-squibb-receives-fda-approval-for-opdivo-as-treatment-for-patients-with-a-type-of-skin-cancer-2017-12,positive,0.928911030292511
1/2/2018 7:02:04 PM,"BRIEF-Aceto's Unit Launches Efavirenz Capsules, 50Mg, 200Mg (ACET, BMY)",Reuters,http://www.businessinsider.com/r-brief-acetos-unit-launches-efavirenz-capsules-50mg-200mg-2018-1,neutral,0.8771997094154358
1/16/2018 6:57:37 AM,The Race To Find A Treatment For NASH ,RTTNews,/news/stocks/the-race-to-find-a-treatment-for-nash-1013102677,neutral,0.8310591578483582
1/18/2018 11:50:00 PM,Bear Stearns Commercial Mortgage Securities Trust 2007-PWR15 -- Moody's Affirms Four Classes of BSCMS 2007-PWR15,Moodys,/news/bonds/bear-stearns-commercial-mortgage-securities-trust-2007-pwr15-moody-s-affirms-four-classes-of-bscms-2007-pwr15-1013256086,neutral,0.8800532817840576
2/5/2018 1:02:36 PM,Bristol-Myers Squibb Co. Reveals Increase In Q4 Earnings,RTTNews,/news/stocks/bristol-myers-squibb-co-reveals-increase-in-q4-earnings-1014966487,positive,0.940254271030426
2/5/2018 1:28:23 PM,Bristol-Myers Squibb Phase 3 CheckMate -227 Study Meets Co-primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-checkmate-227-study-meets-co-primary-endpoint-1014966699,positive,0.8010770678520203
2/5/2018 1:53:56 PM,Bristol-Myers Q4 Results Top View; Meets Primary Endpoint In Lung Cancer Trail ,RTTNews,/news/stocks/bristol-myers-q4-results-top-view-meets-primary-endpoint-in-lung-cancer-trail-1014967061,positive,0.49770283699035645
2/7/2018 9:43:00 PM,Bristol-Myers Squibb Company -- Moody's affirms Bristol-Myers at A2; revises outlook to stable,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-affirms-bristol-myers-at-a2-revises-outlook-to-stable-1015068897,positive,0.815741777420044
2/12/2018 4:15:00 PM,"SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Bristol-Myers Squibb Company (BMY) & Lead Plaintiff Deadline: April 10, 2018",PR Newswire,/news/stocks/shareholder-alert-bronstein-gewirtz-grossman-llc-notifies-investors-of-class-action-against-bristol-myers-squibb-company-bmy-lead-plaintiff-deadline-april-10-2018-1015522327,neutral,0.7539764046669006
2/12/2018 10:20:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bristol-Myers Squibb Company - BMY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-bristol-myers-squibb-company-bmy-1015552149,neutral,0.788838803768158
2/15/2018 7:17:49 AM,"AMAG Gets FDA Nod, ABMD Hits All-time High, GLMD's NAFLD Trial Flops, NKTR Abuzz ",RTTNews,/news/stocks/amag-gets-fda-nod-abmd-hits-all-time-high-glmd-s-nafld-trial-flops-nktr-abuzz-1015856809,positive,0.5203742384910583
2/27/2018 8:41:40 AM,Biotech Stocks Facing FDA Decision In March ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-1017268709,neutral,0.7348413467407227
3/4/2018 3:19:34 AM,An Ear To The Pharma: 7 Stocks To Watch This Week ,RTTNews,/news/stocks/an-ear-to-the-pharma-7-stocks-to-watch-this-week-1017867022,neutral,0.9022789001464844
3/6/2018 1:33:36 PM,Bristol-Myers: Opdivo The Only FDA-approved PD-1 Inhibitor With 4-week Dosing ,RTTNews,/news/stocks/bristol-myers-opdivo-the-only-fda-approved-pd-1-inhibitor-with-4-week-dosing-1018125373,neutral,0.7753928899765015
3/11/2018 1:00:00 PM,SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Bristol-Myers Squibb Company of Class Action Lawsuit and Upcoming Deadline - BMY,PR Newswire,/news/stocks/shareholder-alert-pomerantz-law-firm-reminds-shareholders-with-losses-on-their-investment-in-bristol-myers-squibb-company-of-class-action-lawsuit-and-upcoming-deadline-bmy-1018613044,negative,0.9413332939147949
3/12/2018 8:00:00 AM,Biohaven Restructures License Agreement With Bristol-Myers Squibb To Reduce Royalties Payable On Its Migraine Product Candidates; Transaction Financed Through Private Placement With Leading...,PR Newswire,/news/stocks/biohaven-restructures-license-agreement-with-bristol-myers-squibb-to-reduce-royalties-payable-on-its-migraine-product-candidates-transaction-financed-through-private-placement-with-leading-1018615221,positive,0.8548581004142761
3/13/2018 12:12:00 PM,GRYT Health and Bristol-Myers Squibb Announce New Digital Pilot to Advance Cancer Care through Patient-Driven Insights,PR Newswire,/news/stocks/gryt-health-and-bristol-myers-squibb-announce-new-digital-pilot-to-advance-cancer-care-through-patient-driven-insights-1018643977,neutral,0.5220540761947632
3/13/2018 6:00:00 PM,"Lifshitz & Miller LLP Announces Investigation of Bristol-Myers Squibb Company, Freshpet, Inc., Geothermal, Inc., Henry Schein, Inc., Ply Gem Holdings, Inc., United American Bank and Xunlei Limited",PR Newswire,/news/stocks/lifshitz-miller-llp-announces-investigation-of-bristol-myers-squibb-company-freshpet-inc-geothermal-inc-henry-schein-inc-ply-gem-holdings-inc-united-american-bank-and-xunlei-limited-1018654893,neutral,0.7869312167167664
3/26/2018 1:05:42 PM,BRIEF-Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval Of Opdivo Four-Week Dosing Schedule For Advanced Melanoma And Previously Treated Renal Cell Carcinoma,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/hqgNgqyCAgI/brief-bristol-myers-squibb-receives-positive-chmp-opinion-recommending-approval-of-opdivo-four-week-dosing-schedule-for-advanced-melanoma-and-previously-treated-renal-cell-carcinoma-idUSFWN1R80DM,positive,0.92626953125
3/26/2018 1:06:52 PM,Bristol-Myers Reports Positive CHMP Opinion For Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-reports-positive-chmp-opinion-for-opdivo-quick-facts-1019446515,positive,0.9430184960365295
3/27/2018 1:23:51 PM,Bristol-Myers: FDA To Review SBLA For Opdivo Plus Yervoy - Quick Facts ,RTTNews,/news/stocks/bristol-myers-fda-to-review-sbla-for-opdivo-plus-yervoy-quick-facts-1019568215,neutral,0.5858560800552368
3/28/2018 1:58:32 PM,Biotech Stocks Facing FDA Decision In April ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-1019706162,neutral,0.7716752290725708
3/29/2018 8:42:00 PM,"Bristol-Myers Squibb Stock Shareholder Alert - Kehoe Law Firm, P.C. Investigating",PR Newswire,/news/stocks/bristol-myers-squibb-stock-shareholder-alert-kehoe-law-firm-p-c-investigating-1019877873,neutral,0.943115234375
4/8/2018 5:02:20 AM,"An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) ",RTTNews,/news/stocks/an-ear-to-the-pharma-9-stocks-to-watch-this-week-selb-agle-bpmc-mnov-1020830236,neutral,0.9255437254905701
4/12/2018 1:39:48 PM,BRIEF-Bristol Myers Squibb And Harvard Announce New Fibrosis Research Collaboration,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/Gs4YVlJ4GGo/brief-bristol-myers-squibb-and-harvard-announce-new-fibrosis-research-collaboration-idUSFWN1RP0MH,neutral,0.882992684841156
4/13/2018 10:28:52 PM,BRIEF-Bristol-Myers Squibb And Illumina Announce Collaboration To Develop Companion Diagnostics For Bristol-Myers Squibb's Oncology Immunotherapies,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/kBeU8w8WqNg/brief-bristol-myers-squibb-and-illumina-announce-collaboration-to-develop-companion-diagnostics-for-bristol-myers-squibbs-oncology-immunotherapies-idUSFWN1RQ0M2,positive,0.8063010573387146
4/16/2018 3:23:52 PM,Bristol-Myers Reports Initial Results From Phase 3 Study With Opdivo ,RTTNews,/news/stocks/bristol-myers-reports-initial-results-from-phase-3-study-with-opdivo-1021399095,neutral,0.7426309585571289
4/16/2018 3:33:04 PM,BRIEF-Bristol-Myers Squibb Says Cancer Drug Combo Reduces Death Risk By 42 Pct,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/R6LSVq0tHJk/brief-bristol-myers-squibb-says-cancer-drug-combo-reduces-death-risk-by-42-pct-idUSFWN1RT0N8,positive,0.9048545360565186
4/16/2018 3:33:04 PM,"'We are going to have lung cancer patients living longer and better': A new kind of cancer treatment is about to change how we treat the disease (MRK, BMY)",Business Insider,http://www.businessinsider.com/merck-bms-roche-lung-cancer-immunotherapy-data-2018-4,neutral,0.7182745337486267
4/16/2018 4:27:33 PM,"2 cancer drugmakers just presented key data about how new treatments work in lung cancer — and the markets picked a winner (MRK, BMY)",Business Insider,http://markets.businessinsider.com/news/stocks/merck-bristol-myers-squibb-stock-price-lung-cancer-data-at-aacr-2018-4-1021400484,positive,0.6845757961273193
4/16/2018 11:08:23 PM,BRIEF-Janssen Collaborates With Bristol-Myers Squibb To Develop & Commercialize Factor XIa Inhibitors,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/-c4kHdp1h1Y/brief-janssen-collaborates-with-bristol-myers-squibb-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1RF003,positive,0.61365807056427
4/16/2018 11:10:55 PM,BRIEF-Bristol-Myers Squibb Collaborates With Janssen To Develop & Commercialize Factor XIa Inhibitors,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/BdzHVnX1-zc/brief-bristol-myers-squibb-collaborates-with-janssen-to-develop-commercialize-factor-xia-inhibitors-idUSB8N1KT00R,positive,0.7392256259918213
4/17/2018 8:40:29 AM,"ALKS Pulls Off Sweet Surprise, APRI Thrashed, BMY Gets FDA Nod ",RTTNews,/news/stocks/alks-pulls-off-sweet-surprise-apri-thrashed-bmy-gets-fda-nod-1021423487,positive,0.5449021458625793
4/19/2018 7:57:13 AM,"ANIP, CMD Get FDA Nod, BMY Seeks New Use For Opdivo, Eloxx On Watch ",RTTNews,/news/stocks/anip-cmd-get-fda-nod-bmy-seeks-new-use-for-opdivo-eloxx-on-watch-1021553499,neutral,0.7228530049324036
4/26/2018 1:10:21 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1022391368,positive,0.8698457479476929
4/26/2018 1:36:31 PM,Bristol-Myers Squibb Boosts 2018 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-2018-adj-eps-outlook-quick-facts-1022394341,positive,0.9273940324783325
4/27/2018 1:23:54 PM,Advantagene Enters Clinical Trial Collaboration With Bristol-Myers Squibb ,RTTNews,/news/stocks/advantagene-enters-clinical-trial-collaboration-with-bristol-myers-squibb-1022535590,positive,0.5136268734931946
5/2/2018 2:33:05 PM,BRIEF-Bristol-Myers Squibb And Flatiron Health Expand Collaboration With A Three-Year Agreement,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dspEXo_hJwk/brief-bristol-myers-squibb-and-flatiron-health-expand-collaboration-with-a-three-year-agreement-idUSFWN1S9105,positive,0.9317721724510193
5/3/2018 2:53:45 PM,EMA Validates BMY's Type II Application For Opdivo Plus Yervoy Combination ,RTTNews,/news/stocks/ema-validates-bmy-s-type-ii-application-for-opdivo-plus-yervoy-combination-1023264394,neutral,0.7877100110054016
5/4/2018 2:27:09 PM,"Inside New York City's struggle to become a biotech hub (PFE, BMY)",Business Insider,http://www.businessinsider.com/new-york-city-biotech-hub-ambitions-2018-5,neutral,0.8222765326499939
6/1/2018 1:09:34 PM,Bristol-Myers: CheckMate Trial Shows Benefits Of Opdivo Plus Low-dose Yervoy ,RTTNews,/news/stocks/bristol-myers-checkmate-trial-shows-benefits-of-opdivo-plus-low-dose-yervoy-1026104351,positive,0.8982698321342468
6/2/2018 9:00:11 AM,Bristol-Myers Squibb: FDA Action Removes Partial Hold On CheckMate -602 ,RTTNews,/news/stocks/bristol-myers-squibb-fda-action-removes-partial-hold-on-checkmate-602-1026211397,negative,0.8030303716659546
6/3/2018 12:10:00 AM,"Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018",PR Newswire,/news/stocks/preliminary-data-for-nktr-214-in-combination-with-opdivo-nivolumab-for-patients-with-stage-iv-metastatic-melanoma-renal-cell-carcinoma-and-urothelial-cancers-presented-at-asco-2018-1026280697,neutral,0.7127289772033691
6/4/2018 1:20:52 PM,Bristol-Myers: Opdivo Plus Chemotherapy Shows Improved PFS In CheckMate Study ,RTTNews,/news/stocks/bristol-myers-opdivo-plus-chemotherapy-shows-improved-pfs-in-checkmate-study-1026435628,positive,0.9569115042686462
6/4/2018 8:45:03 PM,"We just got a lot of updates on the state of cancer treatments — here are the winners and losers (BLUE, NKTR, LOXO, MRK, BMY)",Business Insider,http://www.businessinsider.com/asco-updates-on-the-state-of-cancer-treatments-2018-6,neutral,0.9364539980888367
6/17/2018 12:43:57 PM,Bristol-Myers Squibb Announces ELOQUENT-3 Trial Result ,RTTNews,/news/stocks/bristol-myers-squibb-announces-eloquent-3-trial-result-1027158926,neutral,0.849536657333374
6/29/2018 2:03:45 PM,Bristol-Myers Gets Positive CHMP Opinion Recommending Approval Of Opdivo ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-recommending-approval-of-opdivo-1027330690,positive,0.9075096249580383
7/5/2018 1:10:35 PM,Bristol-Myers: European Commission Approves Expanded Indication For Sprycel ,RTTNews,/news/stocks/bristol-myers-european-commission-approves-expanded-indication-for-sprycel-1027343804,positive,0.6096590161323547
7/7/2018 5:03:29 PM,Week Ahead In Pharmaceuticals - Stocks To Watch ,RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-stocks-to-watch-1027348479,neutral,0.8907672166824341
7/11/2018 1:16:33 PM,Bristol-Myers: Opdivo + Low-Dose Yervoy Approved For MSI-H/dMMR MCRC Patients ,RTTNews,/news/stocks/bristol-myers-opdivo-low-dose-yervoy-approved-for-msi-h-dmmr-mcrc-patients-1027358042,positive,0.511167585849762
7/12/2018 8:32:29 AM,"AKCA Gets EC Nod, FDA Panel To Review Malaria Drug Today, OVID Awaits Data In Q3 ",RTTNews,/news/stocks/akca-gets-ec-nod-fda-panel-to-review-malaria-drug-today-ovid-awaits-data-in-q3-1027360877,neutral,0.8872421979904175
7/14/2018 1:56:09 AM,Week Ahead In Pharmaceuticals - 7 Stocks To Watch ,RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-7-stocks-to-watch-1027367265,neutral,0.8682355284690857
7/19/2018 1:17:57 PM,"Bristol-Myers, Gritstone Oncology Collaborate To Evaluate GRANITE-001 ",RTTNews,/news/stocks/bristol-myers-gritstone-oncology-collaborate-to-evaluate-granite-001-1027381818,neutral,0.7077548503875732
7/24/2018 3:02:12 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q2-1027394080,neutral,0.9331842660903931
7/26/2018 9:39:05 AM,Biotech Stocks Facing FDA Decision In August ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-august-1027401882,neutral,0.6419673562049866
7/26/2018 1:09:14 PM,Bristol-Myers Squibb Updates 2018 EPS Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-updates-2018-eps-guidance-quick-facts-1027402788,neutral,0.9288075566291809
7/26/2018 2:11:24 PM,Bristol-Myers Squibb Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q2-adjusted-earnings-beat-estimates-1027403210,positive,0.8615039587020874
7/31/2018 2:06:19 PM,Bristol-Myers Squibb: EC Approves Opdivo For Adjuvant Treatment Of Melanoma ,RTTNews,/news/stocks/bristol-myers-squibb-ec-approves-opdivo-for-adjuvant-treatment-of-melanoma-1027416139,positive,0.9272105097770691
8/2/2018 8:09:00 PM,Moody's: US drug makers face heightened pricing pressure as regulatory risks pick up steam,Moodys,/news/bonds/moody-s-us-drug-makers-face-heightened-pricing-pressure-as-regulatory-risks-pick-up-steam-1027427408,negative,0.825398862361908
8/11/2018 5:17:06 AM,"Week Ahead In Pharmaceuticals: 5 Stocks To Watch (REGN, PFE, ALT...) ",RTTNews,/news/stocks/week-ahead-in-pharmaceuticals-5-stocks-to-watch-regn-pfe-alt-1027451315,neutral,0.8848251700401306
8/17/2018 1:05:36 PM,Bristol-Myers Squibb Says FDA Approves Opdivo ,RTTNews,/news/stocks/bristol-myers-squibb-says-fda-approves-opdivo-1027466998,neutral,0.8129111528396606
8/23/2018 1:17:14 PM,"Bristol-Myers: FDA To Review SBLA For Empliciti With Pomalidomide, Dexamethasone ",RTTNews,/news/stocks/bristol-myers-fda-to-review-sbla-for-empliciti-with-pomalidomide-dexamethasone-1027480033,neutral,0.6671406626701355
8/30/2018 2:09:02 PM,FDA Accepts Bristol-Myers' SBLA For Sprycel ,RTTNews,/news/stocks/fda-accepts-bristol-myers-sbla-for-sprycel-1027497049,neutral,0.6241676211357117
9/12/2018 8:16:54 AM,Bristol-Myers Reports Positive Results From Phase 2 Study Of BMS-986165 ,RTTNews,/news/stocks/bristol-myers-reports-positive-results-from-phase-2-study-of-bms-986165-1027526577,positive,0.9423155784606934
9/18/2018 2:15:44 PM,EMA Validates Bristol Myers' Application For New Empliciti-based Combination ,RTTNews,/news/stocks/ema-validates-bristol-myers-application-for-new-empliciti-based-combination-1027543441,neutral,0.7858721017837524
10/11/2018 1:36:23 PM,"Bristol-Myers, Compugen To Jointly Evaluate Combination Of COM701 With Opdivo ",RTTNews,/news/stocks/bristol-myers-compugen-to-jointly-evaluate-combination-of-com701-with-opdivo-1027608539,positive,0.5358821749687195
10/12/2018 1:16:29 PM,Bristol-Myers Says Phase 3 CheckMate -331 Study Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-says-phase-3-checkmate-331-study-fails-to-meet-primary-endpoint-1027612295,negative,0.9590116143226624
10/20/2018 10:51:57 AM,Bristol-Myers Says Follow-up Data Of Opdivo With Yervoy Shows Promising Results ,RTTNews,/news/stocks/bristol-myers-says-follow-up-data-of-opdivo-with-yervoy-shows-promising-results-1027635443,positive,0.949267566204071
10/22/2018 5:43:33 AM,"FDA Extends Date On BMY's SBLA, Genmab Meets Phase 3 Goals, NCNA, LPTX On Watch ",RTTNews,/news/stocks/fda-extends-date-on-bmy-s-sbla-genmab-meets-phase-3-goals-ncna-lptx-on-watch-1027636442,neutral,0.8459468483924866
10/22/2018 9:59:55 AM,Bristol-Myers Announces Data From Two CheckMate Studies Of Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-announces-data-from-two-checkmate-studies-of-opdivo-quick-facts-1027637567,neutral,0.7491652369499207
10/23/2018 3:02:10 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q3-earnings-preview-1027644299,neutral,0.9266072511672974
10/25/2018 1:12:09 PM,Bristol-Myers Squibb Raises FY18 Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-fy18-outlook-quick-facts-1027654142,neutral,0.536719799041748
11/5/2018 1:18:55 PM,"Bristol-Myers, Infinity Pharma To Evaluate Opdivo In Combination With IPI-549 ",RTTNews,/news/stocks/bristol-myers-infinity-pharma-to-evaluate-opdivo-in-combination-with-ipi-549-1027690497,neutral,0.6268852949142456
11/26/2018 6:56:25 AM,Biotech Stocks Facing FDA Decision In December ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-1027753358,neutral,0.5557608604431152
11/26/2018 10:46:24 PM,Bristol-Myers Squibb says cancer drug combination fails maintenance trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/p_2HK_rNAXY/bristol-myers-squibb-says-cancer-drug-combination-fails-maintenance-trial-idUSL4N1Y1597,negative,0.9146149754524231
11/26/2018 11:04:26 PM,UPDATE 1-Bristol-Myers Squibb says cancer drug combination fails late-stage trial,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/wrWlpe96z2o/update-1-bristol-myers-squibb-says-cancer-drug-combination-fails-late-stage-trial-idUSL4N1Y15CE,negative,0.9323534965515137
12/10/2018 8:22:58 AM,"Bristol-Myers Squibb, Vedanta Biosciences In Clinical Collaboration ",RTTNews,/news/stocks/bristol-myers-squibb-vedanta-biosciences-in-clinical-collaboration-1027793190,neutral,0.890906572341919
12/19/2018 10:00:10 AM,Taisho Offers To Purchase Bristol-Myers Squibb's UPSA Consumer Health Unit ,RTTNews,/news/stocks/taisho-offers-to-purchase-bristol-myers-squibb-s-upsa-consumer-health-unit-1027820345,neutral,0.8645826578140259
1/3/2019 8:04:06 AM,"GNMX Plunges On ASCEND Data, FLZN On Track, ALNA To Report Phase 3 Data In 2H ",RTTNews,/news/stocks/gnmx-plunges-on-ascend-data-flzn-on-track-alna-to-report-phase-3-data-in-2h-1027840697,negative,0.598057746887207
1/3/2019 1:17:53 PM,Bristol-Myers To Acquire Celgene; To Be Above 40% EPS Accretive In First Year ,RTTNews,/news/stocks/bristol-myers-to-acquire-celgene-to-be-above-40-eps-accretive-in-first-year-1027841399,positive,0.8787611126899719
1/3/2019 1:36:04 PM,"Bristol-Myers Squibb is buying Celgene in a $74 billion deal (BMY, CELG)",Business Insider,https://www.businessinsider.com/bristol-myers-squibb-buys-celgene-in-74-billion-deal-2019-1,neutral,0.9103530049324036
1/3/2019 9:16:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842816,negative,0.7847279906272888
1/3/2019 9:26:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's reviews Bristol-Myers Squibb for downgrade,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-reviews-bristol-myers-squibb-for-downgrade-1027842828,negative,0.7847279906272888
1/3/2019 11:45:00 PM,Celgene Corporation -- Moody's reviews Celgene's Baa2 rating for upgrade,Moodys,/news/bonds/celgene-corporation-moody-s-reviews-celgene-s-baa2-rating-for-upgrade-1027843083,neutral,0.8928815722465515
1/4/2019 7:47:18 AM,"BTAI Up 105% In 5 Days, NVAX Gets A Shot In The Arm, BMY Snaps Up CELG ",RTTNews,/news/stocks/btai-up-105-in-5-days-nvax-gets-a-shot-in-the-arm-bmy-snaps-up-celg-1027843507,positive,0.9363765716552734
1/23/2019 3:01:34 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q4-earnings-preview-1027889665,neutral,0.9331842660903931
1/24/2019 1:10:52 PM,Bristol-Myers Squibb Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-adjusted-earnings-beat-estimates-1027892744,positive,0.882439911365509
1/24/2019 1:44:15 PM,Bristol-Myers Q4 Adj. Profit Beats View; Withdraws SBLA For Opdivo Plus Yervoy ,RTTNews,/news/stocks/bristol-myers-q4-adj-profit-beats-view-withdraws-sbla-for-opdivo-plus-yervoy-1027892882,negative,0.49823564291000366
2/7/2019 3:36:00 PM,Moody's -  Accelerating efforts to lower drug prices raise financial risk for drug companies,Moodys,/news/bonds/moody-s-accelerating-efforts-to-lower-drug-prices-raise-financial-risk-for-drug-companies-1027934159,positive,0.9009014964103699
2/11/2019 1:15:10 PM,Bristol-Myers: European Commission Approves Sprycel Plus Chemotherapy ,RTTNews,/news/stocks/bristol-myers-european-commission-approves-sprycel-plus-chemotherapy-1027940623,positive,0.6745027899742126
2/15/2019 10:11:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1027957877,neutral,0.876595675945282
2/28/2019 2:53:11 AM,Wellington Management Opposes Bristol-Myers Squibb's Acquisition Of Celgene ,RTTNews,/news/stocks/wellington-management-opposes-bristol-myers-squibb-s-acquisition-of-celgene-1027991293,negative,0.7952787280082703
2/28/2019 2:12:06 PM,"Bristol-Myers' record-breaking $74 billion biotech deal is in jeopardy (BMY, CELG)",Business Insider,https://www.businessinsider.com/bristol-myers-squibb-celgene-deal-in-jeopardy-investor-concerns-2019-2,neutral,0.5912822484970093
2/28/2019 3:54:11 PM,Starboard Value Opposes Bristol-Myers Squibb's Acquisition Of Celgene ,RTTNews,/news/stocks/starboard-value-opposes-bristol-myers-squibb-s-acquisition-of-celgene-1027993990,negative,0.6177608370780945
3/6/2019 1:26:55 PM,Bristol-Myers Says 'acquiring Celgene Is Best Path Forward' For Its Shareholders ,RTTNews,/news/stocks/bristol-myers-says-acquiring-celgene-is-best-path-forward-for-its-shareholders-1028008407,positive,0.7361471056938171
3/6/2019 1:50:17 PM,Starboard Urges All Holders To Vote Against Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/starboard-urges-all-holders-to-vote-against-bristol-myers-celgene-merger-1028008482,neutral,0.8726721405982971
3/19/2019 12:18:05 PM,Starboard Value Urges All Shareholders To Reject Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/starboard-value-urges-all-shareholders-to-reject-bristol-myers-celgene-merger-1028040959,neutral,0.8981608152389526
3/25/2019 12:36:15 PM,Bristol-Myers Urges Shareholders To Vote For Merger Deal With Celgene ,RTTNews,/news/stocks/bristol-myers-urges-shareholders-to-vote-for-merger-deal-with-celgene-1028055275,positive,0.7447274923324585
3/26/2019 3:09:43 PM,FTC Seeks Additional Information On Bristol-Myers - Celgene Merger ,RTTNews,/news/stocks/ftc-seeks-additional-information-on-bristol-myers-celgene-merger-1028059724,neutral,0.9488140344619751
3/28/2019 3:29:35 PM,Starboard Urges Shareholders To Vote Against Bristol-Myers - Celgene Deal ,RTTNews,/news/stocks/starboard-urges-shareholders-to-vote-against-bristol-myers-celgene-deal-1028067305,neutral,0.8360459804534912
4/12/2019 5:40:39 PM,Bristol-Myers Shareholders Approve Celgene Deal ,RTTNews,/news/stocks/bristol-myers-shareholders-approve-celgene-deal-1028107799,neutral,0.8197621703147888
4/17/2019 6:10:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's exchange notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-exchange-notes-under-review-for-downgrade-1028119344,neutral,0.6404576897621155
4/23/2019 3:02:22 PM,Bristol-Myers Squibb earnings preview: what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-earnings-preview-1028129924,neutral,0.9071003198623657
4/25/2019 1:39:42 PM,Bristol-Myers Q1 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-q1-results-top-estimates-1028138610,neutral,0.825646162033081
4/25/2019 11:11:57 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1028141003,positive,0.8698457479476929
5/2/2019 6:07:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers's sr. notes; under review for downgrade,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-s-sr-notes-under-review-for-downgrade-1028163037,neutral,0.6136666536331177
5/8/2019 1:16:24 PM,Bristol-Myers Prices $19 Bln Of Senior Unsecured Notes ,RTTNews,/news/stocks/bristol-myers-prices-19-bln-of-senior-unsecured-notes-1028181292,neutral,0.9324747323989868
6/5/2019 1:23:23 PM,Bristol-Myers To Appoint David Elkins As EVP And CFO ,RTTNews,/news/stocks/bristol-myers-to-appoint-david-elkins-as-evp-and-cfo-1028255928,neutral,0.9418658018112183
6/6/2019 7:13:05 PM,5 Healthcare Stocks to Pick Up From the Wreckage,InvestorPlace,/news/stocks/5-healthcare-stocks-to-pick-up-from-the-wreckage-1028262327,positive,0.9321157932281494
6/7/2019 5:06:26 PM,2 Dividend Stocks to Buy That Are Better Than 3M Stock,InvestorPlace,/news/stocks/2-dividend-stocks-to-buy-that-are-better-than-3m-stock-1028264953,neutral,0.8340665698051453
6/14/2019 6:59:58 PM,7 Top-Rated Biotech Stocks to Invest In Today,InvestorPlace,/news/stocks/7-healthy-biotech-stocks-to-invest-in-1028281710,neutral,0.7840096950531006
6/19/2019 1:17:07 PM,Catalent To Buy Bristol-Myers Squibb's Manufacturing Facility In Italy ,RTTNews,/news/stocks/catalent-to-buy-bristol-myers-squibb-s-manufacturing-facility-in-italy-1028290995,neutral,0.848466694355011
6/24/2019 1:12:40 PM,Bristol-Myers Squibb: Phase 3 Study With Opdivo Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-study-with-opdivo-fails-to-meet-primary-endpoint-1028301437,negative,0.9538488984107971
6/24/2019 1:23:42 PM,Bristol-Myers Squibb Plans To Divest OTEZLA - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-plans-to-divest-otezla-quick-facts-1028301457,neutral,0.9520811438560486
6/24/2019 4:51:13 PM,Bristol-Meyers Squibb News: Why BMY Stock Is Falling Today,InvestorPlace,/news/stocks/bristol-meyers-squibb-news-why-bmy-stock-is-falling-today-1028303872,negative,0.961125373840332
6/24/2019 7:33:11 PM,The 7 Best Acquisitions of 2019,InvestorPlace,/news/stocks/the-7-best-acquisitions-of-2019-1028303860,neutral,0.8142319917678833
6/24/2019 7:47:34 PM,"5 Top Stock Trades for Tuesday: CELG, BMY, CZR",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-bmy-celg-czr-newr-mtch-1028303858,neutral,0.9262828230857849
6/24/2019 8:27:04 PM,"Bristol-Myers Squibb is selling off a blockbuster drug to help its $74 billion merger with Celgene get approved — and now both stocks are tumbling (BMY, CELG)",Business Insider,https://markets.businessinsider.com/news/stocks/bristol-myers-squibb-celgene-stock-price-reaction-to-otezla-divestiture-2019-6-1028303108,negative,0.603106677532196
6/24/2019 8:42:02 PM,"Nasdaq Today: Celgene, Ulta, Caesars’ Buyout",InvestorPlace,/news/stocks/nasdaq-today-celgene-ulta-caesars-buyout-1028303856,neutral,0.9417217969894409
6/24/2019 9:50:00 PM,Bristol-Myers Squibb Company -- Moody's: Bristol's Otezla divestiture credit negative,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-bristol-s-otezla-divestiture-credit-negative-1028303268,neutral,0.8036524653434753
6/25/2019 12:05:35 PM,"3 Big Stock Charts for Tuesday: MGM Resorts, Electronic Arts and Advance Auto Parts",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-mgm-aap-ea-1028307959,neutral,0.9177204966545105
6/25/2019 8:11:08 PM,"5 Top Stock Trades for Wednesday — AGN, ABBV, FDX, MSFT, BB",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-agn-abbv-fdx-msft-bb-1028307924,neutral,0.936821699142456
6/26/2019 4:10:10 PM,The Top 8 Tech Stocks of 2019 (So Far),InvestorPlace,/news/stocks/the-top-8-tech-stocks-of-2019-so-far-1028312008,neutral,0.9203214645385742
6/26/2019 8:46:45 PM,"Nasdaq Today: Semis Rally, Micron Earnings, Suing FB and GOOGL?",InvestorPlace,/news/stocks/nasdaq-today-semis-rally-micron-earnings-suing-fb-and-googl-1028311984,negative,0.8470378518104553
6/27/2019 12:10:29 PM,Remember Your History When It Comes to United Technologies Stock,InvestorPlace,/news/stocks/remember-history-united-technologies-stock-1028315919,neutral,0.9226874113082886
7/2/2019 7:38:28 PM,3 Dow Jones Stocks to Buy for the Second Half,InvestorPlace,/news/stocks/3-dow-jones-stocks-to-buy-for-the-second-half-1028326563,neutral,0.9078968167304993
7/11/2019 7:00:51 PM,4 Drug Stocks Getting Smashed,InvestorPlace,/news/stocks/4-drug-stocks-getting-smashed-1028347976,positive,0.3786196708679199
7/11/2019 8:54:32 PM,Nasdaq Today: Biotech Wrecked; Buy Microsoft? ,InvestorPlace,/news/stocks/nasdaq-today-biotech-wrecked-buy-microsoft-1028347970,neutral,0.9275438189506531
7/18/2019 1:08:54 PM,"Bayer, Bristol-Myers Squibb, Ono Pharma Enter Into Clinical Collaboration ",RTTNews,/news/stocks/bayer-bristol-myers-squibb-ono-pharma-enter-into-clinical-collaboration-1028364102,neutral,0.8712591528892517
7/19/2019 9:49:41 AM,"BMY To Explore Stivarga/Opdivo Combo, MYOK Ahead Of Timeline, UNH On Watch ",RTTNews,/news/stocks/bmy-to-explore-stivarga-opdivo-combo-myok-ahead-of-timeline-unh-on-watch-1028367064,neutral,0.5123056173324585
7/23/2019 6:03:36 PM,Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings,InvestorPlace,/news/stocks/why-bristol-myers-is-down-ahead-of-its-earnings-report-1028378737,negative,0.5643514394760132
7/24/2019 3:02:07 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1028380528,neutral,0.9331842660903931
7/24/2019 3:51:40 PM,"Notable Earnings To Watch On July 25 - MMM, AMZN, GOOGL, LH, AAL, LUV, BMY, HSY ",RTTNews,/news/stocks/notable-earnings-to-watch-on-july-25-mmm-amzn-googl-lh-aal-luv-bmy-hsy-1028381012,neutral,0.8716892004013062
7/24/2019 3:56:48 PM,3 Ways to Play the Historic Bargain In Chinese Stocks,InvestorPlace,/news/stocks/3-ways-to-play-the-historic-bargain-in-chinese-stocks-1028383015,neutral,0.9093244671821594
7/24/2019 11:43:04 PM,Bristol-Myers Squibb Reports Phase 3 CheckMate -227 Trial Results - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-phase-3-checkmate-227-trial-results-quick-facts-1028382526,neutral,0.9310892820358276
7/25/2019 12:10:53 PM,"GEMP Gets Facelift, Castle Bio To Debut Today, What's The Buzz About Baqsimi? ",RTTNews,/news/stocks/gemp-gets-facelift-castle-bio-to-debut-today-what-s-the-buzz-about-baqsimi-1028384130,neutral,0.9065386056900024
7/25/2019 1:16:13 PM,Bristol-Myers Squibb Raises Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-earnings-guidance-quick-facts-1028384454,neutral,0.8285165429115295
7/25/2019 5:59:38 PM,"Bristol-Myers Squibb Earnings: BMY Stock Bounces on Strong Q2, Guidance",InvestorPlace,/news/stocks/bristol-myers-squibb-earnings-boosts-bmy-stock-1028387217,positive,0.9293630123138428
7/25/2019 8:50:54 PM,"Stock Market Today: Boeing, Tesla Tumble on More Worries",InvestorPlace,/news/stocks/stock-market-today-boeing-tesla-tumble-on-more-worries-1028387202,negative,0.9381041526794434
7/26/2019 1:29:36 PM,Bristol-Myers Gets Positive CHMP Opinion For Empliciti ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-empliciti-1028388214,positive,0.9433078169822693
8/1/2019 8:37:20 PM,Stock Market Today: The Tariff Man Is Back,InvestorPlace,/news/stocks/stock-market-today-the-tariff-man-is-back-1028410613,neutral,0.7131724953651428
8/6/2019 6:29:21 AM,Fear Around Bristol-Myers Squibb Stock is Starting to Fade,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-opdivo-otezla-1028422590,negative,0.7555704712867737
8/9/2019 2:04:08 PM,Risk-Takers Have a Reasonable Shot with BMY Stock,InvestorPlace,/news/stocks/risk-takers-have-a-reasonable-shot-with-bmy-stock-1028435580,neutral,0.6980427503585815
8/12/2019 4:10:53 PM,Bristol-Myers Squibb Stock Has Upside — But Mind the Risks,InvestorPlace,/news/stocks/bristol-myers-squibb-stock-upside-mind-risks-1028440085,neutral,0.8782020807266235
8/23/2019 6:00:29 PM,5 Healthcare Stocks to Buy for Healthy Dividends,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-healthy-dividends-1028470706,neutral,0.5437018275260925
8/23/2019 6:37:40 PM,Will Lawsuits Sink Johnson & Johnson Stock?,InvestorPlace,/news/stocks/lawsuits-jnj-stock-probably-not-1028470702,negative,0.6193097829818726
8/26/2019 1:04:31 PM,Amgen To Acquire Otezla For $13.4 Billion In Cash - Quick Facts ,RTTNews,/news/stocks/amgen-to-acquire-otezla-for-13-4-billion-in-cash-quick-facts-1028472744,neutral,0.911559522151947
8/26/2019 3:51:06 PM,"Amgen will buy a blockbuster psoriasis drug for $13.4 billion — and it's part of a plan to get Celgene's mega-merger with Bristol-Myers Squibb approved (AMGN, CELG, BMY)",Business Insider,https://www.businessinsider.com/amgen-buys-celgene-psoriasis-drug-for-13-billion-antitrust-implications-2019-8,positive,0.592563807964325
8/26/2019 5:53:32 PM,Celgene News: CELG Stock Jumps on Sale of Otezla to Amgen,InvestorPlace,/news/stocks/celgene-news-has-celg-stock-up-1028475034,negative,0.7425987124443054
8/26/2019 7:32:00 PM,"5 Top Stock Trades for Tuesday: NFLX, AMGN, ACB, BMY",InvestorPlace,/news/stocks/top-stock-trades-bmy-amgn-nflx-acb-fl-1028475024,neutral,0.9365085959434509
8/26/2019 8:34:50 PM,"Stock Market Today: Biotech in Focus, Trade Talks Steady Stocks",InvestorPlace,/news/stocks/stock-market-today-biotech-in-focus-trade-talks-steady-stocks-1028475022,positive,0.5053696632385254
8/27/2019 3:01:27 PM,4 Biotech Stocks to Buy That Are on the Move,InvestorPlace,/news/stocks/4-biotech-stocks-to-buy-that-are-on-the-move-1028478921,neutral,0.8555207252502441
8/28/2019 2:00:36 PM,10 Best Dividend Stocks to Buy for the Rest of 2019 and Beyond,InvestorPlace,/news/stocks/10-best-dividend-stocks-to-buy-2019-beyond-1028347974,neutral,0.8451084494590759
9/4/2019 1:14:03 PM,Bristol-Myers Squibb To Become Limited Partner Of BioMotiv - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-become-limited-partner-of-biomotiv-quick-facts-1028497144,neutral,0.9106616377830505
9/5/2019 1:55:45 PM,Bristol-Myers' Opdivo Fails To Meet Primary Endpoint In Brain Tumor Study ,RTTNews,/news/stocks/bristol-myers-opdivo-fails-to-meet-primary-endpoint-in-brain-tumor-study-1028501466,negative,0.656440794467926
9/18/2019 7:35:32 PM,"4 Top Stock Trades for Thursday: ROKU, ADBE, BYND",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-roku-adbe-bynd-1028536148,neutral,0.9295516610145569
9/24/2019 1:37:12 PM,Bristol-Myers Squibb Says CHMP Recommends Approval Of Opdivo - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-says-chmp-recommends-approval-of-opdivo-quick-facts-1028547939,neutral,0.6632769107818604
9/24/2019 5:45:00 PM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028549476,positive,0.9256462454795837
9/25/2019 6:36:00 AM,Bristol-Myers Squibb Company -- Moody's: China's rising demand for drugs will fuel foreign pharma companies' growth into 2023,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-china-s-rising-demand-for-drugs-will-fuel-foreign-pharma-companies-growth-into-2023-1028550761,positive,0.9256462454795837
9/27/2019 7:10:39 PM,10 Cheap Stocks to Buy at Less Than 10x Forward Earnings,InvestorPlace,/news/stocks/10-stocks-to-buy-less-10x-forward-earnings-1028560648,neutral,0.8950284719467163
9/27/2019 7:34:40 PM,7 Big Biotech Stocks to Watch,InvestorPlace,/news/stocks/7-big-biotech-stocks-to-watch-1028560645,neutral,0.9301358461380005
9/30/2019 7:38:31 PM,"4 Top Stock Trades for Tuesday: AAPL, DIS, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-aapl-dis-bmy-1028565203,neutral,0.9333475828170776
10/1/2019 3:08:33 PM,4 Healthcare Stocks to Buy Now,InvestorPlace,/news/stocks/4-healthcare-stocks-to-buy-now-1028569344,neutral,0.8973768353462219
10/3/2019 7:02:17 PM,3 Cancer-Fighting Drug Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cancer-fighting-drug-stocks-to-buy-right-now-1028575928,neutral,0.9171133041381836
10/7/2019 4:17:20 PM,10 Great Biotech Stocks to Buy in Q4,InvestorPlace,/news/stocks/great-biotech-stocks-to-buy-q4-1028581895,neutral,0.7856954336166382
10/7/2019 6:51:22 PM,Why Johnson & Johnson Stock Is Not a Screaming Buy,InvestorPlace,/news/stocks/johnson-johnson-jnj-stock-not-screaming-buy-1028581887,neutral,0.9226393103599548
10/7/2019 7:52:32 PM,"5 Top Stock Trades for Tuesday: AAPL, GM, SRPT",InvestorPlace,/news/stocks/5-top-stock-trades-for-tuesday-aapl-gm-srpt-1028581882,neutral,0.9409533739089966
10/22/2019 12:40:32 PM,These New Partnerships are Game Changers for Fitbit Stock,InvestorPlace,/news/stocks/partnerships-game-changers-fitbit-stock-1028619586,neutral,0.7923107147216797
10/22/2019 5:23:57 PM,5 Healthcare Stocks to Buy,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-2-1028620498,neutral,0.8994203805923462
10/22/2019 6:15:57 PM,Fitbit Stock Needs a Viable Growth Narrative for Q3,InvestorPlace,/news/stocks/fitbit-stock-needs-a-viable-growth-narrative-for-q3-1028620791,positive,0.9086201190948486
10/23/2019 11:18:09 AM,"3 Big Stock Charts for Wednesday: Starbucks, Nordstrom, and Salesforce",InvestorPlace,/news/stocks/3-big-stock-charts-wednesday-starbucks-nordstrom-salesforce-com-1028622958,neutral,0.9280065894126892
10/23/2019 12:40:24 PM,"Healthcare Stocks That Hit New Highs ( BNTX, INMD,  BMY,...) ",RTTNews,/news/stocks/healthcare-stocks-that-hit-new-highs-bntx-inmd-bmy-1028622408,positive,0.7604783773422241
10/24/2019 10:36:53 AM,"3 Big Stock Charts for Thursday: Cisco Systems, Eli Lilly, and Colgate-Palmolive",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-cisco-systems-eli-lilly-colgate-palmolive-1028627304,neutral,0.905576229095459
10/31/2019 11:27:44 AM,"3 Big Stock Charts for Thursday: Merck, Anheuser-Busch InBev, and PPG Industries",InvestorPlace,/news/stocks/3-big-stock-charts-thursday-merck-anheuser-busch-inbev-ppg-industries-1028648405,neutral,0.916330873966217
10/31/2019 12:33:48 PM,Bristol-Myers Squibb Boosts FY19 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy19-adj-eps-outlook-quick-facts-1028647708,positive,0.9226676225662231
11/4/2019 12:10:45 PM,"The Gilead Stock Price Might Be Down, but That Doesn’t Mean It’s Cheap",InvestorPlace,/news/stocks/gilead-stock-price-down-mean-cheap-1028656095,negative,0.7800926566123962
11/7/2019 12:19:09 PM,"3 Big Stock Charts for Thursday: Kraft Heinz, Wabtec, and Regeneron Pharmaceuticals",InvestorPlace,/news/stocks/3-big-stock-charts-for-thursday-kraft-heinz-wabtec-and-regeneron-pharmaceuticals-1028669126,neutral,0.9232886433601379
11/7/2019 7:05:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's confirms Bristol-Myers Squibb at A2; negative outlook,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-confirms-bristol-myers-squibb-at-a2-negative-outlook-1028670686,negative,0.6633533239364624
11/8/2019 9:31:09 PM,This $2.7 Billion Deal Is a Shot Across the Bow for Big Pharma,InvestorPlace,/news/stocks/biotech-stocks-big-pharma-deal-1028674828,positive,0.6370862722396851
11/15/2019 12:45:45 PM,"3 Big Stock Charts for Friday: Snap, Pfizer and Splunk",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-snap-pfizer-and-splunk-1028692749,neutral,0.9221505522727966
11/15/2019 11:00:11 PM,Bristol-Myers Squibb wins antitrust approval to buy Celgene on condition it sell psoriasis drug,Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/3KiEXjb4848/bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-on-condition-it-sell-psoriasis-drug-idUSKBN1XP2CH,positive,0.49292629957199097
11/15/2019 11:18:42 PM,"UPDATE 1-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/dVBtPm8Bozg/update-1-bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSL2N27V1N8,positive,0.7600898742675781
11/15/2019 11:19:17 PM,"Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/businessNews/~3/KH3WRo0-CG0/bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSKBN1XP2CH,positive,0.6670133471488953
11/16/2019 12:01:34 AM,"UPDATE 2-Bristol-Myers Squibb wins antitrust approval to buy Celgene, but must divest psoriasis drug",Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/4YttIb-Awc8/update-2-bristol-myers-squibb-wins-antitrust-approval-to-buy-celgene-but-must-divest-psoriasis-drug-idUSL2N27V1N8,positive,0.748733639717102
11/16/2019 4:50:19 PM,Bristol-Myers Squibb Gets FTC Clearance For Celgene Acquisition ,RTTNews,/news/stocks/bristol-myers-squibb-gets-ftc-clearance-for-celgene-acquisition-1028694334,neutral,0.6359490752220154
11/21/2019 9:22:03 PM,Stock Market Today: The Deals Are Getting Done,InvestorPlace,/news/stocks/stock-market-today-the-deals-are-getting-done-1028709885,neutral,0.5620797872543335
11/27/2019 5:17:03 PM,10 Stocks Owned by the World’s Richest and Most Powerful,InvestorPlace,/news/stocks/billionaire-stocks-to-buy-1028722718,neutral,0.9038984775543213
12/2/2019 8:39:48 PM,"4 Top Stock Trades for Tuesday: ROKU, GOGO, BAC, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-tuesday-roku-gogo-bac-bmy-1028731358,neutral,0.9288875460624695
12/5/2019 2:30:18 PM,"Thursday’s Vital Data: Bristol-Myers Squibb, Shopify and Walmart",InvestorPlace,/news/stocks/thursdays-vital-data-bristol-myers-squibb-shopify-and-walmart-1028741424,neutral,0.9093398451805115
12/6/2019 8:54:36 PM,"4 Top Stock Trades for Monday: GS, BIG, BMY",InvestorPlace,/news/stocks/4-top-stock-trades-for-monday-gs-big-bmy-1028745177,neutral,0.9072806239128113
12/6/2019 9:29:00 PM,Bristol-Myers Squibb Company -- Moody's upgrades Celgene to A3,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-upgrades-celgene-to-a3-1028745124,positive,0.893399178981781
12/11/2019 3:38:32 PM,"Amarin Stock Has Lower Risk, But How Much Reward?",InvestorPlace,/news/stocks/amarin-stock-lower-risk-how-much-reward-1028756113,neutral,0.8986406922340393
12/14/2019 11:17:30 AM,Bristol-Myers Wins $752 Mln In US Patent Case Against Gilead Sciences ,RTTNews,/news/stocks/bristol-myers-wins-752-mln-in-us-patent-case-against-gilead-sciences-1028763479,positive,0.5128341317176819
12/16/2019 9:26:31 PM,"Stock Market Today: New Highs; Buy Micron, Nvidia?",InvestorPlace,/news/stocks/stock-market-today-new-highs-buy-micron-nvidia-1028767135,positive,0.5207104682922363
1/2/2020 2:27:25 PM,"Thursday’s Vital Data: Bristol-Myers Squibb, Cronos and Canopy Growth",InvestorPlace,/news/stocks/thursdays-vital-data-bristol-myers-squibb-cronos-and-canopy-growth-1028791689,neutral,0.9034371376037598
1/6/2020 3:12:34 PM,Is Amarin Stock a Top Pick for 2020?,InvestorPlace,/news/stocks/is-amarin-stock-a-top-pick-for-2020-1028796965,neutral,0.8600978851318359
1/14/2020 7:01:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1028817175,neutral,0.876595675945282
1/14/2020 7:01:00 PM,Biogen Inc. -- Moody's announces completion of a periodic review of ratings of Biogen Inc.,Moodys,/news/bonds/biogen-inc-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-biogen-inc-1028817172,neutral,0.8530017733573914
1/14/2020 7:01:00 PM,Celgene Corporation -- Moody's announces completion of a periodic review of ratings of Celgene Corporation,Moodys,/news/bonds/celgene-corporation-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-celgene-corporation-1028817168,neutral,0.9013141393661499
1/21/2020 2:22:04 PM,"Buffett Owns Teva Stock, But Should You?",InvestorPlace,/news/stocks/buffett-owns-teva-stock-but-should-you-1028832732,neutral,0.9392610192298889
1/27/2020 3:11:27 PM,3 Healthcare Stocks Under Pressure from Bernie,InvestorPlace,/news/stocks/3-healthcare-stocks-under-pressure-from-bernie-1028847131,negative,0.9502881765365601
1/31/2020 10:29:42 PM,CORRECTED-UPDATE 1-Bristol-Myers Squibb pulls Opdivo+Yervoy lung application in Europe,Reuters,http://feeds.reuters.com/~r/reuters/companyNews/~3/mduzsprQfAM/corrected-update-1-bristol-myers-squibb-pulls-opdivoyervoy-lung-application-in-europe-idUSL1N2A0237,positive,0.8155555725097656
2/5/2020 3:02:20 PM,Bristol-Myers Squibb is about to announce its earnings — here's what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q4-1028876977,neutral,0.9353700280189514
2/6/2020 1:13:55 PM,Bristol-Myers +3% premarket on Q4 beat,Seeking Alpha,https://seekingalpha.com/news/3539183-bristol-myersplus-3-premarket-on-q4-beat?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8655087947845459
2/6/2020 1:35:31 PM,Bristol-Myers Squibb Guides FY20 In Line With Estimates - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy20-in-line-with-estimates-quick-facts-1028880754,positive,0.6700295805931091
2/6/2020 4:49:53 PM,Merck’s Spinoff Plans Place a Big Bet on Cancer-Fighting Keytruda,InvestorPlace,/news/stocks/mercks-spinoff-plans-place-a-big-bet-on-cancer-fighting-keytruda-1028882432,neutral,0.7825397849082947
2/6/2020 6:06:01 PM,Bristol-Myers Squibb and Merck going opposite ways with PD-1 inhibitors,Seeking Alpha,https://seekingalpha.com/news/3539335-bristol-myers-squibb-and-merck-going-opposite-ways-pdminus-1-inhibitors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8771262168884277
2/7/2020 5:11:04 PM,Gilead an acquisition target? Deep pockets required,Seeking Alpha,https://seekingalpha.com/news/3539763-gilead-acquisition-target-deep-pockets-required?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8995611071586609
2/7/2020 5:50:31 PM,Sell-siders on board with Bristol-Myers Squibb's Q4 & outlook,Seeking Alpha,https://seekingalpha.com/news/3539775-sell-siders-on-board-bristol-myers-squibbs-q4-outlook?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.44624871015548706
2/13/2020 2:58:33 PM,Bristol-Myers: FDA To Review BLA For Liso-cel - Quick Facts ,RTTNews,/news/stocks/bristol-myers-fda-to-review-bla-for-liso-cel-quick-facts-1028903081,neutral,0.6194875240325928
2/20/2020 1:10:52 PM,"At This Point, Even the Coronavirus Can’t Save MMM Stock",InvestorPlace,/news/stocks/the-coronavirus-cant-save-mmm-stock-1028924391,neutral,0.8347102999687195
2/20/2020 4:25:14 PM,VBL Therapeutics announces new study of VB-111 in CRC,Seeking Alpha,https://seekingalpha.com/news/3544020-vbl-therapeutics-announces-new-study-of-vbminus-111-in-crc?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6237232685089111
2/21/2020 2:32:53 PM,Dems attack Trump over stalled efforts to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3544481-dems-attack-trump-over-stalled-efforts-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9021157026290894
2/24/2020 3:10:04 PM,Sanders' big Nevada primary win shakes health-related stocks,Seeking Alpha,https://seekingalpha.com/news/3544817-sanders-big-nevada-primary-win-shakes-health-related-stocks?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.905341386795044
2/28/2020 3:49:19 PM,Traders Are Treating Inovio Like 2018’s Pot Stock Stars,InvestorPlace,/news/stocks/inovio-ino-stock-coronavirus-speculation-1028950545,neutral,0.5932241082191467
3/2/2020 6:26:00 AM,Biotech Stocks Facing FDA Decision In March 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2020-1028953479,neutral,0.8244345188140869
3/2/2020 5:51:53 PM,FDA OKs Sanofi drug for previously treated multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3547590-fda-oks-sanofi-drug-for-previously-treated-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5526718497276306
3/3/2020 7:38:35 PM,Inovio Has Potential Beyond Its Speculative Coronavirus Vaccine,InvestorPlace,/news/stocks/inovio-has-potential-beyond-its-speculative-coronavirus-vaccine-1028961374,positive,0.6861270666122437
3/5/2020 3:40:49 PM,Idera Pharma completes enrollment in late-stage tilsotolimod study in melanoma,Seeking Alpha,https://seekingalpha.com/news/3549060-idera-pharma-completes-enrollment-in-late-stage-tilsotolimod-study-in-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8891914486885071
3/6/2020 1:09:09 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3549367-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9446426630020142
3/6/2020 9:28:29 PM,Ayala Pharmaceuticals on deck for IPO,Seeking Alpha,https://seekingalpha.com/news/3549519-ayala-pharmaceuticals-on-deck-for-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9368786215782166
3/10/2020 8:28:49 PM,"5 Top Stock Trades for Wednesday: AMZN, DKS, AAL, BMY, UAL",InvestorPlace,/news/stocks/5-top-stock-trades-for-wednesday-amzn-dks-aal-bmy-ual-1028982887,neutral,0.9326125979423523
3/11/2020 11:11:10 AM,FDA OKs Opdivo + Yervoy for certain liver cancer patients,Seeking Alpha,https://seekingalpha.com/news/3550459-fda-oks-opdivo-yervoy-for-certain-liver-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7838412523269653
3/13/2020 12:36:02 PM,Healthcare stocks set for rally today,Seeking Alpha,https://seekingalpha.com/news/3551531-healthcare-stocks-set-for-rally-today?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6742607355117798
3/13/2020 9:21:00 PM,Celgene Corporation -- Moody's withdraws Celgene's ratings,Moodys,/news/bonds/celgene-corporation-moody-s-withdraws-celgene-s-ratings-1028995440,negative,0.7339498996734619
3/16/2020 11:14:02 AM,U.S. stocks set to gap down at open,Seeking Alpha,https://seekingalpha.com/news/3551922-u-s-stocks-set-to-gap-down-open?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9542070627212524
3/20/2020 3:23:46 PM,Key events next week - healthcare,Seeking Alpha,https://seekingalpha.com/news/3553839-key-events-next-week-healthcare?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9446426630020142
3/20/2020 7:12:58 PM,"Bristol-Myers Squibb , Sanofi strike out in bid to stop Plavix litigation",Seeking Alpha,https://seekingalpha.com/news/3553920-bristol-myers-squibb-sanofi-strike-out-in-bid-to-stop-plavix-litigation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6911369562149048
3/23/2020 10:58:56 AM,SocGen cuts view on AbbVie in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3554092-socgen-cuts-view-on-abbvie-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6225674152374268
3/23/2020 11:07:49 AM,Bristol-Myers Squibb nixes investor event due to coronavirus outbreak,Seeking Alpha,https://seekingalpha.com/news/3554101-bristol-myers-squibb-nixes-investor-event-due-to-coronavirus-outbreak?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9032304883003235
3/24/2020 10:04:14 AM,Inovio Rise is Today’s Sign of the Stockocalypse,InvestorPlace,/news/stocks/inovio-rise-is-todays-sign-of-the-stockocalypse-1029026114,positive,0.7528964281082153
3/26/2020 11:01:49 AM,FDA OKs Bristol-Myers Squibb's ozanimod for types of multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3555365-fda-oks-bristol-myers-squibbs-ozanimod-for-types-of-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8567525148391724
3/27/2020 6:44:44 AM,"U.S. Now Has Most Virus Cases, BSGM To Develop COVID-19 Drug, FDA Nod For BMY ",RTTNews,/news/stocks/u-s-now-has-most-virus-cases-bsgm-to-develop-covid-19-drug-fda-nod-for-bmy-1029037921,neutral,0.6163011789321899
3/27/2020 1:35:58 PM,European advisory group backs Celgene's ozanimod for type of multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3555874-european-advisory-group-backs-celgenes-ozanimod-for-type-of-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.4013606607913971
3/31/2020 11:40:22 AM,Celgene CVR holders near finish line with bb2121 filing in U.S.,Seeking Alpha,https://seekingalpha.com/news/3556691-celgene-cvr-holders-near-finish-line-bb2121-filing-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8475598096847534
3/31/2020 2:59:16 PM,Searching for a Coronavirus Cure? Avoid Allied Healthcare Stock,InvestorPlace,/news/stocks/searching-for-coronavirus-cure-avoid-ahpi-stock-1029050330,neutral,0.8585194945335388
3/31/2020 6:18:24 PM,Goldman Sachs names top picks for dividend stability,Seeking Alpha,https://seekingalpha.com/news/3556934-goldman-sachs-names-top-picks-for-dividend-stability?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9230116009712219
4/2/2020 11:20:53 AM,Morgan Stanley likes Bristol-Myers Squibb in premarket analyst action,Seeking Alpha,https://seekingalpha.com/news/3557718-morgan-stanley-likes-bristol-myers-squibb-in-premarket-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8694671988487244
4/3/2020 9:26:07 PM,FDA's OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept,Seeking Alpha,https://seekingalpha.com/news/3558395-fdas-oks-new-use-of-acceleron-and-bristol-myers-squibbs-luspatercept?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7326955795288086
4/3/2020 9:26:07 PM,FDA OKs new use of Acceleron and Bristol-Myers Squibb's luspatercept,Seeking Alpha,https://seekingalpha.com/news/3558395-fda-oks-new-use-of-acceleron-and-bristol-myers-squibbs-luspatercept?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.49944818019866943
4/6/2020 9:16:17 AM,New Drugs Approved In The Month Of March ,RTTNews,/news/stocks/new-drugs-approved-in-the-month-of-march-1029066601,neutral,0.5216231346130371
4/6/2020 1:07:43 PM,Is Bitcoin a Safe Haven from the Pandemic?,InvestorPlace,/news/stocks/is-bitcoin-a-safe-haven-from-the-pandemic-1029068176,neutral,0.8273853659629822
4/7/2020 11:22:40 AM,Bristol-Myers Squibb to provide medicines to the unemployed and uninsured,Seeking Alpha,https://seekingalpha.com/news/3558885-bristol-myers-squibb-to-provide-medicines-to-unemployed-and-uninsured?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6018868088722229
4/9/2020 5:13:49 AM,"BMY Awaits FDA Decision, LQDA On Watch, MNOV To Begin Clinical Trial In COVID-19 ",RTTNews,/news/stocks/bmy-awaits-fda-decision-lqda-on-watch-mnov-to-begin-clinical-trial-in-covid-19-1029078082,neutral,0.8286135792732239
4/9/2020 11:43:12 AM,Bristol Myers teams up with NeoImmuneTech to evaluate Nivolumab + NT-17,Seeking Alpha,https://seekingalpha.com/news/3559612-bristol-myers-teams-up-neoimmunetech-to-evaluate-nivolumab-ntminus-17?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7846763730049133
4/14/2020 11:24:00 PM,"Becton, Dickinson and Company -- Moody's corrects the rating on CUSIP 110122BD9",Moodys,/news/bonds/becton-dickinson-and-company-moody-s-corrects-the-rating-on-cusip-110122bd9-1029091545,neutral,0.9001700282096863
4/15/2020 3:38:52 PM,Buying Gilead Sciences Stock Means Buying Into Political Risk,InvestorPlace,/news/stocks/gilead-gild-stock-remdesivir-political-risk-1029095249,neutral,0.9338685870170593
4/20/2020 11:19:12 AM,Opdivo/Cabometyx combo successful in first-line kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3561978-opdivo-cabometyx-combo-successful-in-first-line-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.93892902135849
4/20/2020 1:46:26 PM,"Trading at 52-Week Highs, LLY Stock Is Already Priced to Perfection",InvestorPlace,/news/stocks/hold-off-overvalued-lly-stock-1029107790,positive,0.5579323172569275
4/21/2020 7:39:42 AM,"CYCC In STOPCOVID, EXEL Hits New High, NVS Trialing Malaria Drug For COVID-19 ",RTTNews,/news/stocks/cycc-in-stopcovid-exel-hits-new-high-nvs-trialing-malaria-drug-for-covid-19-1029110457,positive,0.9083878993988037
4/21/2020 3:09:34 PM,Idera's tilsotolimod shows positive effect in mid-stage melanoma study,Seeking Alpha,https://seekingalpha.com/news/3562623-ideras-tilsotolimod-shows-positive-effect-in-mid-stage-melanoma-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9368299841880798
4/24/2020 3:41:09 PM,7 Beautiful Biotech Stocks to Buy Here,InvestorPlace,/news/stocks/7-beautiful-biotech-stocks-to-buy-here-1029127761,neutral,0.8712261319160461
4/28/2020 11:28:34 AM,"3 Big Stock Charts for Tuesday: Johnson & Johnson, Merck, and Bristol-Myers Squibb",InvestorPlace,/news/stocks/3-big-stock-charts-for-tuesday-johnson-johnson-merck-and-bristol-myers-squibb-1029137983,neutral,0.9059588313102722
5/6/2020 3:57:21 PM,Bristol-Myers Squibb Q1 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3570141-bristol-myers-squibb-q1-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.73114413022995
5/7/2020 5:33:38 AM,"FDA Decision On BMY's Drug Postponed, ENTA's PBC Study Fails, MGNX Turns Heads ",RTTNews,/news/stocks/fda-decision-on-bmy-s-drug-postponed-enta-s-pbc-study-fails-mgnx-turns-heads-1029173451,negative,0.8747947216033936
5/7/2020 12:10:44 PM,"Bristol-Myers Squibb affirms guidance, sees 20% earnings growth in 2021",Seeking Alpha,https://seekingalpha.com/news/3571113-bristol-myers-squibb-affirms-guidance-sees-20-earnings-growth-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9407448768615723
5/7/2020 2:18:09 PM,Bristol-Myers Q1 Results Beat View; Cuts 2020 GAAP Profit Outlook ,RTTNews,/news/stocks/bristol-myers-q1-results-beat-view-cuts-2020-gaap-profit-outlook-1029176995,negative,0.8895707130432129
5/7/2020 2:18:29 PM,Bristol-Myers Squibb Co. Q1 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-adjusted-earnings-beat-estimates-1029176994,positive,0.8698457479476929
5/7/2020 3:02:03 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-earnings-preview-stock-1029177189,neutral,0.927060067653656
5/8/2020 12:25:16 PM,"3 Big Stock Charts for Friday: Bristol-Myers Squibb, Eli Lilly, and GlaxoSmithKline",InvestorPlace,/news/stocks/3-big-stock-charts-for-friday-bristol-myers-squibb-eli-lilly-and-glaxosmithkline-1029182410,neutral,0.8863689303398132
5/8/2020 7:34:55 PM,"Time to buy these biopharma names is now, BofA says",Seeking Alpha,https://seekingalpha.com/news/3572315-time-to-buy-biopharma-names-is-now-bofa-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.901307225227356
5/11/2020 12:00:46 PM,Bristol-Myers buys out of milestone and royalty commitment with bluebird for $200M,Seeking Alpha,https://seekingalpha.com/news/3572635-bristol-myers-buys-out-of-milestone-and-royalty-commitment-bluebird-for-200m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6463251709938049
5/13/2020 12:29:00 PM,It’s Time to Buy AbbVie Stock Now After Its Allergan Purchase,InvestorPlace,/news/stocks/its-time-to-buy-abbvie-now-after-its-agn-stock-purchase-1029197990,neutral,0.9100152850151062
5/14/2020 5:15:21 AM,"FDA Snubs BMY And BLUE, Stocks That Moved On ASCO Abstracts (ARVN, CTMX, MGNX) ",RTTNews,/news/stocks/fda-snubs-bmy-and-blue-stocks-that-moved-on-asco-abstracts-arvn-ctmx-mgnx-1029199834,neutral,0.6439523696899414
5/14/2020 9:29:32 PM,"Klarman buys Alphabet, exits Bristol Myers",Seeking Alpha,https://seekingalpha.com/news/3574838-klarman-buys-alphabet-exits-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8117052316665649
5/15/2020 7:59:31 PM,FDA OKs Bristol Myers doublet therapy for first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3575215-fda-oks-bristol-myers-doublet-therapy-for-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6422128081321716
5/19/2020 12:07:33 PM,AbbVie Is More Than Just a Portfolio of Drugs and Acquisitions,InvestorPlace,/news/stocks/whole-of-abbv-stock-more-than-sum-of-parts-1029214731,neutral,0.9493720531463623
5/22/2020 11:46:36 AM,EMA accepts Bristol Myers applications for blood cancer treatments,Seeking Alpha,https://seekingalpha.com/news/3577105-ema-accepts-bristol-myers-applications-for-blood-cancer-treatments?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8820192217826843
5/27/2020 11:23:43 AM,Bristol-Myers' ozanimod OK'd in Europe for type of MS,Seeking Alpha,https://seekingalpha.com/news/3577815-bristol-myers-ozanimod-okd-in-europe-for-type-of-ms?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8555542230606079
5/27/2020 1:38:39 PM,European Commission Approves Bristol Myers' Zeposia - Quick Facts ,RTTNews,/news/stocks/european-commission-approves-bristol-myers-zeposia-quick-facts-1029237130,neutral,0.7127984166145325
5/29/2020 6:00:00 AM,All eyes on ASCO,Seeking Alpha,https://seekingalpha.com/news/3578520-all-eyes-on-asco?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9381866455078125
5/29/2020 12:01:48 PM,European advisory group backs Herceptin biosimilar and generic Eliquis,Seeking Alpha,https://seekingalpha.com/news/3578611-european-advisory-group-backs-herceptin-biosimilar-and-generic-eliquis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.734736442565918
6/1/2020 12:05:19 PM,Bristol Myers launches MS med Zeposia in U.S.,Seeking Alpha,https://seekingalpha.com/news/3578930-bristol-myers-launches-ms-med-zeposia-in-u-s?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7286050915718079
6/1/2020 1:59:55 PM,Compugen: FDA Allows Phase 1/2 Study Evaluating COM701 With BMS-986207 And Nivolumab ,RTTNews,/news/stocks/compugen-fda-allows-phase-1-2-study-evaluating-com701-with-bms-986207-and-nivolumab-1029268522,positive,0.6356878876686096
6/3/2020 11:49:25 AM,Replimune lead drug shows benefit in non-melanoma skin cancer,Seeking Alpha,https://seekingalpha.com/news/3579961-replimune-lead-drug-shows-benefit-in-non-melanoma-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9196963310241699
6/4/2020 2:36:10 PM,Jounce regains rights to cancer candidate from Bristol Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3580481-jounce-regains-rights-to-cancer-candidate-from-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7924689054489136
6/6/2020 3:10:22 PM,AbbVie's Rinvoq tops Bristol-Myers' Orencia in rheumatoid arthritis study,Seeking Alpha,https://seekingalpha.com/news/3580955-abbvies-rinvoq-tops-bristol-myers-orencia-in-rheumatoid-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5877073407173157
6/9/2020 3:10:56 PM,Aggressive Investors Can Do Much Better Than Merck Stock,InvestorPlace,/news/stocks/aggressive-investors-better-mrk-stock-1029293865,positive,0.7292520403862
6/9/2020 4:08:46 PM,Bristol Myers teams up with UbiVac in study of triplet therapy for breast cancer,Seeking Alpha,https://seekingalpha.com/news/3581599-bristol-myers-teams-up-ubivac-in-study-of-triplet-therapy-for-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5731901526451111
6/16/2020 11:31:16 AM,Bristol-Myers initiates debt exchange offers,Seeking Alpha,https://seekingalpha.com/news/3583339-bristol-myers-initiates-debt-exchange-offers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9410542249679565
6/17/2020 4:24:13 PM,3 Dow Jones Companies to Buy When Profit-Taking Kicks In,InvestorPlace,/news/stocks/3-dow-jones-companies-to-buy-when-profit-taking-kicks-in-1029319033,neutral,0.9093377590179443
6/18/2020 11:24:57 AM,Roche's Tecentriq improves response rate in early triple-negative breast cancer,Seeking Alpha,https://seekingalpha.com/news/3584069-roches-tecentriq-improves-response-rate-in-early-triple-negative-breast-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9507790803909302
6/26/2020 1:50:19 PM,10 Value Stocks to Keep on Your Short List,InvestorPlace,/news/stocks/10-value-stocks-keep-short-list-1029346120,neutral,0.9233397245407104
7/2/2020 5:02:06 PM,"Keep an Eye on Royalty Pharma Stock, 2020’s Biggest IPO",InvestorPlace,/news/stocks/keep-eye-rprx-stock-2020-1029363917,neutral,0.9034903645515442
7/10/2020 2:55:15 PM,The 7 Best Dividend-Paying Stocks for Cautious Investors,InvestorPlace,/news/stocks/the-7-best-dividend-paying-stocks-for-cautious-investors-1029384331,neutral,0.5519558787345886
7/15/2020 10:50:50 AM,Microsoft gains foothold in healthcare,InvestorPlace,/news/stocks/microsofts-cloud-gains-foothold-in-healthcare-1029397797,positive,0.8893933892250061
7/22/2020 12:48:58 PM,Undervalued Bristol-Myers Squibb Stock Is Worth 50% More,InvestorPlace,/news/stocks/bmy-stock-very-undervalued-making-stock-a-buy-1029420799,neutral,0.9001969695091248
7/30/2020 9:08:15 AM,"ALEC Falls Despite Promising Results, DNLI Makes Progress In COVID-19 Trial, EARS, ONTX On Watch ",RTTNews,/news/stocks/alec-falls-despite-promising-results-dnli-makes-progress-in-covid-19-trial-ears-ontx-on-watch-1029449238,positive,0.8770734667778015
7/30/2020 2:41:26 PM,5 Undervalued Stocks Cooking Up Must-Have Technologies,InvestorPlace,/news/stocks/5-undervalued-stocks-cooking-up-must-have-tech-1029452323,neutral,0.5400320887565613
8/3/2020 2:54:47 PM,5 Healthcare Stocks for Good (Portfolio) Health,InvestorPlace,/news/stocks/5-healthcare-stocks-for-good-portfolio-health-1029462755,neutral,0.8538075685501099
8/4/2020 11:00:14 AM,Bristol-Myers Squibb Has Great Potential Ahead of Earnings,InvestorPlace,/news/stocks/bmy-stock-earnings-great-upside-potential-1029466313,positive,0.7772058248519897
8/4/2020 1:14:21 PM,Bristol-Myers Squibb Is a Dirt-Cheap Buy Before Earnings,InvestorPlace,/news/stocks/buy-bmy-stock-before-earnings-while-its-still-dirt-cheap-1029467829,neutral,0.913796603679657
8/5/2020 3:04:13 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q2-earnings-preview-1029473227,neutral,0.9091694951057434
8/6/2020 8:49:18 AM,"ABIO To Start Phase 2 COVID-19 Trial In Q4, ACIU On Track, BCLI Expects ALS Trial Data In Nov. ",RTTNews,/news/stocks/abio-to-start-phase-2-covid-19-trial-in-q4-aciu-on-track-bcli-expects-als-trial-data-in-nov-1029476415,neutral,0.6356560587882996
8/6/2020 12:42:21 PM,"Pre-market Movers In Healthcare Sector: AVXL, BEAM, AVGR, BMY... ",RTTNews,/news/stocks/pre-market-movers-in-healthcare-sector-avxl-beam-avgr-bmy-1029477136,neutral,0.9237057566642761
8/6/2020 1:47:07 PM,"Bristol-Myers Slips To Loss In Q2, But Results Top Estimates ",RTTNews,/news/stocks/bristol-myers-slips-to-loss-in-q2-but-results-top-estimates-1029477570,negative,0.8525647521018982
8/6/2020 3:13:08 PM,Bristol-Myers Squibb Earnings: BMY Stock Jumps 2% on Q2 Beats,InvestorPlace,/news/stocks/bristol-myers-squibb-earnings-bmy-stock-jumps-2-on-q2-beats-1029479311,positive,0.9413251876831055
8/6/2020 8:52:05 PM,"5 Top Stock Trades for Friday: UBER, FB, BMY, MU, TWLO",InvestorPlace,/news/stocks/5-top-stock-trades-for-friday-uber-fb-bmy-mu-twlo-1029480516,neutral,0.9374117255210876
8/7/2020 1:36:32 PM,This Company is the Landlord of Life Sciences,InvestorPlace,/news/stocks/this-company-is-the-landlord-of-life-sciences-1029482490,neutral,0.9439411759376526
8/8/2020 9:05:22 PM,Bristol Myers' O+Y extends survival in rare type of thoracic cancer,Seeking Alpha,https://seekingalpha.com/news/3603107-bristol-myers-o-y-extends-survival-in-rare-type-of-thoracic-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9333878755569458
8/21/2020 3:31:12 PM,Eli Lilly (Still) Looks Like the Best Buy in Large-Cap Pharma,InvestorPlace,/news/stocks/lly-stock-still-looks-like-best-buy-large-cap-pharma-1029524567,positive,0.8058719635009766
8/27/2020 2:45:32 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1029537919,neutral,0.6874346733093262
9/14/2020 10:46:52 AM,Avoid General Electric Amid the Current Stock Market Dip,InvestorPlace,/news/stocks/avoid-general-electric-amid-the-current-stock-market-dip-1029585706,neutral,0.5527823567390442
9/17/2020 2:18:31 PM,"Celgene, Dr. Reddy's Reach Settlement Agreement On Patents For REVLIMID Capsules ",RTTNews,/news/stocks/celgene-dr-reddy-s-reach-settlement-agreement-on-patents-for-revlimid-capsules-1029598528,positive,0.8751060962677002
9/22/2020 5:15:55 PM,Pfizer Shares May Catch Momentum Soon From Vaccine Work,InvestorPlace,/news/stocks/pfizer-stock-may-catch-positive-momentum-soon-1029612590,positive,0.9383125305175781
9/25/2020 9:16:35 AM,Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock,InvestorPlace,/news/stocks/bmy-stock-worth-46-percent-more-based-on-history-and-comps-1029623231,neutral,0.8472943305969238
9/29/2020 2:26:20 PM,"Bristol Myers, Acceleron Pharma Announce Health Canada Approval Of Reblozyl ",RTTNews,/news/stocks/bristol-myers-acceleron-pharma-announce-health-canada-approval-of-reblozyl-1029630634,positive,0.7474576234817505
9/30/2020 10:54:07 AM,Abbott Labs Stock is Not Cheap But Should Do Well as Virus Test Debuts,InvestorPlace,/news/stocks/abt-stock-should-do-well-with-its-new-covid-19-test-1029635842,positive,0.621147096157074
10/5/2020 11:17:06 AM,FDA Approves Drug Combination To Treat Mesothelioma ,RTTNews,/news/stocks/fda-approves-drug-combination-to-treat-mesothelioma-1029647276,positive,0.831947386264801
10/5/2020 1:16:00 PM,Bristol Myers Squibb To Buy MyoKardia For $13.1 Bln In Cash - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-buy-myokardia-for-13-1-bln-in-cash-quick-facts-1029647715,neutral,0.8909740447998047
10/5/2020 2:36:03 PM,MyoKardia soars 59% after Bristol-Myers agrees to acquire it for $13 billion in cash,Business Insider,https://www.businessinsider.com/myokardia-stock-price-bristol-myers-acquire-billion-cash-drug-pharma-2020-10,positive,0.5850119590759277
10/5/2020 3:09:53 PM,Bristol Myers Snaps Up MyoKardia For $225/Share ,RTTNews,/news/stocks/bristol-myers-snaps-up-myokardia-for-225-share-1029648357,positive,0.6944342255592346
10/5/2020 5:26:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's affirms Bristol-Myers at A2; outlook remains negative,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-affirms-bristol-myers-at-a2-outlook-remains-negative-1029649061,negative,0.6892862915992737
10/5/2020 5:35:25 PM,M&A News: MyoKardia (MYOK) Stock Soars on Bristol Myers Squibb Deal,InvestorPlace,/news/stocks/ma-news-myokardia-myok-stock-soars-on-bristol-myers-squibb-deal-1029649497,negative,0.9149132370948792
10/7/2020 12:15:39 PM,Bristol Myers' Opdivo shows incremental benefit over chemo in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3620396-bristol-myers-opdivo-shows-incremental-benefit-over-chemo-in-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9417189359664917
10/7/2020 12:33:51 PM,Bristol Myers' ozanimod OK'd in Canada for multiple sclerosis,Seeking Alpha,https://seekingalpha.com/news/3620424-bristol-myers-ozanimod-okd-in-canada-for-multiple-sclerosis?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6720889210700989
10/7/2020 2:23:48 PM,Canada Approves Bristol-Myers' Zeposia To Treat Relapsing Remitting Multiple Sclerosis ,RTTNews,/news/stocks/canada-approves-bristol-myers-zeposia-to-treat-relapsing-remitting-multiple-sclerosis-1029656920,positive,0.7703192830085754
10/7/2020 4:12:52 PM,"Opdivo Plus Chemotherapy As Neoadjuvant Treatment In Resectable NSCLC Trial Hits Key Goal, Says BMY ",RTTNews,/news/stocks/opdivo-plus-chemotherapy-as-neoadjuvant-treatment-in-resectable-nsclc-trial-hits-key-goal-says-bmy-1029657815,positive,0.882851243019104
10/7/2020 4:27:48 PM,7 Biotech Stocks To Buy For Profit From The Vaccine Crunch,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-for-profit-from-the-vaccine-crunch-1029658673,neutral,0.8608306646347046
10/8/2020 7:48:40 AM,"Evotec, Bristol Myers Expand Neuroscience Partnership; Evotec Gains Milestone Payment ",RTTNews,/news/stocks/evotec-bristol-myers-expand-neuroscience-partnership-evotec-gains-milestone-payment-1029659830,positive,0.9501330852508545
10/8/2020 10:01:14 AM,Evotec earns $6M milestone from BMY under neurodegeneration collaboration,Seeking Alpha,https://seekingalpha.com/news/3620685-evotec-earns-6m-milestone-from-bmy-under-neurodegeneration-collaboration?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8023500442504883
10/9/2020 7:00:01 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3621193-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
10/12/2020 3:23:34 PM,Bristol-Myers announces detailed ozanimod data from pivotal ulcerative colitis study,Seeking Alpha,https://seekingalpha.com/news/3621433-bristol-myers-announces-detailed-ozanimod-data-from-pivotal-ulcerative-colitis-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9090190529823303
10/12/2020 5:58:46 PM,Surface Oncology hires bankers to explore sale - StreetInsider,Seeking Alpha,https://seekingalpha.com/news/3621490-surface-oncology-hires-bankers-to-explore-sale-streetinsider?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.911042332649231
10/16/2020 11:53:54 AM,EMA backs Bristol Myers' Opdivo as second-line treatment in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3622822-ema-backs-bristol-myers-opdivo-second-line-treatment-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5278590321540833
10/16/2020 11:53:54 AM,European advisory group backs Bristol Myers' Opdivo as second-line treatment in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3622822-european-advisory-group-backs-bristol-myers-opdivo-second-line-treatment-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7505422830581665
10/16/2020 11:02:00 PM,JPM picks big pharma names to benefit with busy catalyst calendar ahead,Seeking Alpha,https://seekingalpha.com/news/3623038-jpm-picks-big-pharma-names-to-benefit-busy-catalyst-calendar-ahead?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6425065398216248
10/19/2020 11:10:42 AM,FDA OKs accelerated review for Opdivo/Cabometyx combo for kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3623133-fda-oks-accelerated-review-for-opdivo-cabometyx-combo-for-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5226917266845703
10/26/2020 6:45:58 AM,Biotech Stocks Facing FDA Decision In November 2020 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2020-1029718001,neutral,0.7490036487579346
10/28/2020 12:59:39 PM,7 Cutting-Edge Biotech Stocks for Tomorrow ,InvestorPlace,/news/stocks/7-cutting-edge-biotech-stocks-for-tomorrow-1029734117,neutral,0.8713728785514832
11/2/2020 7:10:18 AM,Will Eiger's Zokinvy Make History To Become First-ever Progeria Treatment? ,RTTNews,/news/stocks/will-eiger-s-zokinvy-make-history-to-become-first-ever-progeria-treatment-1029751571,neutral,0.6128451228141785
11/2/2020 3:23:08 PM,7 Healthcare Stocks That Can Survive Massive Reform,InvestorPlace,/news/stocks/7-healthcare-stocks-that-can-survive-massive-reform-1029754648,neutral,0.8727529644966125
11/3/2020 12:23:20 PM,Bristol Myers' deucravacitinib tops Amgen's Otezla in late-stage psoriasis study,Seeking Alpha,https://seekingalpha.com/news/3630264-bristol-myers-deucravacitinib-tops-amgens-otezla-in-late-stage-psoriasis-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.4303787052631378
11/4/2020 1:29:39 PM,Bristol Myers - MyoKardia Deal Receives U.S. Regulatory Approval ,RTTNews,/news/stocks/bristol-myers-myokardia-deal-receives-u-s-regulatory-approval-1029764781,positive,0.9092156291007996
11/4/2020 4:24:35 PM,Bristol Myers Squibb Q3 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3631153-bristol-myers-squibb-q3-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8003865480422974
11/4/2020 5:09:18 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3631230-notable-earnings-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.882573127746582
11/5/2020 1:24:14 PM,Bristol Myers Squibb Raises FY20 Earnings Guidance - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-raises-fy20-earnings-guidance-quick-facts-1029769963,neutral,0.7880158424377441
11/5/2020 2:50:57 PM,"Bristol Myers posts solid Q3 beat with strong performance in key franchises, FY20 outlook raised",Seeking Alpha,https://seekingalpha.com/news/3632257-bristol-myers-posts-solid-q3-beat-strong-performance-in-key-franchises-fy20-outlook-raised?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9531162977218628
11/6/2020 12:40:29 PM,Bristol Myers' O+Y OK'd in Europe for first-line lung cancer,Seeking Alpha,https://seekingalpha.com/news/3633098-bristol-myers-o-y-okd-in-europe-for-first-line-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8296574354171753
11/9/2020 1:06:38 PM,Bristol Myers' deucravacitinib successful in mid-stage psoriatic arthritis study,Seeking Alpha,https://seekingalpha.com/news/3633585-bristol-myers-deucravacitinib-successful-in-mid-stage-psoriatic-arthritis-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6184377074241638
11/9/2020 4:02:00 PM,Bristol-Myers Squibb Company -- Moody's assigns A2 to Bristol-Myers' sr. notes; outlook negative,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-assigns-a2-to-bristol-myers-sr-notes-outlook-negative-1029782082,neutral,0.6693297624588013
11/9/2020 9:50:39 PM,Bristol Myers' Yervoy shows no incremental benefit over Merck's Keytruda alone in lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3634036-bristol-myers-yervoy-shows-no-incremental-benefit-over-mercks-keytruda-alone-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8773897290229797
11/11/2020 4:50:34 PM,7 Biotech Penny Stocks Worth a Gamble,InvestorPlace,/news/stocks/7-biotech-stocks-to-gamble-with-1029793010,neutral,0.7899963855743408
11/11/2020 8:52:12 PM,Nektar Therapeutics immuno-oncology candidates show positive action in early-stage studies,Seeking Alpha,https://seekingalpha.com/news/3635108-nektar-therapeutics-immuno-oncology-candidates-show-positive-action-in-early-stage-studies?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9474529027938843
11/13/2020 8:00:17 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3636251-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
11/15/2020 4:37:27 PM,"Week Ahead In Pharma: FDA Decisions, Data Readouts (ADMP, EIGR, KZIA, AVRO…) ",RTTNews,/news/stocks/week-ahead-in-pharma-fda-decisions-data-readouts-admp-eigr-kzia-avro-1029803879,neutral,0.9442025423049927
11/16/2020 9:48:23 PM,FDA review for Bristol-Myers's liso-cel marketing application to miss the action date,Seeking Alpha,https://seekingalpha.com/news/3636821-fda-review-for-bristol-myerss-liso-cel-marketing-application-to-miss-action-date?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.850679874420166
11/17/2020 8:10:16 AM,"ADMP Snubbed Again, FDA Delay's Decision On BMY's Liso-cel, MRNA's COVID-19 Vaccine 94.5% Effective ",RTTNews,/news/stocks/admp-snubbed-again-fda-delay-s-decision-on-bmy-s-liso-cel-mrna-s-covid-19-vaccine-94-5-effective-1029809234,positive,0.8710684776306152
11/17/2020 10:41:52 AM,"Buffett’s Berkshire Hathaway Buys New Stakes in Vaccine Makers, Cuts Banks",InvestorPlace,/news/stocks/buffets-berkshire-hathaway-stock-buys-new-stakes-in-vaccine-makers-cut-banks-1029809986,neutral,0.8204635381698608
11/17/2020 2:04:21 PM,Bristol Myers completes acquisition of MyoKardia,Seeking Alpha,https://seekingalpha.com/news/3637079-bristol-myers-completes-acquisition-of-myokardia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8672120571136475
11/17/2020 3:10:41 PM,7 Pharmaceutical Stocks to Buy for 2021 and Beyond ,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-2021-and-beyond-1029811903,neutral,0.9023517370223999
11/23/2020 11:52:19 AM,Schrödinger inks multi-target drug discovery deal with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3638576-schrodinger-inks-multi-target-drug-discovery-deal-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5382327437400818
11/23/2020 12:53:41 PM,Schrdinger Enters Into Discovery Collaboration With Bristol Myers Squibb - Quick Facts ,RTTNews,/news/stocks/schrdinger-enters-into-discovery-collaboration-with-bristol-myers-squibb-quick-facts-1029829012,neutral,0.6067034006118774
11/23/2020 8:28:57 PM,"Schrödinger stock scales, upgraded by BofA after collaboration with BMY",Seeking Alpha,https://seekingalpha.com/news/3638810-schrodinger-stock-scales-upgraded-bofa-after-collaboration-bmy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8287429809570312
11/24/2020 4:22:14 PM,Bristol Myers wins EU approval of Opdivo for esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3639128-bristol-myers-wins-eu-approval-of-opdivo-for-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9079118371009827
12/4/2020 4:46:01 PM,Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company,InvestorPlace,/news/stocks/sutro-biopharma-what-to-know-about-stro-stock-1029865897,neutral,0.9380685091018677
12/7/2020 10:52:00 AM,Moody's - Outlook for global pharmaceutical industry revised to positive as COVID-19 vaccines and treatments boost earnings,Moodys,/news/bonds/moody-s-outlook-for-global-pharmaceutical-industry-revised-to-positive-as-covid-19-vaccines-and-treatments-boost-earnings-1029868484,positive,0.9331789612770081
12/7/2020 5:20:23 PM,Johnson & Johnson sees positive data from pair of multiple myeloma approaches at ASH,Seeking Alpha,https://seekingalpha.com/news/3642175-johnson-johnson-sees-positive-data-from-pair-of-multiple-myeloma-approaches-ash?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9478275179862976
12/8/2020 5:08:03 PM,"Checkmate Pharma, Bristol Myers team up for CMP-001/nivolumab combo trial in melanoma",Seeking Alpha,https://seekingalpha.com/news/3642567-checkmate-pharma-bristol-myers-team-up-for-cmpminus-001-nivolumab-combo-trial-in-melanoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7179515957832336
12/8/2020 6:57:24 PM,3 Cheap Dividend Stocks For High Total Returns,InvestorPlace,/news/stocks/3-cheap-dividend-stocks-for-high-total-returns-intc-bmy-kmi-1029874781,positive,0.6156914830207825
12/9/2020 2:24:20 PM,7 Undervalued Stocks to Buy Now,InvestorPlace,/news/stocks/7-undervalued-stocks-to-buy-now-1029877954,positive,0.5283908247947693
12/10/2020 9:17:58 PM,Bristol Myers Squibb hikes dividend by 9% to $0.49,Seeking Alpha,https://seekingalpha.com/news/3643487-bristol-myers-squibb-hikes-dividend-9-to-0_49?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7979477047920227
12/11/2020 12:38:48 PM,European advisory group backs Bristol Myers' Inrebic in myelofibrosis,Seeking Alpha,https://seekingalpha.com/news/3643650-european-advisory-group-backs-bristol-myers-inrebic-in-myelofibrosis?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.46380749344825745
12/11/2020 1:24:46 PM,"Bristol Myers, Cipla settle Revlimid U.S. patent litigation",Seeking Alpha,https://seekingalpha.com/news/3643679-bristol-myers-cipla-settle-revlimid-u-s-patent-litigation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9308957457542419
12/11/2020 1:42:12 PM,"Bristol Myers' Celgene, Cipla Settle U.S. Patent Litigation On Lenalidomide ",RTTNews,/news/stocks/bristol-myers-celgene-cipla-settle-u-s-patent-litigation-on-lenalidomide-1029885163,neutral,0.8567135334014893
12/15/2020 3:52:00 PM,Bristol-Myers Squibb Company -- Moody's announces completion of a periodic review of ratings of Bristol-Myers Squibb Company,Moodys,/news/bonds/bristol-myers-squibb-company-moody-s-announces-completion-of-a-periodic-review-of-ratings-of-bristol-myers-squibb-company-1029894437,neutral,0.876595675945282
12/16/2020 10:47:45 AM,Micro-cap oncology biotech Scopus Biopharma prices downsized $2.75M IPO,Seeking Alpha,https://seekingalpha.com/news/3644762-micro-cap-oncology-biotech-scopus-biopharma-prices-downsized-2_75m-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.4526400566101074
12/17/2020 7:52:45 AM,Evotec Meets Key Milestones In Partnership With Bristol Myers On Targeted Protein Degradation ,RTTNews,/news/stocks/evotec-meets-key-milestones-in-partnership-with-bristol-myers-on-targeted-protein-degradation-1029900939,positive,0.9033125042915344
12/17/2020 11:33:41 AM,Evotec achieves milestones in Bristol Myers pact in targeted protein degradation,Seeking Alpha,https://seekingalpha.com/news/3645207-evotec-achieves-milestones-in-bristol-myers-pact-in-targeted-protein-degradation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9064749479293823
12/23/2020 12:30:41 PM,Bristol-Myers says Opdivo brain cancer study unlikely to meet overall survival endpoint,Seeking Alpha,https://seekingalpha.com/news/3646910-bristol-myers-says-opdivo-brain-cancer-study-unlikely-to-meet-overall-survival-endpoint?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.907738447189331
12/23/2020 1:42:55 PM,Bristol-Myers: Phase 3 CheckMate -548 Trial Will Not Meet Primary Endpoint Of Overall Survival ,RTTNews,/news/stocks/bristol-myers-phase-3-checkmate-548-trial-will-not-meet-primary-endpoint-of-overall-survival-1029916785,negative,0.7257096767425537
12/24/2020 5:12:44 PM,"Analysts predict M&A poised to rebound in next year, fueled by $1.47T in deal making capital",Seeking Alpha,https://seekingalpha.com/news/3647399-analysts-predict-m-poised-to-rebound-in-next-year-fueled-1_47t-in-deal-making-capital?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9501712918281555
12/26/2020 3:15:52 PM,"The Week Ahead In Biotech (Dec. 27-Jan. 2): Data Releases, Regulatory Filings To Move Stocks",Benzinga,/news/stocks/the-week-ahead-in-biotech-dec-27-jan-2-data-releases-regulatory-filings-to-move-stocks-1029919761,neutral,0.6830364465713501
12/28/2020 3:33:59 AM,Biotech Stock Picks That Delivered Triple-digit Gains - Is There More Room To Run? ,RTTNews,/news/stocks/biotech-stock-picks-that-delivered-triple-digit-gains-is-there-more-room-to-run-1029920417,neutral,0.7250792384147644
12/28/2020 12:29:09 PM,Bristol-Myers Squibb’s ulcerative colitis therapy goes under review in Europe,Seeking Alpha,https://seekingalpha.com/news/3647472-bristol-myers-squibb-s-ulcerative-colitis-therapy-goes-under-review-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6740614175796509
12/28/2020 1:09:50 PM,Bristol Myers Squibb: EMA Validates Marketing Authorization Application For Zeposia ,RTTNews,/news/stocks/bristol-myers-squibb-ema-validates-marketing-authorization-application-for-zeposia-1029921156,neutral,0.7262929677963257
12/29/2020 2:09:37 PM,"The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-amphastar-s-generic-glucagon-arcturus-sinks-on-vaccine-data-decision-day-for-osmotica-1029923067,neutral,0.8028444051742554
12/30/2020 6:19:15 PM,Celgene CVRs lose 21% as the deadline for liso-cel approval nears,Seeking Alpha,https://seekingalpha.com/news/3647946-celgene-cvrs-lose-21-deadline-for-liso-cel-approval-nears?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9726426601409912
12/31/2020 5:45:27 PM,7 Cheap Stocks That Can’t Wait for 2021 ,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-now-that-cant-wait-for-2021-1029927440,neutral,0.8863061666488647
1/1/2021 1:30:00 PM,Bristol-Myers says CVR Agreement is terminated,Seeking Alpha,https://seekingalpha.com/news/3648168-bristol-myers-says-cvr-agreement-is-terminated?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6488173007965088
1/4/2021 5:03:29 PM,7 Cheap Stocks to Buy in January For a Quick Buck,InvestorPlace,/news/stocks/7-cheap-stocks-to-buy-in-january-for-a-quick-buck-1029931161,neutral,0.8434223532676697
1/5/2021 7:49:35 AM,Evotec Receives $6 Mln Payment From Bristol Myers On IPSC-based Neuroscience Partnership ,RTTNews,/news/stocks/evotec-receives-6-mln-payment-from-bristol-myers-on-ipsc-based-neuroscience-partnership-1029932303,positive,0.6202167868614197
1/5/2021 12:04:59 PM,Evotec earns $6 milestone under neurodegeneration deal with Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3648700-evotec-earns-6-milestone-under-neurodegeneration-deal-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7351333498954773
1/5/2021 3:53:58 PM,"Cramer Shares His Thoughts On AT&T, Nantkwest And More",Benzinga,/news/stocks/cramer-shares-his-thoughts-on-at-t-nantkwest-and-more-1029934280,neutral,0.933023989200592
1/5/2021 11:37:37 PM,"BofA's biopharma picks into 2021 set to build with new launches, 'beatable' expectations",Seeking Alpha,https://seekingalpha.com/news/3649105-bofas-biopharma-picks-2021-set-to-build-new-launches-beatable-expectations?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9218690395355225
1/8/2021 3:45:12 PM,Dosing underway in OncoSec's Tavo combo trial in skin cancer,Seeking Alpha,https://seekingalpha.com/news/3649976-dosing-underway-in-oncosecs-tavo-combo-trial-in-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7495701313018799
1/8/2021 4:04:57 PM,"Avidity inks research deal with Bristol Myers' subsidiary, gives 2021 pipeline updates",Seeking Alpha,https://seekingalpha.com/news/3649984-avidity-inks-research-deal-bristol-myers-subsidiary-gives-2021-pipeline-updates?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.709804356098175
1/9/2021 7:45:45 PM,"SPACs Attack Recap: SoFi, IPOE, GXGX, ACEV Deals Plus Rumors And Headlines For Week Ending January 8",Benzinga,/news/stocks/spacs-attack-recap-sofi-ipoe-gxgx-acev-deals-plus-rumors-and-headlines-for-week-ending-january-8-1029945206,neutral,0.934537947177887
1/11/2021 12:10:35 PM,Bristol Myers Squibb approves $2B incremental share repurchase authorization,Seeking Alpha,https://seekingalpha.com/news/3650178-bristol-myers-squibb-approves-2b-incremental-share-repurchase-authorization?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.609778106212616
1/11/2021 1:21:55 PM,Bristol Myers Board Authorizes Incremental Share Repurchase - Quick Facts ,RTTNews,/news/stocks/bristol-myers-board-authorizes-incremental-share-repurchase-quick-facts-1029949273,neutral,0.9270337820053101
1/11/2021 3:12:44 PM,"Amgen, AstraZeneca, Bristol Myers Squibb To Evaluate GRAIL's Cancer Early Detection Test ",RTTNews,/news/stocks/amgen-astrazeneca-bristol-myers-squibb-to-evaluate-grail-s-cancer-early-detection-test-1029955729,neutral,0.8859838843345642
1/11/2021 4:59:22 PM,The Top 7 Pharmaceutical Stocks for the Next 10 Years ,InvestorPlace,/news/stocks/the-top-7-pharmaceutical-stocks-for-the-next-10-years-1029956488,neutral,0.8569133877754211
1/11/2021 8:37:03 PM,"Illumina announces strategic partnership with BMY, KURA, MYGN and Merck to advance comprehensive genomic profiling; provides 2021 guidance",Seeking Alpha,https://seekingalpha.com/news/3650460-illumina-announces-strategic-partnership-bmy-kura-mygn-and-merck-to-advance-comprehensive?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8249000310897827
1/12/2021 2:02:22 PM,Bristol Myers' Onureg OK'd in Canada for acute myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/3650696-bristol-myers-onureg-okd-in-canada-for-acute-myeloid-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7285532355308533
1/12/2021 4:32:16 PM,"Even In This Market, There Are Better Choices Than Pfizer Stock",InvestorPlace,/news/stocks/better-choices-than-pfe-stock-1029961129,neutral,0.7564706206321716
1/13/2021 1:25:38 PM,"The Daily Biotech Pulse: Bausch Health Issues Positive Pre-Announcement, Acorda Streamlines Operations",Benzinga,/news/stocks/the-daily-biotech-pulse-bausch-health-issues-positive-pre-announcement-acorda-streamlines-operations-1029963908,neutral,0.9181805849075317
1/13/2021 7:51:59 PM,7 Pharmaceutical Stocks With Exciting Plans for 2021,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-with-exciting-plans-for-2021-1029966098,neutral,0.7265651822090149
1/14/2021 12:44:19 PM,"NantKwest Reports Positive Interim Data In Pancreatic Cancer Trials, Stock Soars",Benzinga,/news/stocks/nantkwest-reports-positive-interim-data-in-pancreatic-cancer-trials-stock-soars-1029967953,positive,0.9492835402488708
1/14/2021 8:34:12 PM,Invitae teams up with healthcare giants to develop MRD detection panel,Seeking Alpha,https://seekingalpha.com/news/3651590-invitae-teams-up-healthcare-giants-to-develop-mrd-detection-panel?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7389795780181885
1/20/2021 12:19:05 PM,Bristol Myers' two expanded use Opdivo applications accepted by FDA,Seeking Alpha,https://seekingalpha.com/news/3652585-bristol-myers-two-expanded-use-opdivo-applications-accepted-by-fda?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7859432697296143
1/20/2021 1:32:35 PM,"The Daily Biotech Pulse: FDA Greenlights Merck's Heart Failure Drug, Histogen Hit With Clinical Hold, Aptorum Gets Nod For Commencing Human Study",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-greenlights-merck-s-heart-failure-drug-histogen-hit-with-clinical-hold-aptorum-gets-nod-for-commencing-human-study-1029985849,neutral,0.48656928539276123
1/21/2021 2:05:24 PM,"The Daily Biotech Pulse: Addex Jumps On Positive Data For Out-Licensed Drug, COVID-19 Vaccine Developer Inovio Announces $150M Follow-On Offering, Boston Scientific Goes Shopping",Benzinga,/news/stocks/the-daily-biotech-pulse-addex-jumps-on-positive-data-for-out-licensed-drug-covid-19-vaccine-developer-inovio-announces-150m-follow-on-offering-boston-scientific-goes-shopping-1029990203,positive,0.7720287442207336
1/22/2021 6:25:38 PM,Exelixis' CABOMETYX-OPDIVO combo wins FDA approval for renal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3653645-exelixiss-cabometyx-opdivo-combo-wins-fda-approval-for-skin-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.940761148929596
1/22/2021 7:36:14 PM,Exelixis' CABOMETYX-OPDIVO combo wins FDA approval for renal cell carcinoma,Seeking Alpha,https://seekingalpha.com/news/3653645-exelixis-cabometyx-opdivo-wins-fda-for-renal-cell-carcinoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.940761148929596
1/29/2021 12:02:52 AM,"Major pharma set for strong 2021, and trading at a 35% discount to market - J.P. Morgan",Seeking Alpha,https://seekingalpha.com/news/3655985-major-pharma-set-for-strong-2021-and-trading-at-a-35-discount-to-market-jp-morgan?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7956919074058533
1/31/2021 4:49:07 AM,Merck’s Keytruda with Yervoy fail to add clinical benefit in non-small cell lung cancer,Seeking Alpha,https://seekingalpha.com/news/3656446-mercks-keytruda-with-yervoy-fail-to-add-clinical-benefit-in-non-small-cell-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8346368670463562
2/1/2021 5:48:38 PM,Bristol Myers granted priority review for Zeposia in ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3656767-bristol-myers-granted-priority-review-for-zeposia-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.683259129524231
2/2/2021 1:08:54 PM,Bristol Myers announces positive data for deucravacitinib in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3657156-bristol-myers-announced-positive-data-for-deucravacitinib-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.932261049747467
2/2/2021 2:05:48 PM,"The Daily Biotech Pulse: Vertex, Pfizer Earnings, Tiziana COVID-19 Vaccine Data, Decision Day For Mallinckrodt's Burn Treatment",Benzinga,/news/stocks/the-daily-biotech-pulse-vertex-pfizer-earnings-tiziana-covid-19-vaccine-data-decision-day-for-mallinckrodt-s-burn-treatment-1030032611,neutral,0.9199008345603943
2/2/2021 3:01:46 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-stock-1030033135,neutral,0.902914822101593
2/3/2021 1:31:17 PM,"The Daily Biotech Pulse: Amgen Earnings, GSK-CureVac Vaccine Collaboration, Mallinckrodt FDA Decision",Benzinga,/news/stocks/the-daily-biotech-pulse-amgen-earnings-gsk-curevac-vaccine-collaboration-mallinckrodt-fda-decision-1030037844,neutral,0.9407050013542175
2/3/2021 5:02:01 PM,Bristol Myers Squibb Q4 2020 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3657833-bristol-myers-squibb-q4-2020-earnings-preview?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8330729603767395
2/3/2021 5:06:11 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3657838-notable-earnings-before-thursdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.882573127746582
2/3/2021 10:18:54 PM,"4 Top Stock Trades for Thursday: AMZN, SPOT, BMY, ABBV",InvestorPlace,/news/stocks/4-top-stock-trades-for-thursday-amzn-spot-bmy-abbv-1030040762,neutral,0.926028311252594
2/4/2021 12:02:55 PM,"Bristol Myers Squibb EPS beats by $0.04, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3658273-bristol-myers-squibb-eps-beats-0_04-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5620662569999695
2/4/2021 12:52:45 PM,"Sana prices upsized IPO at $25, above the expected range, trades today",Seeking Alpha,https://seekingalpha.com/news/3658334-sana-prices-upsized-ipo-at-25-above-the-expected-range-trades-today?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8467878103256226
2/4/2021 1:14:56 PM,Bristol Myers Squibb Raises 2021 Adj. Earnings Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-raises-2021-adj-earnings-guidance-1030043107,neutral,0.8391827344894409
2/4/2021 1:23:49 PM,Bristol-Myers Squibb Co. Q4 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-adjusted-earnings-beat-estimates-1030043142,positive,0.882439911365509
2/4/2021 1:25:00 PM,Bristol Myers Squibb launches tender offers up to $4B,Seeking Alpha,https://seekingalpha.com/news/3658367-bristol-myers-squibb-launches-tender-offers-up-to-4b?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5243399739265442
2/4/2021 1:30:31 PM,Bristol Myers Squibb rises slightly on Q4 results; raises 2021 earnings guidance,Seeking Alpha,https://seekingalpha.com/news/3658322-bristol-myers-squibb-rises-slightly-on-q4-results-raises-2021-earnings-guidance?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9226185083389282
2/4/2021 4:13:16 PM,Mid-Morning Market Update: Markets Open Higher; Bristol-Myers Squibb Profit Beats Estimates,Benzinga,/news/stocks/mid-morning-market-update-markets-open-higher-bristol-myers-squibb-profit-beats-estimates-1030044505,positive,0.9261133670806885
2/4/2021 6:19:03 PM,Mid-Day Market Update: Gold Down 2.5%; Lizhi Shares Spike Higher,Benzinga,/news/stocks/mid-day-market-update-gold-down-2-5-lizhi-shares-spike-higher-1030044966,negative,0.7573593854904175
2/4/2021 9:07:00 PM,Mid-Afternoon Market Update: Dow Surges Over 250 Points; Lannett Shares Plummet,Benzinga,/news/stocks/mid-afternoon-market-update-dow-surges-over-250-points-lannett-shares-plummet-1030045428,negative,0.9602084755897522
2/4/2021 10:19:00 PM,"Onondaga County Industrial Dev. Agy., NY -- Moody's affirms Bristol's A2 rating; revises outlook to stable",Moodys,/news/bonds/onondaga-county-industrial-dev-agy-ny-moody-s-affirms-bristol-s-a2-rating-revises-outlook-to-stable-1030045764,positive,0.900806188583374
2/4/2021 10:30:00 PM,P.R. Ind Tour Ed Med & Env Ctl Facs Fin Auth -- Moody's affirms Bristol's A2 rating; revises outlook to stable,Moodys,/news/bonds/p-r-ind-tour-ed-med-env-ctl-facs-fin-auth-moody-s-affirms-bristol-s-a2-rating-revises-outlook-to-stable-1030045803,positive,0.8667153120040894
2/5/2021 11:13:17 AM,Bolt Biotherapeutics raises $230M in IPO,Seeking Alpha,https://seekingalpha.com/news/3658964-bolt-biotherapeutics-raises-230m-in-ipo?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6293292045593262
2/5/2021 9:13:52 PM,Bristol Myers Squibb wins FDA approval for lymphoma treatment Breyanzi,Seeking Alpha,https://seekingalpha.com/news/3659240-bristol-myers-squibb-receives-fda-approval-for-liso-cel?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8926932215690613
2/6/2021 6:42:05 PM,"The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-feb-7-13-regeneron-fda-decision-earnings-ipos-and-conference-presentations-in-the-spotlight-1030050676,neutral,0.9400112628936768
2/8/2021 1:46:43 PM,FDA OKs Bristol-Myers Squibb's Breyanzi To Treat Large-B-Cell Lymphoma ,RTTNews,/news/stocks/fda-oks-bristol-myers-squibb-s-breyanzi-to-treat-large-b-cell-lymphoma-1030054786,positive,0.5205705165863037
2/8/2021 5:36:14 PM,Bristol Myers Squibb's Inrebic nabs European Commission approval,Seeking Alpha,https://seekingalpha.com/news/3659568-bristol-myers-squibbs-inrebic-nabs-european-commission-approval?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9298849105834961
2/9/2021 1:56:49 PM,Heat Biologics' shares take off after HS-110-OPDIVO combo shines in mid-stage trial,Seeking Alpha,https://seekingalpha.com/news/3659954-heat-biologics-shares-take-off-after-hs-110-opdivo-combo-shines-in-mid-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9220367074012756
2/9/2021 5:03:37 PM,Bristol Myers announces late-stage data for Opdivo in bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3660036-bristol-myers-announces-late-stage-data-for-opdivo-in-bladder-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5486867427825928
2/9/2021 6:54:56 PM,Infinity loses a fifth ahead of key data readout for eganelisib,Seeking Alpha,https://seekingalpha.com/news/3660119-infinity-loses-a-fifth-ahead-of-key-data-readout-for-eganelisib?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9087817668914795
2/10/2021 2:50:03 PM,7 Retirement Stocks to Buy to Supplement Your 401k,InvestorPlace,/news/stocks/7-retirement-stocks-to-buy-to-supplement-your-401k-1030067410,neutral,0.9165034890174866
2/11/2021 1:26:22 PM,"The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts",Benzinga,/news/stocks/the-daily-biotech-pulse-dermtech-soars-on-contract-fluidigm-plunges-on-earnings-decision-day-for-regeneron-bioventus-debuts-1030072237,negative,0.9134436845779419
2/11/2021 3:13:56 PM,Molecular Templates Shares Jump On Research Pact With Bristol-Myers In Cancer Settings,Benzinga,/news/stocks/molecular-templates-shares-jump-on-research-pact-with-bristol-myers-in-cancer-settings-1030073166,positive,0.6676908135414124
2/16/2021 1:15:33 PM,"Bristol-Myers, Sanofi Ordered To Pay $834 Mln Over Plavix In Hawaii ",RTTNews,/news/stocks/bristol-myers-sanofi-ordered-to-pay-834-mln-over-plavix-in-hawaii-1030086313,neutral,0.5024803876876831
2/16/2021 3:02:23 PM,Bristol Myers' REBLOZYL wins Health Canada approval for transfusion-dependent anemia,Seeking Alpha,https://seekingalpha.com/news/3662262-bristol-myers-reblozyl-wins-health-canada-approval-for-transfusion-dependent-anemia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9194534420967102
2/18/2021 7:55:17 PM,Barclays initiates Cytokinetics with an outperform rating,Seeking Alpha,https://seekingalpha.com/news/3663584-barclays-initiates-cytokinetics-with-outperform-rating?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5832058787345886
2/18/2021 8:39:00 PM,Piper Sandler initiates Infinity Pharmaceuticals at overweight,Seeking Alpha,https://seekingalpha.com/news/3663603-piper-sandler-initiates-infinity-pharmaceuticals-at-overweight?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9052838087081909
2/19/2021 1:00:31 PM,3 High-Quality Health Care Companies With Recession-Proof Dividends,InvestorPlace,/news/stocks/3-high-quality-health-care-companies-with-recession-proof-dividends-1030101483,neutral,0.5856398344039917
2/22/2021 5:12:52 PM,Compugen expands deal with Bristol Myers for phase 1b COM701 combo study,Seeking Alpha,https://seekingalpha.com/news/3664386-compugen-expands-deal-with-bristol-myers-for-phase-1b-com701-combo-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7227017879486084
2/22/2021 7:58:25 PM,"Compugen To Test COM701, Opdivo Combination In Solid Tumor Settings",Benzinga,/news/stocks/compugen-to-test-com701-opdivo-combination-in-solid-tumor-settings-1030109054,neutral,0.6225966215133667
2/24/2021 5:36:40 PM,Bristol-Myers receives FDA’s orphan drug designation for multiple myeloma therapy,Seeking Alpha,https://seekingalpha.com/news/3665668-bristol-myers-receives-fdas-orphan-drug-designation-for-antibody-drug-conjugate?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8908625841140747
2/25/2021 2:21:49 PM,Compugen's COM701 Shows Ongoing Durable Signals In Early-Stage Solid Tumor Studies,Benzinga,/news/stocks/compugen-s-com701-shows-ongoing-durable-signals-in-early-stage-solid-tumor-studies-1030123806,positive,0.9508673548698425
2/25/2021 3:29:30 PM,Bluebird bio up after peer-reviewed publication of ide-cel data in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3666495-bluebird-bio-up-after-peer-reviewed-publication-of-ide-cel-data-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9288263916969299
2/26/2021 11:59:05 AM,Bristol Myers' opdivo combo wins positive opinion from EU in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3667040-ema-backs-bristol-myers-opdivo--cabometyx-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.949276864528656
2/28/2021 4:54:54 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1030132296,neutral,0.9465387463569641
3/1/2021 1:34:04 PM,"Citi reiterates buy, boosts price target of Acceleron shares",Seeking Alpha,https://seekingalpha.com/news/3667535-citi-reiterates-buy-boosts-price-target-of-acceleron-shares?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.723895251750946
3/1/2021 7:11:23 PM,7 Value Stocks Ready for the Next 10 Years,InvestorPlace,/news/stocks/7-value-stocks-ready-for-the-next-10-years-1030136985,neutral,0.8458632230758667
3/3/2021 2:10:42 PM,Heat Biologics shares surge 17% premarket as Cantor initiates with overweight rating,Seeking Alpha,https://seekingalpha.com/news/3668714-heat-biologics-shares-surge-premarket-as-cantor-initiates-with-an-overweight-rating?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8903065323829651
3/8/2021 6:37:03 PM,NIH starts trial enrollment for Bristol/Pfizer's Eliquis for blood clots in COVID patients,Seeking Alpha,https://seekingalpha.com/news/3670365-nih-starts-trial-enrollment-for-bristol-pfizer-eliquis-for-blood-clots-in-covid-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6098648905754089
3/12/2021 12:15:36 PM,AVEO Oncology shares surge on Fotvida deal with BMY in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3672174-aveo-oncology-shares-surge-on-fotvida-deal-with-bmy-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5061119198799133
3/12/2021 1:20:50 PM,"AVEO, Bristol Myers To Evaluate Fotivda - Opdivo In Phase 3 Trial In Relapsed Renal Cell Carcinoma ",RTTNews,/news/stocks/aveo-bristol-myers-to-evaluate-fotivda-opdivo-in-phase-3-trial-in-relapsed-renal-cell-carcinoma-1030178326,positive,0.5362814664840698
3/12/2021 1:36:15 PM,"The Daily Biotech Pulse: Novavax Vaccine Data, ContraFect Secures BARDA Funding, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-novavax-vaccine-data-contrafect-secures-barda-funding-2-ipos-1030178427,neutral,0.7880918979644775
3/12/2021 2:36:38 PM,Aveo Pharma's Tivozanib To Be Tested In Combination With Opdivo In Kidney Cancer,Benzinga,/news/stocks/aveo-pharma-s-tivozanib-to-be-tested-in-combination-with-opdivo-in-kidney-cancer-1030178971,neutral,0.5715140104293823
3/12/2021 6:04:49 PM,Merck and Pfizer among top picks to lead 2021 biopharma M&A activity: Goldman Sachs,Seeking Alpha,https://seekingalpha.com/news/3672343-merck-and-pfizer-among-top-picks-to-lead-2021-biopharma-ma-activity-goldman-sachs?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7542276978492737
3/14/2021 5:40:20 AM,"Big Pharma is pushing back the pandemic, but its stocks are cheap - Barron's",Seeking Alpha,https://seekingalpha.com/news/3672437-big-pharma-is-pushing-back-the-pandemic-but-its-stocks-are-cheap-barrons?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6729743480682373
3/15/2021 3:41:39 PM,"AVEO Pharmaceuticals, CANbridge AV-203 Licensing Deal Axed, AVEO Regains Ex-North American Rights",Benzinga,/news/stocks/aveo-pharmaceuticals-canbridge-av-203-licensing-deal-axed-aveo-regains-ex-north-american-rights-1030205307,negative,0.5616282224655151
3/17/2021 2:15:17 PM,3 Biotech Stocks That Could Double In 12 Months,Benzinga,/news/stocks/3-biotech-stocks-that-could-double-in-12-months-1030219865,positive,0.5742610692977905
3/18/2021 8:42:08 AM,Laryngeal Cancer Therapeutics Market To See $635M Growth By 2025 And These 2 Companies Will Be Key Drivers: Research,Benzinga,/news/stocks/laryngeal-cancer-therapeutics-market-to-see-635m-growth-by-2025-and-these-2-companies-will-be-key-drivers-research-1030222527,positive,0.5240161418914795
3/18/2021 8:35:38 PM,Idera shares plunge 66% following phase 3 melanoma candidate failure (updated),Seeking Alpha,https://seekingalpha.com/news/3674219-idera-melanoma-candidate-tilsotolimod-fails-in-phase-3-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9512199759483337
3/19/2021 11:23:08 AM,FDA accepts Bristol Myers Squibb's mavacamten NDA for review,Seeking Alpha,https://seekingalpha.com/news/3674352-fda-accepts-bristol-myers-squibbs-mavacamten-nda-for-review?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7306187152862549
3/19/2021 12:46:47 PM,"The Daily Biotech Pulse: Sarepta Gene Therapy Data, Idera Plunges On Failed Skin Cancer Study, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-sarepta-gene-therapy-data-idera-plunges-on-failed-skin-cancer-study-3-ipos-1030227585,neutral,0.8705223202705383
3/19/2021 7:30:46 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3674473-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
3/19/2021 7:45:18 PM,Tomslist: The 5 Weirdest Penny Stock Stories of the Week,InvestorPlace,/news/stocks/tomslist-the-5-weirdest-penny-stock-stories-of-the-week-1030229255,neutral,0.7754529714584351
3/20/2021 2:52:32 PM,"FDA Decisions For Pfizer, Eli Lilly And Bluebird Bio, Bristol-Meyers Squibb, Plus New Data And Earnings",Benzinga,/news/stocks/fda-decisions-for-pfizer-eli-lilly-and-bluebird-bio-bristol-meyers-squibb-plus-new-data-and-earnings-1030229632,neutral,0.9303885102272034
3/23/2021 4:46:16 PM,Drug pricing legislation introduced by Sanders weighs on pharmas,Seeking Alpha,https://seekingalpha.com/news/3675361-drug-pricing-legislation-introduced-by-sanders-weighs-on-pharmas?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8964439630508423
3/25/2021 12:58:24 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb's Skin Cancer Readout, Cellect Strikes Reverse Merger Deal, Lava Therapeutics Makes Nasdaq Debut",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-s-skin-cancer-readout-cellect-strikes-reverse-merger-deal-lava-therapeutics-makes-nasdaq-debut-1030245316,neutral,0.8989564776420593
3/25/2021 1:33:54 PM,Bristol Myers Squibb Announces Positive Results For Relativity-047 Study- Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-announces-positive-results-for-relativity-047-study-quick-facts-1030245546,positive,0.9203579425811768
3/25/2021 2:57:21 PM,Bristol-Myers’ win in melanoma described as ‘important' sparking gains in related stocks,Seeking Alpha,https://seekingalpha.com/news/3676307-bristol-myers-win-in-melanoma-described-as-important-sparking-gains-in-related-stocks?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9427799582481384
3/25/2021 4:58:33 PM,IMMP Stock: Why Is Biotech Company Immutep Rocketing Higher Today?,InvestorPlace,/news/stocks/immp-stock-why-is-biotech-company-immutep-rocketing-higher-today-1030247058,positive,0.6529900431632996
3/25/2021 5:22:47 PM,"Why Cellect, Immutep, F-star, ProQR and Evofem Are Moving Thursday",Benzinga,/news/stocks/why-cellect-immutep-f-star-proqr-and-evofem-are-moving-thursday-1030246880,neutral,0.9384923577308655
3/27/2021 3:40:18 AM,Bristol Myers and Bluebird bio win FDA approval for ide-cel in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3677011-bristol-myers-and-bluebird-bio-wins-fda-approval-for-ide-cel-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9088566899299622
3/27/2021 6:09:12 AM,Biotech Stocks Facing FDA Decision In April 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2021-1030251629,neutral,0.77876216173172
3/27/2021 3:40:07 PM,"The Week Ahead In Biotech (March 28-April 3): Acadia's Dementia Drug Update, Clinical Readouts, Few Earnings In Holiday-Shortened Week",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-28-april-3-acadia-s-dementia-drug-update-clinical-readouts-few-earnings-in-holiday-shortened-week-1030251902,negative,0.8516553044319153
3/29/2021 2:01:21 PM,FDA Approves First Cell-Based Gene Therapy For Adult Multiple Myeloma Patients ,RTTNews,/news/stocks/fda-approves-first-cell-based-gene-therapy-for-adult-multiple-myeloma-patients-1030254249,neutral,0.4982757568359375
3/29/2021 3:46:27 PM,"Why Humanigen, uniQure, bluebird bio, Amphastar Are Rallying Monday",Benzinga,/news/stocks/why-humanigen-uniqure-bluebird-bio-amphastar-are-rallying-monday-1030254941,neutral,0.6843326687812805
3/30/2021 12:23:54 PM,Bristol-Myers Squibb and Huyabio partner for Opdivo combo,Seeking Alpha,https://seekingalpha.com/news/3677535-bristol-myers-squibb-and-huyabio-partner-for-opdivo-combo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9311160445213318
3/31/2021 1:41:12 PM,"The Daily Biotech Pulse: Pfizer Vaccine 100% Effective In Adolescents, Equillium Readout, Amgen Goes Shopping, Achilles IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-vaccine-100-effective-in-adolescents-equillium-readout-amgen-goes-shopping-achilles-ipo-1030263061,neutral,0.8173462152481079
4/2/2021 5:20:07 PM,IRS alleges Bristol-Myers Squibb owes more than $1B in taxes from offshore scheme - NYT,Seeking Alpha,https://seekingalpha.com/news/3678983-irs-alleges-bristol-myers-squibb-owes-more-than-1b-in-taxes-from-offshore-scheme-nyt?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7147105932235718
4/5/2021 6:29:38 PM,7 Stocks That Could Double by Summer,InvestorPlace,/news/stocks/7-stocks-that-could-double-by-summer-1030274749,neutral,0.5795609354972839
4/8/2021 12:15:35 PM,The 7 Best Startups You Can Buy on StartEngine Right Now,InvestorPlace,/news/stocks/the-7-best-equity-crowdfunding-startups-you-can-buy-on-startengine-right-now-1029812989,neutral,0.905422568321228
4/8/2021 12:29:05 PM,IMMP Stock: The Big Patent News Boosting Immutep Today,InvestorPlace,/news/stocks/immp-stock-the-big-patent-news-boosting-immutep-today-1030286138,positive,0.9349989891052246
4/8/2021 2:14:49 PM,"The Daily Biotech Pulse: Immutep Extends Run, FDA Nod For Gilead, Merck, Bristol-Myers Squibb Release Late-Stage Cancer Immunotherapy Data",Benzinga,/news/stocks/the-daily-biotech-pulse-immutep-extends-run-fda-nod-for-gilead-merck-bristol-myers-squibb-release-late-stage-cancer-immunotherapy-data-1030285466,neutral,0.8932458758354187
4/9/2021 5:25:37 PM,Sanofi confirms partial response for cancer therapy in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3680754-sanofi-confirms-partial-response-for-cancer-therapy-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8046162724494934
4/10/2021 6:11:55 PM,Bristol Myers unveils positive data for Opdivo in late-stage lung cancer study,Seeking Alpha,https://seekingalpha.com/news/3680844-bristol-myers-unveils-positive-data-for-opdivo-in-late-stage-lung-cancer-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9347553849220276
4/13/2021 12:58:17 PM,"IRhythm extends losses as more downgrades pile up, Aphria cut to neutral after earnings miss; and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3681313-irhythm-extends-losses-as-more-downgrades-pile-up-aphria-cut-to-neutral?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.896338701248169
4/13/2021 4:05:53 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-13-2021-1030299179,negative,0.5708066821098328
4/13/2021 4:27:08 PM,Bristol-Myers raised to buy at Truist on pipeline strength,Seeking Alpha,https://seekingalpha.com/news/3681434-bristol-myers-raised-to-buy-at-truist-on-pipeline-strength?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5014994740486145
4/13/2021 6:03:06 PM,Why This Bristol-Myers Squibb Stock Analyst Is Turning Bullish On The Pharma Company's Pipeline,Benzinga,/news/stocks/why-this-bristol-myers-squibb-stock-analyst-is-turning-bullish-on-the-pharma-company-s-pipeline-1030299606,neutral,0.7752826809883118
4/14/2021 11:25:26 PM,Bristol Myers' Nivolumab Approved By EU For Kidney Cancer Treatment ,RTTNews,/news/stocks/bristol-myers-nivolumab-approved-by-eu-for-kidney-cancer-treatment-1030305573,positive,0.7361876368522644
4/15/2021 1:49:24 PM,"The Daily Biotech Pulse: Merck Shelves 2 COVID-19 Studies, Bristol-Myers Squibb Gets European Regulatory Nod, InspireMD's Reverse Split",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-shelves-2-covid-19-studies-bristol-myers-squibb-gets-european-regulatory-nod-inspiremd-s-reverse-split-1030307762,neutral,0.8539385199546814
4/16/2021 5:09:17 PM,FDA approves Bristol's Opdivo as first-line gastric cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3682658-fda-approves-bristol-myers-squibb-opdivo-as-first-line-gastric-cancer-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7022787928581238
4/18/2021 1:18:56 AM,AACR 2021 highlights Eli Lilly’s new KRAS battle; Affimed’s Natural Killer cell therapy,Seeking Alpha,https://seekingalpha.com/news/3682763-eli-lillys-kras-battle-affimeds-new-cell-therapy-graced-aacr-2021?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6620311141014099
4/19/2021 12:35:28 PM,First FDA-approved Immunotherapy For First Treatment Of Gastric Cancer ,RTTNews,/news/stocks/first-fda-approved-immunotherapy-for-first-treatment-of-gastric-cancer-1030316894,neutral,0.5695645809173584
4/20/2021 2:06:58 PM,"The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex",Benzinga,/news/stocks/the-daily-biotech-pulse-q1-beat-from-johnson-johnson-kalvista-study-placed-on-hold-european-label-expansion-for-gw-pharma-s-epidiolex-1030322640,neutral,0.7906162738800049
4/21/2021 12:25:25 PM,"Intuitive Surgical upgraded after earnings beat; Oppenheimer sizes up new Vertex – CRISPR deal, and more in today’s analyst action",Seeking Alpha,https://seekingalpha.com/news/3683885-intuitive-surgical-upgraded-after-earnings-beat-oppenheimer-sizes-up-new-vertex-crispr-deal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8570231795310974
4/22/2021 7:47:21 PM,House Democrats reintroduce bill to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3684755-house-democrats-reintroduce-bill-to-lower-drug-prices?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6614382266998291
4/23/2021 11:03:22 AM,Bristol Myers' Opdivo + Yervoy gets positive CHMP opinion for malignant pleural mesothelioma,Seeking Alpha,https://seekingalpha.com/news/3685006-bristol-myers-opdivo-yervoy-gets-positive-chmp-opinion-for-malignant-pleural-mesothelioma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9456399083137512
4/23/2021 11:03:32 AM,"Accelerated approvals for cancer therapies from Merck, Bristol-Myers and Roche to come under FDA review next week",Seeking Alpha,https://seekingalpha.com/news/3685007-merck-bristol-myers-and-roche-cancer-therapies-to-come-under-fda-review-next-week?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7591325044631958
4/23/2021 1:07:27 PM,Bristol Myers Gets Positive CHMP Opinion For Opdivo Plus Yervoy As First-Line Treatment For MPM ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-as-first-line-treatment-for-mpm-1030338208,positive,0.9381593465805054
4/24/2021 3:24:00 PM,"The Week Ahead In Biotech (April 25-May 1): FDA Decisions For Sol-Gel, Protalix Bio, Ardelyx",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-25-may-1-fda-decisions-for-sol-gel-protalix-bio-ardelyx-1030340692,neutral,0.9154147505760193
4/27/2021 3:02:23 PM,Bristol-Myers Squibb is about to announce earnings — here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q1-1030351680,neutral,0.9328253269195557
4/27/2021 5:31:39 PM,4 Up-and-Coming Stocks to Buy in Shifting Sectors,InvestorPlace,/news/stocks/4-up-and-coming-stocks-to-buy-in-shifting-sectors-1030353596,neutral,0.8458243012428284
4/28/2021 2:29:03 PM,7 Pharmaceutical Stocks With Dividends in Hand,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-dividends-in-hand-1030359387,neutral,0.926287829875946
4/29/2021 10:00:37 AM,7 Pharmaceutical Stocks To Buy For Valuation Plus Solid Dividends,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-to-buy-for-valuation-plus-solid-dividends-1030363716,positive,0.5524899959564209
4/29/2021 11:53:58 AM,Bristol Myers slips 3% as Q1 trails estimates; GAAP EPS guidance raised,Seeking Alpha,https://seekingalpha.com/news/3687774-bristol-myers-slips-3-as-q1-trails-estimates-gaap-eps-guidance-raised?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6849583983421326
4/29/2021 1:40:50 PM,Bristol Myers Squibb Q1 Profit Misses Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-q1-profit-misses-estimates-1030364329,negative,0.8368811011314392
4/29/2021 2:15:50 PM,"The Daily Biotech Pulse: Clinical Setback For Adverum, Galera Posts Data Readout, Moderna To Invest In Vaccine Manufacturing, Decision Day For Ardelyx",Benzinga,/news/stocks/the-daily-biotech-pulse-clinical-setback-for-adverum-galera-posts-data-readout-moderna-to-invest-in-vaccine-manufacturing-decision-day-for-ardelyx-1030364740,neutral,0.771758496761322
4/30/2021 11:44:50 AM,FDA accepts Bristol Myers' Opdivo sBLA for priority review,Seeking Alpha,https://seekingalpha.com/news/3688578-fda-accepts-bristol-myers-opdivo-sbla-for-priority-review?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6888764500617981
4/30/2021 12:29:16 PM,FDA panel denies support for maintaining Bristol's Opdivo as liver cancer treatment,Seeking Alpha,https://seekingalpha.com/news/3688609-fda-panel-denies-support-for-maintaining-bristol-opdivo-as-liver-cancer-treatment?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.48925021290779114
4/30/2021 1:25:49 PM,"Bristol-Myers cut to neutral, Community Health upgraded in today's healthcare analyst action",Seeking Alpha,https://seekingalpha.com/news/3688674-bristol-myers-cut-to-neutral-at-morgan-stanly-community-health-upgraded-after-q1-results?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6803359985351562
4/30/2021 1:31:19 PM,"The Daily Biotech Pulse: Hyperphosphatemia Drug Regulatory Review Extended, Phathom Pharma Data Readout, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-hyperphosphatemia-drug-regulatory-review-extended-phathom-pharma-data-readout-2-ipos-1030369950,neutral,0.8963311314582825
4/30/2021 3:26:18 PM,Bristol-Myers downgraded at Morgan Stanley citing uncertainty over pipeline,Seeking Alpha,https://seekingalpha.com/news/3688742-bristol-myers-downgraded-at-morgan-stanley-citing-uncertainty-over-pipeline?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9518553614616394
4/30/2021 4:04:14 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 30, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-30-2021-1030370728,negative,0.5600295662879944
5/1/2021 5:43:35 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1030373547,neutral,0.9478530883789062
5/4/2021 3:40:26 PM,Shares of major drug makers in focus as House committees hold hearings on drug pricing bill,Seeking Alpha,https://seekingalpha.com/news/3690229-shares-of-major-drug-makers-in-focus-as-house-committees-hold-hearings-on-drug-pricing-bill?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6773344278335571
5/8/2021 2:25:37 PM,Payrolls shock doesn't mean inflation reprieve; Here's a way to position: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3693599-payrolls-shock-doesnt-mean-inflation-reprieve-heres-a-way-to-position-alpha-tactics?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9151424169540405
5/12/2021 3:18:26 PM,Why These 3 Top Stocks Are Better Buys Than Dogecoin,InvestorPlace,/news/stocks/why-these-3-top-stocks-are-better-buys-than-dogecoin-1030422217,neutral,0.7925088405609131
5/12/2021 4:37:14 PM,Bristol presenting slew of Opdivo + Yervoy data at ASCO next month,Seeking Alpha,https://seekingalpha.com/news/3695373-bristol-presenting-slew-of-opdivo-yervoy-data-at-asco-next-month?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.901715099811554
5/14/2021 7:04:33 AM,Cathie Wood Sheds $33.6M Alibaba Shares On Earnings Day,Benzinga,/news/stocks/cathie-wood-sheds-33-6m-alibaba-shares-on-earnings-day-1030429592,negative,0.6546692848205566
5/14/2021 2:25:03 PM,7 Reddit Penny Stocks Promising to Cure Cancer,InvestorPlace,/news/stocks/7-reddit-penny-stocks-promising-cure-cancer-1030431464,positive,0.5661170482635498
5/14/2021 7:30:08 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3696746-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
5/15/2021 3:48:59 PM,"The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off",Benzinga,/news/stocks/the-week-ahead-in-biotech-sanofi-bristol-myers-squibb-await-fda-decisions-earnings-news-flow-tapers-off-1030432632,negative,0.6165412068367004
5/16/2021 2:12:54 AM,Bristol Myers’ mavacamten improves health status in patients with obstructive hypertrophic cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3696875-bristol-myers-mavacamten-improves-patients-with-obstructive-hypertrophic-cardiomyopathy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9334419965744019
5/17/2021 6:35:57 PM,"Wedgewood takes new position in ODFL, trims Apple, Visa adds Progressive",Seeking Alpha,https://seekingalpha.com/news/3697303-wedgewood-takes-new-position-in-odfl-trims-apple-visa-adds-progressive?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.772682785987854
5/18/2021 7:20:45 AM,Cathie Wood Cuts Apple Stake Almost Entirely — And Buys More Coinbase,Benzinga,/news/stocks/cathie-wood-cuts-apple-stake-almost-entirely-—-and-buys-more-coinbase-1030439382,neutral,0.8073784708976746
5/18/2021 11:43:46 AM,Bristol Myers Squibb and Agenus ink exclusive global license for antibody program,Seeking Alpha,https://seekingalpha.com/news/3697662-bristol-myers-squibb-and-agenus-ink-exclusive-global-license-for-antibody-program?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7160522937774658
5/18/2021 2:12:49 PM,"Agenus Grants Bristol Myers Squibb License To Bispecific Antibody Program, AGEN1777 - Quick Facts ",RTTNews,/news/stocks/agenus-grants-bristol-myers-squibb-license-to-bispecific-antibody-program-agen1777-quick-facts-1030441057,neutral,0.7018378973007202
5/18/2021 3:16:15 PM,Bristol Myers Inks $1.6B Licensing Agreement For Agenus' Bispecific Antibody Program In Solid Tumors,Benzinga,/news/stocks/bristol-myers-inks-1-6b-licensing-agreement-for-agenus-bispecific-antibody-program-in-solid-tumors-1030441819,positive,0.8687772154808044
5/18/2021 6:39:22 PM,"Q1 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q1-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030442901,neutral,0.8799788951873779
5/19/2021 10:35:54 AM,Bristol-Myers and Exscientia team up for an AI-driven approach to drug discovery,Seeking Alpha,https://seekingalpha.com/news/3698099-bristol-myers-and-exscientia-team-up-for-an-ai-driven-approach-to-drug-discovery?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7185668349266052
5/19/2021 1:30:16 PM,"The Daily Biotech Pulse: Iovance To Delay Regulatory Filing For Cancer Therapy, Departures At Passage Bio, Positive Readout For Silence Therapeutics",Benzinga,/news/stocks/the-daily-biotech-pulse-iovance-to-delay-regulatory-filing-for-cancer-therapy-departures-at-passage-bio-positive-readout-for-silence-therapeutics-1030445806,neutral,0.6067519783973694
5/19/2021 9:45:01 PM,Bristol's Opdivo + relatlimab combo beats Opdivo alone in melanoma trial,Seeking Alpha,https://seekingalpha.com/news/3698472-bristol-opdivo-relatlimab-combo-beats-opdivo-alone-in-melanoma-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8044126629829407
5/20/2021 2:27:03 PM,"The Daily Biotech Pulse: Pfizer-BioNTech COVID-19 Order Flow Abounds, Voyager CEO, CMO To Depart, Decision Day For Bristol-Myers Squibb, ASCO Abstracts Move Stocks",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-biontech-covid-19-order-flow-abounds-voyager-ceo-cmo-to-depart-decision-day-for-bristol-myers-squibb-asco-abstracts-move-stocks-1030450798,neutral,0.6443597674369812
5/20/2021 4:29:42 PM,7 Value Stocks With at Least 50% Upside,InvestorPlace,/news/stocks/seven-value-stocks-with-at-least-fifty-percent-upside-1030452547,neutral,0.9307652115821838
5/20/2021 5:48:09 PM,Bristol hits 52-week high following release of ASCO abstracts,Seeking Alpha,https://seekingalpha.com/news/3698807-bristol-hits-52-week-high-following-release-of-asco-abstracts?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7499529719352722
5/21/2021 7:30:52 PM,Seeking Alpha Catalyst Watch,Seeking Alpha,https://seekingalpha.com/news/3699216-seeking-alpha-catalyst-watch?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8980498313903809
5/21/2021 8:35:43 PM,Bristol Myers wins positive opinion in Europe for Opdivo and Yervoy combo for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3699260-bristol-myers-wins-positive-opinion-in-europe-for-opdivo-and-yervoy-combo-for-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9486148953437805
5/24/2021 10:00:31 AM,Bristol releases positive new data on ulcerative colitis candidate Zeposia,Seeking Alpha,https://seekingalpha.com/news/3699309-bristol-releases-positive-new-data-on-ulcerative-colitis-candidate-zeposia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5829702019691467
5/24/2021 2:00:02 PM,CAR T therapy competition heats up as Allogene plans pivotal trial,Seeking Alpha,https://seekingalpha.com/news/3699437-car-t-therapy-competition-heats-up-as-allogene-plans-pivotal-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7912172675132751
5/25/2021 12:35:24 PM,Xencor and Bristol Myers Squibb ink technology license agreement,Seeking Alpha,https://seekingalpha.com/news/3699812-xencor-and-bristol-myers-squibb-ink-technology-license-agreement?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8939723968505859
5/25/2021 1:53:39 PM,"The Daily Biotech Pulse: Pfizer In Vaccine Supply Talks With India, Provention In Focus Ahead Of Briefing Doc, NeuroRx To List Via SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-in-vaccine-supply-talks-with-india-provention-in-focus-ahead-of-briefing-doc-neurorx-to-list-via-spac-deal-1030461990,neutral,0.8795015811920166
5/25/2021 2:33:06 PM,"Xencor, Bristol Myers Ink License Deal To Use Xtend XmAb Technology To Treat COVID-19 - Quick Facts ",RTTNews,/news/stocks/xencor-bristol-myers-ink-license-deal-to-use-xtend-xmab-technology-to-treat-covid-19-quick-facts-1030462328,positive,0.7447991371154785
5/27/2021 8:09:10 PM,Phase 2 trials begin of OSE's vaccine with Bristol's Opdivo in NSCLC,Seeking Alpha,https://seekingalpha.com/news/3700956-phase-2-trials-begins-of-oses-vaccine-with-bristols-opdivo-in-nsclc?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7834436297416687
5/27/2021 8:28:59 PM,Bristol Myers wins FDA approval for expanded use of Zeposia in ulcerative colitis,Seeking Alpha,https://seekingalpha.com/news/3700996-bristol-myers-wins-fda-approval-for-expanded-use-of-zeposia-in-ulcerative-colitis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9295312762260437
5/28/2021 2:02:01 PM,"The Daily Biotech Pulse: Biohaven, Bristol-Myers Squibb Snag FDA Approvals, Iterum UTI Drug Review On Track, Centessa Pharmaceuticals Debuts On Nasdaq",Benzinga,/news/stocks/the-daily-biotech-pulse-biohaven-bristol-myers-squibb-snag-fda-approvals-iterum-uti-drug-review-on-track-centessa-pharmaceuticals-debuts-on-nasdaq-1030475070,neutral,0.7768646478652954
5/28/2021 7:00:20 PM,Amgen's Lumakras can target 13% of the NSCLC market,Seeking Alpha,https://seekingalpha.com/news/3701338-amgen-mirati-lumakras-can-target-13-of-the-nsclc-market?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8503681421279907
5/31/2021 5:06:35 PM,"The Week Ahead In Biotech: ASCO Presentations Front And Center, FDA Decisions Due For Scynexis, Liminal And Alkermes",Benzinga,/news/stocks/the-week-ahead-in-biotech-asco-presentations-front-and-center-fda-decisions-due-for-scynexis-liminal-and-alkermes-1030479173,neutral,0.9343029260635376
6/1/2021 3:34:46 PM,BTIG's best and worst stocks for Operation Grand Slam,Seeking Alpha,https://seekingalpha.com/news/3701738-btigs-best-and-worst-stocks-for-operation-grand-slam?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.5692315101623535
6/2/2021 1:24:03 PM,EC Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts ,RTTNews,/news/stocks/ec-approves-bristol-myers-opdivo-plus-yervoy-to-treat-mesothelioma-quick-facts-1030486584,neutral,0.5158997178077698
6/2/2021 2:20:24 PM,"The Daily Biotech Pulse: FDA Nod For Novartis, iRhythm CEO Quits Abruptly, Moderna Inks Vaccine Supply Agreements",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-nod-for-novartis-irhythm-ceo-quits-abruptly-moderna-inks-vaccine-supply-agreements-1030486987,neutral,0.7045095562934875
6/2/2021 2:21:09 PM,Health Canada Approves Bristol Myers' Opdivo Plus Yervoy To Treat Mesothelioma - Quick Facts ,RTTNews,/news/stocks/health-canada-approves-bristol-myers-opdivo-plus-yervoy-to-treat-mesothelioma-quick-facts-1030486996,positive,0.6796274781227112
6/3/2021 2:02:55 PM,Diversifying to Conquer: Fortress Biotech (FBIO) Partnering Expansion Driving Progress in Cancer Immunotherapy and Rare Disease Therapeutics,Benzinga,/news/stocks/diversifying-to-conquer-fortress-biotech-fbio-partnering-expansion-driving-progress-in-cancer-immunotherapy-and-rare-disease-therapeutics-1030490924,positive,0.731474757194519
6/3/2021 2:23:31 PM,"The Daily Biotech Pulse: Merck Completes Organon Spin-Off, Auris Repositions As RNA Therapeutic Company With Trasir Purchase, Replimune's Readout",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-completes-organon-spin-off-auris-repositions-as-rna-therapeutic-company-with-trasir-purchase-replimune-s-readout-1030491248,neutral,0.8467225432395935
6/3/2021 4:15:41 PM,Bristol-Myers sued for $6.4 billion in alleged delay in seeking FDA approval for Celgene drug,Seeking Alpha,https://seekingalpha.com/news/3702981-bristol-myers-sued-for-64-billion-in-alleged-delay-in-seeking-fda-approval-for-celgene-drug?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9300118088722229
6/4/2021 3:39:13 PM,"The Daily Biotech Pulse: Merck, AstraZeneca, Novartis Among Early Presenters At ASCO, Sanofi Strikes Breast Cancer Study Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-astrazeneca-novartis-among-early-presenters-at-asco-sanofi-strikes-breast-cancer-study-pact-1030495387,neutral,0.9197813272476196
6/7/2021 2:52:10 PM,"The Week Ahead In Biotech: Biogen, Alexion And Vertex FDA Decisions, Multiple Conference Presentations On The Deck",Benzinga,/news/stocks/the-week-ahead-in-biotech-biogen-alexion-and-vertex-fda-decisions-multiple-conference-presentations-on-the-deck-1030499585,neutral,0.9329092502593994
6/8/2021 3:37:52 PM,5 Healthcare Stocks to Buy for Their Game-Changing Potential,InvestorPlace,/news/stocks/5-healthcare-stocks-to-buy-for-their-game-changing-potential-1030504685,neutral,0.6112402677536011
6/10/2021 11:21:12 AM,Bristol Myers announces positive topline data for Breyanzi in B-cell Lymphoma as second-line therapy,Seeking Alpha,https://seekingalpha.com/news/3704917-bristol-myers-announces-positive-topline-data-for-breyanzi-in-b-cell-lymphoma-as-second-line-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9208344221115112
6/10/2021 11:23:45 AM,Bristol Myers announces positive topline data for Breyanzi in B-cell Lymphoma as second-line therapy,Seeking Alpha,https://seekingalpha.com/news/3704923-bristol-myers-announces-positive-topline-data-for-breyanzi-in-b-cell-lymphoma-as-second-line-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9208344221115112
6/10/2021 1:59:24 PM,BMY Reports Positive Results From Phase 3 Breyanzi Trial In Second-line Relapsed Or Refractory LBCL ,RTTNews,/news/stocks/bmy-reports-positive-results-from-phase-3-breyanzi-trial-in-second-line-relapsed-or-refractory-lbcl-1030511321,positive,0.9467548727989197
6/10/2021 2:13:41 PM,"The Daily Biotech Pulse: US To Procure 500M Pfizer-BioNTech Vaccine Doses For Donation, Verona Out-Licenses COPD Drug, Nautilus Lists Through SPAC Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-us-to-procure-500m-pfizer-biontech-vaccine-doses-for-donation-verona-out-licenses-copd-drug-nautilus-lists-through-spac-deal-1030511571,neutral,0.7452279329299927
6/11/2021 11:01:19 AM,"Bristol Myers, Acceleron's Reblozyl shows encouraging action in adults with beta thalassemia",Seeking Alpha,https://seekingalpha.com/news/3705553-bristol-myers-accelerons-reblozyl-shows-encouraging-action-in-adults-with-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9428809285163879
6/11/2021 11:43:09 AM,"BMY, Acceleron Announce New Data From Reblozyl Phase 2 Trial For Adults With NTD Beta Thalassemia ",RTTNews,/news/stocks/bmy-acceleron-announce-new-data-from-reblozyl-phase-2-trial-for-adults-with-ntd-beta-thalassemia-1030515035,neutral,0.8035114407539368
6/14/2021 2:34:07 PM,"Exelixis, Bristol Myers To Evaluate XL092-Immuno-oncology Therapies In Advanced Solid Tumors ",RTTNews,/news/stocks/exelixis-bristol-myers-to-evaluate-xl092-immuno-oncology-therapies-in-advanced-solid-tumors-1030519727,neutral,0.7711631059646606
6/16/2021 6:30:10 PM,"Why Kindred Biosciences, Aprea, Catabasis And Inhibikase Are Moving Today",Benzinga,/news/stocks/why-kindred-biosciences-aprea-catabasis-and-inhibikase-are-moving-today-1030529318,neutral,0.9361141920089722
6/17/2021 8:19:05 PM,Bristol-Myers Squibb Company declares $0.49 dividend,Seeking Alpha,https://seekingalpha.com/news/3707463-bristol-myers-squibb-company-declares-0_49-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8658979535102844
6/18/2021 5:15:35 AM,Bristol Myers Enters Into Collaboration For Eisai's MORAb-202 Antibody Drug Conjugate ,RTTNews,/news/stocks/bristol-myers-enters-into-collaboration-for-eisai-s-morab-202-antibody-drug-conjugate-1030534186,positive,0.5024679899215698
6/18/2021 11:17:21 AM,Bristol Myers to pay more than $2 billion to Eisai in a deal for experimental cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3707580-bristol-myers-to-pay-more-than-2-billion-to-eisai-in-a-deal-for-experimental-cancer-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.533284604549408
6/18/2021 1:46:03 PM,"The Daily Biotech Pulse: Orphazyme Falters At FDA, Athira's CEO Placed On Temporary Leave, 5 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-orphazyme-falters-at-fda-athira-s-ceo-placed-on-temporary-leave-5-ipos-1030535179,negative,0.951781153678894
6/18/2021 2:10:31 PM,Could Bristol's up to $3B Eisai deal follow in footsteps of 2019 AstraZeneca deal with Daiichi?,Seeking Alpha,https://seekingalpha.com/news/3707684-could-bristol-up-to-3b-eisai-deal-follow-in-footsteps-of-2019-astrazeneca-deal-with-daiichi?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7558178901672363
6/18/2021 3:59:06 PM,Bristol's up to $3B deal with Eisai puts antibody drug conjugates in the spotlight,Seeking Alpha,https://seekingalpha.com/news/3707699-bristols-up-to-3b-deal-with-eisai-puts-antibody-drug-conjugates-in-the-spotlight?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6646013259887695
6/22/2021 3:12:00 PM,Sen. Wyden releases 'principles for drug pricing reform',Seeking Alpha,https://seekingalpha.com/news/3708721-sen-wyden-releases-principles-for-drug-price-reform?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8699350357055664
6/23/2021 6:44:55 PM,14 Biotech Stocks To Watch Over The Next 6 Months,Benzinga,/news/stocks/14-biotech-stocks-to-watch-over-the-next-6-months-1030548271,neutral,0.9149301052093506
6/24/2021 12:55:16 PM,Prothena secures $80M from Bristol Myers for US license to PRX005,Seeking Alpha,https://seekingalpha.com/news/3709538-prothena-secures-80m-from-bristol-myers-for-us-license-to-prx005?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8402643799781799
6/24/2021 2:59:21 PM,Prothena To Receive $80 Mln From Bristol Myers For US License To PRX005 On Alzheimer's Disease ,RTTNews,/news/stocks/prothena-to-receive-80-mln-from-bristol-myers-for-us-license-to-prx005-on-alzheimer-s-disease-1030551183,positive,0.7840529084205627
6/25/2021 11:33:44 AM,Bristol Myers wins positive CHMP opinion for Abecma in multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3710061-bristol-myers-wins-positive-chmp-opinion-for-abecma-in-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9450388550758362
6/25/2021 11:40:28 AM,Bristol Myers wins positive CHMP opinion for Opdivo in esophageal cancer,Seeking Alpha,https://seekingalpha.com/news/3710065-bristol-myers-wins-positive-chmp-opinion-for-opdivo-in-esophageal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9448764324188232
6/25/2021 1:32:32 PM,"The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-roche-gets-authorization-for-covid-19-treatment-nods-for-sanofi-regeneron-in-europe-osmotica-divestment-2-ipos-1030554577,positive,0.7482125759124756
6/25/2021 1:40:07 PM,Bristol Myers Gets Positive CHMP Opinion For Opdivo To Treat Esophageal Cancer ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-to-treat-esophageal-cancer-1030554603,positive,0.9477167725563049
6/25/2021 1:47:23 PM,Bristol Myers Gets Positive CHMP Opinion For Abecma On Relapsed & Refractory Multiple Myeloma ,RTTNews,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-abecma-on-relapsed-refractory-multiple-myeloma-1030554633,positive,0.9411603212356567
6/28/2021 6:52:51 PM,"Bristol-Myers likely to settle lawsuit related to CVR for Celgene drug potentially for $3B-$4B, analyst says",Seeking Alpha,https://seekingalpha.com/news/3710675-bristol-meyers-likely-to-settle-lawsuit-related-to-cvr-for-celgene-drug-potentially-for-3b-4b-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.544437050819397
6/28/2021 7:28:07 PM,"Bristol-Myers likely to settle lawsuit related to Celgene drug CVR, analyst says",Seeking Alpha,https://seekingalpha.com/news/3710675-bristol-myers-likely-to-settle-lawsuit-related-to-cvr-for-celgene-drug-potentially-for-3b-4b-analyst-says?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5008522272109985
6/29/2021 11:19:02 AM,Bristol Myers' Opdivo + Yervoy combo OK'd in Europe for colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/3710849-bristol-myers-opdivo-yervoy-combo-okd-in-europe-for-colorectal-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5727260112762451
6/29/2021 1:38:19 PM,EC Approves Bristol Myers' Opdivo - Yervoy For Mismatch Repair Deficient Treatment ,RTTNews,/news/stocks/ec-approves-bristol-myers-opdivo-yervoy-for-mismatch-repair-deficient-treatment-1030562314,positive,0.816749095916748
6/29/2021 1:55:35 PM,"Sensei downgraded, PT cut on program discontinuation, Gilead's Yescarta data, and more in analyst action",Seeking Alpha,https://seekingalpha.com/news/3710900-sensei-downgraded-price-target-cut-on-program-discontinuation-gileads-yescarta-data-and-more-in-analyst-action?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.657747745513916
6/30/2021 1:10:30 PM,Dosing underway in Compugen's COM701/Opdivo Phase 1b cohort expansion study,Seeking Alpha,https://seekingalpha.com/news/3711352-dosing-underway-in-compugens-com701opdivo-phase-1b-cohort-expansion-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7646780610084534
7/1/2021 6:50:48 PM,Eisai and Lilly among top H1 gainers in big pharma; Viatris and Merck trail,Seeking Alpha,https://seekingalpha.com/news/3712052-eisai-and-lilly-among-top-h1-gainers-in-big-pharma-as-viatris-and-merck-trail?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8283567428588867
7/6/2021 3:40:59 PM,Agenus receives $200M payment as part of agreement with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3712982-agenus-receives-200m-payment-as-part-of-agreement-with-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6242650747299194
7/7/2021 10:49:38 AM,Mid-size pharmaceutical firms lead bigger rivals in acquisitions this year,Seeking Alpha,https://seekingalpha.com/news/3713185-mid-size-pharmaceutical-firms-lead-bigger-rivals-in-acquisitions-this-year?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6112602353096008
7/8/2021 4:00:00 PM,"After Second Look Oncopeptides' Melflufen Wins Head-To-Head Myeloma Trial, But Difference In OS Triggers FDA Hold",Benzinga,/news/stocks/after-second-look-oncopeptides-melflufen-wins-head-to-head-myeloma-trial-but-difference-in-os-triggers-fda-hold-1030590169,neutral,0.4021012485027313
7/8/2021 4:27:00 PM,Stay Away From Low-Growth Organon,InvestorPlace,/news/stocks/low-growth-weak-catalysts-ogn-stock-unattractive-1030590811,neutral,0.9079623818397522
7/15/2021 12:38:46 PM,"XOMA Buys Royalty, Milestone Interest In Checkmate's Vidutolimod From Kuros Biosciences",Benzinga,/news/stocks/xoma-buys-royalty-milestone-interest-in-checkmate-s-vidutolimod-from-kuros-biosciences-1030610392,neutral,0.8485706448554993
7/15/2021 2:07:56 PM,"The Daily Biotech Pulse: Galapagos Sinks On Data, J&J Recalls Sunscreen Products, FibroGen Awaits AdCom Verdict, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-galapagos-sinks-on-data-j-j-recalls-sunscreen-products-fibrogen-awaits-adcom-verdict-3-ipos-1030610817,neutral,0.6488493084907532
7/16/2021 11:46:00 AM,Bristol-Myers Squibb's Opdivo combo fails to meet main goals in late-stage cancer trial,Seeking Alpha,https://seekingalpha.com/news/3715897-bristol-myers-squibbs-opdivo-combo-fails-to-meet-main-goals-in-late-stage-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.876872181892395
7/16/2021 1:37:29 PM,"The Daily Biotech Pulse: Moderna To Join S&P 500 Index, Thumbs Down For FibroGen's Anemia Drug, Corvus Shelves COVID Study",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-to-join-s-p-500-index-thumbs-down-for-fibrogen-s-anemia-drug-corvus-shelves-covid-study-1030614895,negative,0.7197924256324768
7/16/2021 1:56:15 PM,Bristol Myer : Phase 3 Trial On Head & Neck Cancer Fails To Meet Primary Endpoints ,RTTNews,/news/stocks/bristol-myer-phase-3-trial-on-head-neck-cancer-fails-to-meet-primary-endpoints-1030614936,negative,0.9216133952140808
7/16/2021 4:29:34 PM,Bristol-Myers Squibb settles Spycel patent cases with Dr. Reddy's and Lupin,Seeking Alpha,https://seekingalpha.com/news/3716040-bristol-myers-squibb-settles-spycel-patent-cases-with-dr-reddys-and-lupin?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8360674381256104
7/19/2021 5:26:39 PM,Cytokinetics extends gains as Needham lifts target on trial results for heart disease therapy,Seeking Alpha,https://seekingalpha.com/news/3716483-cytokinetics-extends-gains-as-needham-lifts-target-on-trial-results-for-heart-disease-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9248335957527161
7/19/2021 8:32:34 PM,Analysts See Higher Success Chances For Cytokinetics' Heart Disease Candidate After Positive Phase 2 Data,Benzinga,/news/stocks/analysts-see-higher-success-chances-for-cytokinetics-heart-disease-candidate-after-positive-phase-2-data-1030621590,positive,0.9543949961662292
7/23/2021 1:45:07 PM,"The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-acorda-spikes-on-distribution-deal-alzamend-soars-on-data-pfizer-biontech-to-supply-more-vaccine-doses-3-ipos-1030638740,positive,0.9013097882270813
7/25/2021 3:26:31 PM,"The Week Ahead In Biotech: Big Pharma Earnings, Iterum FDA Decision, Alzheimer's Conference, IPOs and More",Benzinga,/news/stocks/the-week-ahead-in-biotech-july-25-31-big-pharma-earnings-iterum-fda-decision-alzheimer-s-conference-ipos-and-more-1030641744,neutral,0.9177685976028442
7/26/2021 12:25:29 AM,"Benzinga's Bulls And Bears Of The Week: Amazon, Apple, Bitcoin, GameStop, Netflix And More",Benzinga,/news/stocks/benzinga-s-bulls-and-bears-of-the-week-amazon-apple-bitcoin-gamestop-netflix-and-more-1030641885,neutral,0.9401584267616272
7/26/2021 1:57:03 PM,Bristol Myers pulls Opdivo indication for post-Sorafenib hepatocellular carcinoma in U.S.,Seeking Alpha,https://seekingalpha.com/news/3719042-bristol-myers-pulls-opdivo-indication-for-post-sorafenib-hepatocellular-carcinoma-in-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8178214430809021
7/26/2021 3:01:46 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1030644802,neutral,0.9091694951057434
7/27/2021 12:05:28 PM,BridgeBio and Bristol Myers ink deal to study Opdivo/BBP-398 combo in KRAS mutation cancers,Seeking Alpha,https://seekingalpha.com/news/3719567-bridgebio-and-bristol-myers-ink-deal-to-study-opdivobbp-398-combo-in-kras-mutation-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6665523648262024
7/27/2021 12:43:54 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3719608-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.855887770652771
7/27/2021 1:57:04 PM,"BridgeBio, Bristol Myers To Study BBP-398 In Combination With OPDIVO In Advanced Solid Tumors ",RTTNews,/news/stocks/bridgebio-bristol-myers-to-study-bbp-398-in-combination-with-opdivo-in-advanced-solid-tumors-1030649733,neutral,0.6252284049987793
7/28/2021 11:00:13 AM,"Bristol Myers Squibb EPS beats by $0.03, beats on revenue",Seeking Alpha,https://seekingalpha.com/news/3720300-bristol-myers-squibb-eps-beats-0_03-beats-on-revenue?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5575007796287537
7/28/2021 11:54:11 AM,Bristol Myers posts Q2 earnings beat on Opdivo Strength,Seeking Alpha,https://seekingalpha.com/news/3720379-bristol-myers-posts-q2-earnings-beat-on-opdivo-strength?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.513229489326477
7/28/2021 1:41:09 PM,Bristol-Myers Squibb Reaffirms FY21 Adj. EPS Outlook - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy21-adj-eps-outlook-quick-facts-1030655923,neutral,0.8518517017364502
7/28/2021 1:43:00 PM,Bristol-Myers Squibb Co. Q2 adjusted earnings Beat Estimates,RTTNews,/news/stocks/bristol-myers-squibb-co-q2-adjusted-earnings-beat-estimates-1030655922,positive,0.8615039587020874
7/30/2021 11:31:17 AM,Bristol Myers Squibb wins European approval for Opdivo in two GIT cancers,Seeking Alpha,https://seekingalpha.com/news/3722247-bristol-myers-squibb-wins-european-approval-for-opdivo-in-two-git-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8843175768852234
7/30/2021 1:53:58 PM,"The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs",Benzinga,/news/stocks/the-daily-biotech-pulse-erytech-jumps-on-fast-track-designation-glaxosmithkline-fda-nod-alnylam-s-clinical-collaboration-4-ipos-1030667906,positive,0.7937847971916199
7/30/2021 5:21:53 PM,Biogen: Does Aduhelm Make it the Next Dendreon?,InvestorPlace,/news/stocks/biib-stock-does-aduhelm-make-it-the-next-dendreon-1030669123,neutral,0.9347943663597107
8/1/2021 4:13:48 PM,"The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs",Benzinga,/news/stocks/the-week-ahead-in-biotech-aug-1-7-biopharma-earnings-pick-up-pace-eton-awaits-fda-decision-focus-on-pending-clinical-readouts-and-ipos-1030671679,positive,0.8824637532234192
8/2/2021 9:50:15 PM,Bristol withdraws Istodax lymphoma indication after confirmatory trial fails,Seeking Alpha,https://seekingalpha.com/news/3723556-bristol-withdraws-istodax-lymphoma-indication-after-confirmatory-trial-fails?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7515809535980225
8/3/2021 1:55:12 PM,"The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly's Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-buys-translate-bio-in-3-2b-deal-lilly-s-q2-earnings-disappoint-bausch-to-spin-off-medical-aesthetics-business-1030682672,neutral,0.7302419543266296
8/3/2021 11:42:24 PM,'Fast Money Halftime Report' Picks For August 3,Benzinga,/news/stocks/fast-money-halftime-report-picks-for-august-3-1030685950,neutral,0.9150761365890503
8/4/2021 1:52:10 PM,"The Daily Biotech Pulse: Pfizer's Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-s-positive-readout-nrx-strikes-r-d-collaboration-with-mannkind-cerus-invitae-jump-on-earnings-1030688766,positive,0.7550449371337891
8/4/2021 4:04:19 PM,4 Stocks Insiders Are Selling,Benzinga,/news/stocks/4-stocks-insiders-are-selling-1030689983,neutral,0.894290566444397
8/5/2021 2:07:56 PM,"The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-reports-positive-keytruda-readout-moderna-slips-despite-q2-beat-bayer-to-buy-vividion-for-up-to-2b-glycomimetics-gets-new-ceo-1030695873,positive,0.8679100871086121
8/6/2021 1:42:39 PM,"The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-dicerna-slips-on-data-novavax-tightlipped-on-us-vaccine-approval-adagio-ipo-1030701132,negative,0.6754711866378784
8/6/2021 8:00:09 PM,Bioethicist Ezekiel Emanuel under consideration for FDA commissioner - Politico,Seeking Alpha,https://seekingalpha.com/news/3727179-bioethicist-ezekiel-emanuel-under-consideration-for-fda-commissioner-politico?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9355555176734924
8/7/2021 6:34:16 PM,UBS highlights 20 top dividend stocks in tough times for yield: Alpha Tactics,Seeking Alpha,https://seekingalpha.com/news/3727237-ubs-highlights-top-divident-stocks-in-tough-times-for-yield?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8619095683097839
8/10/2021 4:55:01 PM,Moderna's Stock Valuation Goes From 'Unreasonable To Ridiculous': Analyst,Benzinga,/news/stocks/moderna-s-stock-valuation-goes-from-unreasonable-to-ridiculous-analyst-1030714344,neutral,0.5439894795417786
8/12/2021 10:00:53 AM,3 Best Biotech Stocks To Buy for Upcoming Catalysts,InvestorPlace,/news/stocks/3-best-biotech-stocks-to-buy-for-upcoming-catalysts-1030723346,neutral,0.6762979030609131
8/12/2021 4:07:52 PM,CytoSorbents' Antithrombotic Removal System Scores Second FDA Breakthrough Device Tag,Benzinga,/news/stocks/cytosorbents-antithrombotic-removal-system-scores-second-fda-breakthrough-device-tag-1030724927,positive,0.7559819221496582
8/16/2021 7:26:06 PM,Novavax Appoints New CFO Amid Inordinate Delay In COVID-19 Vaccine Authorization,Benzinga,/news/stocks/novavax-appoints-new-cfo-amid-inordinate-delay-in-covid-19-vaccine-authorization-1030735356,negative,0.7961598634719849
8/17/2021 2:28:53 PM,"The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business",Benzinga,/news/stocks/the-daily-biotech-pulse-lilly-reorganizes-business-units-in-neuroscience-focus-helius-medical-spikes-on-breakthrough-designation-ra-medical-sells-dermatology-business-1030738023,neutral,0.9126444458961487
8/17/2021 6:50:26 PM,"Q2 13F Roundup: How Buffett, Einhorn, Ackman And Others Adjusted Their Portfolios",Benzinga,/news/stocks/q2-13f-roundup-how-buffett-einhorn-ackman-and-others-adjusted-their-portfolios-1030739447,neutral,0.8887203335762024
8/17/2021 7:04:09 PM,7 Buffett Stocks to Buy (and Sell) if You Want to Be Like Berkshire,InvestorPlace,/news/stocks/7-buffett-stocks-to-buy-and-sell-if-you-want-to-be-like-berkshire-1030739695,neutral,0.938480794429779
8/20/2021 2:14:06 AM,Acting FDA head Woodcock ruled out as permanent nominee - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3732564-acting-fda-head-woodcock-ruled-out-as-permanent-nominee-bloomberg?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7850376963615417
8/24/2021 2:09:21 PM,"The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal",Benzinga,/news/stocks/the-daily-biotech-pulse-cara-s-korsuva-greenlighted-by-fda-clinical-trial-disappointments-for-novartis-theravance-vertex-inks-crispr-licensing-deal-1030754775,neutral,0.5257495641708374
8/27/2021 1:35:25 PM,"The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration",Benzinga,/news/stocks/the-daily-biotech-pulse-morphosys-incyte-snag-european-nod-immutep-granted-chinese-patent-bolt-biotherapeutics-strike-oncology-collaboration-1030763431,positive,0.5113007426261902
8/31/2021 5:06:03 PM,4 Specialized AI Stocks to Buy for the Boom,InvestorPlace,/news/stocks/4-specialized-ai-stocks-to-buy-for-the-boom-1030770860,neutral,0.8552104830741882
9/2/2021 7:59:28 AM,Evotec Says Bristol Myers Squibb Exercises Option To Enter Global License For EVT8683 ,RTTNews,/news/stocks/evotec-says-bristol-myers-squibb-exercises-option-to-enter-global-license-for-evt8683-1030775347,neutral,0.8653338551521301
9/2/2021 2:19:58 PM,"The Daily Biotech Pulse: Assembly Bio Halts HBV Study, Moderna Initiates Submission For COVID-19 Booster Dose, FDA Nod For BeiGene, Tiziana Out-Licenses Foralumab",Benzinga,/news/stocks/the-daily-biotech-pulse-assembly-bio-halts-hbv-study-moderna-initiates-submission-for-covid-19-booster-dose-fda-nod-for-beigene-tiziana-out-licenses-foralumab-1030776427,neutral,0.8083416223526001
9/3/2021 6:50:43 PM,Wall Street Crime And Punishment: Martha Stewart's Perfectly Ridiculous Stock Scandal,Benzinga,/news/stocks/wall-street-crime-and-punishment-martha-stewart-s-perfectly-ridiculous-stock-scandal-1030780207,neutral,0.7803279161453247
9/5/2021 7:14:08 PM,The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week,Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-5-11-focus-on-conferences-and-clinical-readouts-in-another-quiet-week-1030781044,neutral,0.8742558360099792
9/8/2021 1:32:08 PM,"The Daily Biotech Pulse: MacroGenics' Clinical Trial Disappointment, Sanofi to Buy Kadmon, Alector Loses 2 Key Executives, ADMA's FDA Nod",Benzinga,/news/stocks/the-daily-biotech-pulse-macrogenics-clinical-trial-disappointment-sanofi-to-buy-kadmon-alector-loses-2-key-executives-adma-s-fda-nod-1030786678,neutral,0.5691118240356445
9/10/2021 10:30:38 AM,7 Stocks To Buy To Bet on Underappreciated CEOs,InvestorPlace,/news/stocks/7-stocks-to-buy-to-bet-on-underappreciated-ceos-1030792285,neutral,0.5824403166770935
9/13/2021 5:31:10 PM,7 Stocks to Buy if the Market Crashes in September,InvestorPlace,/news/stocks/7-stocks-to-buy-if-the-market-crashes-in-september-1030796461,neutral,0.8143264651298523
9/15/2021 8:23:34 PM,Narrower drug pricing bill introduced in House by centrist Democrats,Seeking Alpha,https://seekingalpha.com/news/3740127-narrower-drug-pricing-bill-introduced-in-house-by-centrist-democrats?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.681155264377594
9/15/2021 9:20:09 PM,House committee approves portion of spending package that includes drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/3740192-house-committee-approves-portion-of-spending-package-that-includes-drug-price-negotiation?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5973880887031555
9/16/2021 10:19:48 AM,Exelixis/Bristol Myers report new exploratory data for Cabometyx + Opdivo in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3740291-exelixisbristol-myers-report-new-exploratory-data-for-cabometyx-opdivo-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8554710745811462
9/16/2021 11:30:02 AM,7 Stocks to Buy to Invest Like Jim Cramer,InvestorPlace,/news/stocks/7-stocks-to-buy-to-invest-like-jim-cramer-1030804231,neutral,0.9212437868118286
9/17/2021 2:32:49 PM,Gritstone Presents Data From Individualized Neoantigen Immunotherapy In Colorectal Cancer,Benzinga,/news/stocks/gritstone-presents-data-from-individualized-neoantigen-immunotherapy-in-colorectal-cancer-1030807151,neutral,0.8036116361618042
9/17/2021 2:41:12 PM,"Gritstone Unveils ""Off-The-Shelf"" Neoantigen Immunotherapy Data In Lung Cancer",Benzinga,/news/stocks/gritstone-unveils-off-the-shelf-neoantigen-immunotherapy-data-in-lung-cancer-1030807189,neutral,0.7990502119064331
9/19/2021 3:46:51 PM,"The Week Ahead In Biotech (Sept. 19-25): Incyte, Verrica FDA Decisions And Conference Presentations In The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-sept-19-25-incyte-verrica-fda-decisions-and-conference-presentations-in-the-spotlight-1030808489,neutral,0.9415056109428406
9/20/2021 2:24:00 PM,Bristol Myers Reports FDA Priority Review For Relatlimab And Nivolumab Combination ,RTTNews,/news/stocks/bristol-myers-reports-fda-priority-review-for-relatlimab-and-nivolumab-combination-1030809791,neutral,0.827575147151947
9/22/2021 1:01:09 PM,3 Cheap Healthcare Stocks to Buy Right Now,InvestorPlace,/news/stocks/3-cheap-healthcare-stocks-to-buy-right-now-1030815956,neutral,0.910865068435669
9/27/2021 2:22:45 PM,"Bristol Myers: FDA Accepts SBLA For Opdivo Plus Yervoy, Opdivo Plus Chemotherapy In ESCC Patients ",RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-opdivo-plus-yervoy-opdivo-plus-chemotherapy-in-escc-patients-1030825490,positive,0.6099786162376404
9/30/2021 4:20:02 PM,Acceleron downgraded by Piper Sandler on $11.5B Merck acquisition,Seeking Alpha,https://seekingalpha.com/news/3746658-acceleron-downgraded-by-piper-sandler-on-115b-merck-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6792036294937134
9/30/2021 6:01:30 PM,House Judiciary Committee approves bill to expedite biosimilar drugs to market,Seeking Alpha,https://seekingalpha.com/news/3746703-house-judiciary-committee-approves-bill-to-expedite-biosimilar-drugs-to-market?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5914818644523621
10/1/2021 1:56:15 PM,"The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-merck-rallies-on-antiviral-pill-data-gilead-files-for-yescarta-label-expansion-exscientia-ipo-1030836939,neutral,0.8665688037872314
10/7/2021 2:07:25 PM,Bristol Myers Squibb Says Its Phase 2 LATTICE-UC Study Did Not Meet Primary Objective ,RTTNews,/news/stocks/bristol-myers-squibb-says-its-phase-2-lattice-uc-study-did-not-meet-primary-objective-1030850067,negative,0.8917295932769775
10/7/2021 2:23:53 PM,"The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results",Benzinga,/news/stocks/the-daily-biotech-pulse-moderna-invests-in-africa-amgen-announces-neuroscience-r-d-collaboration-decision-day-for-chemocentryx-biophytis-to-restate-results-1030850125,neutral,0.89493727684021
10/12/2021 1:15:38 PM,Agenus to receive $20M from Bristol Myers as dosing starts for AGEN1777 study,Seeking Alpha,https://seekingalpha.com/news/3751566-agenus-to-receive-20m-from-bristol-myers-as-dosing-starts-for-agen1777-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5859948992729187
10/12/2021 2:13:34 PM,"The Daily Biotech Pulse: NRx Stitches COVID-19 Drug Partnership, Protara Gets Nod For Starting Bladder Cancer Study, IGM Moves Beyond Oncology",Benzinga,/news/stocks/the-daily-biotech-pulse-nrx-stitches-covid-19-drug-partnership-protara-gets-nod-for-starting-bladder-cancer-study-igm-moves-beyond-oncology-1030858924,neutral,0.7237186431884766
10/19/2021 6:51:54 AM,Dr. Reddy's Labs Announces FDA Approval For Lenalidomide Capsules - Quick Facts ,RTTNews,/news/stocks/dr-reddy-s-labs-announces-fda-approval-for-lenalidomide-capsules-quick-facts-1030875763,neutral,0.8171594142913818
10/19/2021 10:08:05 AM,FDA approves Dr. Reddy’s Laboratories' generic version of Revlimid,Seeking Alpha,https://seekingalpha.com/news/3754845-fda-approves-dr-reddys-laboratories-generic-version-of-revlimid?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5890536904335022
10/19/2021 2:23:01 PM,"The Daily Biotech Pulse: Entasis, Dermata Spike Higher On Positive Readouts, J&J Q3 EPS Beats Estimates, Wave Life Sciences Regains Right To CNS Portfolio",Benzinga,/news/stocks/the-daily-biotech-pulse-entasis-dermata-spike-higher-on-positive-readouts-j-j-q3-eps-beats-estimates-wave-life-sciences-regains-right-to-cns-portfolio-1030877269,positive,0.9359005689620972
10/19/2021 6:10:09 PM,Abbott Laboratories Q3 earnings preview and review,Seeking Alpha,https://seekingalpha.com/news/3755153-abbott-laboratories-q3-earnings-preview-and-review?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8984233736991882
10/21/2021 2:05:16 PM,"The Daily Biotech Pulse: FDA Authorizes Moderna, J&J Booster Shots; Regulatory Approvals For Bristol-Myers Squibb, Sanofi-Regeneron; Ventyx IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-authorizes-moderna-j-j-booster-shots-regulatory-approvals-for-bristol-myers-squibb-sanofi-regeneron-ventyx-ipo-1030885538,neutral,0.8053776025772095
10/24/2021 5:45:47 PM,"The Week Ahead In Biotech (Oct. 24-30): Eyenovia, ANI Pharma, Clearside Medical FDA Decisions, Merck, Bristol-Myers Squibb Earnings, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-oct-24-30-eyenovia-ani-pharma-clearside-medical-fda-decisions-merck-bristol-myers-squibb-earnings-ipos-and-more-1030891741,neutral,0.9414970874786377
10/25/2021 12:30:12 PM,"Trump's SPAC Partner Emerges As Top WallStreetBets Interest; Facebook, Snapchat, Tesla And These Are Other Top Trends",Benzinga,/news/stocks/trump-s-spac-partner-emerges-as-top-wallstreetbets-interest-facebook-snapchat-tesla-and-these-are-other-top-trends-1030894092,neutral,0.7906410098075867
10/25/2021 3:02:03 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-quarter-earnings-preview-q3-1030894951,neutral,0.9091694951057434
10/26/2021 2:59:35 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3758153-notable-earnings-before-wednesdays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.855887770652771
10/27/2021 1:27:47 PM,Bristol-Myers Squibb Boosts FY21 Outlook As Q3 Results Top Estimates - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy21-outlook-as-q3-results-top-estimates-quick-facts-1030904590,positive,0.9363502264022827
10/28/2021 1:26:15 PM,"Oppenheimer cuts Aurinia to perform on M&A chatter, recent share price rise",Seeking Alpha,https://seekingalpha.com/news/3760060-oppenheimer-cuts-aurinia-to-perform-on-ma-chatter-recent-share-price-rise?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7332212924957275
10/29/2021 1:12:21 PM,Dr. Reddy’s launches generic version of low blood pressure drug Akovaz in US,Seeking Alpha,https://seekingalpha.com/news/3760843-dr-reddys-launches-generic-version-of-low-blood-pressure-drug-akovaz-in-us?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5947295427322388
11/1/2021 3:37:12 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-1-2021-1030922174,negative,0.4976659119129181
11/2/2021 12:12:34 PM,Baird initiates Geron with an outperform on outlook for lead candidate imetelstat,Seeking Alpha,https://seekingalpha.com/news/3762773-baird-initiates-geron-with-an-outperform-on-outlook-for-lead-candidate-imetelstat?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7286728024482727
11/4/2021 12:59:34 PM,Bristol to collaborate with Inspirna on combination using Yervoy for endometrial cancer,Seeking Alpha,https://seekingalpha.com/news/3765156-bristol-to-collaborate-with-inspirna-on-combination-using-yervoy-for-endometrial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.603686511516571
11/8/2021 1:05:04 PM,Bristol Myers Squibb posts encouraging data from late-stage Opdivo lung cancer trial,Seeking Alpha,https://seekingalpha.com/news/3766692-bristol-myers-squibb-posts-encouraging-data-from-late-stage-opdivo-lung-cancer-trial?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9437944293022156
11/8/2021 2:24:25 PM,"The Week Ahead In Biotech (Nov. 7-Nov. 13): Earnings Taper Off, Multiple Conference Presentations, IPOs And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-7-nov-13-earnings-taper-off-multiple-conference-presentations-ipos-and-more-1030949001,negative,0.9685659408569336
11/10/2021 10:00:31 AM,Evotec Reaches Additional Programme Designations Within Collaboration With Bristol Myers ,RTTNews,/news/stocks/evotec-reaches-additional-programme-designations-within-collaboration-with-bristol-myers-1030958174,positive,0.821635365486145
11/11/2021 12:27:37 PM,Bristol-Myers Squibb completes $20M investment in Compugen,Seeking Alpha,https://seekingalpha.com/news/3769400-bristol-myers-squibb-completes-20m-investment-in-compugen?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7356554269790649
11/12/2021 1:18:49 PM,Compugen posts early Phase 1 data for anti-TIGIT antibody in advanced solid tumors,Seeking Alpha,https://seekingalpha.com/news/3770031-compugen-posts-early-phase-1-data-for-anti-tigit-antibody-in-advanced-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.49333807826042175
11/14/2021 3:57:21 PM,"The Week Ahead In Biotech (Nov. 14-Nov. 20): BioMarin FDA Decision, Tapering Earnings News Flow, Conference Presentations And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-nov-14-nov-20-biomarin-fda-decision-tapering-earnings-news-flow-conference-presentations-and-more-1030972118,negative,0.9391730427742004
11/15/2021 5:28:52 PM,Anti-platelet drugs don't help survival in hospitalized COVID-19 patients,Seeking Alpha,https://seekingalpha.com/news/3770794-anti-platelet-drugs-dont-help-survival-in-hospitalized-covid-19-patients?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8408033847808838
11/15/2021 9:47:35 PM,"Warren Buffett's Berkshire Hathaway adds Royalty Pharma, exits Merck",Seeking Alpha,https://seekingalpha.com/news/3770994-warren-buffetts-berkshire-hathaway-adds-royalty-pharma-exits-merck?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9137044548988342
11/16/2021 1:53:22 PM,Phase 2 results show promise for Bristol/J&J venous thromboembolism drug milvexian,Seeking Alpha,https://seekingalpha.com/news/3771370-phase-2-results-show-promise-for-bristol-johnson-johnson-janssen-venous-thromboembolism-drug-milvexian?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9489973783493042
11/16/2021 3:21:46 PM,"Bristol Myers CEO looking for small,  medium-sized deals - WSJ",Seeking Alpha,https://seekingalpha.com/news/3771472-bristol-myers-ceo-looking-for-small-medium-sized-deals-wsj?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9316283464431763
11/18/2021 2:33:44 PM,J&J expects to file for 14 new drugs by 2025 - Reuters,Seeking Alpha,https://seekingalpha.com/news/3772449-johnson-johnson-janssen-expects-to-file-for-14-new-drugs-by-2025-reuters?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8713213801383972
11/18/2021 9:48:24 PM,BMO initiates Bristol-Myers Squibb at outperform; sees 22% upside,Seeking Alpha,https://seekingalpha.com/news/3772655-bmo-initiates-bristol-myers-squibb-at-outperform-sees-22-upside?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8693092465400696
11/19/2021 12:31:32 PM,FDA extends action date for Bristol-Myers Squibb's mavacamten by three months,Seeking Alpha,https://seekingalpha.com/news/3772791-fda-extends-action-date-for-bristol-myers-squibb-mavacamten-by-three-months?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.845386266708374
11/19/2021 2:20:15 PM,"The Daily Biotech Pulse: Connect Biopharma Sinks On Eczema Drug Readout, Enanta Pulls Plug On HBV Drug, Clinical Setback For Merck In HIV Trial",Benzinga,/news/stocks/the-daily-biotech-pulse-connect-biopharma-sinks-on-eczema-drug-readout-enanta-pulls-plug-on-hbv-drug-clinical-setback-for-merck-in-hiv-trial-1030991438,negative,0.458524614572525
11/19/2021 4:08:55 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 19, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-19-2021-1030991825,negative,0.6235838532447815
11/22/2021 5:43:00 PM,"Aurinia falls 28% amid mixed shelf offering, skepticism on buyout rumors",Seeking Alpha,https://seekingalpha.com/news/3773453-aurinia-falls-28-following-amid-mixed-shelf-offering-skepticism-on-buyout-rumors?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9530866146087646
11/22/2021 6:30:58 PM,AUPH Stock: 13 Things to Know About Aurinia Pharma as Shares Crash Today,InvestorPlace,/news/stocks/auph-stock-13-things-to-know-about-aurinia-pharma-as-shares-crash-today-1030995927,neutral,0.871175229549408
11/23/2021 12:25:48 PM,Bristol Myers' Zeposia OK'd in Europe for ulcerative colitis in adults,Seeking Alpha,https://seekingalpha.com/news/3773705-bristol-myers-zeposia-okd-in-europe-for-ulcerative-colitis-in-adults?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5490416884422302
11/23/2021 2:10:10 PM,"The Daily Biotech Pulse: Arrowhead Out-Licenses NASH Drug, Tonix Touts COVID-19 Treatment Data, Aadi Jumps On FDA Nod For Rare Tumor Drug",Benzinga,/news/stocks/the-daily-biotech-pulse-arrowhead-out-licenses-nash-drug-tonix-touts-covid-19-treatment-data-aadi-jumps-on-fda-nod-for-rare-tumor-drug-1030997811,neutral,0.8555189371109009
11/23/2021 2:35:29 PM,Bristol's Zeposia Gets Market Authorization From European Commission ,RTTNews,/news/stocks/bristol-s-zeposia-gets-market-authorization-from-european-commission-1030997886,positive,0.7643882632255554
11/23/2021 3:33:18 PM,AbbVie upgraded to buy at Societe Generale; sees 48% upside,Seeking Alpha,https://seekingalpha.com/news/3773845-societe-generale-upgrades-abbvie-to-buy-sees-48-upside?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8325988054275513
11/26/2021 5:30:33 PM,5 Stocks Insiders Are Selling,Benzinga,/news/stocks/5-stocks-insiders-are-selling-1031006181,neutral,0.8907204270362854
11/29/2021 8:53:36 AM,Biotech Stocks Facing FDA Decision In December 2021 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2021-1031007771,neutral,0.6823664903640747
11/29/2021 1:02:12 PM,FDA and EMA accepts Bristol Myers' applications for deucravacitinib in plaque psoriasis,Seeking Alpha,https://seekingalpha.com/news/3774805-fda-and-ema-accepts-bristol-myers-applications-for-deucravacitinib-in-plaque-psoriasis?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8645042181015015
11/29/2021 2:13:12 PM,Bristol Myers Says FDA Accepts NDA For For Deucravacitinib - Quick Facts ,RTTNews,/news/stocks/bristol-myers-says-fda-accepts-nda-for-for-deucravacitinib-quick-facts-1031008730,neutral,0.7167943120002747
11/30/2021 5:13:05 PM,"Jim Cramer Shares His Thoughts On Chegg, Bristol-Myers Squibb And More",Benzinga,/news/stocks/jim-cramer-shares-his-thoughts-on-chegg-bristol-myers-squibb-and-more-1031012906,neutral,0.9408510327339172
11/30/2021 7:29:27 PM,7 Drug Stocks to Buy Now While They’re Still on Sale,InvestorPlace,/news/stocks/7-drug-stocks-to-buy-now-while-theyre-still-on-sale-1031013701,neutral,0.8935650587081909
12/2/2021 4:06:41 PM,Aurinia Pharmaceuticals gains amid takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3776494-aurinia-pharmaceuticals-gains-on-takeover-speculation?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9189054369926453
12/2/2021 5:16:48 PM,AUPH Stock: The Novartis Takeover Talk That Has Aurinia Pharma Shares Taking Off Today,InvestorPlace,/news/stocks/auph-stock-the-novartis-takeover-talk-that-has-aurinia-pharma-shares-taking-off-today-1031020928,neutral,0.5710656046867371
12/2/2021 6:02:11 PM,Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-december-pdufa-dates-1031020805,neutral,0.9439957737922668
12/3/2021 12:12:59 PM,FDA accepts for priority review Bristol Myers's Reblozyl application in beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3776813-fda-accepts-for-priority-review-bristol-myerss-reblozyl-application-in-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8233966827392578
12/3/2021 1:40:11 PM,"The Daily Biotech Pulse: Protagonist Pulls Plug On Phase 1 Asset, Xenon Aces Mid-Stage Epilepsy Study, Esperion Prices Offering",Benzinga,/news/stocks/the-daily-biotech-pulse-protagonist-pulls-plug-on-phase-1-asset-xenon-aces-mid-stage-epilepsy-study-esperion-prices-offering-1031022833,neutral,0.8068128824234009
12/4/2021 9:00:00 PM,Bristol is one of the worst performing biopharmas this year. Will 2022 be different?,Seeking Alpha,https://seekingalpha.com/news/3777064-bristol-myers-squibb-is-one-of-the-worst-performing-pharmas-this-year-will-2022-be-different?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8360777497291565
12/6/2021 7:17:48 PM,Bolt Biotherapeutics sheds half its value following mid-stage solid tumor data,Seeking Alpha,https://seekingalpha.com/news/3777497-bolt-biotherapeutics-sheds-half-its-value-following-mid-stage-solid-tumor-data?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9234931468963623
12/9/2021 2:03:57 PM,Vir begins mid-stage trial of combo candidate for chronic hepatitis B virus,Seeking Alpha,https://seekingalpha.com/news/3778701-vir-begins-mid-stage-trial-of-combo-candidate-for-chronic-hepatitis-b-virus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6287611722946167
12/9/2021 4:27:21 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 9, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-9-2021-1031036161,negative,0.5978409051895142
12/9/2021 5:07:53 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031036366,neutral,0.928318977355957
12/10/2021 11:00:33 AM,Why You Should Buy Moderna Stock at Every Dip,InvestorPlace,/news/stocks/why-you-should-buy-mrna-stock-at-every-dip-1031038543,neutral,0.9308882355690002
12/13/2021 4:05:33 AM,"Antengene, Bristol Myers To Evaluate ATG-017 In Combination With Opdivo In Advanced Solid Tumors ",RTTNews,/news/stocks/antengene-bristol-myers-to-evaluate-atg-017-in-combination-with-opdivo-in-advanced-solid-tumors-1031040414,neutral,0.5920003056526184
12/13/2021 12:13:52 PM,"Bristol Myers Squibb raises dividend by 10% to $0.54, announces $15B buyback",Seeking Alpha,https://seekingalpha.com/news/3779415-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7697550654411316
12/13/2021 1:57:06 PM,Bristol Myers Board Approves Increase In Quarterly Dividend; Authorizes Additional Share Repurchase ,RTTNews,/news/stocks/bristol-myers-board-approves-increase-in-quarterly-dividend-authorizes-additional-share-repurchase-1031041501,positive,0.8995175957679749
12/13/2021 7:32:25 PM,Why does Pfizer's $6.7B acquisition of Arena Pharmaceuticals make sense? Etrasimod,Seeking Alpha,https://seekingalpha.com/news/3779629-why-does-pfizer-67b-acquisition-of-arena-pharmaceuticals-make-sense-etrasimod?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.917937159538269
12/13/2021 10:24:33 PM,Bristol-Myers Squibb files for mixed shelf offering,Seeking Alpha,https://seekingalpha.com/news/3779710-bristol-myers-squibb-files-for-mixed-shelf-offering?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.734584629535675
12/14/2021 8:50:07 PM,3 Stocks That Can Make You Rich in Just a Few Years,InvestorPlace,/news/stocks/3-stocks-that-can-make-you-rich-in-just-a-few-years-1031044575,neutral,0.8752399682998657
12/15/2021 1:26:51 PM,Exelixis initiates Phase 1b XL092 combo trial in solid tumors,Seeking Alpha,https://seekingalpha.com/news/3780318-exelixis-initiates-phase-1b-xl092-combo-trial-in-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8172602653503418
12/15/2021 5:15:24 PM,Bristol-Myers Squibb wins FDA approval for first graft versus host disease therapy,Seeking Alpha,https://seekingalpha.com/news/3780453-bristol-myers-squibb-wins-fda-approval-for-first-graft-versus-host-disease-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7570414543151855
12/16/2021 12:56:47 PM,FDA Oks Bristol Myers' Orencia To Prevent Graft Versus Host Disease ,RTTNews,/news/stocks/fda-oks-bristol-myers-orencia-to-prevent-graft-versus-host-disease-1031049863,neutral,0.49674052000045776
12/17/2021 4:17:57 PM,"Benzinga's Top Ratings Upgrades, Downgrades For December 17, 2021",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-december-17-2021-1031053650,negative,0.5951844453811646
12/23/2021 12:27:47 PM,Top 10 Blockbuster Drugs In 2021 ,RTTNews,/news/stocks/top-10-blockbuster-drugs-in-2021-1031063755,neutral,0.7226236462593079
12/30/2021 7:20:31 PM,Best Stocks for 2022: Bristol-Myers Squibb Will Offer Huge Returns,InvestorPlace,/news/stocks/best-stocks-for-2022-bristol-myers-squibb-will-offer-huge-returns-1031071810,positive,0.8780637383460999
1/6/2022 12:56:30 PM,7 Pharmaceutical Stocks That Could Make You Rich,InvestorPlace,/news/stocks/7-pharmaceutical-stocks-that-could-make-you-rich-1031081342,neutral,0.9103521108627319
1/10/2022 12:47:19 PM,Century jumps 14% on collaboration with Bristol Myers to develop cell therapies in solid tumor,Seeking Alpha,https://seekingalpha.com/news/3786536-century-jumps-14-on-collaboration-with-bristol-myers-to-develop-cell-therapies-in-solid-tumor?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9378426671028137
1/10/2022 1:13:56 PM,Bristol-Myers sets in-line guidance for 2022; announces $5B accelerated share buybacks,Seeking Alpha,https://seekingalpha.com/news/3786556-bristol-myers-sets-in-line-guidance-for-2022-announces-5b-accelerated-share-buybacks?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5237375497817993
1/10/2022 2:08:00 PM,"Bristol Myers, Century Therapeutics Ink Pact For iPSC-Derived Allogeneic Cell Therapies",Benzinga,/news/stocks/bristol-myers-century-therapeutics-ink-pact-for-ipsc-derived-allogeneic-cell-therapies-1031090714,neutral,0.5614767670631409
1/10/2022 8:01:06 PM,"3 Top Stock Trades for the Week of Jan. 10, 2022",InvestorPlace,/news/stocks/3-top-stock-trades-for-the-week-of-jan-10-2022-1031091902,neutral,0.9109970927238464
1/10/2022 9:35:50 PM,BioAtla collaborates with Bristol Myers Squibb for lead assets,Seeking Alpha,https://seekingalpha.com/news/3786864-bioatla-collaborates-with-bristol-myers-squibb-for-lead-assets?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8092675805091858
1/10/2022 10:05:00 PM,BioAtla Announces Clinical Collaboration with Bristol Myers Squibb to Study Mecbotamab Vedotin (BA3011) and Ozuriftamab Vedotin (BA3021) in Combination with Opdivo® (nivolumab) for Treatment of So...,PR Newswire,/news/stocks/bioatla-announces-clinical-collaboration-with-bristol-myers-squibb-to-study-mecbotamab-vedotin-ba3011-and-ozuriftamab-vedotin-ba3021-in-combination-with-opdivo-nivolumab-for-treatment-of-so-1031092010,positive,0.8761248588562012
1/11/2022 8:02:31 AM,Evotec Gets $15 Mln From Bristol Myers Squibb On Expansion Of Neuroscience Collaboration ,RTTNews,/news/stocks/evotec-gets-15-mln-from-bristol-myers-squibb-on-expansion-of-neuroscience-collaboration-1031092736,positive,0.7823295593261719
1/11/2022 1:18:04 PM,Biomica/Bristol Myers on go with Phase I study of BMC-128 + Opdivo in cancer,Seeking Alpha,https://seekingalpha.com/news/3787035-biomicabristol-myers-on-go-with-phase-i-study-of-bmc-128-opdivo-in-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.532274067401886
1/11/2022 2:20:34 PM,"The Daily Biotech Pulse: Illumina Announces Multiple Partnerships, Immunome Slides On Regulatory Setback For COVID Antibody Drug, Preannouncements Pour In",Benzinga,/news/stocks/the-daily-biotech-pulse-illunina-announces-multiple-partnerships-immunome-slides-on-regulatory-setback-for-covid-antibody-drug-preannouncements-pour-in-1031093838,neutral,0.4198299050331116
1/11/2022 7:55:53 PM,"Bristol Myers, 2seventy Pull Plug On Multiple Myeloma CAR-T As Abecma Sales Gain Momentum",Benzinga,/news/stocks/bristol-myers-2seventy-pull-plug-on-multiple-myeloma-car-t-as-abecma-sales-gain-momentum-1031095004,positive,0.9389562606811523
1/13/2022 12:57:52 PM,Gritstone begins phase 2/3 colorectal cancer trial dosing; positive data in early study,Seeking Alpha,https://seekingalpha.com/news/3787803-gritstone-begins-phase3-colorectal-cancer-trial-dosing-positive-data-in-phase-12-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9223111271858215
1/13/2022 2:18:12 PM,"The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact",Benzinga,/news/stocks/the-daily-biotech-pulse-adagio-s-antibody-effective-against-omicron-sarepta-terminates-gene-therapy-deal-astrazeneca-inks-oncology-pact-1031100084,neutral,0.5166522264480591
1/13/2022 5:57:53 PM,Aurinia Pharmaceuticals drops amid silence on M&A after conference presentations,Seeking Alpha,https://seekingalpha.com/news/3788016-aurinia-pharmaceuticals-drops-amid-silence-on-ma-after-conference-presentations?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.578084409236908
1/13/2022 7:49:28 PM,Aurinia Pharmaceuticals reverses decline after report on potential M&A interest,Seeking Alpha,https://seekingalpha.com/news/3788045-aurinia-pharmaceuticals-reverses-decline-after-report-on-potential-ma-interest?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9517444372177124
1/19/2022 4:54:28 PM,3 Healthcare Stocks Ignoring the Market Mayhem,InvestorPlace,/news/stocks/3-healthcare-stocks-ignoring-the-market-mayhem-1031113540,negative,0.6080142259597778
1/25/2022 6:17:15 PM,"CBO report finds skyrocketing price increases for brand Rx drugs for Medicare, Medicaid",Seeking Alpha,https://seekingalpha.com/news/3791432-cbo-report-finds-skyrocketing-price-increases-for-brand-rx-drugs-for-medicare-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5263795256614685
1/26/2022 2:29:25 PM,"The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data",Benzinga,/news/stocks/the-daily-biotech-pulse-gilead-s-blood-cancer-studies-placed-on-partial-clinical-hold-immunocore-gets-fda-nod-nrx-touts-positive-covid-19-data-1031130804,neutral,0.8202437162399292
1/27/2022 6:57:41 PM,Say Hello to 2022’s Dogs of the Dow: 10 Dividend Stocks to Watch,InvestorPlace,/news/stocks/say-hello-to-2022s-dogs-of-the-dow-10-dividend-stocks-to-watch-1031136826,neutral,0.9087088704109192
1/28/2022 12:27:13 PM,Bristol Myers Squibb granted EU recommendation for CAR T therapy in lymphoma,Seeking Alpha,https://seekingalpha.com/news/3792973-bristol-myers-squibb-granted-eu-recommendation-for-car-t-therapy-in-lymphoma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.866302490234375
1/28/2022 3:27:36 PM,Aurinia Pharmaceuticals quick uptick on renewed takeover speculation on Biogen news,Seeking Alpha,https://seekingalpha.com/news/3793129-aurinia-pharmaceuticals-quick-uptick-on-renewed-takeover-speculation-on-biogen-news?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7676701545715332
1/28/2022 6:15:32 PM,7 Technology Stocks Reporting Earnings the Week of January 31,InvestorPlace,/news/stocks/earnings-reports-to-watch-next-week-1028709625,neutral,0.5936209559440613
1/29/2022 9:00:00 PM,"Vaccines to dominate pharma sales this year, but Bristol could have most best-sellers",Seeking Alpha,https://seekingalpha.com/news/3793190-vaccines-to-have-highest-pharma-sales-this-year-but-bristol-could-have-most-best-sellers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7369605302810669
1/31/2022 2:20:54 PM,"The Week Ahead In Biotech (Jan 31-Feb 5): Merck, Bristol-Myers Squibb, Lilly & Novartis Headline Large-Cap Biopharma Earnings News",Benzinga,/news/stocks/the-week-ahead-in-biotech-jan-31-feb-5-merck-bristol-myers-squibb-lilly-novartis-headline-large-cap-biopharma-earnings-news-1031144306,neutral,0.9110234975814819
1/31/2022 9:38:38 PM,5 Things To Expect This Week,InvestorPlace,/news/stocks/5-things-to-expect-this-week-1031147156,neutral,0.8923014402389526
2/3/2022 12:13:04 PM,Can Bristol Myers (BMY) maintain positive earnings momentum in Q4?,Seeking Alpha,https://seekingalpha.com/news/3795418-can-bristol-myers-bmy-maintain-positive-earnings-momentum-in-q4?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9434247016906738
2/3/2022 2:13:03 PM,"The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation",Benzinga,/news/stocks/the-daily-biotech-pulse-big-pharma-earnings-prove-lackluster-mersana-inks-1b-adc-r-d-deal-syros-gets-orphan-drug-designation-1031158702,negative,0.928947925567627
2/3/2022 3:01:13 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-1031158985,neutral,0.902914822101593
2/3/2022 3:48:38 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3795618-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8830810189247131
2/4/2022 12:00:46 PM,"Bristol Myers Squibb Non-GAAP EPS of $1.83 beats by $0.03, revenue of $12B in-line",Seeking Alpha,https://seekingalpha.com/news/3795965-bristol-myers-squibb-non-gaap-eps-of-1_83-beats-0_03-revenue-of-12b-in-line?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7347656488418579
2/4/2022 12:32:17 PM,Bristol-Myers sets 2022 guidance ahead of consensus after earnings beat,Seeking Alpha,https://seekingalpha.com/news/3795982-bristol-myers-sets-2022-guidance-ahead-of-consensus-after-earnings-beat?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9429609775543213
2/4/2022 1:07:05 PM,Bristol-Myers Squibb Co. Q4 Earnings Summary,RTTNews,/news/stocks/bristol-myers-squibb-co-q4-earnings-summary-1031162269,neutral,0.6528273224830627
2/4/2022 1:19:26 PM,Bristol-Myers Squibb Reaffirms FY22 Adj. EPS Outlook; Swings To Profit In Q4 - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy22-adj-eps-outlook-swings-to-profit-in-q4-quick-facts-1031162301,positive,0.8981807827949524
2/4/2022 1:34:06 PM,"The Daily Biotech Pulse: Sanofi, Bristol-Myers Squibb Gain On Earnings, Valneva-Pfizer Tout Positive Lyme Disease Vaccine Data, UNITY Biotech Restructures",Benzinga,/news/stocks/the-daily-biotech-pulse-sanofi-bristol-myers-squibb-gain-on-earnings-valneva-pfizer-tout-positive-lyme-disease-vaccine-data-unity-biotech-restructures-1031162384,positive,0.8567987680435181
2/4/2022 4:36:55 PM,5 Biotech Stocks to Buy to Benefit From Biden’s New Cancer Cabinet,InvestorPlace,/news/stocks/5-biotech-stocks-to-buy-to-benefit-from-bidens-new-cancer-cabinet-1031163083,neutral,0.7185424566268921
2/8/2022 1:12:54 PM,Bristol Myers awards ~$8M in health equity grants for medically underserved patients,Seeking Alpha,https://seekingalpha.com/news/3797142-bristol-myers-awards-8m-in-health-equity-grants-for-medically-underserved-patients?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8529737591743469
2/8/2022 9:03:43 PM,2 Natural-Killer Cell Therapy Oncology Companies Investors Should Watch,Benzinga,/news/stocks/2-natural-killer-cell-therapy-oncology-companies-investors-should-watch-1031173167,neutral,0.911003828048706
2/9/2022 12:09:17 PM,Bristol Myers Squibb announces $5B in accelerated share repurchase agreements,Seeking Alpha,https://seekingalpha.com/news/3797712-bristol-myers-squibb-announces-5b-in-accelerated-share-repurchase-agreements?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8060895800590515
2/9/2022 2:31:47 PM,"The Daily Biotech Pulse: Bristol-Myers Squibb Announces $5B Accelerated Buyback, Qiagen Reaps COVID Testing Windfall, WORLDSymposium Presentations Kick In",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-squibb-announces-5b-accelerated-buyback-qiagen-reaps-covid-testing-windfall-worldsymposium-presentations-kick-in-1031176974,positive,0.7165576815605164
2/9/2022 2:47:07 PM,Bristol Myers Enters Into $5 Bln ASR Agreements ,RTTNews,/news/stocks/bristol-myers-enters-into-5-bln-asr-agreements-1031177060,neutral,0.7492271661758423
2/14/2022 9:35:53 PM,"Buffett's Berkshire Hathaway adds Activision Blizzard stake, exists Teva",Seeking Alpha,https://seekingalpha.com/news/3799802-buffetts-berkshire-hathaway-adds-activision-blizzard-stake-exists-teva?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9212615489959717
2/15/2022 11:36:33 AM,Exelixis/Bristol-Myers' drug combo shows sustained survival benefits in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/3799945-exelixisbristol-myers-drug-combo-shows-sustained-survival-benefits-in-kidney-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9501340389251709
2/15/2022 5:41:23 PM,GlaxoSmithKline the latest drugmaker to restrict discounts under 340B program,Seeking Alpha,https://seekingalpha.com/news/3800248-glaxosmithkline-latest-drugmaker-restrict-discounts-340b-safety-net-program?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8565000891685486
2/15/2022 7:18:10 PM,Bristol-Myers begins tender offers to buy notes for up to $4B,Seeking Alpha,https://seekingalpha.com/news/3800317-bristol-myers-begins-tender-offers-to-buy-notes-for-up-to-4b?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.5441012382507324
2/15/2022 9:53:21 PM,Bristol Myers Squibb to raise $6B in senior notes offering,Seeking Alpha,https://seekingalpha.com/news/3800455-bristol-myers-squibb-to-raise-6b-in-senior-notes-offering?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5933374762535095
2/16/2022 10:18:00 AM,AstraZeneca's Saphnelo gets approval in EU for systemic lupus erythematosus,Seeking Alpha,https://seekingalpha.com/news/3800544-astrazenecas-saphnelo-gets-approval-in-eu-for-systemic-lupus-erythematosus?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9307350516319275
2/16/2022 12:59:56 PM,Bristol Myers mavacamten for heart disease meets main goal in late-stage study,Seeking Alpha,https://seekingalpha.com/news/3800653-bristol-myers-mavacamten-for-heart-disease-meets-main-goal-in-late-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.6590133309364319
2/16/2022 3:39:01 PM,3 Desirable Drug Stocks With Very Promising Pipelines,InvestorPlace,/news/stocks/3-desirable-drug-stocks-with-very-promising-pipelines-1031201417,positive,0.9052234292030334
2/17/2022 2:00:05 PM,"The Daily Biotech Pulse: J&J Unit Announces Research Collaboration With Remix, Regencell Touts COVID Data, Decision Day For Agios",Benzinga,/news/stocks/the-daily-biotech-pulse-j-j-unit-announces-research-collaboration-with-remix-regencell-touts-covid-data-decision-day-for-agios-1031204785,neutral,0.8754628300666809
2/17/2022 2:26:08 PM,Bristol Myers Says FDA Accepts SBLA For Breyanzi As Second-Line Therapy For LBCL - Quick Facts ,RTTNews,/news/stocks/bristol-myers-says-fda-accepts-sbla-for-breyanzi-as-second-line-therapy-for-lbcl-quick-facts-1031204935,positive,0.5927942991256714
2/18/2022 10:08:16 AM,Bristol Myers' Breyanzi gets FDA priority review for expanded use in blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3801835-bristol-myers-breyanzi-gets-fda-priority-review-for-expanded-use-in-blood-cancer-subtype?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8438941836357117
2/18/2022 12:38:41 PM,Novartis launches generic version of Bristol Myers’ Revlimid in Europe,Seeking Alpha,https://seekingalpha.com/news/3801888-novartis-launches-generic-version-of-bristol-myers-revlimid-in-europe?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7967969179153442
2/18/2022 1:22:40 PM,"The Daily Biotech Pulse: Regeneron-Sanofi Halt Late-Stage Dupixent Study, Agios Gets FDA Nod, Safety Scare For GSK's RSV Vaccine, Shockwave Jumps On Earnings",Benzinga,/news/stocks/the-daily-biotech-pulse-regeneron-sanofi-halt-late-stage-dupixent-study-agios-gets-fda-nod-safety-scare-for-gsk-s-rsv-vaccine-shockwave-jumps-on-earnings-1031208337,neutral,0.4345228672027588
2/18/2022 2:09:33 PM,Agios vindicated with FDA approval for Pyrukynd - H.C. Wainwright,Seeking Alpha,https://seekingalpha.com/news/3801942-agios-stock-gains-as-hc-wainwright-raises-target-on-fda-approval?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9304521679878235
2/22/2022 7:57:48 PM,7 New ETFs To Consider if You Want To Play Today’s Top Trends,InvestorPlace,/news/stocks/7-new-etfs-to-consider-if-you-want-to-play-todays-top-trends-1031217554,neutral,0.9149611592292786
2/25/2022 12:44:30 PM,Bristol Myers Opdivo gets EMA panel nod for use as adjuvant therapy in urothelial cancer,Seeking Alpha,https://seekingalpha.com/news/3805853-bristol-myers-opdivo-gets-ema-panel-nod-for-use-as-adjuvant-therapy-in-urothelial-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7542481422424316
2/28/2022 7:41:42 AM,Biotech Stocks Facing FDA Decision In March 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2022-1031236842,neutral,0.9167487025260925
3/1/2022 7:00:00 PM,Dragonfly Therapeutics Announces Achievement of Phase 1 Clinical Development Milestone for IL-12 Investigational Immunotherapy Program with Bristol Myers Squibb,PR Newswire,/news/stocks/dragonfly-therapeutics-announces-achievement-of-phase-1-clinical-development-milestone-for-il-12-investigational-immunotherapy-program-with-bristol-myers-squibb-1031244173,positive,0.9301982522010803
3/1/2022 9:34:32 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3808072-bristol-myers-squibb-declares-054-dividend?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9446341395378113
3/2/2022 1:08:52 PM,Attention Biotech Investors: Mark Your Calendar For March PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-march-pdufa-dates-1031247139,neutral,0.9465387463569641
3/2/2022 8:48:55 PM,36 Stocks To Watch After Biden's First State of The Union Address,Benzinga,/news/stocks/36-stocks-to-watch-after-biden-s-first-state-of-the-union-address-1031248946,neutral,0.8909978866577148
3/3/2022 6:43:20 PM,Companies warn sanctions can disrupt medical supplies to Russia - Reuters,Seeking Alpha,https://seekingalpha.com/news/3809259-companies-warn-sanctions-can-disrupt-medical-supplies-to-russia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.939359724521637
3/7/2022 9:27:58 AM,Bristol Myers Opdivo combo gets FDA nod for expanded use in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3810049-bristol-myers-opdivo-combo-gets-fda-nod-for-expanded-use-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9065856337547302
3/7/2022 1:16:21 PM,Teva launches first generic of Bristol's Revlimid,Seeking Alpha,https://seekingalpha.com/news/3810142-teva-launches-first-generic-of-bristol-myers-squibb-revlimid?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7909349203109741
3/7/2022 3:50:09 PM,Aurinia Pharmaceuticals gains on report investors pushing for sale,Seeking Alpha,https://seekingalpha.com/news/3810237-aurinia-pharmaceuticals-gains-on-report-investor-pushing-for-sale?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9222245216369629
3/9/2022 11:24:06 AM,7 Biotech Stocks With Key Catalysts in March,InvestorPlace,/news/stocks/7-biotech-stocks-with-key-catalysts-in-march-1031265751,positive,0.5710039138793945
3/9/2022 11:40:07 AM,8 Strong Uptrend Stocks to Buy on the Next Dip,InvestorPlace,/news/stocks/8-strong-uptrend-stocks-to-buy-on-the-next-dip-1031265802,positive,0.8061007261276245
3/9/2022 4:35:04 PM,What Stocks Does 'The Big Short' Investor Michael Burry Own?,Benzinga,/news/stocks/what-stocks-does-the-big-short-investor-michael-burry-own-1031267025,neutral,0.927925705909729
3/10/2022 12:35:12 PM,7 Drug Stocks to Consider After the Viatris Plunge,InvestorPlace,/news/stocks/7-drug-stocks-to-consider-after-the-viatris-plunge-abbv-bmy-gsk-vtrs-jnj-teva-pfe-nvs-mrk-1031269941,neutral,0.926745593547821
3/12/2022 7:20:14 PM,Drugmakers face clinical trial disruptions amid Russia - Ukraine conflict,Seeking Alpha,https://seekingalpha.com/news/3812903-drugmakers-face-clinical-trial-disruptions-amid-russia-ukraine-conflict?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9664651155471802
3/13/2022 10:37:36 PM,"The Week Ahead In Biotech (March 13-19): Bristol-Myers Squibb's Melanoma Drug Decision, Multiple Conference Presentations And Earnings Dominate Proceedings",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-13-19-bristol-myers-squibb-s-melanoma-drug-decision-multiple-conference-presentations-and-earnings-dominate-proceedings-1031275983,negative,0.7026292085647583
3/14/2022 12:38:57 PM,"Bristol Myers Squibb, Nektar Say Phase 3 PIVOT IO-001 Trial Fails To Meet Endpoints ",RTTNews,/news/stocks/bristol-myers-squibb-nektar-say-phase-3-pivot-io-001-trial-fails-to-meet-endpoints-1031277512,negative,0.9354894757270813
3/14/2022 1:29:23 PM,Nektar slips after setback for lead asset bringing similar drugs into focus,Seeking Alpha,https://seekingalpha.com/news/3813105-alks-stock-slips-after-setback-for-nektars-lead-asset?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.963058352470398
3/14/2022 2:17:48 PM,Why Nektar Therapeutics Shares Are Falling Today,Benzinga,/news/stocks/why-nektar-therapeutics-shares-are-falling-today-1031277975,negative,0.9622109532356262
3/14/2022 2:47:17 PM,Nektar hit by “major” setback with melanoma trial failure for lead asset - BofA,Seeking Alpha,https://seekingalpha.com/news/3813147-nektar-hit-by-major-setback-with-melanoma-trial-failure---bofa?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9561156630516052
3/14/2022 4:07:30 PM,"Bristol Myers, Nektar Melanoma Doublet Therapy Trial Fails To Show Clinical Benefit",Benzinga,/news/stocks/bristol-myers-nektar-melanoma-doublet-therapy-trial-fails-to-show-clinical-benefit-1031278396,negative,0.8053054213523865
3/14/2022 5:43:17 PM,Why is Nektar Therapeutics (NKTR) Stock Down Today?,InvestorPlace,/news/stocks/why-is-nektar-therapeutics-nktr-stock-down-today-1031278798,negative,0.9478865265846252
3/15/2022 5:02:42 PM,3 Top Stock Trades for This Week,InvestorPlace,/news/stocks/3-top-stock-trades-for-this-week-1031282462,neutral,0.9186509847640991
3/17/2022 11:00:45 AM,7 Michael Burry Stocks to Buy as ‘The Big Short’ Investor Makes Moves,InvestorPlace,/news/stocks/7-michael-burry-stocks-to-buy-as-the-big-short-investor-makes-moves-1031288213,neutral,0.8774725794792175
3/19/2022 2:11:59 PM,Bristol Myers Squibb: FDA Approves Opdualag For Patients With Unresectable Or Metastatic Melanoma ,RTTNews,/news/stocks/bristol-myers-squibb-fda-approves-opdualag-for-patients-with-unresectable-or-metastatic-melanoma-1031292986,positive,0.8078122735023499
3/19/2022 5:10:09 PM,Bristol gains approval of first-in-class immunotherapy for melanoma Opdualag,Seeking Alpha,https://seekingalpha.com/news/3815159-bristol-gains-approval-of-first-in-class-immunotherapy-for-melanoma-opdualag?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9466915130615234
3/20/2022 1:40:47 PM,MDNA: No Read-Through for MDNA11 Based on Nektar Failure…,Benzinga,/news/stocks/mdna-no-read-through-for-mdna11-based-on-nektar-failure…-1031293351,neutral,0.7202043533325195
3/20/2022 4:42:56 PM,"The Week Ahead In Biotech (March 20-26): Focus On Zogenix FDA Decision, Dermatology Conference Presentations & Earnings",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-20-26-focus-on-zogenix-fda-decision-dermatology-conference-presentations-earnings-1031293398,neutral,0.9397634863853455
3/21/2022 1:29:17 PM,Volastra in up to $1.1B development deal with Bristol-Myers Squibb for oncology candidates,Seeking Alpha,https://seekingalpha.com/news/3815353-volastra-in-up-to-11b-development-deal-with-bristol-myers-squibb-for-oncology-candidates?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7855406403541565
3/22/2022 3:50:28 AM,"Transcenta, Bristol To Evaluate TST001 - Opdivo Combination For Gastroesophageal Junction Cancer ",RTTNews,/news/stocks/transcenta-bristol-to-evaluate-tst001-opdivo-combination-for-gastroesophageal-junction-cancer-1031296718,neutral,0.5273317098617554
3/23/2022 12:43:16 PM,"The Daily Biotech Pulse: Pfizer Reports Positive Ulcerative Colitis Study Data, Novavax COVID Shot Authorized For Adolescents In India, Argenx Stock Sale",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-reports-positive-ulcerative-colitis-study-data-novavax-covid-shot-authorized-for-adolescents-in-india-argenx-stock-sale-1031301077,neutral,0.5290578603744507
3/25/2022 11:33:49 AM,Bristol Myers Squibb announces a delay for FDA review of beta thalassemia therapy,Seeking Alpha,https://seekingalpha.com/news/3817401-bristol-myers-squibb-announces-a-delay-for-fda-review-of-beta-thalassemia-therapy?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.7697078585624695
3/25/2022 12:19:39 PM,Bristol Myers Squibb: FDA Extends PDUFA Goal Date For Reblozy By Three Months For Full Review ,RTTNews,/news/stocks/bristol-myers-squibb-fda-extends-pdufa-goal-date-for-reblozy-by-three-months-for-full-review-1031307751,positive,0.4901542663574219
3/25/2022 12:50:02 PM,"The Daily Biotech Pulse: MEI Pharma Wilts On Adverse Regulatory Development, Decision Day For Zogenix, AN2 Therapeutics IPO",Benzinga,/news/stocks/the-daily-biotech-pulse-mei-pharma-wilts-on-adverse-regulatory-development-decision-day-for-zogenix-an2-therapeutics-ipo-1031307839,negative,0.8759176135063171
3/27/2022 10:40:40 PM,"The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck  Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-march-27-april-2-lipocine-akebia-merck-await-fda-verdicts-adcom-test-for-amylyx-biontech-earnings-and-more-1031310198,neutral,0.9233648180961609
3/28/2022 7:31:43 AM,Biotech Stocks Facing FDA Decision In April 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-april-2022-1031310826,neutral,0.9148069024085999
3/28/2022 10:25:11 AM,Which Chinese Stocks Will Be Delisted? 8 in U.S. Crosshairs,InvestorPlace,/news/stocks/which-chinese-stocks-will-be-delisted-8-in-u-s-crosshairs-1031311449,neutral,0.8751969933509827
3/29/2022 12:26:22 PM,Bristol Myers’ lung cancer therapy undergoes EU review for use before surgery,Seeking Alpha,https://seekingalpha.com/news/3818366-bristol-myerss-lung-cancer-therapy-undergoes-eu-review-for-use-before-surgery?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.811159074306488
3/30/2022 2:05:30 PM,How to Buy Digital World Acquisition at Nearly Half the Price,InvestorPlace,/news/stocks/how-to-buy-digital-world-acquisition-dwac-stock-half-price-1031319385,neutral,0.9208335876464844
4/1/2022 9:16:51 PM,Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-april-pdufa-dates-1031327374,neutral,0.9468021392822266
4/3/2022 11:32:49 PM,"The Week Ahead In Biotech (April 3-April 9): BioXcel FDA Decision, Neurology Conference Presentations Take The Spotlight",Benzinga,/news/stocks/the-week-ahead-in-biotech-april-3-april-9-bioxcel-fda-decision-neurology-conference-presentations-take-the-spotlight-1031328267,neutral,0.9425358772277832
4/4/2022 11:00:37 AM,7 No-Brainer Stocks to Buy for April,InvestorPlace,/news/stocks/7-no-brainer-stocks-to-buy-for-april-ko-intc-bmy-skws-nflx-grmn-ttd-1031329577,neutral,0.9104050993919373
4/4/2022 11:06:57 AM,Bristol Myers posts long-term data for heart-disease drug in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/3820260-bristol-myers-posts-long-term-data-for-heart-disease-drug-in-late-stage-trial?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.591098427772522
4/5/2022 10:59:46 AM,7 Biotech Stocks to Buy With Key Catalysts for April,InvestorPlace,/news/stocks/7-biotech-stocks-to-buy-with-key-catalysts-for-april-1031332726,neutral,0.7184773087501526
4/5/2022 11:16:29 AM,Bristol Myers's Opdivo gets approval for 2 cancer types in EU,Seeking Alpha,https://seekingalpha.com/news/3820670-bristol-myerss-opdivo-gets-approval-for-2-cancer-types-in-eu?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.865609347820282
4/5/2022 1:48:52 PM,"The Daily Biotech Pulse: Thervance Gains On Positive Late-Stage Readout, Bristol-Myers Squibb Snags 3 Approvals In Europe, Decision Day For BioXcel",Benzinga,/news/stocks/the-daily-biotech-pulse-thervance-gains-on-positive-late-stage-readout-bristol-myers-squibb-snags-3-approvals-in-europe-decision-day-for-bioxcel-1031332845,positive,0.9342629909515381
4/5/2022 3:55:53 PM,Bristol Myers' CAR T cell therapy Breyanzi gets approval in EU to treat certain blood cancers,Seeking Alpha,https://seekingalpha.com/news/3820839-bristol-myers-car-t-cell-therapy-breyanzi-gets-approval-in-eu-to-treat-certain-blood-cancers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9097154140472412
4/5/2022 9:37:56 PM,MindMed Appoints Francois Lilienthal As New CCO,Benzinga,/news/stocks/mindmed-appoints-francois-lilienthal-as-new-cco-1031334555,neutral,0.931117832660675
4/6/2022 1:51:54 PM,Bristol-Myers Squibb downgraded at Morgan Stanley on revenue growth concerns,Seeking Alpha,https://seekingalpha.com/news/3821149-bristol-myers-squibb-downgraded-at-morgan-stanley-on-revenue-growth-concerns?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9343669414520264
4/6/2022 4:16:32 PM,"Benzinga's Top Ratings Upgrades, Downgrades For April 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-april-6-2022-1031337076,neutral,0.5202337503433228
4/7/2022 7:38:30 PM,Life sciences companies drive healthcare stocks to lead S&P 500,Seeking Alpha,https://seekingalpha.com/news/3821820-life-sciences-companies-drive-healthcare-stocks-to-lead-sp-500?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8493631482124329
4/8/2022 11:25:37 AM,Best Stocks for 2022: Bristol-Myers Squibb Isn’t Done Growing,InvestorPlace,/news/stocks/best-stocks-for-2022-bmy-stock-isnt-done-growing-1031342774,neutral,0.868756890296936
4/8/2022 12:12:15 PM,Bipartisan legislation aims to increase value-based purchasing for pricey drugs in Medicaid,Seeking Alpha,https://seekingalpha.com/news/3821989-bipartisan-legislation-aims-to-increase-value-based-purchasing-for-pricey-drugs-in-medicaid?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9119019508361816
4/8/2022 1:52:26 PM,"The Daily Biotech Pulse: Evotec Earns $16M Milestone Payment, Genmab Hit With Adverse Tribunal Ruling, Quidel Announces Above-Consensus Q1 Revenues And More",Benzinga,/news/stocks/the-daily-biotech-pulse-evotec-earns-16m-milestone-payment-genmab-hit-with-adverse-tribunal-ruling-quidel-announces-above-consensus-q1-revenues-and-more-1031342792,positive,0.7685925364494324
4/8/2022 6:38:50 PM,3 Recession-Proof Dividend Stocks to Buy,InvestorPlace,/news/stocks/3-recession-proof-stocks-to-buy-for-income-1031343772,neutral,0.8319101929664612
4/8/2022 9:02:51 PM,Why Bicycle Therapeutics Stock Is Soaring Today,Benzinga,/news/stocks/why-bicycle-therapeutics-stock-is-soaring-today-1031343779,positive,0.7996294498443604
4/9/2022 4:00:14 PM,Healthcare stocks outperform as investors look for safety,Seeking Alpha,https://seekingalpha.com/news/3822171-healthcare-stocks-outperform-as-investors-look-for-safety?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9504940509796143
4/11/2022 4:34:55 PM,Bristol Myers highlights potential of Opdivo when used before surgery in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3822396-bristol-myers-says-opdivo-was-effective-when-used-before-surgery-in-lung-cancer?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6198558211326599
4/14/2022 8:45:21 PM,"Nektar, Bristol Myers to end development program for bempegaldesleukin/Opdivo combo",Seeking Alpha,https://seekingalpha.com/news/3823602-nektar-bristol-myers-to-end-development-program-for-bempegaldesleukinopdivo-combo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8901360034942627
4/14/2022 10:30:00 PM,Nektar and Bristol Myers Squibb Announce Update on Clinical Development Program for Bempegaldesleukin (BEMPEG) in Combination with Opdivo (nivolumab),PR Newswire,/news/stocks/nektar-and-bristol-myers-squibb-announce-update-on-clinical-development-program-for-bempegaldesleukin-bempeg-in-combination-with-opdivo-nivolumab-1031357993,neutral,0.632594108581543
4/15/2022 9:15:54 AM,"Nektar, Bristol Myers To Discontinue Clinical Program For Bempegaldesleukin With Opdivo ",RTTNews,/news/stocks/nektar-bristol-myers-to-discontinue-clinical-program-for-bempegaldesleukin-with-opdivo-1031358564,neutral,0.7813259959220886
4/18/2022 2:25:31 PM,Nektar stock slumps 36% on Goldman Sachs downgrade following bempeg program termination,Seeking Alpha,https://seekingalpha.com/news/3823886-nektar-stock-slumps-36-on-goldman-sachs-downgrade-following-bempeg-program-termination?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9705228209495544
4/18/2022 2:49:10 PM,Read Why Did Bristol Myers and Nektar End $3.6B Immuno-Oncology Program,Benzinga,/news/stocks/read-why-did-bristol-myers-and-nektar-end-3-6b-immuno-oncology-program-1031360967,neutral,0.8959856033325195
4/18/2022 3:25:20 PM,"Benzinga's Daily Brief On Trending Tickers For April 18, 2022: Casa Systems, Twitter, DiDi Global, And More",Benzinga,/news/stocks/benzinga-s-daily-brief-on-trending-tickers-for-april-18-2022-casa-systems-twitter-didi-global-and-more-1031361132,neutral,0.9462705254554749
4/19/2022 6:07:59 AM,"Bristol-Myers to begin including R&D charges with Q1, sees 10c impact from IPRD",Seeking Alpha,https://seekingalpha.com/news/3824123-bristol-myers-to-begin-including-rd-charges-with-q1-sees-10c-impact-from-iprd?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8545092344284058
4/22/2022 12:00:43 AM,Pfizer: What Comes After the Covid-19 Fire?,InvestorPlace,/news/stocks/pfe-stock-what-comes-after-the-covid-fire-1031373557,neutral,0.8588875532150269
4/22/2022 5:35:18 PM,"Evelo Biosciences names former Alnylam, MyoKardia CEOs as strategic advisors",Seeking Alpha,https://seekingalpha.com/news/3825890-evelo-biosciences-names-former-alnylam-myokardia-ceos-as-strategic-advisors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9506841897964478
4/23/2022 8:00:00 PM,COVID therapies and vaccines propel rise in spending on medicines in 2021,Seeking Alpha,https://seekingalpha.com/news/3825965-covid-therapies-and-vaccines-propel-rise-in-spending-on-medicines-in-2021?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9413689970970154
4/25/2022 9:26:09 PM,"Nektar Therapeutics unveils restructuring plan, laying off 70% of its workforce",Seeking Alpha,https://seekingalpha.com/news/3826475-nektar-therapeutics-unveils-restructuring-plan-laying-off-70-of-its-workforce?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9647687077522278
4/28/2022 2:55:37 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/3828682-notable-earnings-before-fridays-open?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8830810189247131
4/28/2022 3:01:13 PM,Here's what Wall Street expects from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q1-earnings-preview-1031397521,neutral,0.9091694951057434
4/28/2022 3:54:00 PM,Will Bristol Myers Squibb positive earnings momentum continue in Q1?,Seeking Alpha,https://seekingalpha.com/news/3828705-will-bristol-myers-squibb-positive-earnings-momentum-continue-in-q1?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.92706298828125
4/29/2022 5:22:31 AM,FDA Approves Bristol Myers' Camzyos For Heart Disease ,RTTNews,/news/stocks/fda-approves-bristol-myers-camzyos-for-heart-disease-1031399608,neutral,0.7105446457862854
4/29/2022 10:24:10 AM,LianBio stock soars 20% as partner Bristol Myers wins FDA nod for Camzyos to treat heart disorder,Seeking Alpha,https://seekingalpha.com/news/3829239-lianbio-stock-soars-20-as-partner-bristol-myers-wins-fda-nod-for-camzyos-to-treat-heart-disorder?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9072629809379578
4/29/2022 11:01:43 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.96 beats by $0.07, revenue of $11.6B beats by $260M",Seeking Alpha,https://seekingalpha.com/news/3829265-bristol-myers-squibb-non-gaap-eps-of-1_96-beats-0_07-revenue-of-11_6b-beats-260m?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5223515033721924
4/29/2022 12:06:32 PM,"Bristol Myers stock dips despite Q1 beat, as FY22 EPS outlook trimmed, Revlimid to see decline",Seeking Alpha,https://seekingalpha.com/news/3829329-bristol-myers-stock-dips-despite-q1-beat-as-fy22-eps-outlook-trimmed-revlimid-to-see-decline?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9564273357391357
4/29/2022 1:33:01 PM,"Bristol-Myers Squibb Slashes FY22 EPS, Adj. EPS Outlook; Q1 Results Top Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-slashes-fy22-eps-adj-eps-outlook-q1-results-top-estimates-1031402185,negative,0.9463164806365967
4/29/2022 3:00:32 PM,"The Daily Biotech Pulse: FDA Approves Bristol Myers' Oral Heart Disease Drug, European Approval For Merck's Keytruda, Genocea Restructures, Zymeworks' Takeover Bid",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-approves-bristol-myers-oral-heart-disease-drug-european-approval-for-merck-s-keytruda-genocea-restructures-zymeworks-takeover-bid-1031402592,positive,0.6426585912704468
4/29/2022 3:06:28 PM,Bristol Myers Squibb Reports FDA Approval Of Camzyos - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-reports-fda-approval-of-camzyos-quick-facts-1031402643,positive,0.6695755124092102
4/29/2022 4:43:00 PM,"Despite FDA approval for heart condition drug mavacamten, LianBio stock falls 24%",Seeking Alpha,https://seekingalpha.com/news/3829552-despite-fda-approval-for-heart-condition-drug-mavacamten-lianbio-stock-falls-24?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9699722528457642
4/30/2022 8:00:00 PM,U.S. pharmaceutical sector fails to spring higher amid lackluster April performance,Seeking Alpha,https://seekingalpha.com/news/3829651-us-pharmaceutical-sector-fails-to-spring-higher-amid-lackluster-april-performance?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6144388914108276
5/1/2022 2:31:26 PM,Attention Biotech Investors: Mark Your Calendar For May PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-may-pdufa-dates-1031404843,neutral,0.9478530883789062
5/2/2022 6:05:13 AM,Biotech Stocks Facing FDA Decision In May 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2022-1031405313,neutral,0.9221025705337524
5/2/2022 1:16:21 PM,Gilead to develop Dragonfly natural killer cell engager immunotherapy; $300M upfront,Seeking Alpha,https://seekingalpha.com/news/3829992-gilead-to-develop-dragonfly-natural-killer-cell-engager-immunotherapy-300m-upfront?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7901163697242737
5/2/2022 3:44:25 PM,What 4 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-4-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031409196,neutral,0.9117707014083862
5/3/2022 10:34:01 AM,Goldman highlights top sector picks for high dividend growth and yield,Seeking Alpha,https://seekingalpha.com/news/3830044-goldman-highlights-sector-picks-for-high-dividend-growth-and-yield?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7869226336479187
5/10/2022 3:23:19 PM,"The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves",Benzinga,/news/stocks/the-daily-biotech-pulse-pfizer-acquires-migraine-drugmaker-for-11b-biogen-files-for-second-alzheimer-s-drug-approval-longeveron-ceo-leaves-1031442487,neutral,0.898991048336029
5/10/2022 3:28:57 PM,Bristol Myers extends protein degradation deal with Evotec,Seeking Alpha,https://seekingalpha.com/news/3836012-bristol-myers-extends-protein-degradation-deal-with-evotec?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5445957183837891
5/10/2022 4:46:58 PM,"Evotec, Bristol Myers Extend Partnership In Protein Degradation ",RTTNews,/news/stocks/evotec-bristol-myers-extend-partnership-in-protein-degradation-1031442825,positive,0.7561391592025757
5/11/2022 10:26:59 PM,The Top 10 Stocks Helping Warren Buffett Beat the Market,InvestorPlace,/news/stocks/the-top-10-stocks-helping-warren-buffett-beat-the-market-1031450438,positive,0.5588307976722717
5/12/2022 11:56:14 AM,Bristol Myers and BridgeBio Pharma partner for cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3837652-bbio-stock-climbs-after-agreement-with-bristol-myers-squibb?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7592321634292603
5/12/2022 11:57:47 AM,Bristol Myers' deucravacitinib maintains efficacy at 2 years against plaque psoriasis in study,Seeking Alpha,https://seekingalpha.com/news/3837653-bristol-myers-deucravacitinib-maintains-efficacy-at-2-years-against-plaque-psoriasis-in-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8334671258926392
5/12/2022 2:42:55 PM,"The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More",Benzinga,/news/stocks/the-daily-biotech-pulse-bristol-myers-bridgebio-ink-oncology-pact-fda-nod-for-lava-therapeutics-blood-cancer-study-and-more-1031453570,neutral,0.9403820037841797
5/12/2022 3:48:34 PM,BridgeBio Inks Licensing Pact With Bristol Myers For SHP2 Inhibitor In Oncology,Benzinga,/news/stocks/bridgebio-inks-licensing-pact-with-bristol-myers-for-shp2-inhibitor-in-oncology-1031454165,positive,0.918920636177063
5/13/2022 11:19:50 AM,"Bristol Myers to sell East Syracuse, New York production facility",Seeking Alpha,https://seekingalpha.com/news/3838497-bristol-myers-to-sell-east-syracuse-new-york-production-facility?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9272549748420715
5/13/2022 1:21:36 PM,Bristol Myers To Sell East Syracuse Manufacturing Facility To Korea's LOTTE; Terms Not Disclosed ,RTTNews,/news/stocks/bristol-myers-to-sell-east-syracuse-manufacturing-facility-to-korea-s-lotte-terms-not-disclosed-1031458433,neutral,0.9382349848747253
5/13/2022 4:38:25 PM,"The Daily Biotech Pulse: FDA Orphan Drug Tags For Neurocrine, Editas Candidates; Sale of BridgeBio's PRV; RMAT Designation For PolarityTE's Product",Benzinga,/news/stocks/the-daily-biotech-pulse-fda-orphan-drug-tags-for-neurocrine-editas-candidates-sale-of-bridgebio-s-prv-rmat-designation-for-polarityte-s-product-1031459211,neutral,0.8146160244941711
5/16/2022 12:01:25 PM,Bristol Myers' Opdivo/Yervoy combo fails to improve overall survival in certain bladder cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3839084-bristol-myers-opdivoyervoy-combo-fails-to-improve-overall-survival-in-certain-bladder-cancer-patients-in-trial?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6984430551528931
5/16/2022 1:23:58 PM,Bristol Myers Squibb: Phase 3 CheckMate -901 Trial Fails To Meet Primary Endpoint ,RTTNews,/news/stocks/bristol-myers-squibb-phase-3-checkmate-901-trial-fails-to-meet-primary-endpoint-1031464053,negative,0.9407751560211182
5/16/2022 10:31:40 PM,"Berkshire Hathaway takes 2.5% stake in Citi in Q1, exits Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/3839678-berkshire-hathaway-takes-25-stake-in-citi-in-q1-exits-wells-fargo?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.9384966492652893
5/17/2022 12:39:47 PM,Idera halts melanoma trial for cancer candidate after early positive results,Seeking Alpha,https://seekingalpha.com/news/3839915-idra-stock-surges-on-positive-results-for-melanoma-candidate?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6378729343414307
5/17/2022 4:20:53 PM,7 ETFs to Pick-Up From the Tech Wreck,InvestorPlace,/news/stocks/7-etfs-to-pick-up-from-the-tech-wreck-1031469495,positive,0.9378713965415955
5/18/2022 12:05:08 PM,Immatics begins dosing of IMA203 with Bristol Myers' Opdivo in trial to treat solid tumors,Seeking Alpha,https://seekingalpha.com/news/3840366-immatics-begins-dosing-of-ima203-with-bristol-myers-opdivo-in-trial-to-treat-solid-tumors?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5399047136306763
5/18/2022 1:45:06 PM,Purple Biotech initiates phase 2 study for its antibody CM24 in pancreatic cancer patients,Seeking Alpha,https://seekingalpha.com/news/3840457-purple-biotech-initiates-phase-2-study-for-its-antibody-cm24-in-pancreatic-cancer-patients?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.5077489614486694
5/20/2022 4:32:44 PM,Legendary Investor Michael Burry Is Betting Against Apple (AAPL) Stock,InvestorPlace,/news/stocks/legendary-investor-michael-burry-is-betting-against-apple-aapl-stock-1031479283,neutral,0.8856273293495178
5/20/2022 8:54:19 PM,Bristol-Myers Squibb's azacitidine granted additional indication for juvenile leukemia,Seeking Alpha,https://seekingalpha.com/news/3841501-bristol-myers-squibbs-azacitidine-granted-additional-indication-for-juvenile-leukemia?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6156024932861328
5/22/2022 9:58:01 PM,"The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More",Benzinga,/news/stocks/the-week-ahead-in-biotech-may-22-28-verrica-bristol-myers-squibb-fda-decisions-medtronic-earnings-conference-presentations-more-1031480317,neutral,0.9357399940490723
5/24/2022 7:43:07 PM,Michael Burry Says 2022 Is a ‘Plane Crash.’ Here’s What the Legendary Investor Is Betting On.,InvestorPlace,/news/stocks/michael-burry-says-2022-is-a-plane-crash-heres-what-the-legendary-investor-is-betting-on-1031486237,neutral,0.9287131428718567
5/25/2022 12:35:58 PM,Karyopharm begins dosing in late-stage study of selinexor combo therapy for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/3842591-karyopharm-begins-dosing-in-late-stage-study-of-selinexor-combo-therapy-for-multiple-myeloma?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.6542250514030457
5/27/2022 4:04:02 PM,Biotech Stocks Facing FDA Decision In June 2022 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-june-2022-1031493578,neutral,0.9180289506912231
5/30/2022 1:56:19 PM,"Bristol-Myers, Novartis win FDA label expansions for cancer medications",Seeking Alpha,https://seekingalpha.com/news/3843682-bristol-myers-novartis-win-fda-label-expansions-for-cancer-medications?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8181806802749634
5/31/2022 7:44:43 PM,Takeda CEO says drugmakers face pricing pressure due to global crises,Seeking Alpha,https://seekingalpha.com/news/3844113-takeda-ceo-says-drugmakers-face-pricing-pressure-due-to-global-crises?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.9459705948829651
5/31/2022 9:42:54 PM,Attention Biotech Investors: Mark Your Calendar For These June PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-june-pdufa-dates-1031499656,neutral,0.9482179284095764
6/1/2022 12:39:43 PM,Bristol Myers' deucravacitinib improves disease activity in lupus patients in mid-stage study,Seeking Alpha,https://seekingalpha.com/news/3844340-bristol-myers-deucravacitinib-improves-disease-activity-in-lupus-patients-in-mid-stage-study?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9482873678207397
6/1/2022 8:44:10 PM,Sana Biotechnology to develop Washington manufacturing facility saving $100M,Seeking Alpha,https://seekingalpha.com/news/3844761-sana-biotechnology-to-develop-washington-manufacturing-facility-saving-100m?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.7274730205535889
6/2/2022 1:23:43 PM,Immatics stock rises on cell therapy program collaboration with Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3845000-immatics-stock-rises-on-cell-therapy-program-collaboration-with-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.8744016289710999
6/2/2022 2:18:11 PM,"Immatics, Bristol Myers Squibb Expand Strategic Alliance To Develop TCR-T, CAR-T Programs ",RTTNews,/news/stocks/immatics-bristol-myers-squibb-expand-strategic-alliance-to-develop-tcr-t-car-t-programs-1031505159,positive,0.8454151153564453
6/2/2022 3:54:05 PM,Bristol Myers discloses topline results for arthritis drug in COVID-19,Seeking Alpha,https://seekingalpha.com/news/3845077-bmy-stock-lower-after-topline-results-for-arthritis-drug-in-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7884497046470642
6/2/2022 4:25:53 PM,Johnson & Johnson arthritis drug leads to clinical improvement in hospitalized COVID-19,Seeking Alpha,https://seekingalpha.com/news/3845099-johnson-johnson-arthritis-drug-leads-to-clinical-improvement-in-hospitalized-covid-19?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.950898289680481
6/3/2022 1:36:50 PM,Turning Point climbs 116% on buyout deal with Bristol Myers for over $4B in cash,Seeking Alpha,https://seekingalpha.com/news/3845418-bmy-stock-flat-tptx-stock-surges-on-4b-acquisition-deal?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9197240471839905
6/3/2022 2:43:41 PM,TPTX Stock Soars 115% as Bristol-Myers Announces Takeover of Turning Point Therapeutics,InvestorPlace,/news/stocks/tptx-stock-soars-115-as-bristol-myers-announces-takeover-of-turning-point-therapeutics-1031508825,positive,0.4479972720146179
6/3/2022 3:14:31 PM,Bristol Myers Squibb To Acquire Turning Point Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-turning-point-therapeutics-quick-facts-1031508506,neutral,0.9387122988700867
6/3/2022 3:35:19 PM,Bristol Myers downgraded at Raymond James after Turning Point acquisition,Seeking Alpha,https://seekingalpha.com/news/3845549-bmy-stock-downgraded-at-raymond-james-after-turning-point-acquisition?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.8083151578903198
6/3/2022 4:16:56 PM,"Blueprint Medicines, Mirati, Immunogen gain following Turning Point sale to Bristol Myers (update)",Seeking Alpha,https://seekingalpha.com/news/3845503-blueprint-medicines-deciphera-black-diamond-gain-following-turning-point-sale-to-bristol-myers?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.8779632449150085
6/3/2022 7:22:52 PM,What 7 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-7-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031509118,neutral,0.9192204475402832
6/3/2022 9:11:37 PM,6 Biotech Stocks to Buy Now Ahead of These June Catalysts,InvestorPlace,/news/stocks/6-biotech-stocks-june-catalysts-1031509381,neutral,0.8837399482727051
6/3/2022 9:31:45 PM,Bristol-Myers Squibb withdraws sBLA for Reblozyl in non-transfusion beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3845696-bristol-myers-squibb-withdraws-sbla-for-reblozyl-in-non-transfusion-beta-thalassemia?utm_source=markets.businessinsider.com&utm_medium=referral,negative,0.6905609965324402
6/5/2022 10:09:23 PM,"The Week Ahead In Biotech (June 5-11): Adcom Test For Novavax, ASCO Presentations, Enzo Biochem Earnings And More",Benzinga,/news/stocks/the-week-ahead-in-biotech-june-5-11-adcom-test-for-novavax-asco-presentations-enzo-biochem-earnings-and-more-1031509946,neutral,0.8043581247329712
6/6/2022 11:00:51 AM,7 Cheap Growth Stocks That Won’t Stay That Way for Long,InvestorPlace,/news/stocks/7-cheap-growth-stocks-that-wont-stay-that-way-for-long-1031510595,neutral,0.8345869779586792
6/6/2022 11:49:52 AM,Bristol Myers Opdivo/Yervoy combo shows survival benefit for lung cancer patients in 3-year data,Seeking Alpha,https://seekingalpha.com/news/3845848-bristol-myers-opdivoyervoy-combo-shows-survival-benefit-for-lung-cancer-patients-in-3-year-data?utm_source=markets.businessinsider.com&utm_medium=referral,positive,0.9548504948616028
6/6/2022 5:12:03 PM,"Benzinga's Top Ratings Upgrades, Downgrades For June 6, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-june-6-2022-1031511325,neutral,0.5026867389678955
6/7/2022 8:00:16 PM,"New drugs cost an average of $180K per year, new study finds",Seeking Alpha,https://seekingalpha.com/news/3846439-new-drugs-cost-an-average-of-180k-per-year-new-study-finds?utm_source=markets.businessinsider.com&utm_medium=referral,neutral,0.7216758728027344
6/9/2022 6:26:10 PM,Wells Fargo highlights potential targets as biotech M&A accelerates,Seeking Alpha,https://seekingalpha.com/news/3847403-wells-fargo-highlights-potential-targets-as-biotech-ma-accelerates?utm_source=businessinsider&utm_medium=referral,positive,0.8801780939102173
6/9/2022 11:15:00 PM,7 Blue-Chip Stocks With Strong Dividend Yields,InvestorPlace,/news/stocks/7-blue-chip-stocks-with-strong-dividend-yields-2-1031520851,positive,0.8644109964370728
6/10/2022 6:00:59 PM,"Catalyst watch: Kroger earnings, Powell speaks, Cisco event, Ethereum PoS test",Seeking Alpha,https://seekingalpha.com/news/3847702-catalyst-watch-kroger-earnings-powell-speaks-cisco-event-ethereum-pos-test?utm_source=businessinsider&utm_medium=referral,neutral,0.9379705190658569
6/10/2022 9:53:38 PM,Goldman Sachs comes under SEC civil probe over ESG funds - WSJ,Seeking Alpha,https://seekingalpha.com/news/3847829-goldman-sachs-comes-under-sec-probe-on-esg-funds-wsj?utm_source=businessinsider&utm_medium=referral,negative,0.9274108409881592
6/13/2022 8:43:01 PM,HC Wainwright Says This Lymphoma Candidate Has Better Response Rates Than Approved Medications,Benzinga,/news/stocks/hc-wainwright-says-this-lymphoma-candidate-has-better-response-rates-than-approved-medications-1031526010,positive,0.9443436861038208
6/14/2022 1:28:36 PM,Bristol Myers tops S&P 500 with largest intangible adjustment in 2021,Seeking Alpha,https://seekingalpha.com/news/3848429-bristol-myers-tops-sp-500-with-largest-intangible-adjustment-in-2021?utm_source=businessinsider&utm_medium=referral,positive,0.8711011409759521
6/14/2022 1:57:38 PM,Wells Fargo unveils its recession stock portfolio,Seeking Alpha,https://seekingalpha.com/news/3848418-wells-fargo-unveils-its-recession-stock-portfolio?utm_source=businessinsider&utm_medium=referral,neutral,0.9255277514457703
6/15/2022 8:18:17 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3849008-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9446341395378113
6/17/2022 8:23:52 PM,The 5 Top Profit & Protection Stocks to Buy for 2022,InvestorPlace,/news/stocks/the-5-top-profit-protection-stocks-to-buy-for-2022-1031536315,neutral,0.9284602999687195
6/24/2022 3:30:56 PM,Bristol-Myers Squibb hits 52-week high; shares up 27% YTD,Seeking Alpha,https://seekingalpha.com/news/3851621-bristol-myers-squibb-hits-52-week-high-shares-up-27-ytd?utm_source=businessinsider&utm_medium=referral,positive,0.9426729679107666
6/24/2022 6:13:59 PM,Bristol-Myers MS drug linked to better COVID response with mRNA shots,Seeking Alpha,https://seekingalpha.com/news/3851697-bristol-myers-ms-drug-linked-to-better-covid-response-with-mrna-shots?utm_source=businessinsider&utm_medium=referral,positive,0.8316783308982849
6/24/2022 9:29:05 PM,Bristol-Myers Squibb bid to dismiss $6.4B lawsuit from Celgene shareholders denied - Reuters,Seeking Alpha,https://seekingalpha.com/news/3851842-bristol-myers-squibb-bid-to-dismiss-64b-lawsuit-from-celgene-shareholders-denied-reuters?utm_source=businessinsider&utm_medium=referral,negative,0.5336297750473022
6/28/2022 3:48:01 PM,Canada approves Bristol-Myers' Opdivo for bladder cancer patients with certain conditions,Seeking Alpha,https://seekingalpha.com/news/3852526-canada-approves-bristol-myers-opdivo-for-bladder-cancer-patients-with-certain-conditions?utm_source=businessinsider&utm_medium=referral,positive,0.7053929567337036
6/29/2022 3:36:20 AM,BMY : Canada Approves OPDIVO For Treatment Of Certain Patients Diagnosed With Urothelial Cancer ,RTTNews,/news/stocks/bmy-canada-approves-opdivo-for-treatment-of-certain-patients-diagnosed-with-urothelial-cancer-1031556062,positive,0.895380437374115
6/29/2022 3:50:08 PM,5 S&P 500 Stocks Ready to Break Out,InvestorPlace,/news/stocks/sp-500-stocks-ready-to-break-out-1031558401,neutral,0.7080056667327881
6/29/2022 6:06:23 PM,"The Daily Biotech Pulse: Eli Lilly Modifies COVID-19 Treatment Pact, Oyster Point Outlines Restructuring Plan, Icosavax Posts Interim RSV Vaccine Data",Benzinga,/news/stocks/the-daily-biotech-pulse-eli-lilly-modifies-covid-19-treatment-pact-oyster-point-outlines-restructuring-plan-icosavax-posts-interim-rsv-vaccine-data-1031558382,neutral,0.9134541153907776
7/1/2022 11:26:23 AM,Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates,Benzinga,/news/stocks/attention-biotech-investors-mark-your-calendar-for-these-july-pdufa-dates-1031562548,neutral,0.9478203058242798
7/3/2022 6:00:00 PM,"With just 16 new drugs approved in H1 2022, FDA poised for slew of approvals in H2",Seeking Alpha,https://seekingalpha.com/news/3853856-with-just-16-new-drugs-approved-in-h1-2022-fda-poised-for-slew-of-approvals-in-h2?utm_source=businessinsider&utm_medium=referral,neutral,0.6703073382377625
7/6/2022 2:23:02 PM,6 Stocks Hedge Funds Love in a Recession,InvestorPlace,/news/stocks/stocks-hedge-funds-love-in-a-recession-1031570801,negative,0.7146030068397522
7/6/2022 5:22:36 PM,U.S. Senate Democrats advance deal to lower drug prices,Seeking Alpha,https://seekingalpha.com/news/3854684-us-senate-democrats-in-agreement-to-lower-drug-prices?utm_source=businessinsider&utm_medium=referral,positive,0.7087152004241943
7/8/2022 4:17:59 PM,Best Stocks for 2022: Bristol-Myers Squibb Is Having a Great Year,InvestorPlace,/news/stocks/best-stocks-for-2022-bristol-myers-squibb-1031576071,positive,0.9064211845397949
7/15/2022 2:31:31 PM,"Aurinia Pharma tumbles after takeover speculation cools on new exec hires, exec departure",Seeking Alpha,https://seekingalpha.com/news/3857223-aurinia-pharma-tumbles-after-takeover-speculation-cools-on-new-exec-hires-exec-departure?utm_source=businessinsider&utm_medium=referral,negative,0.8935180306434631
7/17/2022 10:50:02 AM,"Best Stocks for 2022: After Two Quarters, Who Holds The Lead?",InvestorPlace,/news/stocks/best-stocks-for-2022-after-two-quarters-who-holds-lead-1031591864,neutral,0.9161376357078552
7/18/2022 6:58:43 PM,Top pharma lobby says R&D spending reached a peak in 2021,Seeking Alpha,https://seekingalpha.com/news/3857699-top-pharma-lobby-says-rd-spending-reached-a-peak-in-2021?utm_source=businessinsider&utm_medium=referral,positive,0.9346282482147217
7/19/2022 12:09:23 PM,Bristol Myers extends tender offer period for $4.1B Turning Point acquisition,Seeking Alpha,https://seekingalpha.com/news/3857977-bristol-myers-extends-tender-offer-period-for-41b-turning-point-acquisition?utm_source=businessinsider&utm_medium=referral,neutral,0.8166531324386597
7/19/2022 6:33:55 PM,Cancer immunotherapy biotech Immatics up 18% on 4x normal volume,Seeking Alpha,https://seekingalpha.com/news/3858219-cancer-immunotherapy-biotech-immatics-up-17-on-4x-normal-volume?utm_source=businessinsider&utm_medium=referral,positive,0.9510902166366577
7/19/2022 8:30:19 PM,"Psychedelics Management Updates: Two Top Companies Appoint New CEOs, Here's What We Know",Benzinga,/news/stocks/psychedelics-management-updates-two-top-companies-appoint-new-ceos-here-s-what-we-know-1031598273,neutral,0.9228947162628174
7/20/2022 4:18:23 PM,Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate,Seeking Alpha,https://seekingalpha.com/news/3858614-arcellx-named-new-buy-at-canaccord-genuity-on-multiple-myeloma-candidate?utm_source=businessinsider&utm_medium=referral,neutral,0.7260497808456421
7/20/2022 10:00:43 PM,7 Best Pharmaceutical Stocks to Buy Now,InvestorPlace,/news/stocks/best-pharmaceutical-stocks-1031602627,neutral,0.879433810710907
7/22/2022 11:23:46 AM,Bristol-Myers new immunotherapy Opdualag gets EMA panel nod to treat skin cancer,Seeking Alpha,https://seekingalpha.com/news/3859540-bristol-myers-new-immunotherapy-opdualag-gets-ema-panel-nod-to-treat-skin-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.7769601345062256
7/22/2022 3:21:00 PM,"Bristol Myers U.S., German antitrust filings for Turning Point expected very soon (update)",Seeking Alpha,https://seekingalpha.com/news/3859302-bristol-myers-us-german-antitrust-filings-for-turning-point-expected-very-soon-report?utm_source=businessinsider&utm_medium=referral,neutral,0.8339062929153442
7/22/2022 11:59:12 PM,Recap Of Friday's Biotech Catalysts - End Of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031608647,neutral,0.9370302557945251
7/23/2022 8:15:00 PM,"Drug pricing legislation will affect biopharma revenue, but impact is manageable - RBC",Seeking Alpha,https://seekingalpha.com/news/3859761-drug-pricing-legislation-will-affect-biopharma-revenue-but-impact-is-manageable-rbc?utm_source=businessinsider&utm_medium=referral,neutral,0.8448383808135986
7/24/2022 3:00:43 PM,7 Best Cash Cow Stocks to Buy for Stable Returns,InvestorPlace,/news/stocks/best-cash-cow-stocks-1031609438,neutral,0.777340829372406
7/24/2022 10:37:06 PM,"Apple, Meta, Pfizer Among Key Companies Reporting In The Week Ahead, As Earnings Pick Up Pace",Benzinga,/news/stocks/apple-meta-pfizer-among-key-companies-reporting-in-the-week-ahead-as-earning-picks-up-pace-1031609526,positive,0.8915559649467468
7/26/2022 1:50:58 PM,Will Bristol Myers Squibb positive earnings momentum continue in Q2?,Seeking Alpha,https://seekingalpha.com/news/3860531-will-bristol-myers-squibb-positive-earnings-momentum-continue-in-q2?utm_source=businessinsider&utm_medium=referral,positive,0.9266335964202881
7/26/2022 3:01:13 PM,What Wall Street expects from Bristol-Myers Squibb's earnings,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q2-earnings-preview-1031615553,neutral,0.9331842660903931
7/26/2022 3:50:03 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinias-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral,negative,0.8486039042472839
7/26/2022 4:08:38 PM,Patent challenge on Aurinia's Lupkynis could impact takeover interest near-term - Cantor,Seeking Alpha,https://seekingalpha.com/news/3860602-patent-challenge-on-aurinia-lupkynis-could-impact-takeover-interest-near-term-cantor?utm_source=businessinsider&utm_medium=referral,negative,0.8486039042472839
7/27/2022 11:02:11 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.93 beats by $0.12, revenue of $11.9B beats by $400M, cuts FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3861183-bristol-myers-squibb-non-gaap-eps-of-193-beats-by-012-revenue-of-119b-beats-by-400m-cuts-fy22-outlook?utm_source=businessinsider&utm_medium=referral,negative,0.9293258190155029
7/27/2022 12:00:03 PM,Bristol Myers slips as forex impact triggers 2022 guidance cut,Seeking Alpha,https://seekingalpha.com/news/3861255-bmy-stock-slips-as-forex-impact-triggers-2022-guidance-cut?utm_source=businessinsider&utm_medium=referral,negative,0.9485333561897278
7/27/2022 1:32:41 PM,Bristol-Myers Squibb Reaffirms FY22 Adj. EPS Outlook; Q2 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-reaffirms-fy22-adj-eps-outlook-q2-results-top-estimates-1031620017,positive,0.7166619896888733
7/27/2022 3:28:18 PM,"Daily Biotech Pulse: Teva's Opioids Settlement, Criminal Investigation Against Cassava, Durable Responses For IN8bio's Leukemia Therapy",Benzinga,/news/stocks/daily-biotech-pulse-teva-s-opioids-settlement-criminal-investigation-against-cassava-durable-responses-for-in8bio-s-leukemia-therapy-1031621034,neutral,0.751183807849884
7/28/2022 5:39:16 PM,Expert Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/expert-ratings-for-bristol-myers-squibb-1031626653,neutral,0.8719897866249084
7/29/2022 11:22:02 AM,Bristol Myers Opdivo/Yervoy combo fails as post-surgical therapy in kidney cancer in phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3863067-bristol-myers-opdivoyervoy-combo-fails-as-post-surgical-therapy-in-kidney-cancer-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral,negative,0.8159286379814148
7/29/2022 1:56:39 PM,Bristol Myers: CheckMate -914 Part A Trial With Opdivo Plus Yervoy Fails To Meet Primary Goal ,RTTNews,/news/stocks/bristol-myers-checkmate-914-part-a-trial-with-opdivo-plus-yervoy-fails-to-meet-primary-goal-1031629807,negative,0.8772652745246887
7/29/2022 4:27:45 PM,"Daily Biotech Pulse: Bausch Health To Appeal Xifaxan Patent Decision, Bristol Myers Drug Combo Fails In Kidney Cancer Trial, Sarepta's Duchenne Candidate Update",Benzinga,/news/stocks/daily-biotech-pulse-bausch-health-to-appeal-xifaxan-patent-decision-bristol-myers-drug-combo-fails-in-kidney-cancer-trial-sarepta-s-duchenne-candidate-update-1031630398,negative,0.49885469675064087
7/29/2022 11:24:17 PM,Recap Of Friday's Biotech Catalysts - End of The Day Summary,Benzinga,/news/stocks/recap-of-friday-s-biotech-catalysts---end-of-the-day-summary-1031631044,neutral,0.9370302557945251
8/4/2022 5:18:38 PM,Eli Lilly ordered to pay $183M in whistleblower Medicaid fraud case - Bloomberg,Seeking Alpha,https://seekingalpha.com/news/3867381-eli-lilly-ordered-to-pay-183m-in-whistleblower-medicaid-fraud-case-bloomberg?utm_source=businessinsider&utm_medium=referral,negative,0.879170298576355
8/7/2022 10:19:22 PM,$35 per month capped insulin for private insurance kept out of Inflation Reduction Act,Seeking Alpha,https://seekingalpha.com/news/3868539-35-per-month-capped-insulin-for-private-insurance-kept-out-of-inflation-reduction-act-passed-by-senate?utm_source=businessinsider&utm_medium=referral,neutral,0.5326845645904541
8/8/2022 3:44:30 PM,Nektar downgraded at JPMorgan citing setup after end to anti-cancer program,Seeking Alpha,https://seekingalpha.com/news/3868851-nektar-downgraded-at-jpmorgan-citing-setup-after-end-to-anti-cancer-program?utm_source=businessinsider&utm_medium=referral,negative,0.6578017473220825
8/10/2022 11:16:16 AM,"Bristol Myers, 2seventy bio score trial win for multiple myeloma candidate",Seeking Alpha,https://seekingalpha.com/news/3870557-tsvt-stock-soars-after-trial-win-with-bristol-myers-for-multiple-myeloma-drug?utm_source=businessinsider&utm_medium=referral,positive,0.6403949856758118
8/10/2022 11:25:30 AM,"Bristol Myers, GentiBio ink up to $1.9B pact to develop therapies for inflammatory bowel diseases",Seeking Alpha,https://seekingalpha.com/news/3870566-bristol-myers-gentibio-ink-up-to-19b-pact-to-develop-therapies-for-inflammatory-bowel-diseases?utm_source=businessinsider&utm_medium=referral,positive,0.8246113657951355
8/10/2022 2:30:31 PM,2seventy Bio Shares Jump On Positive Data From Bristol Myers-Partnered Cancer Immunotherapy,Benzinga,/news/stocks/2seventy-bio-shares-jump-on-positive-data-from-bristol-myers-partnered-cancer-immunotherapy-1031670516,positive,0.6152242422103882
8/10/2022 5:33:08 PM,"Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial",Benzinga,/news/stocks/biotech-daily-cancer-causing-impurities-in-merck-s-diabetic-drug-vir-bio-gsk-shun-fda-submission-plans-for-covid-19-treatment-aethlon-s-monkeypox-trial-1031671419,neutral,0.8316500782966614
8/11/2022 12:23:03 AM,Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-wednesday-s-biotech-catalysts---end-of-the-day-summary-1031672483,neutral,0.9346833229064941
8/14/2022 5:48:06 PM,Analysts rule out major industry impact from drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3872629-analysts-rule-out-major-industry-impact-from-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8447363376617432
8/15/2022 8:46:33 PM,Why Michael Burry Is Betting Big on Just ONE Secretive Stock,InvestorPlace,/news/stocks/why-michael-burry-is-betting-big-on-just-one-secretive-stock-1031685177,neutral,0.9348410964012146
8/16/2022 11:45:24 AM,"Bristol Myers' $4.1B Turning Point acquisition gets clearance in US, Germany, set to close",Seeking Alpha,https://seekingalpha.com/news/3873537-bristol-myers-41b-turning-point-acquisition-gets-clearance-in-us-germany-set-to-close?utm_source=businessinsider&utm_medium=referral,positive,0.8734362125396729
8/16/2022 3:54:34 PM,"Scion Asset Management exits all positions, holding just one stock- Geo Group",Seeking Alpha,https://seekingalpha.com/news/3873725-scion-asset-management-exits-all-positions-holding-just-one-stock-geo-group?utm_source=businessinsider&utm_medium=referral,neutral,0.6279377937316895
8/17/2022 6:58:50 PM,Michael Burry Puts His Money Where His Mouth Is For Market Crash Prediction: But Did He Sell Too Soon?,Benzinga,/news/stocks/michael-burry-puts-his-money-where-his-mouth-is-for-market-crash-prediction-but-did-he-sell-too-soon-1031690845,neutral,0.8620142340660095
8/23/2022 1:01:38 PM,Bristol Myers gets Health Canada nod for Opdivo combo use before surgery in lung cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3875777-bristol-myers-gets-health-canada-nod-for-opdivo-combo-use-before-surgery-in-lung-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.7122778296470642
8/23/2022 2:52:48 PM,Bristol Myers: Health Canada Approves OPDIVO Plus Platinum-doublet Chemotherapy ,RTTNews,/news/stocks/bristol-myers-health-canada-approves-opdivo-plus-platinum-doublet-chemotherapy-1031700513,positive,0.5435909032821655
8/24/2022 12:53:43 AM,Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary,Benzinga,/news/stocks/recap-of-tuesday-s-biotech-catalysts---end-of-the-day-summary-1031701797,neutral,0.9340888261795044
8/27/2022 9:08:07 AM,Biotech Stocks Facing FDA Decision In September ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-1031709034,neutral,0.6874346733093262
8/29/2022 4:44:50 PM,"Bristol-Myers falls 5%, most in two years, after mid-stage data for blood thinner",Seeking Alpha,https://seekingalpha.com/news/3877518-bmy-stock-falls-after-mid-stage-data-for-blood-thinner?utm_source=businessinsider&utm_medium=referral,negative,0.9234603047370911
8/31/2022 8:52:36 PM,"Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know",Benzinga,/news/stocks/bluebird-bio-seeks-back-to-back-nods-go-or-no-go-for-revance-s-botox-rival-amylyx-twin-hurdles-and-more-september-s-key-pdufa-catalysts-biotech-investors-must-know-1031717312,neutral,0.754786491394043
9/1/2022 11:30:33 AM,5 Stocks That Michael Burry Just Dumped From His Portfolio,InvestorPlace,/news/stocks/5-stocks-that-michael-burry-just-dumped-from-his-portfolio-1031718929,neutral,0.8701650500297546
9/7/2022 2:14:42 PM,Cipla Gets Final Approval For Generic Version Of Revlimid - Quick Facts ,RTTNews,/news/stocks/cipla-gets-final-approval-for-generic-version-of-revlimid-quick-facts-1031728987,positive,0.8484627604484558
9/11/2022 11:03:19 PM,7 Blue-Chip Stocks to Buy Before the Bull Market Returns,InvestorPlace,/news/stocks/blue-chip-stocks-to-buy-before-bull-market-returns-1031630381,neutral,0.8826736211776733
9/12/2022 10:22:20 AM,Bristol Myers stock rises on FDA approval of psoriasis therapy Sotyktu; presents long-term efficacy data,Seeking Alpha,https://seekingalpha.com/news/3881893-bristol-myers-stock-rises-on-fda-approval-of-psoriasis-therapy-sotyktu-presents-long-term-efficacy-data?utm_source=businessinsider&utm_medium=referral,positive,0.8936725854873657
9/12/2022 12:30:53 PM,Why Clovis Oncology Is Trading Higher By 14%; Here Are 28 Stocks Moving Premarket,Benzinga,/news/stocks/why-clovis-oncology-is-trading-higher-by-14-here-are-28-stocks-moving-premarket-1031736782,neutral,0.8209140300750732
9/12/2022 12:40:20 PM,"ASTS, ONTX and BITF among pre market gainers",Seeking Alpha,https://seekingalpha.com/news/3881955-asts-ontx-and-bitf-among-pre-market-gainers?utm_source=businessinsider&utm_medium=referral,positive,0.8919186592102051
9/12/2022 1:30:50 PM,Bristol-Myers Squibb To $87? Here Are 5 Other Price Target Changes For Monday,Benzinga,/news/stocks/bristol-myers-squibb-to-87-here-are-5-other-price-target-changes-for-monday-1031736928,neutral,0.9026398062705994
9/12/2022 1:35:31 PM,"Bristol-Myers Squibb, Carvana And Some Other Big Stocks Recording Gains In Today's Pre-Market Session",Benzinga,/news/stocks/bristol-myers-squibb-carvana-and-some-other-big-stocks-recording-gains-in-today-s-pre-market-session-1031736970,positive,0.9375017285346985
9/12/2022 1:37:05 PM,Bristol-Myers Squibb (BMY) Stock Jumps 8% as FDA Approves Psoriasis Treatment,InvestorPlace,/news/stocks/bristol-myers-squibb-bmy-stock-jumps-8-as-fda-approves-psoriasis-treatment-1031737488,positive,0.9333909153938293
9/12/2022 1:50:38 PM,Adobe (ADBE) Stock Slips on Analyst Downgrade,InvestorPlace,/news/stocks/adobe-adbe-stock-slips-on-analyst-downgrade-1031737531,negative,0.9656839966773987
9/12/2022 2:03:30 PM,QSR Stock Pops as Burger Kings Announces $400 Million Investment,InvestorPlace,/news/stocks/qsr-stock-pops-as-burger-kings-announces-400-million-investment-1031737598,neutral,0.46301978826522827
9/12/2022 2:44:36 PM,"HC Wainwright Cuts Price Target On This Stock By 73%, Also Check Out Other Major PT Changes Here",Benzinga,/news/stocks/hc-wainwright-cuts-price-target-on-this-stock-by-73-also-check-out-other-major-pt-changes-here-1031737265,neutral,0.8956565260887146
9/12/2022 2:48:55 PM,Ventyx stock soars 69% as analysts see Sotyktu approval sans warning a 'win' for TYK2 class,Seeking Alpha,https://seekingalpha.com/news/3882039-ventyx-stock-soars-as-analysts-see-sotyktu-approval-sans-warning-a-win-for-tyk2-class?utm_source=businessinsider&utm_medium=referral,positive,0.9173105955123901
9/12/2022 4:19:33 PM,Onconova rigosertib/Opdivo combo shows promise in advanced lung cancer in trial,Seeking Alpha,https://seekingalpha.com/news/3882075-onconova-rigosertibopdivo-combo-shows-promise-in-advanced-lung-cancer-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9258413910865784
9/12/2022 6:45:41 PM,"Why Ventyx Biosciences Is Trading Higher By 70%, Here Are 46 Stocks Moving In Monday's Mid-Day Session",Benzinga,/news/stocks/why-ventyx-biosciences-is-trading-higher-by-70-here-are-46-stocks-moving-in-monday-s-mid-day-session-1031737993,neutral,0.8831570148468018
9/12/2022 10:04:36 PM,5 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/5-analysts-have-this-to-say-about-bristol-myers-squibb-1031738282,neutral,0.9105390906333923
9/12/2022 11:06:14 PM,Expert Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/expert-ratings-for-bristol-myers-squibb-1031738397,neutral,0.8719897866249084
9/13/2022 9:01:20 AM,"NIO, Lucid Group And Other Big Gainers From Monday",Benzinga,/news/stocks/nio-lucid-group-and-other-big-gainers-from-monday-1031738922,positive,0.7303787469863892
9/13/2022 10:30:24 AM,7 Screaming Buy Stock Picks to Beat the September Market Slump,InvestorPlace,/news/stocks/7-screaming-buy-stock-picks-to-beat-the-september-market-slump-1031739340,positive,0.8326027989387512
9/13/2022 11:15:00 AM,Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday,Benzinga,/news/stocks/why-tuesday-morning-shares-tumbled-31-here-are-66-biggest-movers-from-yesterday-1031739149,negative,0.6191527843475342
9/13/2022 8:38:58 PM,Amgen drops to six-month low amid latest challenges to pipeline,Seeking Alpha,https://seekingalpha.com/news/3882497-amgn-stock-drops-to-six-month-low-amid-latest-challenges?utm_source=businessinsider&utm_medium=referral,negative,0.9649937748908997
9/14/2022 11:58:17 AM,US Stock Futures Rise After Recording Worst Sell-Off Since June 2020; PPI Data In Focus,Benzinga,/news/stocks/us-stock-futures-rise-after-recording-worst-sell-off-since-june-2020-ppi-data-in-focus-1031742133,negative,0.823169469833374
9/14/2022 1:18:29 PM,"Bristol-Myers cut to hold at Bereneberg citing U.S. pricing reforms, patent cliff",Seeking Alpha,https://seekingalpha.com/news/3882692-bmy-stock-cut-to-hold-at-bereneberg-on-us-pricing-reforms-patent-cliff?utm_source=businessinsider&utm_medium=referral,negative,0.5620698928833008
9/14/2022 4:07:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-september-14-2022-1031743148,neutral,0.5372791290283203
9/14/2022 8:18:51 PM,Bristol Myers Squibb declares $0.54 dividend,Seeking Alpha,https://seekingalpha.com/news/3882835-bristol-myers-squibb-company-declares-0_54-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.9446341395378113
9/14/2022 8:46:14 PM,These 5 Experts See A Market Crash Ahead: What Do BZ Readers Think?,Benzinga,/news/etf/these-5-experts-see-a-market-crash-ahead-what-do-bz-readers-think-1031743729,neutral,0.545100212097168
9/15/2022 12:10:24 PM,Bristol Myers Opdivo shows survival benefit as adjuvant therapy for skin cancer in trial,Seeking Alpha,https://seekingalpha.com/news/3882972-bristol-myers-opdivo-shows-survival-benefit-as-adjuvant-therapy-for-skin-cancer-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9376823902130127
9/19/2022 10:00:06 AM,7 Penny Stocks That Actually Have a Buy Rating,InvestorPlace,/news/stocks/7-penny-stocks-with-buy-ratings-to-keep-your-eye-on-1031750175,neutral,0.9222168326377869
9/19/2022 10:09:27 AM,"AutoZone, bluebird bio And 3 Stocks To Watch Heading Into Monday",Benzinga,/news/stocks/autozone-bluebird-bio-and-3-stocks-to-watch-heading-into-monday-1031749980,neutral,0.9174557328224182
9/19/2022 11:32:56 AM,"US Stock Futures Down Ahead Of Fed's Rate Decision This Week, Crude Oil Drops Over 1%",Benzinga,/news/stocks/us-stock-futures-down-ahead-of-fed-s-rate-decision-this-week-crude-oil-drops-over-1-1031750084,negative,0.9565421938896179
9/20/2022 8:18:52 PM,3 Stocks That Could Rocket on Biden’s Cancer Moonshot,InvestorPlace,/news/stocks/3-stocks-that-could-rocket-on-bidens-cancer-moonshot-1031754919,neutral,0.8138480186462402
9/21/2022 10:13:03 PM,"CPRX, BMY: Insiders are Selling These 2 Pharma Stocks; Should You?",TipRanks,/news/stocks/cprx-bmy-insiders-are-selling-these-2-pharma-stocks-should-you-1031757894,neutral,0.8650880455970764
9/23/2022 11:46:34 AM,Artivion stock falls as apixaban fails vs warfarin in reducing blood clots in aortic valve patients; reaffirms outlook,Seeking Alpha,https://seekingalpha.com/news/3885575-artivion-stock-falls-as-apixaban-fails-vs-warfarin-in-reducing-blood-clots-in-aortic-valve-patients-stops-trial-reaffirms-outlook?utm_source=businessinsider&utm_medium=referral,negative,0.9699043035507202
9/23/2022 5:05:53 PM,"Insiders Selling Nasdaq, Bristol-Myers Squibb And This Consumer Defensive Stock",Benzinga,/news/stocks/insiders-selling-nasdaq-bristol-myers-squibb-and-this-consumer-defensive-stock-1031762182,neutral,0.8798633813858032
9/28/2022 10:17:23 PM,These Stocks Are On The Radar After Biogen-Eisai's Surprising Alzheimer's Trial Win,Benzinga,/news/stocks/these-stocks-are-on-the-radar-after-biogen-eisai-s-surprising-alzheimer-s-trial-win-1031771238,neutral,0.5415459275245667
10/4/2022 4:30:31 AM,"LLY, ISRG, or BMY: Which Healthcare Stock Could Yield Better Returns?",TipRanks,/news/stocks/lly-isrg-or-bmy-which-healthcare-stock-could-yield-better-returns-1031780497,neutral,0.8583230376243591
10/4/2022 12:18:44 PM,Autolus stock rises on Bristol Myers contract for use of safety switch with cell therapies,Seeking Alpha,https://seekingalpha.com/news/3888414-autolus-stock-rises-on-bristol-myers-contract-for-use-of-safety-switch-with-cell-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.8189197182655334
10/4/2022 1:00:39 PM,Exelixis expands cancer clinical trial collaboration & supply pact with Bristol-Myers,Seeking Alpha,https://seekingalpha.com/news/3888447-exelixis-expands-cancer-clinical-trial-collaboration--supply-pact-with-bristol-myers?utm_source=businessinsider&utm_medium=referral,positive,0.8675119280815125
10/4/2022 2:25:03 PM,Exelixis Expands Agreement With Bristol Myers For STELLAR-002 Trial - Quick Facts ,RTTNews,/news/stocks/exelixis-expands-agreement-with-bristol-myers-for-stellar-002-trial-quick-facts-1031781492,positive,0.938662588596344
10/4/2022 4:50:57 PM,Bristol in collaboration pact with tiny biotech SyntheX on targeted protein degraders,Seeking Alpha,https://seekingalpha.com/news/3888591-bristol-in-collaboration-pact-with-tiny-biotech-synthex-on-targeted-protein-degraders?utm_source=businessinsider&utm_medium=referral,positive,0.6944814324378967
10/4/2022 6:09:33 PM,HHS change to Medicare payments for biosimilars aims to spur uptake,Seeking Alpha,https://seekingalpha.com/news/3888611-hhs-change-to-medicare-payments-for-biosimilars-aims-to-spur-uptake?utm_source=businessinsider&utm_medium=referral,positive,0.9251479506492615
10/4/2022 8:09:04 PM,Best Stocks 2022: These 3 Factors Can Send Sonic Automotive (SAH) Stock Soaring in Q4,InvestorPlace,/news/stocks/best-stocks-2022-these-3-factors-can-send-sonic-automotive-sah-stock-soaring-in-q4-1031782939,positive,0.9230083227157593
10/5/2022 8:01:34 PM,Best Stocks 2022: Why Bristol-Myers Squibb (BMY) Stock Is a Clear Winner,InvestorPlace,/news/stocks/best-stocks-2022-why-bristol-myers-squibb-bmy-stock-is-a-clear-winner-1031785682,positive,0.6270912289619446
10/7/2022 11:25:53 AM,Knight's affiliate files for Brazilian approval of cancer drug tafasitamab,Seeking Alpha,https://seekingalpha.com/news/3889584-knights-affiliate-files-for-brazilian-approval-of-cancer-drug-tafasitamab?utm_source=businessinsider&utm_medium=referral,neutral,0.8017383217811584
10/7/2022 5:21:22 PM,PureTech Health Confirms 'Possible' Merger With Nektar Therapeutics,Benzinga,/news/stocks/puretech-health-confirms-possible-merger-with-nektar-therapeutics-1031790389,neutral,0.6866515278816223
10/10/2022 11:35:59 AM,Merck's Acceleron buy shows results as sotatercept meets main goal in trial to treat high pressure in lungs,Seeking Alpha,https://seekingalpha.com/news/3889939-mercks-acceleron-buy-shows-results-as-sotatercept-meets-main-goal-in-trial-to-treat-high-pressure-in-lungs?utm_source=businessinsider&utm_medium=referral,positive,0.8756797313690186
10/10/2022 1:06:03 PM,Bristol-Myers cut to Neutral at Guggenheim citing overly bullish consensus,Seeking Alpha,https://seekingalpha.com/news/3889989-bmy-stock-cut-to-neutral-at-guggenheim-citing-overly-bullish-consensus?utm_source=businessinsider&utm_medium=referral,negative,0.9258175492286682
10/10/2022 3:59:33 PM,6 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/6-analysts-have-this-to-say-about-bristol-myers-squibb-1031793346,neutral,0.9050684571266174
10/10/2022 4:08:11 PM,"Benzinga's Top Ratings Upgrades, Downgrades For October 10, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-october-10-2022-1031793370,neutral,0.5087153315544128
10/10/2022 5:04:52 PM,What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031793557,neutral,0.9208806753158569
10/10/2022 6:09:22 PM,GOP senators introduce bill to undo Medicare prescription drug negotiation,Seeking Alpha,https://seekingalpha.com/news/3890099-gop-senators-introduce-bill-to-undo-medicare-prescription-drug-negotiation?utm_source=businessinsider&utm_medium=referral,neutral,0.5134321451187134
10/10/2022 8:10:08 PM,The 7 Most Undervalued Value Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-most-undervalued-value-stocks-to-buy-now-1031794052,neutral,0.7967768907546997
10/11/2022 5:49:38 PM,"BridgeBio stock rises as BBP-398, Lumakras combo for lung cancer gets FDA fast track status",Seeking Alpha,https://seekingalpha.com/news/3890439-bridgebio-stock-rises-as-bbp-398-lumakras-combo-gets-fda-fast-track-status?utm_source=businessinsider&utm_medium=referral,positive,0.8679677248001099
10/14/2022 12:24:33 PM,Biden to sign Executive Order tasking HHS to find additional ways to lower drug costs,Seeking Alpha,https://seekingalpha.com/news/3891387-biden-to-sign-executive-order-tasking-hhs-to-find-additional-ways-to-lower-drug-costs-medicare?utm_source=businessinsider&utm_medium=referral,positive,0.8669120669364929
10/17/2022 2:34:50 PM,Morgan Stanley says large cap healthcare remains attractive amid macro concerns,Seeking Alpha,https://seekingalpha.com/news/3891861-morgan-stanely-says-large-cap-healthcare-remains-attractive-amid-macro-concerns?utm_source=businessinsider&utm_medium=referral,positive,0.9349676966667175
10/18/2022 1:59:33 PM,What Is Going on With AVEO Pharmaceuticals (AVEO) Stock Today?,InvestorPlace,/news/stocks/what-is-going-on-with-aveo-pharmaceuticals-aveo-stock-today-1031813929,negative,0.6325019598007202
10/19/2022 9:36:38 PM,Bristol-Myers' Opdivo cancer drug reduces risk of death in resected stage II melanoma,Seeking Alpha,https://seekingalpha.com/news/3892931-bristol-myers-opdivo-cancer-drug-reduces-risk-of-death-in-resected-stage-ii-melanoma?utm_source=businessinsider&utm_medium=referral,positive,0.8359518647193909
10/20/2022 5:19:54 PM,Prescription drugs make up a rising share of Medicare spending – study,Seeking Alpha,https://seekingalpha.com/news/3893317-prescription-drugs-account-for-a-rising-chunk-of-medicare-spending-study?utm_source=businessinsider&utm_medium=referral,neutral,0.7574052214622498
10/21/2022 10:39:48 AM,Aurinia announces resignations of medical chief and senior research executive,Seeking Alpha,https://seekingalpha.com/news/3893596-auph-stock-slips-on-resignations-of-medical-chief-senior-research-executive?utm_source=businessinsider&utm_medium=referral,negative,0.8748167157173157
10/21/2022 11:24:42 AM,Bristol Myers heart drug Camzyos gets FDA review for expanded use,Seeking Alpha,https://seekingalpha.com/news/3893619-bristol-myers-heart-drug-camzyos-gets-fda-review-for-expanded-use?utm_source=businessinsider&utm_medium=referral,positive,0.6582342982292175
10/21/2022 5:16:55 PM,"Earnings week ahead: Apple, Alphabet, Amazon, Meta, Boeing and more",Seeking Alpha,https://seekingalpha.com/news/3893730-earnings-week-ahead-apple-alphabet-amazon-meta-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9336963295936584
10/21/2022 5:56:11 PM,"Talks begin with pharma, health insurers over negotiating drug prices for Medicare",Seeking Alpha,https://seekingalpha.com/news/3893788-talks-begin-with-pharma-health-insurers-over-negotiating-drug-prices-for-medicare?utm_source=businessinsider&utm_medium=referral,neutral,0.6700778007507324
10/25/2022 2:07:37 PM,Bristol Myers Squibb Q3 2022 Earnings Preview,Seeking Alpha,https://seekingalpha.com/news/3894760-bristol-myers-squibb-q3-2022-earnings-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.8280310034751892
10/25/2022 3:01:13 PM,Bristol-Myers Squibb earnings: here's what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-quarter-earnings-preview-q3-1031832929,neutral,0.9348831176757812
10/25/2022 3:10:05 PM,Notable earnings before Wednesday's open,Seeking Alpha,https://seekingalpha.com/news/3894799-notable-earnings-before-wednesdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.855887770652771
10/26/2022 7:17:42 AM,"Bristol Myers Squibb Non-GAAP EPS of $1.99 beats by $0.16, revenue of $11.22B beats by $40M, re-affirms FY22 outlook",Seeking Alpha,https://seekingalpha.com/news/3895253-bristol-myers-squibb-non-gaap-eps-of-199-beats-by-016-revenue-of-1122b-beats-by-40m-re-affirms-fy22-outlook?utm_source=businessinsider&utm_medium=referral,positive,0.5221533179283142
10/26/2022 9:04:38 AM,"Bristol Myers Q3 sales fall amid generic competition to Revlimid, forex woes",Seeking Alpha,https://seekingalpha.com/news/3895281-bristol-myers-q3-sales-fall-amid-generic-competition-to-revlimid-forex-woes?utm_source=businessinsider&utm_medium=referral,negative,0.9728875160217285
10/26/2022 10:18:48 AM,Bristol Myers MS drug Zeposia recipients mounted serologic response to COVID vaccines in trial,Seeking Alpha,https://seekingalpha.com/news/3895308-bristol-myers-ms-drug-zeposia-recipients-mounted-serologic-response-to-covid-vaccines-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.8629590272903442
10/27/2022 12:35:35 PM,Morgan Stanley Sticks to Its Sell Rating for Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-sell-rating-for-bristol-myers-bmy-1031843403,neutral,0.7295572757720947
10/27/2022 12:38:16 PM,Atlantic Equities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1031843386,neutral,0.5524477958679199
10/27/2022 1:00:07 PM,Bristol extends agreement with Obsidian Therapeutics for cell therapies for cancer,Seeking Alpha,https://seekingalpha.com/news/3896463-bristol-extends-agreement-with-obsidian-therapeutics-for-cell-therapies-for-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.9120392799377441
10/27/2022 1:40:59 PM,Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-and-abbvie-abbv-1031843968,neutral,0.9116553664207458
10/27/2022 2:30:00 PM,Obsidian Therapeutics Announces Extension of Multi-Year Collaboration Agreement with Bristol Myers Squibb,PR Newswire,/news/stocks/obsidian-therapeutics-announces-extension-of-multi-year-collaboration-agreement-with-bristol-myers-squibb-1031843274,positive,0.917220413684845
10/27/2022 4:00:39 PM,Analyst Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/analyst-ratings-for-bristol-myers-squibb-1031844083,neutral,0.9085960984230042
10/27/2022 4:08:59 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031844124,neutral,0.928318977355957
10/27/2022 7:30:41 PM,Wingstop To Rally Around 13%? Plus This Analyst Cuts PT On Cano Health By 50%,Benzinga,/news/stocks/wingstop-to-rally-around-13-plus-this-analyst-cuts-pt-on-cano-health-by-50-1031844778,negative,0.6973364353179932
10/27/2022 8:37:46 PM,"Analyst Sees Market Potential For Arcellx Multiple Myeloma Candidate, Sees 50% Upside In Stock",Benzinga,/news/stocks/analyst-sees-market-potential-for-arcellx-multiple-myeloma-candidate-sees-50-upside-in-stock-1031844903,positive,0.9255242943763733
10/28/2022 1:55:45 PM,Geron draws Outperform rating at Wedbush on prospects for blood disease therapy,Seeking Alpha,https://seekingalpha.com/news/3897283-gern-stock-gains-on-outperform-rating-at-wedbush?utm_source=businessinsider&utm_medium=referral,positive,0.7886582016944885
10/31/2022 11:42:01 AM,Bristol Myers says Merck-partnered blood cancer therapy met main goal in Phase 3 trial,Seeking Alpha,https://seekingalpha.com/news/3897653-bristol-myers-merck-partnered-blood-cancer-therapy-succeeds-in-phase-3-trial?utm_source=businessinsider&utm_medium=referral,neutral,0.575520932674408
11/1/2022 10:31:39 AM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Hologic (HOLX) and Genmab (GMAB)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-hologic-holx-and-genmab-gmab-1031857622,neutral,0.9205641746520996
11/1/2022 5:26:53 PM,Legend Biotech initiated at outperform at Cowen on strength of Carvykti,Seeking Alpha,https://seekingalpha.com/news/3898764-legend-biotech-initiated-at-outperform-at-cowen-on-strength-of-carvykti?utm_source=businessinsider&utm_medium=referral,positive,0.9366981983184814
11/3/2022 12:33:42 PM,Kura Oncology rises on $25M equity investment from Bristol Myers,Seeking Alpha,https://seekingalpha.com/news/3900908-kura-oncology-rises-on-25m-equity-investment-from-bristol-myers?utm_source=businessinsider&utm_medium=referral,positive,0.9174438118934631
11/3/2022 4:30:26 PM,"Cancer drugs launch prices soaring, straining Medicare, report finds",Seeking Alpha,https://seekingalpha.com/news/3901117-cancer-drugs-launch-prices-soaring-straining-medicare-report-finds?utm_source=businessinsider&utm_medium=referral,negative,0.591728687286377
11/4/2022 11:38:11 AM,BioAtla soars 47% as drug shows response in lung cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3901838-bioatla-stock-soars-as-drug-shows-response-in-lung-cancer-patients-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9507717490196228
11/7/2022 9:47:57 AM,GSK's blood cancer therapy Blenrep fails to meet main goal in phase 3 study,Seeking Alpha,https://seekingalpha.com/news/3902419-gsks-blood-cancer-therapy-blenrep-fails-to-meet-main-goal-in-phase-3-study?utm_source=businessinsider&utm_medium=referral,negative,0.9517971277236938
11/7/2022 6:50:06 PM,Bristol Myers bid for $1.2B Gilead patent award rejected by Supreme Court,Seeking Alpha,https://seekingalpha.com/news/3902906-bristol-myers-bid-for-12b-gilead-patent-award-rejected-by-supreme-court?utm_source=businessinsider&utm_medium=referral,negative,0.548741340637207
11/8/2022 7:04:04 PM,The 7 Best Pharma Stocks to Buy Now,InvestorPlace,/news/stocks/the-7-best-pharma-stocks-to-buy-now-1031893081,neutral,0.8310679793357849
11/10/2022 3:20:42 PM,Bristol Myers Squibb's Camzyos approved in Canada for hypertrophic cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3905690-bristol-myers-squibbs-camzyos-approved-in-canada-for-hypertrophic-cardiomyopathy?utm_source=businessinsider&utm_medium=referral,positive,0.7560338377952576
11/10/2022 4:40:43 PM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Precision BioSciences (DTIL) and Immunocore Holdings (IMCR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-precision-biosciences-dtil-and-immunocore-holdings-imcr-1031899596,neutral,0.911342203617096
11/10/2022 4:40:50 PM,Bristol-Myers Squibb To Surge Over 10%? Plus Morgan Stanley Predicts $263 For L3Harris Technologies,Benzinga,/news/stocks/bristol-myers-squibb-to-surge-over-10-plus-morgan-stanley-predicts-263-for-l3harris-technologies-1031899394,positive,0.9376541972160339
11/11/2022 8:16:39 PM,"Healthcare stocks come off lows, worst performing sector among defensive losers (update)",Seeking Alpha,https://seekingalpha.com/news/3906637-healthcare-stocks-fall-across-the-board-as-traders-move-out-of-defensive-sectors?utm_source=businessinsider&utm_medium=referral,negative,0.8541240692138672
11/11/2022 9:31:43 PM,Why Are Healthcare Stocks Down Today?,InvestorPlace,/news/stocks/why-are-healthcare-stocks-down-today-1031905660,negative,0.944724440574646
11/18/2022 1:02:32 PM,8 Analysts Have This to Say About Bristol-Myers Squibb,Benzinga,/news/stocks/8-analysts-have-this-to-say-about-bristol-myers-squibb-1031924934,neutral,0.8949980139732361
11/18/2022 5:58:37 PM,"Benzinga's Top Ratings Upgrades, Downgrades For November 18, 2022",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-november-18-2022-1031925925,negative,0.5206901431083679
11/18/2022 7:00:33 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1031926074,neutral,0.928318977355957
11/18/2022 8:42:20 PM,Credit Suisse Sees Uncertainty On New Product Launch Execution & Growth For Bristol Myers,Benzinga,/news/stocks/credit-suisse-sees-uncertainty-on-new-product-launch-execution-growth-for-bristol-myers-1031926213,negative,0.8633419871330261
11/28/2022 4:27:50 PM,"US Stocks Start Week On Lower Note, Dow Drops Over 100 Points",Benzinga,/news/stocks/us-stocks-start-week-on-lower-note-dow-drops-over-100-points-1031940167,negative,0.945440411567688
11/28/2022 7:01:49 PM,Why Taboola Shares Are Trading Higher By Around 53%? Here Are 53 Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-taboola-shares-are-trading-higher-by-around-53-here-are-53-stocks-moving-in-monday-s-mid-day-session-1031940469,neutral,0.8854047656059265
11/29/2022 2:00:00 PM,Envisagenics Announces Research Collaboration with Bristol Myers Squibb,PR Newswire,/news/stocks/envisagenics-announces-research-collaboration-with-bristol-myers-squibb-1031941958,neutral,0.7235545516014099
11/29/2022 2:19:53 PM,"Envisagenics, Bristol Myers Squibb Enter Research Collaboration - Quick Facts ",RTTNews,/news/stocks/envisagenics-bristol-myers-squibb-enter-research-collaboration-quick-facts-1031942037,neutral,0.9267479181289673
12/6/2022 2:42:02 PM,Compugen COM701 in dual/triple combo shows promise in ovarian cancer patients in trial,Seeking Alpha,https://seekingalpha.com/news/3914333-compugen-com701-in-dualtriple-combo-shows-promise-in-ovarian-cancer-patients-in-trial?utm_source=businessinsider&utm_medium=referral,positive,0.9459928870201111
12/7/2022 12:32:42 PM,Replimune in pact with Roche to study cancer drug combos,Seeking Alpha,https://seekingalpha.com/news/3914812-repl-stock-on-watch-after-deal-with-roche-to-study-cancer-drug-combos?utm_source=businessinsider&utm_medium=referral,neutral,0.6071451902389526
12/7/2022 4:05:11 PM,Replimune Shares Surge After Early Data From Pretreated Melanoma Patients,Benzinga,/news/stocks/replimune-shares-surge-after-early-data-from-pretreated-melanoma-patients-1031958227,positive,0.7057523727416992
12/8/2022 10:00:13 PM,Bristol-Myers Squibb Company  raises quarterly dividend by 5.6% to $0.57/share,Seeking Alpha,https://seekingalpha.com/news/3915505-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral,positive,0.9174990057945251
12/12/2022 6:50:22 PM,Seagen buoyed by Adcetris combo data for classical Hodgkin lymphoma,Seeking Alpha,https://seekingalpha.com/news/3916234-seagen-buoyed-by-adcetris-combo-data-for-classical-hodgkin-lymphoma?utm_source=businessinsider&utm_medium=referral,positive,0.8880804181098938
12/13/2022 2:35:32 PM,"Takeda drives Schrödinger, Ventyx higher after deal for psoriasis candidate",Seeking Alpha,https://seekingalpha.com/news/3916513-sdgr-stock-vtyx-stock-rise-takeda-deal-for-psoriasis-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.4811957776546478
12/14/2022 7:02:53 PM,Colorado becomes fourth state to ask feds to import drugs from Canada,Seeking Alpha,https://seekingalpha.com/news/3917055-colorado-becomes-fourth-state-to-ask-feds-to-import-drugs-from-canada?utm_source=businessinsider&utm_medium=referral,neutral,0.7342978119850159
12/16/2022 10:02:23 AM,"Evotec to get $26M from Bristol Myers as drug projects added under neuroscience 
pact",Seeking Alpha,https://seekingalpha.com/news/3917904-evotec-to-get-26m-from-bristol-myers-as-drug-projects-added-under-neuroscience-pact?utm_source=businessinsider&utm_medium=referral,positive,0.7611533999443054
12/16/2022 11:25:27 AM,7 Top-Rated Large-Cap Stocks to Buy and Hold,InvestorPlace,/news/stocks/large-cap-stocks-to-buy-and-hold-1031827937,neutral,0.8808763027191162
12/23/2022 8:21:12 PM,"Tax-loss selling, window dressing will likely ruin Santa Claus rally - DCLA's Sarat Sethi",Seeking Alpha,https://seekingalpha.com/news/3920543-fed-spooks-santa-claus-rally-dclas-sarat-sethi?utm_source=businessinsider&utm_medium=referral,negative,0.6500760912895203
12/28/2022 10:30:16 AM,InnoCare tafasitamab combo gets approval in Hong Kong for blood cancer subtype,Seeking Alpha,https://seekingalpha.com/news/3920864-innocare-tafasitamab-combo-gets-approval-in-hong-kong-for-blood-cancer-subtype?utm_source=businessinsider&utm_medium=referral,positive,0.9182425737380981
12/30/2022 5:45:22 PM,Merck is best performing large U.S. pharma of 2022,Seeking Alpha,https://seekingalpha.com/news/3921306-merck-is-best-performing-large-us-pharma-of-2022?utm_source=businessinsider&utm_medium=referral,positive,0.9400242567062378
12/31/2022 3:00:00 PM,"Align, Invitae among healthcare stocks SA contributors correctly said to avoid in 2022",Seeking Alpha,https://seekingalpha.com/news/3920820-align-invitae-among-health-names-sa-contributors-correctly-said-to-avoid-in-2022?utm_source=businessinsider&utm_medium=referral,neutral,0.8286207914352417
1/3/2023 8:00:43 PM,What 6 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-6-analyst-ratings-have-to-say-about-bristol-myers-squibb-1031998485,neutral,0.9208806753158569
1/4/2023 3:30:34 PM,Aurinia Pharmaceuticals gains amid M&A speculation following patent settlement,Seeking Alpha,https://seekingalpha.com/news/3922000-aurinia-pharmaceuticals-gains-amid-ma-speculation-following-patent-settlement?utm_source=businessinsider&utm_medium=referral,positive,0.9193614721298218
1/5/2023 9:24:26 PM,"Century Therapeutics cutting 25% of staff, prioritizing pipeline programs",Seeking Alpha,https://seekingalpha.com/news/3922512-century-therapeutics-cutting-25-of-staff-prioritizing-pipeline-programs?utm_source=businessinsider&utm_medium=referral,negative,0.958207905292511
1/6/2023 2:23:25 PM,"Century Therapeutics Announces Internal Portfolio Prioritization, Analyst Views It As Incrementally Positive",Benzinga,/news/stocks/century-therapeutics-announces-internal-portfolio-prioritization-analyst-views-it-as-incrementally-positive-1032004211,positive,0.8256479501724243
1/6/2023 6:30:04 PM,"Catalyst watch: ICR Conference, JPMorgan Healthcare Conference, CPI, major bank reports",Seeking Alpha,https://seekingalpha.com/news/3922727-catalyst-watch-icr-conference-jpmorgan-healthcare-conference-cpi-major-banks-report?utm_source=businessinsider&utm_medium=referral,neutral,0.9261020421981812
1/6/2023 11:26:24 PM,5 Top Pharma Stocks of 2022 to Buy for the Long Haul,InvestorPlace,/news/stocks/5-top-pharma-stocks-of-2022-to-buy-for-the-long-haul-1032005182,neutral,0.8010982871055603
1/8/2023 5:33:53 PM,The 7 Most Undervalued Value Stocks to Buy Now   ,InvestorPlace,/news/stocks/undervalued-value-stocks-1031662465,neutral,0.7967768907546997
1/9/2023 1:31:54 PM,"Schrödinger inks drug discovery licensing deals with Bristol Myers, Otsuka",Seeking Alpha,https://seekingalpha.com/news/3922934-schrdinger-inks-drug-discovery-licensing-deals-with-bristol-myers-otsuka?utm_source=businessinsider&utm_medium=referral,positive,0.7813616394996643
1/9/2023 3:43:18 PM,Bristol-Myers Squibb rebuffed again by Supreme Court on $1.2B Gilead patent dispute,Seeking Alpha,https://seekingalpha.com/news/3923014-bristol-myers-squibb-rebuffed-again-by-supreme-court-on-12b-gilead-patent-dispute?utm_source=businessinsider&utm_medium=referral,negative,0.875603199005127
1/10/2023 5:32:45 PM,BioAtla sinks 47% after early results for lead candidate in solid tumor,Seeking Alpha,https://seekingalpha.com/news/3923414-bcab-stock-sinks-early-results-for-lead-candidate-in-solid-tumor?utm_source=businessinsider&utm_medium=referral,negative,0.8374838829040527
1/11/2023 6:26:34 PM,Supreme Court declines to hear Pfizer case on financial assistance to Medicare enrollees,Seeking Alpha,https://seekingalpha.com/news/3923848-supreme-court-declines-to-hear-pfizer-case-on-financial-assistance-to-medicare-enrollees?utm_source=businessinsider&utm_medium=referral,negative,0.8500069379806519
1/11/2023 8:35:28 PM,Medicare to publish drugs targeted for pricing negotiations in September,Seeking Alpha,https://seekingalpha.com/news/3923880-medicare-publish-drugs-targeted-pricing-negotiations-in-september?utm_source=businessinsider&utm_medium=referral,neutral,0.9117305874824524
1/13/2023 1:19:29 PM,7 Dividend-Paying Large-Cap Stocks to Buy in January,InvestorPlace,/news/stocks/7-dividend-paying-large-cap-stocks-to-buy-in-january-1032017485,neutral,0.9035688042640686
1/15/2023 5:00:03 PM,Drugmakers welcome new year with 450 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/3924676-pfizer-abbvie-gsk-eli-lilly-among-drugmakers-to-raise-prices?utm_source=businessinsider&utm_medium=referral,positive,0.8843088150024414
1/17/2023 4:01:25 PM,"Benzinga's Top Ratings Upgrades, Downgrades For January 17, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-january-17-2023-1032022889,negative,0.5494208931922913
1/17/2023 6:36:59 PM,Bristol-Myers earns bullish views at Cantor on breakout potential,Seeking Alpha,https://seekingalpha.com/news/3925135-bmy-stock-earns-bullish-views-cantor-breakout-potential?utm_source=businessinsider&utm_medium=referral,positive,0.8574527502059937
1/18/2023 4:10:10 PM,"Neurodegenerative Diseases Focused Company Goes Public Via Wilbur Ross-Backed SPAC, Joins Alzheimer's Race To Compete Biogen",Benzinga,/news/stocks/neurodegenerative-diseases-focused-company-goes-public-via-wilbur-ross-backed-spac-joins-alzheimer-s-race-to-compete-biogen-1032025916,neutral,0.6879987716674805
1/21/2023 9:40:00 PM,"AstraZeneca, Biogen, Bristol, and Eli Lilly among companies w/ blockbuster potential drugs",Seeking Alpha,https://seekingalpha.com/news/3926479-astrazeneca-biogen-bristol-and-eli-lilly-among-companies-with-blockbuster-potential-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.9066246747970581
1/22/2023 5:00:19 PM,Global drug spending to reach $1.9T by 2027 – IQVIA,Seeking Alpha,https://seekingalpha.com/news/3926554-global-drug-spending-reach-usd-two-trillion-2027-iqvia?utm_source=businessinsider&utm_medium=referral,positive,0.8150347471237183
1/26/2023 12:22:33 PM,Bristol Myers says trial for CAR T therapy met main goal in leukemia,Seeking Alpha,https://seekingalpha.com/news/3928300-bristol-myers-says-trial-car-t-therapy-met-main-goal-leukemia?utm_source=businessinsider&utm_medium=referral,neutral,0.7440834641456604
1/26/2023 4:40:17 PM,"iVexSol closes $23.8M series A-3 financing by Bristol Myers Squibb, Charles River, Asahi Kasei",Seeking Alpha,https://seekingalpha.com/news/3928506-ivexsol-closes-238m-series-a-3-financing-by-bristol-myers-squibb-charles-river-asahi-kasei?utm_source=businessinsider&utm_medium=referral,neutral,0.8946512341499329
1/27/2023 11:52:56 AM,Bristol Myers psoriasis drug Sotyktu an inch away from EU approval with EMA panel nod,Seeking Alpha,https://seekingalpha.com/news/3928867-bristol-myers-psoriasis-drug-sotyktu-an-inch-away-from-eu-approval-with-ema-panel-nod?utm_source=businessinsider&utm_medium=referral,negative,0.9320433139801025
1/27/2023 12:19:52 PM,Bristol Myers wins EU backing to expand label for anemia therapy,Seeking Alpha,https://seekingalpha.com/news/3928887-bristol-myers-wins-eu-backing-to-expand-label-for-anemia-therapy?utm_source=businessinsider&utm_medium=referral,positive,0.9191467761993408
1/27/2023 5:55:12 PM,"Earnings week ahead: Amazon, Apple, Meta, Alphabet, ExxonMobil, GM, AMD and more",Seeking Alpha,https://seekingalpha.com/news/3929027-earnings-week-ahead-amazon-apple-meta-alphabet-exxonmobil-gm-amd-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.936018705368042
1/28/2023 6:00:40 PM,The use of artificial intelligence in medical devices and drug development,Seeking Alpha,https://seekingalpha.com/news/3929184-the-growing-use-of-artificial-intelligence-in-medical-devices-diagnostics-drug-development?utm_source=businessinsider&utm_medium=referral,neutral,0.9313576817512512
1/29/2023 11:25:33 PM,"Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch",Benzinga,/news/stocks/can-market-sustain-upward-momentum-in-tech-heavy-earnings-week-apple-amazon-amd-alphabet-ford-among-key-quarterly-reports-to-watch-1032048678,neutral,0.7459164261817932
1/31/2023 9:56:29 PM,Prothena says Alzheimer’s candidate was safe in early-stage trial,Seeking Alpha,https://seekingalpha.com/news/3930173-prothena-says-alzheimers-candidate-was-safe-early-stage-trial?utm_source=businessinsider&utm_medium=referral,positive,0.7339814305305481
2/1/2023 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-quarter-earnings-preview-q4-1032058995,neutral,0.9266072511672974
2/1/2023 3:55:38 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3930495-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.882573127746582
2/1/2023 5:10:02 PM,Will Bristol Myers Q4 revenues see boost from potential blockbuster Sotyktu?,Seeking Alpha,https://seekingalpha.com/news/3930535-will-bristol-myers-q4-revenues-see-boost-from-potential-blockbuster-sotyktu?utm_source=businessinsider&utm_medium=referral,positive,0.9421020150184631
2/2/2023 12:00:23 PM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $1.82 beats by $0.09, revenue of $11.4B beats by $200M",Seeking Alpha,https://seekingalpha.com/news/3931120-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-1_82-beats-0_09-revenue-of-11_4b-beats?utm_source=businessinsider&utm_medium=referral,neutral,0.5407183766365051
2/2/2023 12:34:23 PM,"Nasdaq Futures Fly As Meta Keeps Tech Earnings' Buoyancy Intact: Will Apple, Amazon, Alphabet Toe In Line?",Benzinga,/news/stocks/nasdaq-futures-fly-as-meta-keeps-tech-earnings-buoyancy-intact-will-apple-amazon-alphabet-toe-in-line-1032062305,neutral,0.744346559047699
2/2/2023 1:08:58 PM,Bristol Myers Q4 revenue falls as Revlimid continues to take hit from generics; FY23 outlook in higher range,Seeking Alpha,https://seekingalpha.com/news/3931196-bristol-myers-q4-revenue-falls-as-revlimid-continues-to-take-hit-from-generics-fy23-outlook-in-higher-range?utm_source=businessinsider&utm_medium=referral,negative,0.9728373289108276
2/2/2023 1:29:07 PM,Bristol-Myers Squibb Guides FY23 Adj. EPS In Line; Q4 Results Top Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy23-adj-eps-in-line-q4-results-top-estimates-1032062561,positive,0.9190890789031982
2/2/2023 6:12:11 PM,"Merck, GM among BofA's latest Alpha Surprise picks",Seeking Alpha,https://seekingalpha.com/news/3931429-merck-gm-among-bofas-latest-alpha-surprise-picks?utm_source=businessinsider&utm_medium=referral,neutral,0.8229635953903198
2/2/2023 7:11:33 PM,U.K. pharma lobby urges govt. to halt plans to raise revenue recovery rates,Seeking Alpha,https://seekingalpha.com/news/3931486-uk-pharma-lobby-urges-govt-to-halt-plans-to-raise-revenue-recovery-rates?utm_source=businessinsider&utm_medium=referral,negative,0.9276774525642395
2/3/2023 11:05:16 AM,Bank of America Securities Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032065673,neutral,0.8846294283866882
2/3/2023 12:15:47 PM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032065948,neutral,0.7452192306518555
2/3/2023 12:26:02 PM,Bristol Myers (BMY) Receives a Buy from BMO Capital,TipRanks,/news/stocks/bristol-myers-bmy-receives-a-buy-from-bmo-capital-1032065909,neutral,0.7515376210212708
2/3/2023 12:26:06 PM,Atlantic Equities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/atlantic-equities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1032065906,neutral,0.5524477958679199
2/3/2023 1:01:15 PM,What 5 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-5-analyst-ratings-have-to-say-about-bristol-myers-squibb-1032065811,neutral,0.9139577746391296
2/3/2023 4:25:34 PM,Morgan Stanley Reaffirms Their Sell Rating on Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-sell-rating-on-bristol-myers-bmy-1032066590,neutral,0.8245803713798523
2/3/2023 7:30:12 PM,"Catalyst watch: Google talks AI, Nordstrom drama and Canada Goose event",Seeking Alpha,https://seekingalpha.com/news/3931946-catalyst-watch-google-talks-ai-nordstrom-drama-and-canada-goose-event?utm_source=businessinsider&utm_medium=referral,neutral,0.948539137840271
2/6/2023 4:05:11 PM,Truist Financial Remains a Buy on Bristol Myers (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-bmy-1032070846,neutral,0.9028178453445435
2/6/2023 5:56:09 PM,Teva follows AbbVie to leave top pharma industry group,Seeking Alpha,https://seekingalpha.com/news/3932426-teva-follows-abbvie-to-leave-top-pharma-industry-group?utm_source=businessinsider&utm_medium=referral,neutral,0.6935388445854187
2/10/2023 12:18:08 PM,Medicare mulls rebates in 2025 for drug prices rising faster than inflation,Seeking Alpha,https://seekingalpha.com/news/3934728-medicare-mulls-rebates-in-2025-for-drug-prices-rising-faster-than-inflation?utm_source=businessinsider&utm_medium=referral,neutral,0.5336910486221313
2/10/2023 4:46:18 PM,"Bristol-Myers, 2seventy post late-stage data for CAR-T therapy in multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/3934866-bristol-myers-2seventy-late-stage-data-car-t-therapy-multiple-myeloma?utm_source=businessinsider&utm_medium=referral,positive,0.7861077785491943
2/10/2023 6:28:27 PM,"Bristol Myers-2seventy Partnered Abecma Cuts Risk Of Disease Progression, Death By 51% In Pretreated Myeloma Patients",Benzinga,/news/stocks/bristol-myers-2seventy-partnered-abecma-cuts-risk-of-disease-progression-death-by-51-in-pretreated-myeloma-patients-1032087011,positive,0.9183033108711243
2/11/2023 9:00:00 PM,"Super Bowl ads boost sales of drugs, yet only handful of companies advertising this year",Seeking Alpha,https://seekingalpha.com/news/3934902-super-bowl-ads-boost-sales-of-drugs-yet-only-two-companies-advertising-this-year?utm_source=businessinsider&utm_medium=referral,neutral,0.5102319121360779
2/13/2023 3:57:12 PM,"Wainwright initiates Arcellx with a buy on CAR-T pipeline, partnership with Gilead's Kite",Seeking Alpha,https://seekingalpha.com/news/3935243-wainwright-initiates-arcellx-with-a-buy-on-car-t-pipeline-partnership-with-gilead-kite?utm_source=businessinsider&utm_medium=referral,positive,0.5246887803077698
2/14/2023 10:59:48 AM,"Bristol Myers Opdivo, Exelixis/Ipsen's Cabometyx combo shows survival benefit in kidney cancer in 3 year data",Seeking Alpha,https://seekingalpha.com/news/3935573-bristol-myers-opdivo-exelixisipsens-cabometyx-combo-shows-survival-benefit-in-kidney-cancer-in-3-year-data?utm_source=businessinsider&utm_medium=referral,positive,0.9435105323791504
2/14/2023 3:05:50 PM,"Keros Therapeutics a buy at Cowen on candidates for PAH, myelofibrosis",Seeking Alpha,https://seekingalpha.com/news/3935749-keros-therapeutics-a-buy-at-cowen-on-candidates-for-pah-myelofibrosis?utm_source=businessinsider&utm_medium=referral,neutral,0.7974507808685303
2/15/2023 6:14:32 PM,Medicare mulls limiting per month costs for generic drugs at $2,Seeking Alpha,https://seekingalpha.com/news/3936542-medicare-mulls-limiting-per-month-costs-for-generic-drugs-at-2?utm_source=businessinsider&utm_medium=referral,neutral,0.42181921005249023
2/15/2023 7:09:07 PM,3 ETFs Investors Can Buy to Weather a Recession,TipRanks,/news/stocks/3-etfs-investors-can-buy-to-weather-a-recession-1032100105,neutral,0.8542205691337585
2/17/2023 4:01:46 PM,Bristol's Opdivo improves disease-free survival in urothelial carcinoma over long term,Seeking Alpha,https://seekingalpha.com/news/3937750-bristol-opdivo-improves-disease-free-survival-in-urothelial-carcinoma-over-long-term?utm_source=businessinsider&utm_medium=referral,positive,0.9530866146087646
2/17/2023 6:35:08 PM,I ‘Tricked’ ChatGPT Into Picking Stocks to Buy. Here’s What It Said.,InvestorPlace,/news/stocks/i-tricked-chatgpt-into-picking-stocks-to-buy-heres-what-it-said-1032106844,neutral,0.9173052310943604
2/19/2023 5:00:10 PM,The next big wave of patent cliffs is ahead; expect biopharma M&A to rise – report,Seeking Alpha,https://seekingalpha.com/news/3937885-next-big-wave-of-patent-cliffs-ahead-biopharma-m-and-a-to-rise?utm_source=businessinsider&utm_medium=referral,positive,0.9136704206466675
2/24/2023 2:23:12 PM,Why Nektar Therapeutics Stock Is Plunging Today,Benzinga,/news/stocks/why-nektar-therapeutics-stock-is-plunging-today-1032123579,negative,0.9471486806869507
2/25/2023 9:00:00 PM,"Pharmas, medtechs dominate list of innovation leaders thanks to patents",Seeking Alpha,https://seekingalpha.com/news/3940793-pharmas-medtechs-dominate-list-of-innovation-leaders-thanks-to-patents?utm_source=businessinsider&utm_medium=referral,neutral,0.6739815473556519
2/27/2023 1:57:14 PM,7 Dividend Stocks to Buy During a Market Downturn,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-during-a-market-downturn-1032127983,neutral,0.8892592191696167
2/28/2023 1:08:21 PM,"Bristol Myers Opdivo for skin cancer gets review in US, EU",Seeking Alpha,https://seekingalpha.com/news/3941763-bristol-myers-opdivo-for-skin-cancer-gets-review-in-us-eu?utm_source=businessinsider&utm_medium=referral,neutral,0.5590630769729614
3/2/2023 11:07:41 AM,Bristol Myers wins $6.4B lawsuit over cancer drug delay,Seeking Alpha,https://seekingalpha.com/news/3943111-bristol-myers-wins-64b-lawsuit-over-cancer-drug-delay?utm_source=businessinsider&utm_medium=referral,negative,0.7192996740341187
3/2/2023 1:01:02 PM,"Bristol-Myers, Janssen launch late-stage Librexia program evaluating milvexian",Seeking Alpha,https://seekingalpha.com/news/3943202-bristol-myers-janssen-launch-late-stage-librexia-program-evaluating-milvexian?utm_source=businessinsider&utm_medium=referral,neutral,0.653527021408081
3/3/2023 12:35:32 PM,EC approves Bristol Myers' Reblozyl for anemia due to beta thalassemia,Seeking Alpha,https://seekingalpha.com/news/3943800-ec-approves-bristol-myers-reblozyl-for-anemia-due-to-beta-thalassemia?utm_source=businessinsider&utm_medium=referral,neutral,0.7264078259468079
3/3/2023 1:19:21 PM,"Bristol Myers, Viz.ai team up to deploy AI tool to detect heart disease",Seeking Alpha,https://seekingalpha.com/news/3943827-bristol-myers-vizai-team-up-to-deploy-ai-tool-to-detect-heart-disease?utm_source=businessinsider&utm_medium=referral,positive,0.4973417818546295
3/3/2023 9:18:56 PM,Bristol-Myers Squibb Company  declares $0.57 dividend,Seeking Alpha,https://seekingalpha.com/news/3944131-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.8358882069587708
3/4/2023 6:45:00 PM,Pharma R&D funding soared to a new record in 2022 as oncology candidates dominate pipelines,Seeking Alpha,https://seekingalpha.com/news/3944195-pharma-research-developmeny-funding-soared-to-a-new-record-in-2022-as-oncology-candidates-dominate-pipelines?utm_source=businessinsider&utm_medium=referral,positive,0.9410833716392517
3/6/2023 1:42:34 PM,Ikena gains on FDA’s fast track status for bladder cancer candidate,Seeking Alpha,https://seekingalpha.com/news/3944409-ikna-stock-gains-fdas-fast-track-status-bladder-cancer-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.9220680594444275
3/6/2023 2:00:56 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1032147149,neutral,0.928318977355957
3/6/2023 4:00:36 PM,"Benzinga's Top Ratings Upgrades, Downgrades For March 6, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-march-6-2023-1032147650,negative,0.4970482587814331
3/7/2023 10:45:06 AM,Bank of America Securities Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032149733,neutral,0.8846294283866882
3/7/2023 12:33:25 PM,Biden to announce plan to keep Medicare solvent beyond 2050,Seeking Alpha,https://seekingalpha.com/news/3944823-biden-to-announce-plan-to-keep-medicare-solvent-beyond-2050?utm_source=businessinsider&utm_medium=referral,positive,0.5336588621139526
3/7/2023 9:30:42 PM,Quant Ratings Updated on 157 Stocks,InvestorPlace,/news/stocks/20230307-quant-ratings-1032151646,neutral,0.9291962385177612
3/8/2023 1:34:07 AM,Health Care ETFs Have Lost In The Last Month - These Top Pharma Stocks Are The Reason,Benzinga,/news/stocks/health-care-etfs-have-lost-in-the-last-month---these-top-pharma-stocks-are-the-reason-1032151775,negative,0.9652081727981567
3/8/2023 11:41:29 AM,Sleep-at-night stocks for those hedging or risk averse,Seeking Alpha,https://seekingalpha.com/news/3945026-sleep-at-night-stocks-for-those-hedging-or-risk-averse?utm_source=businessinsider&utm_medium=referral,neutral,0.782947838306427
3/9/2023 2:30:05 PM,Teva Pharmaceutical launches additional dosage strengths of generic Revlimid,Seeking Alpha,https://seekingalpha.com/news/3945980-teva-pharmaceutical-launches-additional-dosage-strengths-of-generic-revlimid?utm_source=businessinsider&utm_medium=referral,positive,0.8296595215797424
3/9/2023 6:55:10 PM,Biden budget to save $160B by allowing Medicare to negotiate prices for more drugs,Seeking Alpha,https://seekingalpha.com/news/3946094-biden-budget-to-save-160b-by-allowing-medicare-to-negotiate-prices-for-more-drugs?utm_source=businessinsider&utm_medium=referral,positive,0.8639830350875854
3/13/2023 12:07:25 PM,"Pfizer, AbbVie, BMS among firms at risk of U.S. drug price negotiations - report",Seeking Alpha,https://seekingalpha.com/news/3946793-pfizer-abbvie-bristol-myers-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.6864009499549866
3/16/2023 7:51:21 AM,Evotec Announces Progress In Protein Degradation Partnership With Bristol Myers ,RTTNews,/news/stocks/evotec-announces-progress-in-protein-degradation-partnership-with-bristol-myers-1032171647,positive,0.901192307472229
3/16/2023 6:15:32 PM,Medicare publishes initial guidance on drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3948265-medicare-publishes-initial-guidance-on-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.9513847827911377
3/20/2023 11:10:18 AM,Analysts Offer Insights on Healthcare Companies: Kinnate Biopharma (KNTE) and Bristol Myers (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-kinnate-biopharma-knte-and-bristol-myers-bmy-1032178490,neutral,0.896805465221405
3/20/2023 3:21:16 PM,"Takeda's Highest Dose Psoriasis Candidate Can Potentially Beat Bristol Myers' Approved Drug, Analyst Says",Benzinga,/news/stocks/takeda-s-highest-dose-psoriasis-candidate-can-potentially-beat-bristol-myers-approved-drug-analyst-says-1032179263,positive,0.9455244541168213
3/23/2023 12:29:24 PM,"BridgeBio starts dosing in phase 1/2 trial of BBP-398, Opdivo combo for solid tumors",Seeking Alpha,https://seekingalpha.com/news/3950325-bridgebio-starts-dosing-in-phase-12-trial-of-bbp-398-opdivo-combo-for-solid-tumors?utm_source=businessinsider&utm_medium=referral,neutral,0.6677441596984863
3/23/2023 6:33:09 PM,White House seeking alternative supply chains for pharmaceutical ingredients,Seeking Alpha,https://seekingalpha.com/news/3950575-white-house-alternative-supply-chains-pharmaceutical-ingredients-drug-shortages?utm_source=businessinsider&utm_medium=referral,neutral,0.6495416164398193
3/23/2023 7:56:20 PM,Aurinia Pharmaceuticals gains amid renewed takeover speculation,Seeking Alpha,https://seekingalpha.com/news/3950664-aurinia-pharmaceuticals-gains-amid-renewed-takeover-speculation?utm_source=businessinsider&utm_medium=referral,positive,0.9290063977241516
3/24/2023 5:01:00 PM,FDA draft guidance impacts companies using accelerated approval for oncology drugs,Seeking Alpha,https://seekingalpha.com/news/3951000-fda-draft-guidance-impacts-companies-accelerated-approval-oncology-drugs?utm_source=businessinsider&utm_medium=referral,neutral,0.6456912755966187
3/24/2023 9:06:23 PM,BridgeBio Pharma jumps on report of takeover interest,Seeking Alpha,https://seekingalpha.com/news/3951153-bridgebio-jumps-on-report-of-takeover-interest?utm_source=businessinsider&utm_medium=referral,negative,0.7288680672645569
3/28/2023 10:24:03 AM,Evotec gets $50M upfront from Bristol Myers in pact to develop neuro disease drugs,Seeking Alpha,https://seekingalpha.com/news/3951755-evotec-gets-50m-upfront-bristol-myers-neuro-disease-drug-pact?utm_source=businessinsider&utm_medium=referral,neutral,0.5036173462867737
3/28/2023 10:26:13 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032196474,neutral,0.7452192306518555
3/28/2023 12:18:24 PM,Evotec Stock Up As It Extends Neurodegeneration Partnership With Bristol Myers Squibb ,RTTNews,/news/stocks/evotec-stock-up-as-it-extends-neurodegeneration-partnership-with-bristol-myers-squibb-1032196425,positive,0.9481427073478699
3/28/2023 12:32:05 PM,Bristol Myers' psoriasis drug Sotyktu gets approval in EU,Seeking Alpha,https://seekingalpha.com/news/3951828-bristol-myers-psoriasis-drug-sotyktu--approval-in-eu?utm_source=businessinsider&utm_medium=referral,positive,0.9110098481178284
3/31/2023 1:00:59 PM,Bristol Myers' blood cancer drug Breyanzi gets EMA greenlight for earlier use,Seeking Alpha,https://seekingalpha.com/news/3953140-bristol-myers-blood-cancer-drug-breyanzi-gets-ema-greenlight-for-earlier-use?utm_source=businessinsider&utm_medium=referral,positive,0.9079647064208984
4/6/2023 1:19:05 AM,MRK vs. BMY: Which Pharmaceutical Stock is Better?,TipRanks,/news/stocks/mrk-vs-bmy-which-pharmaceutical-stock-is-better-1032217882,neutral,0.8298038840293884
4/6/2023 4:35:54 PM,FDA forces pre-term birth drug off the market after 12 years,Seeking Alpha,https://seekingalpha.com/news/3955084-fda-pulls-pre-term-birth-drug-makena-off-market?utm_source=businessinsider&utm_medium=referral,negative,0.8911572098731995
4/7/2023 6:15:29 PM,"Catalyst Watch: Eyes on inflation data, big bank earnings",Seeking Alpha,https://seekingalpha.com/news/3955188-catalyst-watch-eyes-on-inflation-data-big-bank-earnings?utm_source=businessinsider&utm_medium=referral,neutral,0.9218350052833557
4/11/2023 12:56:42 PM,US DOJ asks appeals court to block Texas judge abortion pill ruling,Seeking Alpha,https://seekingalpha.com/news/3955611-us-doj-asks-appeals-court-block-texas-judge-abortion-pill-ruling?utm_source=businessinsider&utm_medium=referral,negative,0.7583171129226685
4/11/2023 3:21:35 PM,Foundation Medicine to develop companion diagnostic for Bristol Myers' cancer drug repotrectinib,Seeking Alpha,https://seekingalpha.com/news/3955679-foundation-medicine-bristol-myers-to-develop-companion-diagnostic-for-repotrectinib?utm_source=businessinsider&utm_medium=referral,neutral,0.5533040165901184
4/13/2023 9:02:47 AM,"Appeals court permits limited access to abortion pill, blocks part of Texas ruling",Seeking Alpha,https://seekingalpha.com/news/3956187-appeals-court-partially-allows-access-abortion-pill?utm_source=businessinsider&utm_medium=referral,neutral,0.5150914192199707
4/14/2023 9:32:00 AM,Ghana 1st in world to approve new malaria vaccine by Oxford,Seeking Alpha,https://seekingalpha.com/news/3956507-ghana-1st-in-world-approve-new-malaria-vaccine-oxford?utm_source=businessinsider&utm_medium=referral,positive,0.6195564866065979
4/16/2023 10:30:42 AM,7 Sorry Pharma Stocks to Sell in April Before It’s Too Late,InvestorPlace,/news/stocks/7-sorry-pharma-stocks-to-sell-in-april-before-its-too-late-1032234376,neutral,0.8589942455291748
4/18/2023 9:08:17 AM,"Bristol Myers, 2seventy bio blood cancer drug Abecma gets review in US, EU, Japan for expanded use",Seeking Alpha,https://seekingalpha.com/news/3957205-bristol-myers-2seventy-cancer-drug-abecma-gets-review-us-eu-japan?utm_source=businessinsider&utm_medium=referral,positive,0.8365820050239563
4/18/2023 12:59:59 PM,Guardant Health cancer immunotherapy response test covered by Medicare,Seeking Alpha,https://seekingalpha.com/news/3957308-guardant-health-cancer-immunotherapy-response-test-covered-medicare?utm_source=businessinsider&utm_medium=referral,neutral,0.9468145966529846
4/19/2023 1:24:40 AM,COWZ ETF: A Cash Cow for Your Portfolio,TipRanks,/news/stocks/cowz-etf-a-cash-cow-for-your-portfolio-1032241273,neutral,0.9224590063095093
4/19/2023 11:48:49 AM,Legend Biotech adds 18% after leaked report on JNJ-partnered CAR-T therapy,Seeking Alpha,https://seekingalpha.com/news/3957646-jnj-stock-legend-biotech-stock-gain-on-leaked-carvykti-data?utm_source=businessinsider&utm_medium=referral,neutral,0.7947260141372681
4/19/2023 6:00:09 PM,"Geron, CTI rally after leaked data for Legend Biotech’s blood cancer drug",Seeking Alpha,https://seekingalpha.com/news/3957879-geron-stock-cti-stock-rally-after-leaked-carvykti-data?utm_source=businessinsider&utm_medium=referral,negative,0.8521285057067871
4/19/2023 8:16:05 PM,Amgen wins appeals court ruling in patent dispute over psoriasis drug Otezla,Seeking Alpha,https://seekingalpha.com/news/3957938-amgen-stock-wins-appeals-court-ruling-otezla-patent-dispute?utm_source=businessinsider&utm_medium=referral,negative,0.7487333416938782
4/20/2023 9:57:40 AM,Bristol Myers inks up to $1B license deal with Tubulis to develop cancer drugs,Seeking Alpha,https://seekingalpha.com/news/3958092-bristol-myers-inks-up-to-1b-cancer-drug-license-deal-tubulis?utm_source=businessinsider&utm_medium=referral,positive,0.7885685563087463
4/21/2023 1:09:00 PM,"Bristol Myers, LianBio's heart drug Camzyos gets priority review in China",Seeking Alpha,https://seekingalpha.com/news/3958657-bristol-myers-lianbios-heart-drug-camzyos-gets-priority-review-china?utm_source=businessinsider&utm_medium=referral,neutral,0.6401622295379639
4/21/2023 5:01:07 PM,Where Bristol-Myers Squibb Stands With Analysts,Benzinga,/news/stocks/where-bristol-myers-squibb-stands-with-analysts-1032250262,neutral,0.928318977355957
4/21/2023 5:09:23 PM,Legend Biotech up 10% on confirming Carvykti multiple myeloma data,Seeking Alpha,https://seekingalpha.com/news/3958762-legend-biotech-up-10-confirming-carvykti-multiple-myeloma-data?utm_source=businessinsider&utm_medium=referral,positive,0.9354594349861145
4/21/2023 5:30:41 PM,"Earnings Week Ahead: Amazon, Meta Platforms, Alphabet, Coca-Cola, Boeing, and more",Seeking Alpha,https://seekingalpha.com/news/3958718-earnings-week-ahead-amazon-meta-platforms-alphabet-coca-cola-boeing-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9372533559799194
4/23/2023 4:00:00 PM,What is behind biotech M&A resurgence?,Seeking Alpha,https://seekingalpha.com/news/3958874-reasons-for-biotech-buyout-resurgence?utm_source=businessinsider&utm_medium=referral,neutral,0.902015209197998
4/24/2023 9:10:58 PM,Is Aurinia Pharmaceuticals Up for Grabs? Shareholder Suggests a Quick Sale for a Bigger Payday,Benzinga,/news/stocks/is-aurinia-pharmaceuticals-up-for-grabs-shareholder-suggests-a-quick-sale-for-a-bigger-payday-1032255367,neutral,0.8560241460800171
4/25/2023 3:38:42 PM,Bipartisan agreement reached in Senate prescription drug price legislation,Seeking Alpha,https://seekingalpha.com/news/3959793-bipartisan-agreement-reached-senate-prescription-drug-price-legislation?utm_source=businessinsider&utm_medium=referral,positive,0.810508668422699
4/26/2023 11:54:22 AM,Bristol Myers to acquire viral vector manufacturing site in Illinois from Novartis,Seeking Alpha,https://seekingalpha.com/news/3960367-bristol-myers-to-acquire-viral-vector-manufacturing-site-in-illinois-from-novartis?utm_source=businessinsider&utm_medium=referral,neutral,0.7011262774467468
4/26/2023 12:53:02 PM,"Bristol Myers, LianBio's heart drug Camzyos meets main goal in Chinese patients study",Seeking Alpha,https://seekingalpha.com/news/3960417-bristol-myers-lianbio-heart-drug-meets-main-goal-in-chinese-patients?utm_source=businessinsider&utm_medium=referral,neutral,0.6751120090484619
4/26/2023 2:58:15 PM,Will Bristol-Myers Squibb Q4 positive trend continue in Q1?,Seeking Alpha,https://seekingalpha.com/news/3960510-will-bristol-myers-squibb-q4-positive-trend-continue-in-q1?utm_source=businessinsider&utm_medium=referral,neutral,0.6600391864776611
4/26/2023 3:01:13 PM,Bristol-Myers Squibb earnings preview: what Wall Street is expecting,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q1-quarterly-earnings-preview-1032263676,neutral,0.902914822101593
4/26/2023 3:07:35 PM,Notable earnings before Thursday's open,Seeking Alpha,https://seekingalpha.com/news/3960517-notable-earnings-before-thursdays-open?utm_source=businessinsider&utm_medium=referral,positive,0.882573127746582
4/26/2023 5:21:35 PM,Democratic senators introduce bill to enhance CMS drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/3960629-democratic-senators-introduce-bill-enhance-cms-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,positive,0.8721350431442261
4/27/2023 11:33:03 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $2.05 beats by $0.05, revenue of $11.3B misses by $290M",Seeking Alpha,https://seekingalpha.com/news/3961249-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-2_05-beats-0_05-revenue-of-11_3b-misses?utm_source=businessinsider&utm_medium=referral,neutral,0.5690464377403259
4/27/2023 12:17:08 PM,Bristol Myers stock dips as Q1 revenue falls amid generic impact on Revlimid,Seeking Alpha,https://seekingalpha.com/news/3961290-bristol-myers-stock-dips-revenue-falls-amid-generic-impact-on-revlimid?utm_source=businessinsider&utm_medium=referral,negative,0.9672209620475769
4/27/2023 1:04:48 PM,"Stocks Rise On Strong Earnings, Expectation Of Fed Rate Hikes Ending: Analyst Says 'No Earnings Recession In Cards Yet'",Benzinga,/news/stocks/us-stocks-eye-higher-open-as-meta-q1-uplifts-tech-sector-analyst-says-no-earnings-recession-in-cards-yet-1032268050,positive,0.7996720671653748
4/27/2023 1:27:59 PM,Bristol-Myers Squibb Affirms FY23 Outlook; Q1 Adj. EPS Tops Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-affirms-fy23-outlook-q1-adj-eps-tops-estimates-1032268243,positive,0.4834666848182678
4/27/2023 5:01:56 PM,"Hot Stocks: TDOC, LLY, ROKU and CMCSA rises on earnings; DBX falls on layoffs; LUV, CAT and BMY slides",Seeking Alpha,https://seekingalpha.com/news/3961499-hot-stocks-tdoc-lly-roku-and-cmcsa-rises-on-earnings-dbx-fallss-on-layoffs-luv-cat-and-bmy-slides?utm_source=businessinsider&utm_medium=referral,negative,0.907573938369751
4/28/2023 6:05:34 AM,Goldman Sachs Keeps Their Buy Rating on Bristol Myers (BMY),TipRanks,/news/stocks/goldman-sachs-keeps-their-buy-rating-on-bristol-myers-bmy-1032272324,neutral,0.9156487584114075
4/28/2023 8:25:46 AM,Barclays Sticks to Their Hold Rating for Bristol Myers (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-bristol-myers-bmy-1032272676,neutral,0.8699195981025696
4/28/2023 8:45:36 AM,"Bristol Myers, LianBio's heart therapy Camzyos gets EMA panel nod",Seeking Alpha,https://seekingalpha.com/news/3961897-bristol-myers-lianbios-heart-therapy-camzyos-gets-ema-panel-nod?utm_source=businessinsider&utm_medium=referral,positive,0.5644873380661011
4/28/2023 9:25:08 AM,Morgan Stanley Sticks to Their Sell Rating for Bristol Myers (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-their-sell-rating-for-bristol-myers-bmy-1032272873,neutral,0.8202100992202759
4/28/2023 10:21:23 AM,"Bristol Myers Opdivo, Yervoy get EMA panel backing for skin cancer in adolescents",Seeking Alpha,https://seekingalpha.com/news/3961918-bristol-myers-opdivo-yervoy-get-ema-panel-backing-for-skin-cancer-in-adolescents?utm_source=businessinsider&utm_medium=referral,positive,0.683417022228241
5/1/2023 9:25:25 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032277519,neutral,0.7452192306518555
5/1/2023 11:51:02 AM,"Bristol Myers, Merck anemia therapy undergoes U.S. and EU review for label expansion",Seeking Alpha,https://seekingalpha.com/news/3962527-bristol-myers-merck-anemia-drug-us-eu-reviews-label-expansion?utm_source=businessinsider&utm_medium=referral,neutral,0.684217095375061
5/1/2023 5:29:00 PM,"Abbvie, Bristol Myers competed with Merck in sale of Prometheus - report",Seeking Alpha,https://seekingalpha.com/news/3962788-abbvie-bristol-myers-competed-with-merck-in-sale-of-prometheus-report?utm_source=businessinsider&utm_medium=referral,positive,0.8889114856719971
5/1/2023 5:57:18 PM,"Bristol-Myers Squibb's Breyanzi Aces Two Lymphoma Studies On Overall Response Rate Endpoint, Plus New Collaboration",Benzinga,/news/stocks/bristol-myers-squibb-s-breyanzi-aces-two-lymphoma-studies-on-overall-response-rate-endpoint-plus-new-collaboration-1032278774,neutral,0.7893444895744324
5/5/2023 12:10:21 PM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol Myers (BMY), Chimerix (CMRX) and Moderna (MRNA)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bristol-myers-bmy-chimerix-cmrx-and-moderna-mrna-1032297263,negative,0.8994053602218628
5/6/2023 3:00:34 AM,XLV: 5 Reasons to Put This Healthcare ETF on Your Radar,TipRanks,/news/stocks/xlv-5-reasons-to-put-this-healthcare-etf-on-your-radar-1032298857,neutral,0.9032704830169678
5/9/2023 12:56:49 PM,Big pharma maps legal strategy against U.S. drug pricing regulation – Reuters,Seeking Alpha,https://seekingalpha.com/news/3967966-big-pharma-maps-legal-strategy-against-drug-pricing-regulation?utm_source=businessinsider&utm_medium=referral,neutral,0.9252360463142395
5/10/2023 7:17:12 PM,Vanda to consider options after appeals court ruling on Hetlioz generics,Seeking Alpha,https://seekingalpha.com/news/3969409-vanda-stock-slips-appeals-court-reaffirms-hetlioz-generics?utm_source=businessinsider&utm_medium=referral,neutral,0.6695426106452942
5/13/2023 8:00:00 PM,Cancer therapies spending set to surge through end of decade,Seeking Alpha,https://seekingalpha.com/news/3971001-cancer-therapies-spending-set-surge-through-end-decade?utm_source=businessinsider&utm_medium=referral,positive,0.9407322406768799
5/16/2023 12:52:10 PM,AstraZeneca to exit leading U.S. drug industry group PhRMA,Seeking Alpha,https://seekingalpha.com/news/3972045-astrazeneca-stock-exits-leading-us-drug-lobby-phrma?utm_source=businessinsider&utm_medium=referral,neutral,0.6984094977378845
5/17/2023 4:13:55 PM,Prothena adds former FDA neuro chief Billy Dunn to director board,Seeking Alpha,https://seekingalpha.com/news/3972658-prothena-stock-adds-ex-fda-neuro-chief-billy-dunn-board?utm_source=businessinsider&utm_medium=referral,neutral,0.9268184900283813
5/18/2023 12:50:29 PM,Zai Lab gets priority review for lung cancer dug repotrectinib in China,Seeking Alpha,https://seekingalpha.com/news/3972983-zai-lab-gets-priority-review-for-lung-cancer-dug-repotrectinib-in-china?utm_source=businessinsider&utm_medium=referral,positive,0.8455615639686584
5/18/2023 3:23:30 PM,Arcellx a buy at Truist on unique cancer cell therapies,Seeking Alpha,https://seekingalpha.com/news/3973091-arcellx-buy-at-truist-unique-cancer-cell-therapies?utm_source=businessinsider&utm_medium=referral,neutral,0.8696115612983704
5/18/2023 4:13:46 PM,Supreme Court rules against Amgen in Repatha patent dispute with Sanofi/ Regeneron,Seeking Alpha,https://seekingalpha.com/news/3973082-supreme-court-rules-against-amgen-rapatha-patent-dispute?utm_source=businessinsider&utm_medium=referral,negative,0.7930808663368225
5/19/2023 10:59:40 PM,Intensity Therapeutics upsizes proposed IPO to $15M from $8M,Seeking Alpha,https://seekingalpha.com/news/3973606-intensity-therapeutics-upsizes-proposed-ipo-to-15m-from-8m?utm_source=businessinsider&utm_medium=referral,positive,0.9375886917114258
5/21/2023 4:00:17 PM,Billions of dollars at stake as FDA shortcut allows half-proven drugs - report,Seeking Alpha,https://seekingalpha.com/news/3973623-billions-fda-shortcut-allows-half-proven-drugs?utm_source=businessinsider&utm_medium=referral,negative,0.7357140183448792
5/22/2023 4:13:22 PM,Bristol-Myers pulmonary fibrosis candidate reduces lung decline rate,Seeking Alpha,https://seekingalpha.com/news/3973845-bristol-myers-pulmonary-fibrosis-candidate-reduces-lung-function-decline-rate?utm_source=businessinsider&utm_medium=referral,positive,0.9179062247276306
5/23/2023 2:55:05 AM,Goldman Sachs Sticks to Their Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/goldman-sachs-sticks-to-their-buy-rating-for-bristol-myers-bmy-1032343893,neutral,0.8857643008232117
5/23/2023 3:15:12 AM,Bank of America Securities Sticks to Its Buy Rating for Bristol Myers (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-buy-rating-for-bristol-myers-bmy-1032343918,neutral,0.8851891160011292
5/23/2023 10:55:09 AM,BMO Capital Keeps Their Buy Rating on Bristol Myers (BMY),TipRanks,/news/stocks/bmo-capital-keeps-their-buy-rating-on-bristol-myers-bmy-1032344865,neutral,0.915664553642273
5/23/2023 8:30:34 PM,Quant Ratings Updated on 119 Stocks,InvestorPlace,/news/stocks/20230523-quant-ratings-1032346659,neutral,0.9240883588790894
5/25/2023 1:22:09 PM,"Bristol Myers, J&J's blood clot therapy milvexian gets FDA fast track status",Seeking Alpha,https://seekingalpha.com/news/3975069-bristol-myers-jjs-blood-clot-drug-milvexian-gets-fda-fast-track-tag?utm_source=businessinsider&utm_medium=referral,positive,0.8501814007759094
5/25/2023 7:23:24 PM,Mirati tumbles after study failure for cancer drug; Oppenheimer upgrades,Seeking Alpha,https://seekingalpha.com/news/3975194-mirati-stock-falls-study-failure-oppenheimer-upgrades?utm_source=businessinsider&utm_medium=referral,negative,0.8996387720108032
5/26/2023 12:51:14 PM,Bristol Myers Opdivo gets EMA panel backing for expanded use in lung cancer,Seeking Alpha,https://seekingalpha.com/news/3975409-bristol-myers-opdivo-gets-ema-panel-backing-for-expanded-use?utm_source=businessinsider&utm_medium=referral,positive,0.9117432832717896
5/30/2023 11:42:47 AM,Bristol Myers granted FDA priority review for lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/3975738-bristol-myers-stock-wins-fda-review-lung-cancer-drug?utm_source=businessinsider&utm_medium=referral,positive,0.7803330421447754
6/1/2023 11:20:14 AM,Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY) and Bristol Myers (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-alnylam-pharma-alny-and-bristol-myers-bmy-1032363937,neutral,0.9229180812835693
6/5/2023 8:55:16 AM,Barclays Remains a Hold on Bristol Myers (BMY),TipRanks,/news/stocks/barclays-remains-a-hold-on-bristol-myers-bmy-1032369660,neutral,0.9149487614631653
6/5/2023 9:10:18 AM,"Analysts Conflicted on These Healthcare Names: Amicus (FOLD), Teladoc (TDOC) and Bristol Myers (BMY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amicus-fold-teladoc-tdoc-and-bristol-myers-bmy-1032369703,negative,0.6508927941322327
6/7/2023 8:50:29 AM,"Analysts Offer Insights on Healthcare Companies: Thermo Fisher (TMO), Sanofi (OtherSNYNF) and Bristol Myers (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-thermo-fisher-tmo-sanofi-othersnynf-and-bristol-myers-bmy-1032375151,neutral,0.91046142578125
6/7/2023 9:01:18 AM,"Analysts Offer Insights on Healthcare Companies: Bristol Myers (BMY), Edwards Lifesciences (EW) and Amedisys (AMED)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-bmy-edwards-lifesciences-ew-and-amedisys-amed-1032375205,neutral,0.9114871621131897
6/8/2023 10:15:54 PM,Bristol-Myers gets FDA approval for Devens cell therapy manufacturing facility,Seeking Alpha,https://seekingalpha.com/news/3978826-bristol-myers-gets-fda-approval-for-devens-cell-therapy-manufacturing-facility?utm_source=businessinsider&utm_medium=referral,positive,0.8726339340209961
6/9/2023 11:11:57 AM,AstraZeneca in pact with Quell Therapeutics for Treg cell therapies,Seeking Alpha,https://seekingalpha.com/news/3978896-astrazeneca-stock-co-develop-treg-cell-therapies?utm_source=businessinsider&utm_medium=referral,positive,0.6778474450111389
6/9/2023 1:26:24 PM,"AbbVie, Amgen among firms targeted for Medicare inflation penalties",Seeking Alpha,https://seekingalpha.com/news/3978943-abbvie-among-firms-targeted-for-medicare-inflation-penalties?utm_source=businessinsider&utm_medium=referral,neutral,0.5447226762771606
6/9/2023 6:15:10 PM,Don’t Forget About Cyclical Value. 3 Stocks to Consider,TipRanks,/news/stocks/don-t-forget-about-cyclical-value-3-stocks-to-consider-1032381469,neutral,0.9298282265663147
6/13/2023 11:03:59 AM,Seagen posts 93% complete remission for lymphoma therapy in Phase 2 trial,Seeking Alpha,https://seekingalpha.com/news/3979459-seagen-lymphoma-drug-adcetris-sets-93-complete-remission?utm_source=businessinsider&utm_medium=referral,positive,0.9012816548347473
6/14/2023 8:20:46 PM,Bristol-Myers Squibb Company  declares $0.57 dividend,Seeking Alpha,https://seekingalpha.com/news/3979948-bristol-myers-squibb-company-declares-0_57-dividend?utm_source=businessinsider&utm_medium=referral,neutral,0.8358882069587708
6/16/2023 11:10:50 AM,"Dividend Roundup: Southwest Airlines, Philip Morris, Microsoft, Target, and more",Seeking Alpha,https://seekingalpha.com/news/3980282-dividend-roundup-southwest-airlines-phillip-morris-microsoft-target-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9456132650375366
6/16/2023 10:11:45 PM,Bristol Meyers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-meyers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9449897408485413
6/20/2023 10:50:07 AM,"Analysts’ Top Healthcare Picks: Rhythm Pharmaceuticals (RYTM), Axonics Modulation Technologies (AXNX)",TipRanks,/news/stocks/analysts-top-healthcare-picks-rhythm-pharmaceuticals-rytm-axonics-modulation-technologies-axnx-1032398478,positive,0.7734414339065552
6/20/2023 12:12:53 PM,Bristol Myers reportedly sues over new Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/3980604-bristol-myers-reportedly-sues-over-new-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral,negative,0.9511773586273193
6/20/2023 12:18:59 PM,3 AI Stocks That Could Skyrocket Your Wealth,InvestorPlace,/news/stocks/3-ai-stocks-that-could-skyrocket-your-wealth-1032398783,neutral,0.6398195028305054
6/20/2023 4:36:03 PM,"Alexandria Research completes sale of five facilities, reiterates 2023 guidance",Seeking Alpha,https://seekingalpha.com/news/3981077-alexandria-research-completes-sale-of-five-facilities-reiterates-2023-guidance?utm_source=businessinsider&utm_medium=referral,neutral,0.9287493228912354
6/21/2023 3:44:52 PM,Top pharma lobby sues U.S. govt. over Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3981469-top-pharma-lobby-sues-us-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,negative,0.9452309608459473
6/22/2023 12:41:24 AM,7 Healthcare Stocks to Make You the Millionaire Next Door,InvestorPlace,/news/stocks/7-healthcare-stocks-to-make-you-the-millionaire-next-door-1032403201,neutral,0.8931552767753601
6/25/2023 4:00:43 PM,What is behind big pharma's underperformance?,Seeking Alpha,https://seekingalpha.com/news/3982575-pharma-underperforms-amid-regulatory-woes?utm_source=businessinsider&utm_medium=referral,negative,0.6917400360107422
6/26/2023 9:11:43 PM,Bristol-Myers Squibb wins EC approval of Camzyos for cardiomyopathy,Seeking Alpha,https://seekingalpha.com/news/3982986-bristol-myers-squibb-wins-ec-approval-camzyos-cardiomyopathy?utm_source=businessinsider&utm_medium=referral,positive,0.8626744151115417
6/26/2023 10:22:00 PM,Bristol Myers Camzyos Gets European Commission Approval ,RTTNews,/news/stocks/bristol-myers-camzyos-gets-european-commission-approval-1032410780,neutral,0.8010593056678772
6/28/2023 11:00:45 AM,Fresh Blood: 3 Stocks Ready to Rally Under New CEOs,InvestorPlace,/news/stocks/3-stocks-ready-to-rally-under-new-ceos-1032414676,positive,0.6786442995071411
6/28/2023 5:00:34 PM,Analyst Expectations for Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032415602,positive,0.9069193005561829
6/30/2023 11:48:19 AM,"Dividend Roundup: General Mills, Mastercard, JPMorgan, Verizon, and more",Seeking Alpha,https://seekingalpha.com/news/3984403-dividend-roundup-general-mills-mastercard-jpmorgan-verizon-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9471454620361328
6/30/2023 4:41:16 PM,Medicare revises guidance on drug price negotiations amid lawsuits,Seeking Alpha,https://seekingalpha.com/news/3984642-medicare-revises-guidance-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.9015730619430542
7/5/2023 6:12:16 PM,Why Is Allarity Therapeutics (ALLR) Stock Up 30% Today?,InvestorPlace,/news/stocks/why-is-allarity-therapeutics-allr-stock-up-30-today-1032428359,positive,0.9176499247550964
7/9/2023 4:00:00 PM,Goldman Sachs sees rays of hope in underperforming health sector,Seeking Alpha,https://seekingalpha.com/news/3986286-goldman-sachs-sees-hope-underperforming-health-sector?utm_source=businessinsider&utm_medium=referral,positive,0.9371913075447083
7/10/2023 10:45:33 AM,Bristol Myers (BMY) Has a New Rating from SVB Securities,TipRanks,/news/stocks/bristol-myers-bmy-has-a-new-rating-from-svb-securities-1032434511,neutral,0.839126467704773
7/10/2023 3:43:53 PM,ImmunityBio phase 1 data finds combo may induce tumor regression,Seeking Alpha,https://seekingalpha.com/news/3986506-immunitybio-phase-1-data-finds-combo-may-induce-tumor-regression?utm_source=businessinsider&utm_medium=referral,neutral,0.6004655957221985
7/10/2023 5:02:11 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 10, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-10-2023-1032435238,neutral,0.4958181381225586
7/10/2023 9:26:45 PM,Bristol gains worldwide license to Prothena Alzheimer's candidate,Seeking Alpha,https://seekingalpha.com/news/3986600-bristol-gains-worldwide-license-prothena-alzheimers-candidate?utm_source=businessinsider&utm_medium=referral,positive,0.7921682000160217
7/11/2023 7:50:42 AM,Evotec Get $40 Mln Payment As Bristol Myers Enters Global Licence Agreement ,RTTNews,/news/stocks/evotec-get-40-mln-payment-as-bristol-myers-enters-global-licence-agreement-1032436681,positive,0.7611410617828369
7/11/2023 9:35:11 AM,Bristol Myers (BMY) Gets a Hold from Barclays,TipRanks,/news/stocks/bristol-myers-bmy-gets-a-hold-from-barclays-1032437138,neutral,0.7452192306518555
7/11/2023 10:49:40 AM,Bristol Myers inks licensing pact under Evotec neuroscience deal,Seeking Alpha,https://seekingalpha.com/news/3986680-bristol-myers-licenses-evotech-neuroscience-deal?utm_source=businessinsider&utm_medium=referral,positive,0.7375001311302185
7/11/2023 11:43:48 AM,Bristol Myers succeeds in Phase 3 trial for Opdivo in bladder cancer,Seeking Alpha,https://seekingalpha.com/news/3986700-bristol-myers-hits-phase-3-win-opdivo-bladder-cancer?utm_source=businessinsider&utm_medium=referral,positive,0.8845394849777222
7/11/2023 7:02:45 PM,Israel's Purple reports encouraging early data for pancreatic cancer drug,Seeking Alpha,https://seekingalpha.com/news/3986877-israels-purple-reports-encouraging-early-data-for-pancreatic-cancer-drug?utm_source=businessinsider&utm_medium=referral,positive,0.941918134689331
7/12/2023 6:05:31 PM,Merck intensifies legal fight to halt Medicare drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/3987148-merck-files-motion-in-suit-halt-medicare-drug-pricing-law?utm_source=businessinsider&utm_medium=referral,negative,0.7759579420089722
7/14/2023 5:02:15 PM,"Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2023",Benzinga,/news/stocks/benzinga-s-top-ratings-upgrades-downgrades-for-july-14-2023-1032447974,neutral,0.4949886202812195
7/15/2023 6:00:00 PM,Atrial fibrillation drug market expected to decline as brand therapies go generic,Seeking Alpha,https://seekingalpha.com/news/3987824-atrial-fibrillation-drug-market-expected-decline-brand-therapies-generic?utm_source=businessinsider&utm_medium=referral,negative,0.9694817066192627
7/16/2023 4:00:00 PM,"Eli Lilly, Merck among top pharma picks in Barclays Q2 preview",Seeking Alpha,https://seekingalpha.com/news/3987868-eli-lilly-merck-among-top-pharma-picks-in-barclays-q2-preview?utm_source=businessinsider&utm_medium=referral,neutral,0.4974316656589508
7/17/2023 12:14:12 AM,"HSBC bullish on Roche, Lonza; bearish on Bristol-Myers, GSK, Moderna",Seeking Alpha,https://seekingalpha.com/news/3987876-hsbc-bullish-on-roche-lonza-bearish-on-bristol-myers-gsk-moderna?utm_source=businessinsider&utm_medium=referral,positive,0.48026981949806213
7/18/2023 5:33:04 PM,J&J becomes latest Big Pharma to sue over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/3988476-jj-becomes-latest-big-pharma-to-sue-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral,negative,0.9197932481765747
7/19/2023 8:00:22 PM,Analyst Expectations for Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032460076,positive,0.9069193005561829
7/21/2023 11:35:06 AM,Bristol Myers nabs EU endorsement for Opdivo in melanoma,Seeking Alpha,https://seekingalpha.com/news/3989567-bristol-myers-nabs-eu-backing-for-opdivo-melanoma?utm_source=businessinsider&utm_medium=referral,neutral,0.5633153915405273
7/21/2023 2:22:22 PM,CHMP Recommends Approval Of Bristol Myers' Opdivo For Adjuvant Treatment For Melanoma ,RTTNews,/news/stocks/chmp-recommends-approval-of-bristol-myers-opdivo-for-adjuvant-treatment-for-melanoma-1032465750,positive,0.7878928780555725
7/21/2023 7:00:10 PM,"Catalyst Watch: Earnings blitz, central bank meetings, UPS strike jitters and Barbenheimer",Seeking Alpha,https://seekingalpha.com/news/3989741-catalyst-watch-earnings-blitz-central-bank-meetings-ups-strike-jitters-and-barbenheimer?utm_source=businessinsider&utm_medium=referral,neutral,0.847836434841156
7/21/2023 7:31:28 PM,The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-now-july-2023-1032466871,neutral,0.902970552444458
7/24/2023 11:34:11 AM,Immatics climbs 8% on $35M investment by Bristol Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/3989979-immatics-climbs-8-on-35m-investment-by-bristol-myers-squibb?utm_source=businessinsider&utm_medium=referral,positive,0.9342327117919922
7/24/2023 4:05:16 PM,Why Immatics Shares Are Rising Today,Benzinga,/news/stocks/why-immatics-shares-are-rising-today-1032470698,positive,0.6441779732704163
7/26/2023 3:01:13 PM,Here's what to expect from Bristol-Myers Squibb's earnings report,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q2-earnings-preview-stock-1032479770,neutral,0.9250919222831726
7/26/2023 5:20:41 PM,Bristol-Myers Squibb set to continue streak of EPS beats with Q2 results,Seeking Alpha,https://seekingalpha.com/news/3991373-bristol-myers-squibb-set-continue-streak-eps-beats-q2-results?utm_source=businessinsider&utm_medium=referral,positive,0.9075319170951843
7/27/2023 9:05:39 AM,Bank of America Securities Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bank-of-america-securities-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032483491,neutral,0.8767873048782349
7/27/2023 11:00:44 AM,"Bristol-Myers Squibb Company Non-GAAP EPS of $1.75 misses by $0.24, revenue of $11.2B misses by $610M",Seeking Alpha,https://seekingalpha.com/news/3991942-bristol-myers-squibb-company-non-gaap-eps-of-175-misses-by-024-revenue-of-112b-misses-by-610m?utm_source=businessinsider&utm_medium=referral,positive,0.5083335638046265
7/27/2023 12:17:16 PM,Bristol-Myers sets below-consensus guidance amid generic competition,Seeking Alpha,https://seekingalpha.com/news/3992051-bristol-myers-squibb-stock-falls-amid-q2-mis?utm_source=businessinsider&utm_medium=referral,negative,0.9419868588447571
7/27/2023 1:27:00 PM,"6 stocks to watch on Thursday: Netflix, Mastercard, AbbVie, McDonald's and more",Seeking Alpha,https://seekingalpha.com/news/3992133-6-stocks-to-watch-on-thursday-netflix-mastercard-abbvie-mcdonalds-and-more?utm_source=businessinsider&utm_medium=referral,neutral,0.9269358515739441
7/27/2023 1:30:32 PM,Bristol-Myers Squibb Slashes FY23 Outlook As Q2 Results Miss Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-slashes-fy23-outlook-as-q2-results-miss-estimates-1032484112,negative,0.9711324572563171
7/27/2023 7:37:23 PM,"Bristol slumps to 52-week low on earnings, guidance disappointments",Seeking Alpha,https://seekingalpha.com/news/3992324-bristol-slumps-52-week-low-earnings-guidance-disappointments?utm_source=businessinsider&utm_medium=referral,negative,0.9600732326507568
7/28/2023 9:16:00 AM,Barclays Keeps Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-keeps-their-hold-rating-on-bristol-myers-squibb-bmy-1032489191,neutral,0.9139901399612427
7/28/2023 11:45:32 AM,BMO Capital Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bmo-capital-sticks-to-their-buy-rating-for-bristol-myers-squibb-bmy-1032489794,neutral,0.6654700636863708
7/28/2023 1:40:20 PM,"Analysts Offer Insights on Healthcare Companies: Anixa Biosciences (ANIX), Roche Holding AG (OtherRHHVF) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-anixa-biosciences-anix-roche-holding-ag-otherrhhvf-and-bristol-myers-squibb-bmy-1032490223,neutral,0.9083561301231384
7/28/2023 1:47:07 PM,2seventy bio downgraded at Morgan Stanley after Abecma sales,Seeking Alpha,https://seekingalpha.com/news/3992869-2seventy-bio-stock-downgraded-at-morgan-stanley-abecma?utm_source=businessinsider&utm_medium=referral,neutral,0.6446185111999512
7/28/2023 1:48:11 PM,Roku To Rally Around 25%? Here Are 10 Other Analyst Forecasts For Friday,Benzinga,/news/stocks/roku-to-rally-around-25-here-are-10-other-analyst-forecasts-for-friday-1032489755,neutral,0.9126666188240051
7/30/2023 7:00:57 PM,3 Millionaire-Maker Biotech Stocks to Buy Before the Window Closes,InvestorPlace,/news/stocks/3-millionaire-maker-biotech-stocks-to-buy-before-the-window-closes-1032492374,neutral,0.854169487953186
8/1/2023 2:25:30 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1032497502,neutral,0.90272456407547
8/1/2023 11:10:35 AM,Looking for a Bargain? 7 Blue-Chip Stocks to Buy That Are Down 5% in 2023,InvestorPlace,/news/stocks/looking-for-a-bargain-7-blue-chip-stocks-to-buy-that-are-down-5-in-2023-1032500151,negative,0.9714455604553223
8/10/2023 11:36:21 AM,Bristol Myers announces $4B accelerated share buybacks,Seeking Alpha,https://seekingalpha.com/news/4000815-bristol-myers-stock-gains-on-share-buybacks?utm_source=businessinsider&utm_medium=referral,neutral,0.8815011978149414
8/10/2023 1:57:38 PM,Bristol-Myers Squibb To Buyback $4 Bln Of Shares Under Accelerated Share Repurchase ,RTTNews,/news/stocks/bristol-myers-squibb-to-buyback-4-bln-of-shares-under-accelerated-share-repurchase-1032540131,neutral,0.6820967197418213
8/10/2023 3:00:00 PM,Medicare Part D drug price increases far exceed inflation - AARP,Seeking Alpha,https://seekingalpha.com/news/4000101-medicare-part-d-drug-price-increases-far-exceed-inflation?utm_source=businessinsider&utm_medium=referral,positive,0.8962881565093994
8/10/2023 8:04:28 PM,Dr. Reddy's launches generic version of Kombiglyze XR in US,Seeking Alpha,https://seekingalpha.com/news/4001262-dr-reddys-launches-generic-version-of-kombiglyze-xr-in-us?utm_source=businessinsider&utm_medium=referral,positive,0.5773813724517822
8/13/2023 6:00:00 PM,Pharma under threat from bill to expand drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4002034-pharma-under-threat-bill-expand-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.5231571793556213
8/16/2023 4:50:11 PM,Bristol touts updated data on lung cancer candidate repotrectinib,Seeking Alpha,https://seekingalpha.com/news/4003550-bristol-touts-updated-data-lung-cancer-candidate-repotrectinib?utm_source=businessinsider&utm_medium=referral,neutral,0.8791170716285706
8/17/2023 11:15:18 AM,Bristol-Myers Squibb (BMY) Gets a Buy from BMO Capital,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-bmo-capital-1032562888,neutral,0.5294864773750305
8/18/2023 5:10:25 PM,"AARP, Public Citizen file briefs in Medicare drug price negotiations case",Seeking Alpha,https://seekingalpha.com/news/4004411-aarp-public-citizen-file-briefs-medicare-drug-price-negotiations-case?utm_source=businessinsider&utm_medium=referral,neutral,0.8961257338523865
8/21/2023 7:26:37 PM,Lawsuits unlikely to hinder Medicare drug price negotiations – UBS,Seeking Alpha,https://seekingalpha.com/news/4004908-lawsuits-wont-hurt-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,negative,0.8472161889076233
8/22/2023 8:38:01 PM,3 Sorry Pharma Stocks to Sell in August Before It’s Too Late,InvestorPlace,/news/stocks/3-sorry-pharma-stocks-to-sell-in-august-before-its-too-late-1032574450,neutral,0.8722027540206909
8/22/2023 9:03:43 PM,Bristol wins European approval of Opdivo as adjuvant for melanoma,Seeking Alpha,https://seekingalpha.com/news/4005323-bristol-wins-european-approval-opdivo-adjuvant-melanoma?utm_source=businessinsider&utm_medium=referral,positive,0.9329231381416321
8/23/2023 2:27:22 PM,Roche sends anti-TIGIT developers higher after cancer drug data (update),Seeking Alpha,https://seekingalpha.com/news/4005456-roche-send-anti-tigit-developers-higher-after-cancer-drug-data?utm_source=businessinsider&utm_medium=referral,positive,0.6301692128181458
8/23/2023 11:42:25 PM,Biotech Breakthroughs: 3 Companies on the Cusp of Major Discoveries,InvestorPlace,/news/stocks/biotech-breakthroughs-3-companies-on-the-cusp-of-major-discoveries-1032578042,positive,0.49478787183761597
8/24/2023 1:44:18 PM,Drugs picked for Medicare price negotiations to be announced on Tuesday – Politico,Seeking Alpha,https://seekingalpha.com/news/4005992-drug-list-picked-medicare-price-negotiations-due-tuesday?utm_source=businessinsider&utm_medium=referral,neutral,0.9293889403343201
8/25/2023 3:54:51 PM,AstraZeneca latest drugmaker to challenge Medicare drug price negotiation,Seeking Alpha,https://seekingalpha.com/news/4006445-astrazeneca-latest-drugmaker-challenge-medicare-drug-price-negotiation?utm_source=businessinsider&utm_medium=referral,negative,0.4302646219730377
8/25/2023 7:00:25 PM,"Catalyst Watch: Spotlight on Lululemon, drug pricing and the August jobs report",Seeking Alpha,https://seekingalpha.com/news/4006432-catalyst-watch-spotlight-on-lululemon-drug-pricing-and-the-august-jobs-report?utm_source=businessinsider&utm_medium=referral,neutral,0.8996149301528931
8/26/2023 6:00:00 PM,Crohn's disease drugmakers set to benefit from expected rise in cases,Seeking Alpha,https://seekingalpha.com/news/4006563-crohns-disease-drugmakers-benefit-expected-rise-cases?utm_source=businessinsider&utm_medium=referral,positive,0.9470041394233704
8/27/2023 4:00:00 PM,Wall Street lists potential targets for Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4006581-wall-street-lists-targets-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral,neutral,0.8904427886009216
8/28/2023 2:00:00 PM,Cellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform,PR Newswire,/news/stocks/cellares-announces-bristol-myers-squibb-has-joined-technology-adoption-partnership-program-to-evaluate-automated-manufacturing-of-car-t-cell-therapy-on-the-cell-shuttle-platform-1032585677,positive,0.7870553731918335
8/28/2023 6:05:07 PM,Bristol's Camzyos shows long-term benefit for heart condition,Seeking Alpha,https://seekingalpha.com/news/4006799-bristol-camzyos-long-term-benefit-heart-condition?utm_source=businessinsider&utm_medium=referral,positive,0.9154165387153625
8/29/2023 10:53:40 AM,"Bristol Myers, Merck win U.S. label expansion for Reblozyl",Seeking Alpha,https://seekingalpha.com/news/4006945-bristol-myers-merck-win-us-label-expansion-reblozyl?utm_source=businessinsider&utm_medium=referral,positive,0.7746843695640564
8/29/2023 11:45:20 AM,Medicare lists first ten drugs selected for pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4006764-medicare-lists-first-ten-drugs-picked-pricing-talks?utm_source=businessinsider&utm_medium=referral,neutral,0.9310519099235535
8/29/2023 2:33:29 PM,"Coinbase Global, Bristol-Myers Squibb And 2 Other Stocks Insiders Are Selling",Benzinga,/news/stocks/coinbase-global-bristol-myers-squibb-and-2-other-stocks-insiders-are-selling-1032588879,neutral,0.9179867506027222
8/29/2023 7:29:57 PM,Republicans say Medicare drug negotiations will mean fewer new meds,Seeking Alpha,https://seekingalpha.com/news/4007245-republicans-say-medicare-drug-negotiations-fewer-new-meds?utm_source=businessinsider&utm_medium=referral,negative,0.855467677116394
8/29/2023 7:40:54 PM,"Bristol Myers' Expanded Approval For Anemia Drug, Shows Superior Efficacy Over Concurrent Blood Transfusion",Benzinga,/news/stocks/bristol-myers-expanded-approval-for-anemia-drug-shows-superior-efficacy-over-concurrent-blood-transfusion-1032590291,positive,0.952968180179596
9/3/2023 4:00:00 PM,Why is big pharma unmoved despite Medicare pricing threat?,Seeking Alpha,https://seekingalpha.com/news/4008703-why-big-pharma-unmoved-despite-medicare-pricing-threat?utm_source=businessinsider&utm_medium=referral,neutral,0.7872204184532166
9/5/2023 11:37:27 AM,Bristol Myers in pact for autoimmune disease therapy,Seeking Alpha,https://seekingalpha.com/news/4008980-bristol-myers-zenas-biopharma-pact-autoimmune-disease-therapy?utm_source=businessinsider&utm_medium=referral,neutral,0.7102959752082825
9/7/2023 12:37:27 AM,How To Earn $500 From Pfizer Stock With Shares Trading At 52-Week Low,Benzinga,/news/stocks/how-to-earn-500-from-pfizer-stock-with-shares-trading-at-52-week-low-1032610884,neutral,0.9390365481376648
9/7/2023 4:55:40 AM,Bristol-Myers Squibb (BMY) Gets a Buy from Goldman Sachs,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-goldman-sachs-1032611252,positive,0.6553388237953186
9/7/2023 7:39:56 PM,Astellas withdraws federal lawsuit over Medicare drug pricing,Seeking Alpha,https://seekingalpha.com/news/4010044-astellas-withdraws-federal-lawsuit-over-medicare-drug-pricing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8975496888160706
9/8/2023 1:14:42 PM,The 3 Best Pharma Stocks to Buy Now: September 2023,InvestorPlace,/news/stocks/the-3-best-pharma-stocks-to-buy-now-september-2023-1032616131,neutral,0.9364477396011353
9/8/2023 7:00:57 PM,"Catalyst Watch: Arm IPO, Apple event, and Senate AI Forum with Musk, Zuckerberg, and Gates",Seeking Alpha,https://seekingalpha.com/news/4010342-catalyst-watch-arm-ipo-apple-event-and-senate-ai-forum-with-musk-zuckerberg-and-gates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9412830471992493
9/11/2023 12:20:32 PM,Marker gains as lymphoma therapy leads to complete remission,Seeking Alpha,https://seekingalpha.com/news/4010535-marker-stock-gains-complete-remission-lymphoma-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9430500268936157
9/12/2023 1:38:17 PM,Geron rises as Goldman Sachs upgrades citing FDA nod for imetelstat,Seeking Alpha,https://seekingalpha.com/news/4010966-geron-stock-rises-goldman-sachs-upgrades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.4903317987918854
9/12/2023 8:43:53 PM,Recent Pullback Buying Opportunity For Blood Cancer Firm Geron: Goldman Sachs,Benzinga,/news/stocks/recent-pullback-buying-opportunity-for-blood-cancer-firm-geron-goldman-sachs-1032624669,neutral,0.6506264805793762
9/13/2023 8:18:14 PM,The Next Walgreens CEO? My Top 3 Picks to Replace Roz Brewer.,InvestorPlace,/news/stocks/the-next-walgreens-ceo-my-top-3-picks-to-replace-roz-brewer-1032628468,neutral,0.90023273229599
9/14/2023 8:30:37 PM,The 3 Most Undervalued Pharma Stocks to Buy in September 2023,InvestorPlace,/news/stocks/the-3-most-undervalued-pharma-stocks-to-buy-in-september-2023-1032631934,neutral,0.7669090628623962
9/15/2023 8:55:47 AM,Bristol-Myers Squibb (BMY) Gets a Buy from Bank of America Securities,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-buy-from-bank-of-america-securities-1032632911,positive,0.6607738137245178
9/15/2023 10:15:29 AM,Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1032633149,neutral,0.9158970713615417
9/15/2023 10:46:50 AM,Three stocks strategies heading into Q4 from Goldman,Seeking Alpha,https://seekingalpha.com/news/4010492-three-stocks-strategies-going-heading-into-q4-from-goldman?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.930094301700592
9/15/2023 12:10:16 PM,Analysts Offer Insights on Healthcare Companies: Ascendis Pharma (ASND) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-ascendis-pharma-asnd-and-bristol-myers-squibb-bmy-1032633453,neutral,0.908336877822876
9/15/2023 1:35:53 PM,Goldman Sachs Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/goldman-sachs-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032633849,neutral,0.8967522382736206
9/18/2023 1:57:00 AM,Samsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance,PR Newswire,/news/stocks/samsung-biologics-announces-expanded-strategic-agreement-with-bristol-myers-squibb-to-manufacture-an-antibody-cancer-drug-substance-1032635242,positive,0.917752742767334
9/18/2023 7:59:46 PM,Anemia Advantage For GSK's Blood Cancer Therapy Could Influence Market Share Despite Incyte's Jakafi Comparison,Benzinga,/news/stocks/anemia-advantage-for-gsk-s-blood-cancer-therapy-could-influence-market-share-despite-incyte-s-jakafi-comparison-1032638040,neutral,0.5495537519454956
9/19/2023 2:25:22 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1032638379,neutral,0.90272456407547
9/19/2023 8:33:26 PM,Quant Ratings Updated on 98 Stocks,InvestorPlace,/news/stocks/091923-quant-ratings-1032641584,neutral,0.9306342005729675
9/24/2023 8:00:35 PM,Beware! 3 Healthcare Stocks Waving Massive Red Flags Right Now.,InvestorPlace,/news/stocks/beware-3-healthcare-stocks-waving-massive-red-flags-right-now-1032651288,negative,0.7834724187850952
10/2/2023 3:32:07 PM,Q4 Stock Predictions: 3 Pharma Stocks Ready to Roar Into 2024,InvestorPlace,/news/stocks/q4-stock-predictions-3-pharma-stocks-ready-to-roar-into-2024-1032671152,neutral,0.8758506178855896
10/2/2023 11:09:29 PM,Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs,InvestorPlace,/news/stocks/cancer-drug-approval-3-biotech-stocks-on-the-brink-of-breakthroughs-1032671847,neutral,0.7332881689071655
10/6/2023 12:30:00 PM,Paradigm and Bristol Myers Squibb collaborate to build a new model for clinical trials,PR Newswire,/news/stocks/paradigm-and-bristol-myers-squibb-collaborate-to-build-a-new-model-for-clinical-trials-1032684128,neutral,0.6036726832389832
10/9/2023 3:11:42 AM,Bristol Myers To Acquire Mirati Therapeutics In Deal Worth Up To $5.8 Bln ,RTTNews,/news/stocks/bristol-myers-to-acquire-mirati-therapeutics-in-deal-worth-up-to-5-8-bln-1032686840,neutral,0.8050466775894165
10/9/2023 9:20:32 AM,"Analysts’ Top Healthcare Picks: Resmed (RMD), Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-resmed-rmd-bristol-myers-squibb-bmy-1032688055,positive,0.6541132926940918
10/9/2023 9:55:48 AM,Goldman Sachs Recommends Buy Rating for BMY: Acquisition of MRTX Bolsters Revenue Growth and Long-Term Prospects,TipRanks,/news/stocks/goldman-sachs-recommends-buy-rating-for-bmy-acquisition-of-mrtx-bolsters-revenue-growth-and-long-term-prospects-1032688099,positive,0.9549154043197632
10/9/2023 11:57:25 AM,"Tesla, Mirati Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session",Benzinga,/news/stocks/tesla-mirati-therapeutics-and-other-big-stocks-moving-lower-in-monday-s-pre-market-session-1032688124,negative,0.9662717580795288
10/9/2023 7:11:36 PM,"Stocks Halt Gains, Oil, Treasuries Rally As Investors React to Israel-Hamas Conflict: What's Driving Markets Monday?",Benzinga,/news/etf/stocks-halt-gains-oil-treasuries-rally-as-investors-react-to-israel-hamas-conflict-what-s-driving-markets-monday-1032689801,negative,0.8868167400360107
10/9/2023 7:30:06 PM,Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session,Benzinga,/news/stocks/why-parazero-technologies-shares-are-trading-higher-by-over-100-here-are-other-stocks-moving-in-monday-s-mid-day-session-1032689828,neutral,0.8747981190681458
10/10/2023 4:20:34 AM,"Analysts Are Bullish on Top Healthcare Stocks: Bristol-Myers Squibb (BMY), Johnson & Johnson (JNJ)",TipRanks,/news/stocks/analysts-are-bullish-on-top-healthcare-stocks-bristol-myers-squibb-bmy-johnson-johnson-jnj-1032690640,neutral,0.5469281673431396
10/10/2023 8:20:10 AM,Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-eli-lilly-co-lly-and-bristol-myers-squibb-bmy-1032691280,neutral,0.9204502701759338
10/10/2023 10:46:47 PM,7 Innovator Stocks Primed for Exceptional Growth,InvestorPlace,/news/stocks/7-innovator-stocks-primed-for-exceptional-growth-1032694094,positive,0.7996546030044556
10/12/2023 3:19:24 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032700617,neutral,0.8461885452270508
10/13/2023 12:00:35 PM,3 Healthcare Stocks To Make You The Millionaire Next Door: October Edition,InvestorPlace,/news/stocks/3-healthcare-stocks-to-make-you-the-millionaire-next-door-october-edition-1032704000,neutral,0.9228016138076782
10/19/2023 8:11:36 PM,7 Healthcare Stocks That Can Cure a Lackluster Portfolio,InvestorPlace,/news/stocks/healthcare-stocks-to-buy-4-1032722294,neutral,0.7649614810943604
10/20/2023 8:40:07 AM,"Analysts Offer Insights on Healthcare Companies: Royalty Pharma (RPRX), Bristol-Myers Squibb (BMY) and Edwards Lifesciences (EW)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-royalty-pharma-rprx-bristol-myers-squibb-bmy-and-edwards-lifesciences-ew-1032723592,neutral,0.913282573223114
10/20/2023 3:00:16 PM,What 12 Analyst Ratings Have To Say About Bristol-Myers Squibb,Benzinga,/news/stocks/what-12-analyst-ratings-have-to-say-about-bristol-myers-squibb-1032724304,neutral,0.9235079884529114
10/20/2023 10:08:03 PM,"Investor Risk Sentiment Wavers Amid War, Interest Rate Concerns; Tesla Earnings Disappoint: The Week In The Markets",Benzinga,/news/etf/investor-risk-sentiment-wavers-amid-war-interest-rate-concerns-tesla-earnings-disappoint-the-week-in-the-markets-1032725210,negative,0.9567456245422363
10/24/2023 2:47:19 PM,'Never Buy A Drug Stock Just For The Yield': Jim Cramer On This Big Pharma Company,Benzinga,/news/stocks/never-buy-a-drug-stock-just-for-the-yield-jim-cramer-on-this-big-pharma-company-1032733252,neutral,0.9392249584197998
10/24/2023 3:21:37 PM,LianBio Reaches Agreement With Bristol Myers Squibb For Mavacamten; Stock Up ,RTTNews,/news/stocks/lianbio-reaches-agreement-with-bristol-myers-squibb-for-mavacamten-stock-up-1032733684,positive,0.918516993522644
10/24/2023 5:48:58 PM,Why Is LianBio (LIAN) Stock Up 130% Today?,InvestorPlace,/news/stocks/why-lianbio-lian-stock-up-130-percent-today-1032734783,positive,0.6409769058227539
10/25/2023 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-q3-earnings-preview-1032738729,neutral,0.9266072511672974
10/26/2023 9:31:17 AM,"Geoff Meacham’s Optimistic Buy Rating for Bristol-Myers Squibb: Assessing Upcoming Results, Strategic Acquisitions and ‘Big 9’ Product Performance",TipRanks,/news/stocks/geoff-meacham-s-optimistic-buy-rating-for-bristol-myers-squibb-assessing-upcoming-results-strategic-acquisitions-and-big-9-product-performance-1032745759,neutral,0.7695609927177429
10/26/2023 1:43:13 PM,Bristol-Myers Squibb Boosts FY23 Adj. EPS Outlook As Q3 Adj. EPS Tops Estimates ,RTTNews,/news/stocks/bristol-myers-squibb-boosts-fy23-adj-eps-outlook-as-q3-adj-eps-tops-estimates-1032743473,positive,0.9439443945884705
10/26/2023 7:23:50 PM,"US Stocks Sink, VIX Soars As Overheated Economy, Mixed Earnings Complicate Fed's Path: What's Driving Markets Thursday?",Benzinga,/news/stocks/us-stocks-sink-vix-soars-as-overheated-economy-mixed-earnings-complicate-fed-s-action-what-s-driving-markets-thursday-1032745198,negative,0.9391444325447083
10/27/2023 7:40:17 AM,"Analysts Conflicted on These Healthcare Names: Amgen (AMGN), Immutep (IMMP) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-amgen-amgn-immutep-immp-and-bristol-myers-squibb-bmy-1032749776,negative,0.7041301727294922
10/27/2023 11:36:51 AM,Hold Rating on Bristol-Myers Squibb: An Analysis of Future Challenges and Investment Strategies,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-an-analysis-of-future-challenges-and-investment-strategies-1032750156,neutral,0.9148544669151306
10/27/2023 7:47:57 PM,Bristol Myers Squibb Analysts Slash Their Forecasts Following Q3 Results,Benzinga,/news/stocks/bristol-myers-squibb-analysts-slash-their-forecasts-following-q3-results-1032749611,negative,0.9559521079063416
10/27/2023 8:13:44 PM,Pharma Giant Bristol-Myers Stock At 52-Week Low: Analyst Sees Uncertainty In Near-Term Outlook,Benzinga,/news/stocks/pharma-giant-bristol-myers-stock-at-52-week-low-analyst-sees-uncertainty-in-near-term-outlook-1032749657,negative,0.9620029330253601
10/28/2023 5:15:33 PM,Biotech Stocks Facing FDA Decision In November 2023 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-november-2023-1032750454,neutral,0.911858320236206
10/30/2023 3:01:03 PM,"Karyopharm Enters Clinical Trial Collaboration, Supply Agreement With Bristol-Myers Squibb ",RTTNews,/news/stocks/karyopharm-enters-clinical-trial-collaboration-supply-agreement-with-bristol-myers-squibb-1032754488,positive,0.7606137990951538
10/31/2023 6:50:16 AM,"Analysts Offer Insights on Healthcare Companies: NovoCure (NVCR), Insmed (INSM) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-novocure-nvcr-insmed-insm-and-bristol-myers-squibb-bmy-1032760985,neutral,0.918052077293396
10/31/2023 12:10:43 PM,"Analysts Are Bullish on These Healthcare Stocks: Conmed (CNMD), Resmed (RMD)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-conmed-cnmd-resmed-rmd-1032761561,neutral,0.633213460445404
11/1/2023 1:08:03 AM,Bristol Myers Squibb Elects Christopher Boerner To Serve As Chair Of Board ,RTTNews,/news/stocks/bristol-myers-squibb-elects-christopher-boerner-to-serve-as-chair-of-board-1032761556,neutral,0.9404630661010742
11/2/2023 9:10:58 AM,Bristol-Myers Squibb: A Hold Rating Amid Concerns over Sales Growth and Competitive Pressure – An Analysis by Berenberg Bank’s Luisa Hector,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amid-concerns-over-sales-growth-and-competitive-pressure-–-an-analysis-by-berenberg-bank-s-luisa-hector-1032772397,negative,0.9400418400764465
11/7/2023 1:55:28 AM,Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/berenberg-bank-remains-a-hold-on-bristol-myers-squibb-bmy-1032787543,neutral,0.8375291228294373
11/13/2023 4:36:30 PM,Debt-Fueled Buybacks: 3 Stocks Undeterred by Rising Rates,InvestorPlace,/news/stocks/debt-fueled-buybacks-3-stocks-undeterred-by-rising-rates-1032814009,positive,0.7317014336585999
11/15/2023 6:00:55 PM,The Latest Analyst Ratings for Bristol-Myers Squibb,Benzinga,/news/stocks/the-latest-analyst-ratings-for-bristol-myers-squibb-1032824134,neutral,0.9381066560745239
11/20/2023 1:49:25 PM,"Bristol Myers Squibb, 2seventy Bio Issue Update On FDA Review For Abecma ",RTTNews,/news/stocks/bristol-myers-squibb-2seventy-bio-issue-update-on-fda-review-for-abecma-1032835270,neutral,0.9325470924377441
11/20/2023 3:08:46 PM,Why Is Bristol-Myers Squibb (BMY) Stock Down Today?,InvestorPlace,/news/stocks/why-is-bristol-myers-squibb-bmy-stock-down-today-1032836230,negative,0.9120900630950928
11/20/2023 3:47:36 PM,Uber Stock Falls After Announcement of $1.2 Billion Convertible Notes Offering,InvestorPlace,/news/stocks/uber-stock-falls-after-announcement-of-1-2-billion-convertible-notes-offering-1032836306,negative,0.9334620237350464
11/20/2023 4:00:27 PM,Dutch Bros (BROS) Stock Gains on JPMorgan Upgrade,InvestorPlace,/news/stocks/dutch-bros-bros-stock-gains-on-jpmorgan-upgrade-1032836349,positive,0.6456183791160583
11/20/2023 8:58:21 PM,Analyst Assess Implications of Bristol Myers' Investigational Blood Thinner Post Bayer Trial Setback Amid Shaken Investor Confidence,Benzinga,/news/stocks/analyst-assess-implications-of-bristol-myers-investigational-blood-thinner-post-bayer-trial-setback-amid-shaken-investor-confidence-1032836877,negative,0.9359135627746582
11/21/2023 1:56:19 AM,Soothing Stocks: 7 Reliable Picks to Ease Your Market Jitters,InvestorPlace,/news/stocks/soothing-stocks-7-reliable-picks-to-ease-your-market-jitters-1032837327,neutral,0.7981265783309937
11/21/2023 10:31:10 AM,Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY) and AbbVie (ABBV),TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-and-abbvie-abbv-1032840916,negative,0.7395573854446411
11/26/2023 9:43:24 PM,3 Resilient Stocks with Massive Potential to Boost Your Wealth,InvestorPlace,/news/stocks/3-resilient-stocks-with-massive-potential-to-boost-your-wealth-1032849635,positive,0.8403179049491882
11/27/2023 2:37:27 PM,Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 4% Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-say-hold-these-3-health-care-stocks-with-over-4-dividend-yields-1032851232,neutral,0.8461885452270508
11/28/2023 12:30:00 PM,Avidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC™ Platform Technology,PR Newswire,/news/stocks/avidity-biosciences-announces-expansion-of-cardiovascular-collaboration-with-bristol-myers-squibb-for-up-to-five-targets-utilizing-avidity-s-proprietary-aoc-platform-technology-1032854231,positive,0.8431615233421326
11/28/2023 12:53:28 PM,Avidity Biosciences Inks Global Licensing And Research Collaboration Deal With Bristol Myers Squibb ,RTTNews,/news/stocks/avidity-biosciences-inks-global-licensing-and-research-collaboration-deal-with-bristol-myers-squibb-1032854290,positive,0.8555451035499573
11/28/2023 3:09:27 PM,Why Is Avidity Biosciences (RNA) Stock Up 15% Today?,InvestorPlace,/news/stocks/why-is-avidity-biosciences-rna-stock-up-15-today-1032855547,positive,0.8940277695655823
11/28/2023 3:17:30 PM,Why Is RNA Therapeutics-Focused Avidity Biosciences Stock Trading Higher Today?,Benzinga,/news/stocks/why-is-rna-therapeutics-focused-avidity-biosciences-stock-trading-higher-today-1032855069,neutral,0.4537310004234314
11/30/2023 2:25:51 AM,Truist Financial Sticks to Its Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-sticks-to-its-buy-rating-for-bristol-myers-squibb-bmy-1032862770,neutral,0.7322041392326355
12/5/2023 2:12:51 PM,Bristol Myers: FDA Accepts SBLA For Opdivo Combination For Priority Review ,RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-opdivo-combination-for-priority-review-1032874084,positive,0.5876180529594421
12/6/2023 3:26:56 PM,2024's Potential Stock Surprises: Goldman Sachs Unveils S&P 500 Laggards For Major Gains,Benzinga,/news/stocks/2024-s-potential-stock-surprises-goldman-sachs-unveils-s-p-500-laggards-for-major-gains-1032878413,neutral,0.7751442790031433
12/7/2023 12:50:32 PM,Bristol Myers Squibb To Repurchase Additional $3 Bln Of Shares ,RTTNews,/news/stocks/bristol-myers-squibb-to-repurchase-additional-3-bln-of-shares-1032881459,neutral,0.8483071327209473
12/8/2023 1:04:58 PM,Insiders Buying Bristol-Myers Squibb And 3 Other Stocks,Benzinga,/news/stocks/insiders-buying-bristol-myers-squibb-and-3-other-stocks-1032885253,neutral,0.9243345856666565
12/11/2023 12:17:08 PM,Bristol-Myers Squibb: Hold Rating Affirmed Amid Progress and Considerations in Drug Development,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-affirmed-amid-progress-and-considerations-in-drug-development-1032891210,positive,0.9404309988021851
12/12/2023 3:00:06 PM,Bristol Myers Squibb's Mega $8.4B Oncology Bet - Secures Exclusive License With SystImmune,Benzinga,/news/stocks/bristol-myers-squibb-further-diversifies-oncology-portfolio-with-mega-8-4b-deal-1032893319,positive,0.6502244472503662
12/13/2023 6:18:24 AM,Bristol-Myers Squibb Hold Rating: Balancing CAR-T Therapy Prospects with Manufacturing and Market Constraints,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-balancing-car-t-therapy-prospects-with-manufacturing-and-market-constraints-1032898378,neutral,0.7894827723503113
12/14/2023 1:00:00 PM,Terray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb,PR Newswire,/news/stocks/terray-therapeutics-announces-multi-target-collaboration-with-bristol-myers-squibb-1032900567,positive,0.4955127537250519
12/14/2023 1:13:08 PM,"Terray, Bristol Myers Squibb Join To Identify Small Molecule Therapeutics Using TNova Platform ",RTTNews,/news/stocks/terray-bristol-myers-squibb-join-to-identify-small-molecule-therapeutics-using-tnova-platform-1032900655,neutral,0.6984479427337646
12/17/2023 5:35:39 PM,7 Stocks with Strong Insider Buying: December 2023,InvestorPlace,/news/stocks/7-stocks-with-strong-insider-buying-december-2023-1032907072,neutral,0.850240170955658
12/20/2023 5:39:46 PM,3 Potential Turnaround Stocks to Buy for Big Rewards in 2024,InvestorPlace,/news/stocks/3-potential-turnaround-stocks-to-buy-for-big-rewards-in-2024-1032917080,neutral,0.631753146648407
12/22/2023 1:20:59 PM,Bristol Myers Squibb To Acquire Karuna Therapeutics For $330/share Cash ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-karuna-therapeutics-for-330-share-cash-1032922004,neutral,0.9199858903884888
12/22/2023 5:20:07 PM,"Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday",Benzinga,/news/stocks/karuna-therapeutics-jumps-following-takeover-by-bristol-myers-joins-rocket-lab-usa-altair-engineering-and-other-big-stocks-moving-higher-on-friday-1032922858,positive,0.9259609580039978
12/22/2023 6:07:59 PM,"With Karuna Therapeutics $14B Deal, Bristol Myers Is Serious For Re-Establishing Its Neurology Portfolio: Analyst",Benzinga,/news/stocks/with-karuna-therapeutics-14b-deal-bristol-myers-is-serious-for-re-establishing-its-neurology-portfolio-analyst-1032923010,positive,0.6027708053588867
12/22/2023 6:18:34 PM,Gold Moves Higher; US Consumer Sentiment Improves In December,Benzinga,/news/stocks/gold-moves-higher-us-consumer-sentiment-improves-in-december-1032923027,positive,0.9468288421630859
12/22/2023 7:04:25 PM,"S&P 500, Nasdaq 100 Aim For 8th Week Of Gains As Fed's Inflation Gauge Cools: What's Driving Markets Friday?",Benzinga,/news/stocks/s-p-500-nasdaq-100-aim-for-8th-week-of-gains-as-fed-s-inflation-gauge-cools-what-s-driving-markets-friday-1032923094,neutral,0.7574973106384277
12/22/2023 7:28:37 PM,Why AAR Shares Are Trading Lower By 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session,Benzinga,/news/stocks/why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-friday-s-mid-day-session-1032923121,negative,0.8336851000785828
12/22/2023 8:47:48 PM,Dow Edges Lower; Nike Sales Miss Estimates,Benzinga,/news/stocks/dow-edges-lower-nike-sales-miss-estimates-1032923197,negative,0.9666873216629028
12/26/2023 11:05:33 AM,Hold Rating on Bristol-Myers Squibb Amid Strategic Karuna Acquisition and Long-Term Growth Prospects,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-strategic-karuna-acquisition-and-long-term-growth-prospects-1032926503,positive,0.9486283659934998
12/26/2023 11:41:12 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Sarepta Therapeutics (SRPT), AlloVir (ALVR) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-sarepta-therapeutics-srpt-allovir-alvr-and-bristol-myers-squibb-bmy-1032926491,negative,0.7809678316116333
12/26/2023 1:18:41 PM,Bristol Myers Squibb To Acquire RayzeBio For $62.50/share In All-cash Deal ,RTTNews,/news/stocks/bristol-myers-squibb-to-acquire-rayzebio-for-62-50-share-in-all-cash-deal-1032925528,neutral,0.9142457842826843
12/26/2023 3:10:15 PM,Why Is RayzeBio (RYZB) Stock Up 100% Today?,InvestorPlace,/news/stocks/why-is-rayzebio-ryzb-stock-up-100-today-1032926088,positive,0.7323812246322632
12/26/2023 8:02:49 PM,Bristol-Myers' Acquisition Of Karuna Therapeutics Paves Way For Aggressive Global Marketing Of KarXT: Analyst,Benzinga,/news/stocks/bristol-myers-acquisition-of-karuna-therapeutics-paves-way-for-aggressive-global-marketing-of-karxt-analyst-1032926298,positive,0.8689960837364197
12/27/2023 6:25:58 AM,Bristol-Myers Squibb’s Strategic Expansion: Buy Rating Affirmed Following RayzeBio Acquisition,TipRanks,/news/stocks/bristol-myers-squibb-s-strategic-expansion-buy-rating-affirmed-following-rayzebio-acquisition-1032928641,positive,0.4934150278568268
12/27/2023 10:26:23 AM,Buy Rating on Bristol-Myers Squibb: Strategic Acquisitions Bolster Oncology Portfolio Despite Near-Term Earnings Dilution,TipRanks,/news/stocks/buy-rating-on-bristol-myers-squibb-strategic-acquisitions-bolster-oncology-portfolio-despite-near-term-earnings-dilution-1032928858,positive,0.9502608180046082
12/27/2023 12:16:05 PM,Bristol-Myers Squibb (BMY) Gets a Hold from Cantor Fitzgerald,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-cantor-fitzgerald-1032928898,neutral,0.6411511898040771
12/27/2023 1:00:13 PM,Analyst Expectations For Bristol-Myers Squibb's Future,Benzinga,/news/stocks/analyst-expectations-for-bristol-myers-squibb-s-future-1032927723,positive,0.9069193005561829
12/27/2023 3:06:32 PM,Meta To Rally Over 18%? Here Are 10 Top Analyst Forecasts For Wednesday,Benzinga,/news/stocks/meta-to-rally-over-18-here-are-10-top-analyst-forecasts-for-wednesday-1032927940,neutral,0.9123877286911011
12/27/2023 6:42:14 PM,"Recent M&A Bodes Well For Targeted Cancer Therapy Player Fusion Pharmaceuticals, Analyst Say AstraZeneca Is Favorably Positioned",Benzinga,/news/stocks/recent-m-a-bodes-well-for-targeted-cancer-therapy-player-fusion-pharmaceuticals-analyst-say-astrazeneca-is-favorably-positioned-1032928584,positive,0.94742351770401
12/27/2023 6:59:59 PM,Why Is Cytokinetics (CYTK) Stock Up 70% Today?,InvestorPlace,/news/stocks/why-is-cytokinetics-cytk-stock-up-70-today-1032928698,positive,0.8379680514335632
12/28/2023 6:19:47 PM,Cytokinetics' Drug Potential: Analyst Suggests Key Role Of Established Pharma For Potential Launch,Benzinga,/news/stocks/cytokinetics-drug-potential-analyst-suggests-key-role-of-established-pharma-for-potential-launch-1032930741,positive,0.7084631323814392
12/29/2023 2:30:13 AM,Wall Street Analysts Are Bullish on Top Healthcare Picks,TipRanks,/news/stocks/wall-street-analysts-are-bullish-on-top-healthcare-picks-1032932343,positive,0.552167534828186
1/3/2024 6:29:31 PM,"This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns",Benzinga,/news/stocks/this-analyst-downgrades-bristol-myers-squibb-cautions-amid-product-launch-and-revenue-concerns-1032940889,negative,0.9435461163520813
1/3/2024 11:17:42 PM,7 Stocks Primed for a Spectacular Comeback in 2024,InvestorPlace,/news/stocks/7-stocks-primed-for-a-spectacular-comeback-in-2024-1032941382,positive,0.8261495232582092
1/4/2024 8:27:35 PM,3 Dividend Stocks for Strong Returns in 2024 and Beyond,InvestorPlace,/news/stocks/3-dividend-stocks-for-strong-returns-in-2024-and-beyond-1032944373,positive,0.9438294768333435
1/5/2024 10:35:26 AM,Buy Rating Justified: Bristol-Myers Squibb’s Growth Prospects Bolstered by Strong Pipeline and Strategic Acquisitions,TipRanks,/news/stocks/buy-rating-justified-bristol-myers-squibb-s-growth-prospects-bolstered-by-strong-pipeline-and-strategic-acquisitions-1032947167,positive,0.9520081281661987
1/9/2024 10:12:21 AM,Bristol-Myers Squibb: A Cautious Hold Amid Long-Term Growth Prospects,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amid-long-term-growth-prospects-1032955143,negative,0.5234808325767517
1/19/2024 1:05:15 PM,Senate panel to consider subpoenas for J&J and Merck CEOs,Seeking Alpha,https://seekingalpha.com/news/4056351-sen-bernie-sanders-weighs-subpoenas-jj-merck-ceos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5767493844032288
1/19/2024 6:24:22 PM,Mirati Therapeutics ticks higher amid Nasdaq delisting for sale to Bristol-Myers,Seeking Alpha,https://seekingalpha.com/news/4056557-mirati-therapeutics-ticks-higher-amid-nasdaq-delisting-for-sale-to-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6177183985710144
1/19/2024 8:55:45 PM,Ikena Oncology Refocuses on Key Programs: Analysts Maintain Outperform Ratings Amid Strategic Organizational Changes,Benzinga,/news/stocks/ikena-oncology-refocuses-on-key-programs-analysts-maintain-outperform-ratings-amid-strategic-organizational-changes-1032980970,negative,0.5106011033058167
1/20/2024 4:25:35 PM,Bristol Opdivo/Yervoy combo for colorectal cancer boosted by new data,Seeking Alpha,https://seekingalpha.com/news/4056644-bristol-opdivo-yervoy-combo-colorectal-cancer-boosted-new-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.942532479763031
1/22/2024 7:37:43 PM,Bristol-Myers almost lost Karuna buyout to third party,Seeking Alpha,https://seekingalpha.com/news/4057026-bristol-myers-almost-lost-karuna-buyout-third-party?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8851534128189087
1/22/2024 8:40:18 PM,"Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Bristol-Myers Squibb (BMY) and Immunocore Holdings (IMCR)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-evolus-eols-bristol-myers-squibb-bmy-and-immunocore-holdings-imcr-1032987232,neutral,0.9132720232009888
1/22/2024 10:49:49 PM,Bristol's Opdivo + Yervoy combo excels over long term in kidney cancer,Seeking Alpha,https://seekingalpha.com/news/4057161-bristol-opdivo-yervoy-combo-excels-long-term-kidney-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9244074821472168
1/23/2024 4:09:28 AM,CAR-T therapies to get boxed warning on blood cancer risk,Seeking Alpha,https://seekingalpha.com/news/4057175-car-t-therapies-get-boxed-warning-blood-cancer-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7862139940261841
1/23/2024 8:25:50 AM,Barclays Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1032987155,neutral,0.8420034646987915
1/23/2024 1:51:17 PM,Bristol Myers sees $0.35 per share impact as Mirati acquisition completes,Seeking Alpha,https://seekingalpha.com/news/4057339-bristol-myers-squibb-mirati-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8846189379692078
1/23/2024 3:11:34 PM,Bristol Myers Squibb Completes Acquisition Of Mirati For Upto $5.8 Bln ,RTTNews,/news/stocks/bristol-myers-squibb-completes-acquisition-of-mirati-for-upto-5-8-bln-1032988040,positive,0.5067291855812073
1/23/2024 10:06:38 PM,7 Beaten-Down Value Stocks Poised for an Epic Turnaround,InvestorPlace,/news/stocks/7-beaten-down-value-stocks-poised-for-an-epic-turnaround-1032989561,neutral,0.41875192523002625
1/26/2024 12:16:34 PM,PBMs ramp up lobbying efforts amid growing public scrutiny,Seeking Alpha,https://seekingalpha.com/news/4058952-pbms-ramp-up-lobbying-amid-growing-public-scrutiny?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9376140832901001
1/26/2024 1:09:58 PM,Bristol-Myers Squibb wins EU nod for expanded Abecma indication,Seeking Alpha,https://seekingalpha.com/news/4059013-bristol-myers-squibb-abecma-expanded-eu-nod?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7708374857902527
1/26/2024 3:46:58 PM,Bristol-Myers's Abecma Receives CHMP Recommendation For Market Authorization ,RTTNews,/news/stocks/bristol-myers-s-abecma-receives-chmp-recommendation-for-market-authorization-1033001136,neutral,0.7754833102226257
1/26/2024 5:01:25 PM,3 Healthcare Stocks at 52-Week Lows: Buy or Bye?,InvestorPlace,/news/stocks/3-healthcare-stocks-at-52-week-lows-buy-or-bye-1033001939,negative,0.7319077253341675
1/28/2024 5:00:53 PM,Big Pharma earnings season in spotlight amid positive sentiment,Seeking Alpha,https://seekingalpha.com/news/4059361-big-pharma-earnings-spotlight-positive-sentiment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8954368233680725
1/29/2024 5:14:01 PM,"Marathon Petroleum, Exxon among BofA picks for options opportunity on earnings surprise",Seeking Alpha,https://seekingalpha.com/news/4059539-marathon-petroleum-exxon-among-bofa-picks-for-options-opportunity-on-earnings-surprise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7842940092086792
1/29/2024 8:13:38 PM,Karuna’s KarXT tops Evaluate’s most anticipated drug list,Seeking Alpha,https://seekingalpha.com/news/4059673-karuna-karxt-tops-evaluate-most-anticipated-drug-list?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7358655333518982
1/30/2024 12:25:14 PM,Regulatory applications accepted in the U.S. and Japan for Bristol Myers Squibb’s Breyanzi,Seeking Alpha,https://seekingalpha.com/news/4059943-regulatory-applications-accepted-in-the-us-and-japan-for-bristol-myers-squibbs-breyanzi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6283910274505615
1/30/2024 12:50:11 PM,Pfizer beats with COVID franchise despite Q4 revenue miss,Seeking Alpha,https://seekingalpha.com/news/4059957-pfizer-beats-covid-franchise-despite-q4-revenue-miss?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7736058831214905
1/30/2024 1:49:38 PM,Did You Miss These 3 High-Yielding Dividend Stocks In Health Care Sector From Wall Street's Most Accurate Analysts?,Benzinga,/news/stocks/did-you-miss-these-3-high-yielding-dividend-stocks-in-health-care-sector-from-wall-street-s-most-accurate-analysts-1033009690,neutral,0.8292561769485474
1/30/2024 3:00:42 PM,"Bristol-Myers Says Regulatory Applications For Breyanzi Accepted By FDA, Japan's MHLW ",RTTNews,/news/stocks/bristol-myers-says-regulatory-applications-for-breyanzi-accepted-by-fda-japan-s-mhlw-1033010243,neutral,0.6343348026275635
2/1/2024 3:00:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4061340-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8830810189247131
2/1/2024 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-q4-earnings-preview-1033020715,neutral,0.9266072511672974
2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-opening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49058493971824646
2/1/2024 3:13:39 PM,U.S. govt. opens bids in Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4061377-ppening-bids-sent-drugs-picked-medicare-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49058493971824646
2/1/2024 9:30:02 PM,Earnings preview: Bristol Myers seen reporting lower Q4 earnings Friday,Seeking Alpha,https://seekingalpha.com/news/4061685-earnings-preview-bristol-myers-seen-reporting-lower-q4-earnings-friday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9716586470603943
2/2/2024 1:17:57 AM,Bristol-Myers Squibb: A Cautious Hold Amidst Financial Uncertainties and Product Launches,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amidst-financial-uncertainties-and-product-launches-1033022906,negative,0.6475326418876648
2/2/2024 12:01:52 PM,Bristol-Myers Squibb beats top-line and bottom-line estimates; initiates FY24 outlook,Seeking Alpha,https://seekingalpha.com/news/4061943-bristol-myers-squibbbeats-top-line-and-bottom-line-estimates-initiates-fy24-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7320365905761719
2/2/2024 12:49:26 PM,Bristol-Myers Squibb beats in Q4 as Eliquis and Opdivo outperform,Seeking Alpha,https://seekingalpha.com/news/4061968-bristol-myers-squibb-q4-beats-driven-eliquis-and-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8962094187736511
2/2/2024 1:07:20 PM,"Bristol-Myers Squibb Co. Q4 Profit Decreases, but beats estimates",RTTNews,/news/stocks/bristol-myers-squibb-co-q4-profit-decreases-but-beats-estimates-1033024635,negative,0.9638311266899109
2/2/2024 1:26:08 PM,Bristol-Myers Squibb Guides FY24 Adj. EPS Above Estimates As Q4 Results Top Estimates - Update ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy24-adj-eps-above-estimates-as-q4-results-top-estimates-update-1033024683,neutral,0.8557939529418945
2/4/2024 8:26:49 PM,Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033027473,neutral,0.809019923210144
2/5/2024 7:55:59 AM,Barclays Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033029365,neutral,0.8420034646987915
2/5/2024 12:28:26 PM,"Bristol Myers, 2seventy bio to face FDA panel in March for Abecma decision",Seeking Alpha,https://seekingalpha.com/news/4062480-bristol-myers-faces-fda-panel-abecma-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8479851484298706
2/5/2024 12:58:08 PM,Hold Rating on Bristol-Myers Squibb Amid Balanced Growth and Execution Challenges,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-balanced-growth-and-execution-challenges-1033031057,positive,0.930197536945343
2/5/2024 1:41:00 PM,Undervalued Gems: 7 Stocks Set for a Major Rebound,InvestorPlace,/news/stocks/undervalued-gems-7-stocks-set-for-a-major-rebound-1033030315,positive,0.6081776022911072
2/6/2024 1:19:58 PM,Bristol Myers cut at Redburn as looming headwinds offset buyouts,Seeking Alpha,https://seekingalpha.com/news/4063080-bristol-myers-stock-cut-redburn-atlantic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8923797607421875
2/6/2024 1:54:09 PM,Uber To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/uber-to-rally-around-15-here-are-10-top-analyst-forecasts-for-tuesday-1033034665,neutral,0.9135574698448181
2/6/2024 8:19:40 PM,"UBS Bullish On This Depression Drug Maker, Says Alzheimer's Agitation Data Is Attractive Catalyst",Benzinga,/news/stocks/ubs-bullish-on-this-depression-drug-maker-says-alzheimer-s-agitation-data-is-attractive-catalyst-1033036588,positive,0.8985599279403687
2/7/2024 1:30:24 PM,"Analysts Offer Insights on Healthcare Companies: Arrowhead Pharmaceuticals (ARWR), Waters (WAT) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-arrowhead-pharmaceuticals-arwr-waters-wat-and-bristol-myers-squibb-bmy-1033042129,neutral,0.9140424132347107
2/7/2024 1:35:55 PM,"Bristol Myers granted FDA, EU reviews for Opdivo label expansion",Seeking Alpha,https://seekingalpha.com/news/4063806-bristol-myers-granted-fda-eu-reviews-for-opdivo-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.610630989074707
2/7/2024 6:40:44 PM,3 Blue-Chip Stocks to Buy at a 52-Week Low in February,InvestorPlace,/news/stocks/want-blue-chip-stocks-at-a-low-price-here-are-3-solid-options-1033042564,negative,0.8401287198066711
2/8/2024 9:10:42 PM,7 Biotech Stocks Fighting America’s Deadliest Diseases,InvestorPlace,/news/stocks/7-biotech-stocks-fighting-americas-deadliest-diseases-1033048253,neutral,0.7001750469207764
2/9/2024 12:24:06 PM,Pharma CEOs defend high drug prices; blame PBMs at Senate hearing,Seeking Alpha,https://seekingalpha.com/news/4065061-pharma-ceos-defend-high-drug-prices-blame-pbms-senate-hearing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6773605346679688
2/9/2024 1:57:00 PM,"7 stocks to watch on Friday: Major drugmakers on Senate hearing, PepsiCo and more",Seeking Alpha,https://seekingalpha.com/news/4065116-7-stocks-to-watch-on-friday-major-drugmakers-on-senate-hearing-pepsico-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9030511379241943
2/12/2024 1:21:45 PM,"Bristol Myers Squibb, RayzeBio Report Expiration Of HSR Act Waiting Period ",RTTNews,/news/stocks/bristol-myers-squibb-rayzebio-report-expiration-of-hsr-act-waiting-period-1033056612,neutral,0.6734176874160767
2/12/2024 1:57:56 PM,7 Dividend Stocks to Buy at a 52-Week Low ,InvestorPlace,/news/stocks/7-dividend-stocks-that-are-ready-for-a-bounce-back-year-1033057146,neutral,0.8719378709793091
2/12/2024 4:36:24 PM,RayzeBio ticks higher after HSR waiting period for Bristol Myers deal expires,Seeking Alpha,https://seekingalpha.com/news/4065612-rayzebio-ticks-higher-after-hsr-waiting-period-for-bristol-myers-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.481595516204834
2/13/2024 2:01:27 AM,Federal judge dismisses PhRMA challenge to Medicare price negotiations,Seeking Alpha,https://seekingalpha.com/news/4065840-federal-judge-tosses-phrma-lawsuit-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6178929805755615
2/14/2024 12:28:54 PM,Bristol Myers wins FDA review for label expansion of lung cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4066637-bristol-myers-wins-fda-review-cancer-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8747702836990356
2/14/2024 12:54:01 PM,Wall Street's Most Accurate Analysts' Views On 3 Health Care Stocks Delivering High-Dividend Yields,Benzinga,/news/stocks/wall-street-s-most-accurate-analysts-views-on-3-health-care-stocks-delivering-high-dividend-yields-1033066002,neutral,0.7807834148406982
2/14/2024 5:03:40 PM,Bristol-Myers' Augtyro Receives Priority Review Status From FDA ,RTTNews,/news/stocks/bristol-myers-augtyro-receives-priority-review-status-from-fda-1033067503,positive,0.745320200920105
2/14/2024 9:45:18 PM,Bristol Myers urges investors to reject mini-tender offer,Seeking Alpha,https://seekingalpha.com/news/4067189-bristol-myers-urges-investors-to-reject-mini-tender-offer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5895505547523499
2/14/2024 11:50:22 PM,"Tudor Investment exits Airbnb, Adobe; boosts Nvidia, Splunk",Seeking Alpha,https://seekingalpha.com/news/4067303-tudor-investment-exits-airbnb-adobe-boosts-nvidia-splunk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9427438974380493
2/15/2024 7:51:12 AM,Bristol Myers Squibb prices $13B senior notes at varying maturities,Seeking Alpha,https://seekingalpha.com/news/4067330-bristol-myers-squibb-prices-13b-senior-notes-at-varying-maturities?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9346209168434143
2/15/2024 9:13:52 PM,7 Contrarian Biotech Stocks to Consider Amid Sector Weakness,InvestorPlace,/news/stocks/7-contrarian-biotech-stocks-to-consider-amid-sector-weakness-1033073521,neutral,0.7290653586387634
2/21/2024 1:04:09 PM,The 3 Best Stocks Beginning Investors Can Buy: February 2024,InvestorPlace,/news/stocks/the-3-best-stocks-beginning-investors-can-buy-february-2024-1033087518,neutral,0.9318463206291199
2/21/2024 4:03:58 PM,"UBS cuts BioXcel to neutral; cites regulatory issues, financing",Seeking Alpha,https://seekingalpha.com/news/4069650-ubs-cuts-bioxcel-to-neutral-cites-regulatory-issues-financing?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5994259715080261
2/21/2024 8:06:10 PM,Mental Health Mavericks: 3 Stocks Changing the Game,InvestorPlace,/news/stocks/mental-health-mavericks-3-stocks-changing-the-game-1033089514,neutral,0.8695485591888428
2/22/2024 2:24:03 PM,Immunocore to work with Bristol on combination melanoma therapy trial,Seeking Alpha,https://seekingalpha.com/news/4070346-immunocore-work-bristol-combination-melanoma-therapy-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6133092045783997
2/23/2024 12:30:21 PM,Bristol Myers blood disorder therapy endorsed in EU for label expansion,Seeking Alpha,https://seekingalpha.com/news/4070991-bristol-myers-wins-eu-backing-expand-label-reblozyl?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8798993825912476
2/23/2024 1:19:34 PM,Bristol Myers Squibb: Approx. 86% Of RayzeBio Common Stock Validly Tendered As Of Expiration Time ,RTTNews,/news/stocks/bristol-myers-squibb-approx-86-of-rayzebio-common-stock-validly-tendered-as-of-expiration-time-1033097084,neutral,0.9296106696128845
2/25/2024 5:00:00 PM,Radiopharmaceutical market expected to reach ~$14B by 2032,Seeking Alpha,https://seekingalpha.com/news/4071376-radiopharmaceutical-market-reach-14b-by-2032?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.753372311592102
2/26/2024 11:55:00 AM,3 Highly Rated Biotech Stocks to Buy for 300% Gains,InvestorPlace,/news/stocks/3-highly-rated-biotech-stocks-to-buy-for-300-gains-1033102093,positive,0.5116611123085022
2/26/2024 4:59:38 PM,Karuna Therapeutics drops on no apparent news amid deal with Bristol-Myers Squibb,Seeking Alpha,https://seekingalpha.com/news/4071718-karuna-therapeutics-drops-on-no-apparent-news-amid-deal-with-bristol-myers-squibb?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9064037203788757
2/27/2024 10:58:02 AM,Bristol-Myers Squibb: Balancing Growth Prospects Against Market Challenges and Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-balancing-growth-prospects-against-market-challenges-and-uncertainties-1033107719,neutral,0.7032407522201538
2/27/2024 11:02:30 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Staar Surgical (STAA), Krystal Biotech (KRYS) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-staar-surgical-staa-krystal-biotech-krys-and-bristol-myers-squibb-bmy-1033107687,negative,0.7407286167144775
2/27/2024 1:37:09 PM,Minerva falls as FDA rejects schizophrenia therapy,Seeking Alpha,https://seekingalpha.com/news/4072211-minerva-stock-falls-fda-rejects-schizophrenia-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9438061714172363
2/28/2024 9:52:49 AM,Biotech Stocks Facing FDA Decision In March 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-march-2024-1033111344,neutral,0.9174318909645081
2/28/2024 11:31:34 PM,Schrodinger down 15% after hours on soft 2024 guidance,Seeking Alpha,https://seekingalpha.com/news/4073589-schrodinger-down-15-after-hours-soft-2024-guidance?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9571810960769653
3/1/2024 12:30:00 PM,The Hot List: 3 AI Stocks Worth Buying on Weakness,InvestorPlace,/news/stocks/the-hot-list-3-ai-stocks-worth-buying-on-weakness-1033123124,neutral,0.8718505501747131
3/1/2024 6:10:27 PM,Medicare price negotiations survive another legal challenge,Seeking Alpha,https://seekingalpha.com/news/4074801-medicare-price-negotiations-survive-legal-challenge?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.850996196269989
3/1/2024 9:21:07 PM,Bristol-Myers Squibb Company  declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4074882-bristol-myers-squibb-company-declares-0_60-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7695336937904358
3/4/2024 7:08:25 PM,Biden says drugmakers to continue to engage in Medicare drug price negoiations,Seeking Alpha,https://seekingalpha.com/news/4075531-biden-says-drugmakers-continue-engage-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8006861805915833
3/4/2024 7:56:37 PM,Biden to launch task force to target health care costs - report,Seeking Alpha,https://seekingalpha.com/news/4075586-biden-launch-task-force-target-health-care-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8196350336074829
3/6/2024 1:40:00 PM,Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town,InvestorPlace,/news/stocks/millionaires-blueprint-7-must-have-stocks-for-your-road-to-wealthy-town-1033137473,neutral,0.8420636653900146
3/6/2024 10:40:54 PM,Biden to push for expanding Medicare drug pricing program,Seeking Alpha,https://seekingalpha.com/news/4076912-biden-to-push-for-expanding-medicare-drug-pricing-program?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7659493088722229
3/7/2024 5:45:31 PM,Bristol-Myers wins FDA nod for Opdivo combo as first line bladder cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4077300-bristol-myers-wins-fda-nod-expand-opdivo-label?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9237843751907349
3/7/2024 8:52:40 PM,"Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley",Benzinga,/news/stocks/arcellx-s-lead-asset-can-potentially-outperform-bristol-myers-squibb-johnson-johnson-s-multiple-myeloma-cell-therapies-morgan-stanley-1033143791,positive,0.6205326914787292
3/8/2024 8:00:00 PM,"Catalyst Watch: Oracle earnings, Arm IPO lockup, and triple-witching day",Seeking Alpha,https://seekingalpha.com/news/4076911-catalyst-watch-oracle-earnings-arm-ipo-lockup-and-triple-witching-day?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7499243021011353
3/10/2024 5:08:00 PM,Cantor sees strong year ahead for oncology M&A,Seeking Alpha,https://seekingalpha.com/news/4077812-patent-cliffs-could-fuel-increased-ma-in-oncology-this-year-cantor-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9445049166679382
3/11/2024 5:15:19 PM,"Societe Generale cuts Bristol Myers to hold, cites patent expiries",Seeking Alpha,https://seekingalpha.com/news/4078102-societe-generale-cuts-bristol-myers-to-hold-cites-patent-expiries?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5927624106407166
3/12/2024 12:37:30 PM,Truist Financial Keeps Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-keeps-their-buy-rating-on-bristol-myers-squibb-bmy-1033155954,neutral,0.8915891051292419
3/12/2024 5:26:43 PM,CytomX falls as Bristol Myers ends deal for cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4078539-cytomx-stock-falls-bristol-myers-cancer-therapy-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9253641366958618
3/13/2024 1:44:45 PM,"J&J, Bristol Myers slip as FDA comments on CAR-T drugs ahead of AdCom",Seeking Alpha,https://seekingalpha.com/news/4078882-jj-bristol-myers-slip-fda-comments-car-t-drugs-adcom?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9218680262565613
3/14/2024 11:16:08 AM,Hold Rating on Bristol-Myers Squibb Amid Concerns Over Abecma’s Efficacy and Safety,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-concerns-over-abecma-s-efficacy-and-safety-1033164389,negative,0.945932924747467
3/14/2024 6:10:57 PM,Karuna Therapeutics gains as HSR waiting period for Bristol-Myers deal expires (update),Seeking Alpha,https://seekingalpha.com/news/4079400-karuna-therapeutics-gains-as-hsr-waiting-period-for-bristol-myers-deal-expires?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6138559579849243
3/14/2024 6:54:38 PM,Biotech bankruptcies hit a record despite sector’s recovery,Seeking Alpha,https://seekingalpha.com/news/4079630-biotech-bankruptcies-hit-record-despite-sectors-recovery?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.761096179485321
3/15/2024 10:17:01 AM,FDA approves expanded use of Bristol Myers CAR T-cell therapy,Seeking Alpha,https://seekingalpha.com/news/4079828-fda-approves-expanded-use-of-bristol-myers-car-t-cell-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6091277599334717
3/15/2024 2:06:29 PM,Geron surges after FDA AdCom backing for lead drug,Seeking Alpha,https://seekingalpha.com/news/4079976-geron-stock-surges-fda-adcom-backs-imetelstat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8468474745750427
3/15/2024 5:25:53 PM,Johnson & Johnson wins FDA AdCom backing for Carvykti label expansion,Seeking Alpha,https://seekingalpha.com/news/4080088-jj-wins-fda-adcom-carvykti-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8676285147666931
3/16/2024 11:58:13 AM,Bristol Myers wins FDA AdCom backing for Abecma label expansion,Seeking Alpha,https://seekingalpha.com/news/4080229-bristol-myers-wins-fda-adcom-backing-abecma-labeling?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8285631537437439
3/18/2024 9:15:27 AM,Hold Rating on Bristol-Myers Squibb Amid Mixed Clinical Outcomes and Market Competition,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mixed-clinical-outcomes-and-market-competition-1033172153,negative,0.965503454208374
3/18/2024 1:08:03 PM,Perspective Therapeutics partners with Bristol Myers for its metastatic melanoma treatment study,Seeking Alpha,https://seekingalpha.com/news/4080434-perspective-therapeutics-partners-with-bristol-myers-for-its-metastatic-melanoma-treatment-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5977878570556641
3/18/2024 2:01:49 PM,Bristol Myers Squibb Completes Acquisition Of Karuna Therapeutics - Quick Facts ,RTTNews,/news/stocks/bristol-myers-squibb-completes-acquisition-of-karuna-therapeutics-quick-facts-1033172279,neutral,0.8067030310630798
3/19/2024 5:37:25 AM,Hold Rating on Bristol-Myers Squibb Amidst NSCLC Trial Uncertainties and Pending KarXT Results,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amidst-nsclc-trial-uncertainties-and-pending-karxt-results-1033175058,negative,0.4953266680240631
3/19/2024 12:19:47 PM,AstraZeneca-Fusion deal reignites radiopharma space,Seeking Alpha,https://seekingalpha.com/news/4080965-fusion-pharma-stock-jumps-astrazeneca-hunts-radiopharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6613722443580627
3/19/2024 1:08:39 PM,Perspective Therapeutics Inks Clinical Trial Collaboration Agreement With Bristol Myers ,RTTNews,/news/stocks/perspective-therapeutics-inks-clinical-trial-collaboration-agreement-with-bristol-myers-1033176103,positive,0.8416003584861755
3/20/2024 11:28:13 AM,Bristol Myers hits late-stage win for liver cancer therapy,Seeking Alpha,https://seekingalpha.com/news/4081496-bristol-myers-stock-gains-trial-win-liver-cancer-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6628748178482056
3/20/2024 1:00:32 PM,Labcorp expands Alzheimer's testing portfolio with new diagnostic,Seeking Alpha,https://seekingalpha.com/news/4081545-labcorp-expands-alzheimers-test-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8395876288414001
3/20/2024 9:53:04 PM,Bristol Myers gets EU approval for Abecma for multiple myeloma,Seeking Alpha,https://seekingalpha.com/news/4081853-bristol-myers-gets-eu-approval-for-abecma-for-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8894930481910706
3/21/2024 5:21:53 PM,China's Xi Jinping plans to meet with U.S. CEOs in China next week - report,Seeking Alpha,https://seekingalpha.com/news/4082269-chinas-xi-jinping-plans-to-meet-with-us-ceos-in-china-next-week-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9264614582061768
3/26/2024 5:37:15 PM,"BTIG upgrades Nuvation to buy, cites AnHeart acquisition",Seeking Alpha,https://seekingalpha.com/news/4083900-btig-upgrades-nuvation-to-buy-cites-anheart-acquisition?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8620338439941406
3/27/2024 5:57:50 PM,The Healthcare Bargain Blitz: 7 Undervalued Stocks to Inject into Your Portfolio,InvestorPlace,/news/stocks/the-healthcare-bargain-blitz-7-undervalued-stocks-to-inject-into-your-portfolio-1033202581,neutral,0.8907579779624939
3/28/2024 8:39:29 PM,Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease,Seeking Alpha,https://seekingalpha.com/news/4085190-bristol-myers-drug-zeposia-fails-phase-3-study-for-crohns-disease?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5800988674163818
3/29/2024 10:40:00 AM,The 3 Best Biotech Stocks to Buy in Q2 2024,InvestorPlace,/news/stocks/the-3-best-biotech-stocks-to-buy-in-q2-2024-1033208071,neutral,0.7683516144752502
4/1/2024 1:56:39 PM,Zai Lab: Bristol Myers' KRYSTAL-12 Confirmatory Trial With Adagrasib Meets Meets Primary Endpoint ,RTTNews,/news/stocks/zai-lab-bristol-myers-krystal-12-confirmatory-trial-with-adagrasib-meets-meets-primary-endpoint-1033210730,positive,0.6552766561508179
4/1/2024 2:57:29 PM,Zai Lab reports Krazati lung cancer study meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4085685-zai-lab-reports-krazati-lung-cancer-study-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7992708086967468
4/1/2024 6:16:16 PM,The Bargain Hunter’s Dream: 3 Underpriced Stocks Poised for Massive Gains,InvestorPlace,/news/stocks/the-bargain-hunters-dream-3-underpriced-stocks-poised-for-massive-gains-1033212301,neutral,0.744431734085083
4/2/2024 4:13:19 PM,Merger Mania: 3 Potential Takeover Targets to Watch for Lucrative Buyouts,InvestorPlace,/news/stocks/merger-mania-3-potential-takeover-targets-to-watch-for-lucrative-buyouts-1033216143,neutral,0.921463668346405
4/3/2024 9:16:52 AM,Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1033218697,neutral,0.8568522334098816
4/3/2024 5:07:34 PM,Bristol Myers wins label expansion for anemia therapy in EU,Seeking Alpha,https://seekingalpha.com/news/4086933-bristol-myers-wins-eu-label-expansion-anemia-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9028072953224182
4/4/2024 3:12:55 PM,Top buy-rated stocks and sell-rated stocks within Health Care - Citi,Seeking Alpha,https://seekingalpha.com/news/4087312-top-buy-rated-stocks-and-sell-rated-stocks-within-health-care-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9045203924179077
4/4/2024 10:43:54 PM,"Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More",Benzinga,/news/stocks/biotech-stock-roundup-iron-verv-down-on-study-updates-bmys-drug-news-more-1033223986,neutral,0.9049677848815918
4/5/2024 1:33:47 PM,"Bristol Myers, 2seventy bio's Abecma approved for earlier line multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/4087581-bristol-myers-2seventy-bio-receive-fda-approval-for-abecma-to-treat-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7116872072219849
4/5/2024 2:16:16 PM,"Biggest stock mover today: GCTS, TSVT, GRIN, ANGO, ATUS, and more",Seeking Alpha,https://seekingalpha.com/news/4087498-biggest-stock-mover-today-grindrod-shipping-holdings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8726267218589783
4/5/2024 4:04:14 PM,"Bristol Myers, 2seventy Bio Get FDA Nod For Abecma For Relapsed Multiple Myeloma Patients ",RTTNews,/news/stocks/bristol-myers-2seventy-bio-get-fda-nod-for-abecma-for-relapsed-multiple-myeloma-patients-1033226250,positive,0.773354709148407
4/5/2024 5:54:07 PM,The 3 Most Undervalued Biotech Stocks to Buy in April 2024,InvestorPlace,/news/stocks/the-3-most-undervalued-biotech-stocks-to-buy-in-april-2024-1033226729,neutral,0.7530435919761658
4/6/2024 12:38:09 PM,Johnson & Johnson wins FDA nod for Carvykti label expansion,Seeking Alpha,https://seekingalpha.com/news/4087716-jj-wins-fda-nod-carvykti-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8747882843017578
4/6/2024 7:21:29 PM,Bristol-Myers highlights safety of KarXT schizophrenia therapy,Seeking Alpha,https://seekingalpha.com/news/4087724-bristol-myers-schizophrenia-therapy-safe-late-stage-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6911635398864746
4/7/2024 12:00:00 PM,"Phathom Pharma, Rhythm, Vaxcyte most likely takeover targets in pharma - analyst",Seeking Alpha,https://seekingalpha.com/news/4087726-phathom-pharma-rhythm-vaxcyte-most-likely-takeover-targets-in-pharma-analyst?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9427610039710999
4/7/2024 5:31:00 PM,Morgan Stanley sees Fed rate cut fueling biotech stocks,Seeking Alpha,https://seekingalpha.com/news/4087727-fed-rate-cut-should-fuel-biotech-outperformance-morgan-stanley-says?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5271162986755371
4/8/2024 9:47:43 AM,Bristol-Myers Squibb’s Hold Rating: Balancing KarXT’s Efficacy and Safety with Financial Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-s-hold-rating-balancing-karxt-s-efficacy-and-safety-with-financial-uncertainties-1033229670,positive,0.6751924157142639
4/8/2024 3:38:08 PM,Bristol Myers reports positive Phase 3 data for schizophrenia drug,Seeking Alpha,https://seekingalpha.com/news/4087959-bristol-myers-reports-positive-phase-3-data-for-schizophrenia-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9480310082435608
4/8/2024 4:00:46 PM,Bristol Myers releases encouraging data for Krazati in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4087973-bristol-myers-releases-encouraging-data-for-krazati-in-colorectal-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9440761804580688
4/9/2024 8:19:09 PM,Bristol Myers Squibb snaps a six day losing spell,Seeking Alpha,https://seekingalpha.com/news/4088370-bristol-myers-squibb-snaps-a-six-day-losing-spell?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7430396676063538
4/10/2024 6:18:46 AM,Hold Rating on Bristol-Myers Squibb Amid Promising Yet Incomplete KarXT Schizophrenia Trial Data,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-promising-yet-incomplete-karxt-schizophrenia-trial-data-1033236280,negative,0.6859230399131775
4/11/2024 1:47:56 PM,The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today,InvestorPlace,/news/stocks/the-5-billion-reason-alpine-immune-sciences-alpn-stock-is-up-30-today-1033241236,positive,0.9471536874771118
4/11/2024 5:49:13 PM,"If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names",InvestorPlace,/news/stocks/if-you-can-only-buy-one-biotech-stock-in-april-it-better-be-one-of-these-3-names-1033242242,neutral,0.942658543586731
4/12/2024 9:25:45 AM,Bristol-Myers Squibb: A Buy Rating on Undervaluation and Promising Product Portfolio,TipRanks,/news/stocks/bristol-myers-squibb-a-buy-rating-on-undervaluation-and-promising-product-portfolio-1033244086,positive,0.9129468202590942
4/12/2024 10:00:36 AM,Analysts Have Conflicting Sentiments on These Healthcare Companies: Bristol-Myers Squibb (BMY) and Roche Holding AG (OtherRHHVF),TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-bristol-myers-squibb-bmy-and-roche-holding-ag-otherrhhvf-1033244262,negative,0.9415408372879028
4/12/2024 11:00:00 AM,Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024,InvestorPlace,/news/stocks/wall-street-favorites-3-warren-buffett-stocks-with-strong-buy-ratings-for-april-2024-1033243869,positive,0.5594310164451599
4/12/2024 8:18:42 PM,"Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom",Benzinga,/news/stocks/small-cap-cancer-drug-developer-agenus-highlights-encouraging-data-from-colorectal-cancer-but-funding-concerns-loom-1033245379,negative,0.8585379123687744
4/15/2024 9:51:31 PM,3 Pharma Stocks That Are Money-Printing Machines in 2024,InvestorPlace,/news/stocks/3-pharma-stocks-that-are-money-printing-machines-in-2024-1033250995,neutral,0.9306191205978394
4/16/2024 4:22:50 PM,"As more rare disease therapies launch, their prices are rising",Seeking Alpha,https://seekingalpha.com/news/4089415-more-rare-disease-therapies-launch-their-prices-rising?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7529379725456238
4/17/2024 7:20:39 PM,3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500,InvestorPlace,/news/stocks/3-undervalued-dividend-stocks-to-buy-now-to-beat-the-sp-500-1033259364,positive,0.9383369088172913
4/18/2024 10:10:26 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Accolade (ACCD), Ultragenyx Pharmaceutical (RARE) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-accolade-accd-ultragenyx-pharmaceutical-rare-and-bristol-myers-squibb-bmy-1033262170,negative,0.6607417464256287
4/18/2024 11:00:23 AM,AbbVie buyout Cerevel posts late-stage win for Parkinson’s disease drug,Seeking Alpha,https://seekingalpha.com/news/4090847-abbvie-buyout-cerevel-marks-trial-win-parkinsons-disease-drug?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9050069451332092
4/19/2024 10:13:03 AM,FDA requires labeling changes to CAR-T cell therapies to reflect cancer risk,Seeking Alpha,https://seekingalpha.com/news/4091378-fda-requires-changes-car-t-cell-therapy-boxed-warning?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9190294742584229
4/19/2024 6:30:20 PM,These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?,InvestorPlace,/news/stocks/these-3-small-cap-stocks-are-up-304-in-2024-can-they-run-higher-1033267239,positive,0.6921050548553467
4/21/2024 12:00:00 PM,"Earnings week ahead: Tesla, Meta Platforms, Google, Microsoft, Intel, Exxon Mobil, and more",Seeking Alpha,https://seekingalpha.com/news/4091495-earnings-week-ahead-tesla-meta-platforms-google-microsoft-intel-exxon-mobil-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9310646057128906
4/21/2024 6:42:04 PM,Goldman picks top capex and R&D stocks,Seeking Alpha,https://seekingalpha.com/news/4091724-goldman-picks-top-capex-and-rd-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9173787832260132
4/22/2024 12:00:00 PM,5 Crash-Proof Stocks to Buy Immediately,InvestorPlace,/news/stocks/5-crash-proof-stocks-to-buy-immediately-1033270786,neutral,0.8640131950378418
4/22/2024 1:51:41 PM,"Bristol-Myers, Cellares ink $380M CAR-T therapies supply deal",Seeking Alpha,https://seekingalpha.com/news/4091926-bristol-myers-cellares-ink-380m-car-t-therapies-supply-deal?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7903437614440918
4/23/2024 4:33:52 PM,S&P 500 stocks with biggest estimated EPS declines for Q1,Seeking Alpha,https://seekingalpha.com/news/4092482-sp-500-stocks-with-biggest-estimated-eps-decrease-this-season?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9589558243751526
4/24/2024 3:01:13 PM,Bristol-Myers Squibb earnings preview: what to expect,Markets Insider Automation,/news/stocks/bristol-myers_squibb-stock-price-q1-earnings-preview-1033281945,neutral,0.9071003198623657
4/25/2024 9:35:46 AM,Bristol-Myers Squibb: A Hold Rating Amid Mixed Financial Outlook and Upcoming Strategic Updates,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amid-mixed-financial-outlook-and-upcoming-strategic-updates-1033287828,negative,0.9663342237472534
4/25/2024 11:01:03 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of -$4.40 beats by $0.02, revenue of $11.78B beats by $330M",Seeking Alpha,https://seekingalpha.com/news/4093952-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-4_40-beats-0_02-revenue-of-11_78b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.4840677082538605
4/25/2024 11:44:29 AM,"Bristol-Myers in charts: Revenue from Eliquis rises, while Opdivo drops in Q1",Seeking Alpha,https://seekingalpha.com/news/4093975-bristol-myers-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9714019894599915
4/25/2024 11:56:55 AM,Bristol-Myers posts Q1 beat despite growth headwinds,Seeking Alpha,https://seekingalpha.com/news/4094029-bristol-myers-stock-falls-despite-q1-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.934116780757904
4/25/2024 1:18:56 PM,Bristol-Myers Squibb Co. Q1 Earnings Summary,RTTNews,/news/stocks/bristol-myers-squibb-co-q1-earnings-summary-1033287334,neutral,0.7025710344314575
4/25/2024 1:41:36 PM,Bristol Myers Squibb Posts Loss In Q1; Updates 2024 Non-GAAP EPS Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-posts-loss-in-q1-updates-2024-non-gaap-eps-guidance-1033287464,negative,0.9421530961990356
4/25/2024 2:02:44 PM,"Biggest stock movers today: LUV, META, IBM, F, and more",Seeking Alpha,https://seekingalpha.com/news/4093836-biggest-stock-movers-today-meta-ibm-f-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9200066924095154
4/25/2024 2:08:18 PM,"Bristol-Myers to cut 2,200 jobs as part of $1.5B cost savings plan",Seeking Alpha,https://seekingalpha.com/news/4094160-bristol-myers-stock-drops-amid-plans-cut-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.943364679813385
4/25/2024 3:50:29 PM,Bristol-Myers Squibb Layoffs 2024: What to Know About the Latest BMY Job Cuts,InvestorPlace,/news/stocks/bristol-myers-squibb-layoffs-2024-what-to-know-about-the-latest-bmy-job-cuts-1033289272,negative,0.8673571348190308
4/25/2024 3:55:40 PM,"BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q1 2024",InvestorPlace,/news/stocks/bmy-stock-earnings-bristol-myers-squibb-for-q1-of-2024-1033289509,positive,0.8527534604072571
4/25/2024 4:05:19 PM,PLTR Stock: Palantir Beefs Up Healthcare AI Work Through Parexel Deal,InvestorPlace,/news/stocks/pltr-stock-palantir-beefs-up-healthcare-ai-work-through-parexel-deal-1033289489,positive,0.6252148151397705
4/26/2024 4:16:21 AM,"Bristol-Myers Q1 Loss Narrower Than Expected, Sales Beat",Benzinga,/news/stocks/bristol-myers-q1-loss-narrower-than-expected-sales-beat-1033290926,negative,0.9027861952781677
4/26/2024 8:47:50 AM,Barclays Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-hold-rating-for-bristol-myers-squibb-bmy-1033293617,neutral,0.8906672596931458
4/26/2024 9:19:06 AM,Bristol-Myers Squibb: Hold Rating Amid Mixed Performance and Future Revenue Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-amid-mixed-performance-and-future-revenue-concerns-1033293814,negative,0.9690801501274109
4/26/2024 9:25:46 AM,"Analysts Offer Insights on Healthcare Companies: Universal Health (UHS), Laboratory (LH) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-universal-health-uhs-laboratory-lh-and-bristol-myers-squibb-bmy-1033293790,neutral,0.9093376398086548
4/26/2024 11:40:35 AM,Analysts Conflicted on These Healthcare Names: Viking Therapeutics (VKTX) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-viking-therapeutics-vktx-and-bristol-myers-squibb-bmy-1033294775,negative,0.6259808540344238
4/26/2024 3:38:32 PM,Bristol Myers: CHMP Recommends Approval Of Opdivo In Combination With Cisplatin And Gemcitabine ,RTTNews,/news/stocks/bristol-myers-chmp-recommends-approval-of-opdivo-in-combination-with-cisplatin-and-gemcitabine-1033294190,positive,0.6704318523406982
4/26/2024 4:56:53 PM,19 out 20 S&P 500 healthcare companies beat profit estimates - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4095057-19-out-20-sp-500-healthcare-companies-beat-profit-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6158697009086609
4/26/2024 6:32:03 PM,"Bristol, Sanofi, Takeda gain positive CHMP recommendations",Seeking Alpha,https://seekingalpha.com/news/4095088-bristol-sanofi-takeda-gain-positive-chmp-recommendations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9253723621368408
4/26/2024 7:00:25 PM,Peeling Back The Layers: Exploring Bristol-Myers Squibb Through Analyst Insights,Benzinga,/news/stocks/peeling-back-the-layers-exploring-bristol-myers-squibb-through-analyst-insights-1033295400,neutral,0.9009020328521729
4/27/2024 7:39:17 PM,Amgen’s Blincyto data send Cullinan higher,Seeking Alpha,https://seekingalpha.com/news/4095218-cullinan-stock-rises-amgens-blincyto-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9120351076126099
4/29/2024 10:56:23 AM,"Bristol Myers, Repertoire to develop tolerizing vaccines in multi-year pact",Seeking Alpha,https://seekingalpha.com/news/4095339-bristol-myers-repertoire-to-develop-tolerizing-vaccines-in-multi-year-pact?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6080503463745117
4/29/2024 11:18:18 AM,"Analysts Are Bullish on These Healthcare Stocks: Atricure (ATRC), Alkermes (ALKS)",TipRanks,/news/stocks/analysts-are-bullish-on-these-healthcare-stocks-atricure-atrc-alkermes-alks-1033301050,neutral,0.8474738597869873
4/29/2024 12:26:06 PM,Repertoire Immune Medicines In Strategic Partnership With Bristol Myers Squibb ,RTTNews,/news/stocks/repertoire-immune-medicines-in-strategic-partnership-with-bristol-myers-squibb-1033299445,neutral,0.7374743223190308
4/30/2024 7:20:50 AM,"Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Bristol-Myers Squibb (BMY) and Laboratory (LH)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-edwards-lifesciences-ew-bristol-myers-squibb-bmy-and-laboratory-lh-1033305216,neutral,0.9157887697219849
4/30/2024 1:49:06 PM,"J&J, Bristol Myers latest to lose bids to halt Medicare price negotiations",Seeking Alpha,https://seekingalpha.com/news/4096283-jj-bristol-myers-lose-bid-halt-medicare-price-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9564803242683411
4/30/2024 5:10:58 PM,"Stifel, Morgan Stanley bullish on newly public Contineum",Seeking Alpha,https://seekingalpha.com/news/4096594-stifel-morgan-stanley-bullish-on-newly-public-contineum?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.774071991443634
4/30/2024 7:47:54 PM,Biotech Stocks Facing FDA Decision In May 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-may-2024-1033308434,neutral,0.9209955334663391
5/1/2024 10:37:36 AM,Hold Rating on Bristol-Myers Squibb Amid Earnings Uncertainty and Strategic Investments,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-earnings-uncertainty-and-strategic-investments-1033313614,negative,0.8670031428337097
5/1/2024 12:37:31 PM,Pfizer raises guidance amid cost savings,Seeking Alpha,https://seekingalpha.com/news/4097227-pfizer-stock-gains-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.899852454662323
5/1/2024 4:12:21 PM,"Editas, Bristol Myers extend T cell therapy collaboration",Seeking Alpha,https://seekingalpha.com/news/4097559-editas-bristol-myers-extend-t-cell-therapy-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8037158846855164
5/2/2024 7:04:30 PM,Schrodinger gets rights to cancer drug candidate back from Bristol,Seeking Alpha,https://seekingalpha.com/news/4099038-schrodinger-gets-rights-cancer-drug-candidate-back-bristol?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8209497928619385
5/4/2024 7:30:00 PM,Pharma R&D productivity seen improving for the first time in years - Deloitte,Seeking Alpha,https://seekingalpha.com/news/4099974-pharma-research-development-productivity-improving-first-time-years?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9528807997703552
5/6/2024 10:00:00 AM,Uncover the Potential: 3 Discounted Stocks Ready for a Comeback,InvestorPlace,/news/stocks/uncover-the-potential-3-discounted-stocks-ready-for-a-comeback-1033332169,neutral,0.8702154159545898
5/6/2024 2:09:54 PM,Bristol Myers Says Type II Variation Application For Opdivo + Yervoy Granted EMA Validation ,RTTNews,/news/stocks/bristol-myers-says-type-ii-variation-application-for-opdivo-yervoy-granted-ema-validation-1033332657,neutral,0.7769479155540466
5/6/2024 4:11:46 PM,FDA accepts Bristol Myers application for injected Opdivo,Seeking Alpha,https://seekingalpha.com/news/4100501-fda-accepts-bristol-myers-application-for-injected-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5047880411148071
5/6/2024 6:22:51 PM,Maximize Your Dividends: 7 Stocks Trading Under $50 with 5%+ Yields,InvestorPlace,/news/stocks/maximize-your-dividends-7-stocks-trading-under-50-with-5-yields-1033334935,neutral,0.8463090062141418
5/7/2024 9:22:54 AM,"Analysts Offer Insights on Healthcare Companies: Lyra Therapeutics (LYRA), Bristol-Myers Squibb (BMY) and Axsome Therapeutics (AXSM)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-lyra-therapeutics-lyra-bristol-myers-squibb-bmy-and-axsome-therapeutics-axsm-1033338974,neutral,0.9137399792671204
5/9/2024 4:41:08 PM,A Look at Pharma ETFs Post Q1 Earnings,Benzinga,/news/etf/a-look-at-pharma-etfs-post-q1-earnings-1033357001,neutral,0.9325221180915833
5/10/2024 6:13:46 PM,AI-discovered drugs have an 80%–90% success rate: study,Seeking Alpha,https://seekingalpha.com/news/4104786-ai-discovered-drugs-have-an-8090-success-rate-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5321407318115234
5/10/2024 9:13:16 PM,Bristol Myers' Opdivo fails in Phase 3 lung cancer study,Seeking Alpha,https://seekingalpha.com/news/4104879-bristol-myers-opdivo-fails-in-phase-3-lung-cancer-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8093110918998718
5/13/2024 11:58:54 AM,Merck discontinues testing of experimental skin cancer combo therapy,Seeking Alpha,https://seekingalpha.com/news/4105055-merck-discontinues-testing-of-experimental-skin-cancer-combo-therapy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9100384712219238
5/13/2024 10:47:36 PM,Wells Fargo Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033373030,neutral,0.809019923210144
5/14/2024 10:46:00 AM,Dividend Capture Captains: The 3 Best Blue-Chip Stocks for Tactical Traders,InvestorPlace,/news/stocks/dividend-capture-captains-the-3-best-blue-chip-stocks-for-tactical-traders-1033375424,neutral,0.8380470275878906
5/15/2024 9:36:48 PM,Bristol Myers' Breyanzi gains additional indication for follicular lymphoma,Seeking Alpha,https://seekingalpha.com/news/4107041-bristol-myers-squibb-breyanzi-gains-additional-indication-follicular-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9256910681724548
5/15/2024 9:47:35 PM,Tudor Investment's top buys and sells in Q1,Seeking Alpha,https://seekingalpha.com/news/4107057-tudor-investments-top-buys-and-sells-in-q1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8940815925598145
5/16/2024 11:15:00 AM,7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs,InvestorPlace,/news/stocks/7-pharma-stocks-harnessing-ai-brainpower-for-big-breakthroughs-1033392344,positive,0.5881009101867676
5/16/2024 3:35:19 PM,Hold Rating on Bristol-Myers Squibb Amid Mounting Competition and Flat Growth Projections,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mounting-competition-and-flat-growth-projections-1033394845,negative,0.9241331815719604
5/17/2024 7:47:17 PM,AbbVie Is 'Successfully Positioned To Absorb Humira Biosimilar Erosion':  Analyst,Benzinga,/news/stocks/abbvie-is-successfully-positioned-to-absorb-humira-biosimilar-erosion-analyst-1033400477,positive,0.9092691540718079
5/18/2024 6:52:07 PM,"Novo Nordisk, J&J lead R&D rankings in big pharma: report",Seeking Alpha,https://seekingalpha.com/news/4108110-novo-nordisk-j-j-lead-rd-big-pharma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8400078415870667
5/19/2024 7:05:03 PM,SA Roundtable: Are Eli Lilly and Novo Nordisk overvalued?,Seeking Alpha,https://seekingalpha.com/news/4108152-sa-roundtable-are-eli-lilly-and-novo-nordisk-overvalued?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8515270948410034
5/21/2024 11:29:59 AM,Bristol-Myers says FDA has revised decision date on injected Opdivo,Seeking Alpha,https://seekingalpha.com/news/4108688-bristol-myers-injected-opdivo-new-fda-decision-date?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5019626021385193
5/21/2024 11:45:00 AM,3 Bargain Stocks to Buy Now: May 2024,InvestorPlace,/news/stocks/3-bargain-stocks-to-buy-now-may-2024-1033406804,neutral,0.9335039258003235
5/22/2024 9:45:41 AM,Bristol-Myers Squibb (BMY) Gets a Hold from Wells Fargo,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-wells-fargo-1033411491,positive,0.49491503834724426
5/22/2024 7:38:02 PM,"Bristol-Myers, Sanofi liability in Hawaii Plavix litigation tops $900M",Seeking Alpha,https://seekingalpha.com/news/4109535-bristol-myers-sanofi-ordered-pay-916m-in-hawaii-plavix-case?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7716389894485474
5/22/2024 8:22:24 PM,"Bristol-Myers Squibb snaps six days of losses, trades in the green",Seeking Alpha,https://seekingalpha.com/news/4109575-bristol-myers-squibb-snaps-six-days-of-losses-trades-in-the-green?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8081246018409729
5/23/2024 6:49:06 PM,Bristol Myers Updates Action Date for Subcutaneous Opdivo,Benzinga,/news/stocks/bristol-myers-updates-action-date-for-subcutaneous-opdivo-1033416965,neutral,0.8463682532310486
5/24/2024 7:00:53 PM,"Catalyst Watch: Costco earnings, M&A drama, Viking ratings, and a key inflation read",Seeking Alpha,https://seekingalpha.com/news/4110251-catalyst-watch-costco-earnings-ma-drama-viking-ratings-and-a-key-inflation-read?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9077320694923401
5/25/2024 2:24:03 PM,"Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo",Seeking Alpha,https://seekingalpha.com/news/4110471-viking-crispr-cytokinetics-m-a-targets-wells-fargo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9204940795898438
5/27/2024 10:13:00 AM,3 Blue-Chip Stocks to Buy at 52-Week Lows in May,InvestorPlace,/news/stocks/3-blue-chip-stocks-to-buy-at-52-week-lows-in-may-1033423869,negative,0.8905453085899353
5/28/2024 8:23:34 PM,Bristol Myers licenses second compound from Prothena,Seeking Alpha,https://seekingalpha.com/news/4110917-bristol-myers-licenses-second-compound-from-prothena?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7815749645233154
5/29/2024 11:56:10 AM,Truist Financial Sticks to Their Buy Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-sticks-to-their-buy-rating-for-bristol-myers-squibb-bmy-1033432461,neutral,0.8393563628196716
5/29/2024 2:04:43 PM,Bristol-Myers gets EU approval for Opdivo for bladder cancer,Seeking Alpha,https://seekingalpha.com/news/4111155-bristol-myers-gets-eu-approval-for-opdivo-for-bladder-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9154051542282104
5/30/2024 10:10:00 AM,7 Underappreciated Stocks With 25% Return Potential in 2024,InvestorPlace,/news/stocks/7-underappreciated-stocks-with-25-return-potential-in-2024-1033435401,negative,0.8916043043136597
5/30/2024 4:22:21 PM,Bristol Myers' Breyanzi gains additional indication for mantle cell lymphoma,Seeking Alpha,https://seekingalpha.com/news/4111641-bristol-myers-squibb-breyanzi-gains-additional-indication-mantle-cell-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8878173828125
5/31/2024 4:19:46 PM,Novartis boasts Scemblix beats tyrosine kinase inhibitors for chronic myeloid leukemia,Seeking Alpha,https://seekingalpha.com/news/4111998-novartis-boasts-scemblix-beats-tyrosine-kinase-inhibitors-chronic-myeloid-leukemia?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7673798203468323
5/31/2024 8:31:58 PM,Immunocore touts updated phase 1 results for melanoma asset brenetafusp,Seeking Alpha,https://seekingalpha.com/news/4112056-immunocore-touts-updated-phase-1-results-melanoma-asset-brenetafusp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9202131628990173
6/1/2024 12:53:44 PM,Bristol Myers lung cancer drug Krazati succeeds in late-stage trial,Seeking Alpha,https://seekingalpha.com/news/4112126-bristol-myers-wins-late-stage-trial-krazati?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5941676497459412
6/2/2024 6:00:00 PM,Emerging and Chinese pharmas playing greater role in oncology drug development,Seeking Alpha,https://seekingalpha.com/news/4112099-emerging-chinese-pharmas-playing-greater-role-oncology-drug-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.578883171081543
6/3/2024 3:10:17 PM,Bristol's Breyanzi demonstrates efficacy across a range of B-cell malignancies,Seeking Alpha,https://seekingalpha.com/news/4112361-bristols-breyanzi-demonstrates-efficacy-across-range-b-cell-malignancies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9185623526573181
6/3/2024 4:03:10 PM,"GSK says Blenrep combo cuts disease progression, death in multiple myeloma",Seeking Alpha,https://seekingalpha.com/news/4112369-gsk-says-belnrep-combo-cuts-disease-progression-death-multiple-myeloma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.41479137539863586
6/3/2024 6:25:56 PM,Bristol Myers' 3 Breyanzi Trials Show Consistent Benefit Across B-Cell Malignancies ,RTTNews,/news/stocks/bristol-myers-3-breyanzi-trials-show-consistent-benefit-across-b-cell-malignancies-1033446790,positive,0.9537686705589294
6/4/2024 8:30:15 AM,"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ultragenyx Pharmaceutical (RARE), Xeris Pharmaceuticals (XERS) and Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ultragenyx-pharmaceutical-rare-xeris-pharmaceuticals-xers-and-bristol-myers-squibb-bmy-1033449003,negative,0.9204422831535339
6/4/2024 2:26:59 PM,"Bristol's Opdivo + Yervoy bests Lenvima, Nexavar in first-line liver cancer",Seeking Alpha,https://seekingalpha.com/news/4112739-bristol-opdivo-yervoy-bests-lenvima-nexavar-first-line-liver-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6381374001502991
6/5/2024 1:15:55 PM,Bristol Myers Squibb inks clinical trial pact with I-Mab,Seeking Alpha,https://seekingalpha.com/news/4113128-i-mab-stock-gains-study-pact-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8819604516029358
6/5/2024 1:42:49 PM,I-Mab Inks Partnership With Bristol Myers Squibb To Evaluate Givastomig In Combination Study ,RTTNews,/news/stocks/i-mab-inks-partnership-with-bristol-myers-squibb-to-evaluate-givastomig-in-combination-study-1033453070,positive,0.7270317077636719
6/6/2024 11:40:22 AM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and Ionis Pharmaceuticals (IONS),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-ionis-pharmaceuticals-ions-1033458252,neutral,0.9111501574516296
6/6/2024 2:47:18 PM,"Goldman cuts 2seventy bio to neutral, cites competition concerns",Seeking Alpha,https://seekingalpha.com/news/4113699-goldman-cuts-2seventy-bio-to-neutral-cites-competition-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6006229519844055
6/6/2024 4:05:40 PM,Replimune up 30% on results for RP1 combo in melanoma,Seeking Alpha,https://seekingalpha.com/news/4113744-replimune-up-30-results-rp1-combo-melanoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9508306980133057
6/6/2024 9:36:29 PM,Halozyme's ENHANZE Product Gets New Patent Grant in EU,Benzinga,/news/stocks/halozyme-s-enhanze-product-gets-new-patent-grant-in-eu-1033459113,positive,0.7392568588256836
6/7/2024 10:39:00 AM,Geron jumps as FDA approves lead asset for blood cancer,Seeking Alpha,https://seekingalpha.com/news/4113925-geron-stock-gains-rytelo-approval?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5721281170845032
6/7/2024 7:00:58 PM,"Catalyst Watch: Apple's WWDC, Tesla's annual meeting, Fed's dot plot, and GameStop volatility",Seeking Alpha,https://seekingalpha.com/news/4114173-catalyst-watch-apples-wwdc-teslas-shareholder-meeting-fomc-meeting-and-gamestop-volatility?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8829658031463623
6/8/2024 1:00:00 PM,The 7 Most Undervalued Under-$50 Stocks to Buy in June 2024,InvestorPlace,/news/stocks/the-7-most-undervalued-under-50-stocks-to-buy-in-june-2024-1033462733,neutral,0.7153183817863464
6/8/2024 2:19:36 PM,"AstraZeneca dominates, Merck’s Keytruda beaten as ASCO 2024 concludes",Seeking Alpha,https://seekingalpha.com/news/4114301-astrazeneca-dominates-merck-beaten-asco-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7508279085159302
6/8/2024 2:19:47 PM,Bristol Myers Squibb wins antitrust case against insurers regarding generics,Seeking Alpha,https://seekingalpha.com/news/4114300-bristol-myers-squibb-wins-antitrust-case-against-insurers-regarding-generics?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7623018622398376
6/10/2024 4:00:00 PM,7 Stocks Warren Buffett Has Sold in the Past Year (and You Should Too),InvestorPlace,/news/stocks/7-stocks-warren-buffett-has-sold-in-the-past-year-and-you-should-too-1033466529,neutral,0.9107916355133057
6/11/2024 2:00:00 PM,3 Penny Stocks to Buy if You Want to Spend Less and Earn More,InvestorPlace,/news/stocks/3-penny-stocks-to-buy-if-you-want-to-spend-less-and-earn-more-1033469513,neutral,0.8977555632591248
6/12/2024 12:11:43 PM,"Analysts Conflicted on These Healthcare Names: SAGE Therapeutics (SAGE), Bristol-Myers Squibb (BMY) and Cellectis SA (CLLS)",TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-sage-therapeutics-sage-bristol-myers-squibb-bmy-and-cellectis-sa-clls-1033473470,negative,0.7146685123443604
6/13/2024 9:28:51 PM,Bristol Myers gets FDA approval for Autyro for NTRK-positive cancers,Seeking Alpha,https://seekingalpha.com/news/4115993-bristol-myers-gets-fda-approval-for-autyro-for-ntrk-positive-cancers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8004509210586548
6/14/2024 7:55:36 PM,EU to require additional cancer risk labeling on CAR T therapies,Seeking Alpha,https://seekingalpha.com/news/4116402-eu-to-require-additional-cancer-risk-labeling-on-car-t-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8998953700065613
6/17/2024 7:27:56 PM,7 Breakthrough Biotech Stocks for a Shot of Portfolio Adrenaline,InvestorPlace,/news/stocks/7-breakthrough-biotech-stocks-for-a-shot-of-portfolio-adrenaline-1033485033,neutral,0.792426347732544
6/18/2024 11:04:41 AM,Bristol-Myers Squibb Company declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4116876-bristol-myers-squibb-company-declares-0_60-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7695336937904358
6/19/2024 6:17:23 PM,3 Warren Buffett Stocks to Buy Now: June 2024,InvestorPlace,/news/stocks/3-warren-buffett-stocks-to-buy-now-june-2024-1033491003,neutral,0.9308607578277588
6/21/2024 11:25:03 AM,Bristol Myers Opdivo injectable accepted for EU review,Seeking Alpha,https://seekingalpha.com/news/4117867-bristol-myers-opdivo-injectable-accepted-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8902266025543213
6/21/2024 6:06:48 PM,Bristol-Myers wins FDA nod to expand label for cancer therapy Krazati,Seeking Alpha,https://seekingalpha.com/news/4118016-bristol-myers-stock-gains-krazati-label-expansion?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9265652894973755
6/23/2024 5:38:49 PM,7 Dividend Stocks to Buy Now: June 2024 ,InvestorPlace,/news/stocks/7-dividend-stocks-to-buy-now-june-2024-1033498164,neutral,0.9362931251525879
6/27/2024 10:56:19 AM,Novo Nordisk buys 2seventy bio’s Hemophilia A program,Seeking Alpha,https://seekingalpha.com/news/4119932-2seventy-bio-stock-gains-novo-buys-assets?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9226239919662476
6/27/2024 5:14:55 PM,You’ve Been Warned! 3 Pharma Stocks to Buy Now or Regret Forever.,InvestorPlace,/news/stocks/youve-been-warned-3-pharma-stocks-to-buy-now-or-regret-forever-1033512708,neutral,0.8092414140701294
6/29/2024 7:44:55 PM,Rising drug costs force a third of Americans to leave prescriptions unfilled: report,Seeking Alpha,https://seekingalpha.com/news/4120808-many-prescriptions-remain-unfilled-amid-soaring-drug-costs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7290327548980713
6/30/2024 2:13:35 PM,Treasure Hunt: 3 Small-Cap Stocks Wall Street Hasn’t Discovered Yet,InvestorPlace,/news/stocks/treasure-hunt-3-small-cap-stocks-wall-street-hasnt-discovered-yet-1033517243,neutral,0.9144802689552307
7/1/2024 12:30:56 AM,"Alnylam, Lilly, AstraZeneca among best performing pharmas, biotechs in Q2",Seeking Alpha,https://seekingalpha.com/news/4120874-alnylam-lilly-astrzeneca-best-performing-pharmas-biotechs-q2?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.770165741443634
7/1/2024 7:03:10 PM,Eisai receives rights to antibody drug conjugate after Bristol ends collaboration,Seeking Alpha,https://seekingalpha.com/news/4121337-eisai-receives-rights-antibody-drug-conjugate-after-bristol-ends-collaboration?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.832201361656189
7/2/2024 12:23:40 PM,J&J says Carvykti beat standard drugs in late-stage blood cancer trial,Seeking Alpha,https://seekingalpha.com/news/4121567-jj-carvykti-beat-standard-drugs-blood-cancer?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9461308717727661
7/5/2024 10:45:00 AM,3 Hidden Stock Gems That Wall Street Is Overlooking,InvestorPlace,/news/stocks/3-hidden-stock-gems-that-wall-street-is-overlooking-1033531639,neutral,0.8924282789230347
7/8/2024 10:43:00 AM,3 Defensive Stocks to Buy During the Market Dip,InvestorPlace,/news/stocks/3-defensive-stocks-to-buy-during-the-market-dip-1033535387,neutral,0.9135308265686035
7/9/2024 11:40:00 AM,The 7 Best Warren Buffett Stocks to Buy in July 2024,InvestorPlace,/news/stocks/the-best-warren-buffett-stocks-7-names-to-buy-in-july-1033539110,neutral,0.930526614189148
7/10/2024 8:48:55 AM,Barclays Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-remains-a-hold-on-bristol-myers-squibb-bmy-1033542872,neutral,0.9059340953826904
7/10/2024 4:00:00 PM,3 Undervalued Stocks Ready for a Breakout This Summer,InvestorPlace,/news/stocks/3-undervalued-stocks-ready-for-a-breakout-this-summer-1033544286,positive,0.5584270358085632
7/11/2024 12:46:20 PM,Morgan Stanley Sticks to Its Sell Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-sticks-to-its-sell-rating-for-bristol-myers-squibb-bmy-1033548019,neutral,0.8499215245246887
7/11/2024 6:23:24 PM,3 Under-$10 Biotech Stocks That Could Make You Rich,InvestorPlace,/news/stocks/3-under-10-biotech-stocks-that-could-make-you-rich-1033548360,neutral,0.8671849966049194
7/12/2024 5:27:22 PM,Bristol Myers Squibb Suffers a Larger Drop Than the General Market: Key Insights,Benzinga,/news/stocks/bristol-myers-squibb-suffers-a-larger-drop-than-the-general-market-key-insights-1033551112,negative,0.8689418435096741
7/12/2024 6:50:39 PM,Legend Biotech surges amid takeover speculation (update),Seeking Alpha,https://seekingalpha.com/news/4124018-legend-biotech-surges-amid-takeover-speculation?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7466818690299988
7/12/2024 7:00:29 PM,"Catalyst Watch: Netflix, Taiwan Semi, Amazon, and HashiCorp are in the spotlight",Seeking Alpha,https://seekingalpha.com/news/4123992-catalyst-watch-netflix-taiwan-semi-amazon-and-hashicorp-are-in-the-spotlight?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9270133972167969
7/13/2024 6:03:47 PM,"Morgan Stanley sees $180B patent cliff, $380B deal capacity fueling biopharma M&A",Seeking Alpha,https://seekingalpha.com/news/4124109-morgan-stanley-sees-180b-patent-cliff-380b-deal-capacity-fueling-biopharma-ma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8902468085289001
7/15/2024 12:45:43 PM,Hold Rating on Bristol-Myers Squibb Amid Balanced Strengths and Long-Term Revenue Concerns,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-balanced-strengths-and-long-term-revenue-concerns-1033556220,positive,0.9193552136421204
7/16/2024 4:15:22 AM,Bristol-Myers Squibb: Hold Rating Maintained Amid Growth Challenges and Uncertain Long-Term Prospects,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-maintained-amid-growth-challenges-and-uncertain-long-term-prospects-1033557977,negative,0.9366030097007751
7/17/2024 6:09:20 PM,Big pharma rally after J&J earnings,Seeking Alpha,https://seekingalpha.com/news/4125149-big-pharma-rally-after-jj-earnings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.510947585105896
7/19/2024 12:01:22 PM,Bristol Myers’ immunotherapy combo undergoes EU review for liver cancer,Seeking Alpha,https://seekingalpha.com/news/4125791-bristol-myers-immunotherapy-combo-gets-eu-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.533932089805603
7/19/2024 1:53:12 PM,Bristol Myers Squibb Receives EMA Validation For Opdivo Plus Yervoy For Treatment Of HCC ,RTTNews,/news/stocks/bristol-myers-squibb-receives-ema-validation-for-opdivo-plus-yervoy-for-treatment-of-hcc-1033572039,positive,0.8813326358795166
7/19/2024 7:00:00 PM,"Catalyst watch: Earnings deluge, Farnborough Airshow, Paris Olympics, and Trump talks crypto",Seeking Alpha,https://seekingalpha.com/news/4125573-catalyst-watch-earnings-deluge-farnborough-airshow-paris-olympics-and-trump-talks-crypto?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8376868367195129
7/19/2024 7:25:48 PM,7 Value Stocks to Buy at a 52-Week Low in July,InvestorPlace,/news/stocks/7-value-stocks-to-buy-at-a-52-week-low-in-july-1033573491,negative,0.8950303792953491
7/20/2024 11:55:00 AM,3 Defensive Stocks to Shield Your Portfolio in July,InvestorPlace,/news/stocks/3-defensive-stocks-to-shield-your-portfolio-in-july-1033573764,neutral,0.9126730561256409
7/20/2024 7:58:00 PM,Financials dominate in Q2 as Wall Street slides amidst concerns on tech - Earnings Scorecard,Seeking Alpha,https://seekingalpha.com/news/4125975-financials-dominate-in-q2-as-wall-street-slides-amidst-concerns-on-tech-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9675024151802063
7/21/2024 11:00:00 AM,Here are Big Pharma’s leading blockbuster makers,Seeking Alpha,https://seekingalpha.com/news/4126044-eli-lilly-astrazeneca-top-blockbuster-makers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.773925244808197
7/21/2024 12:01:00 PM,"Earnings week ahead: TSLA, GOOG, IBM, AAL, GM, F, VZ, T, and more",Seeking Alpha,https://seekingalpha.com/news/4125930-earnings-week-ahead-tsla-goog-ibm-aal-gm-f-vz-t-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9146556854248047
7/22/2024 1:02:13 AM,Kamala Harris' potential impact on health care stocks,Seeking Alpha,https://seekingalpha.com/news/4126065-kamala-harris-potential-impact-health-care-stocks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.49974894523620605
7/22/2024 8:00:42 PM,A Glimpse Into The Expert Outlook On Bristol-Myers Squibb Through 4 Analysts,Benzinga,/news/stocks/a-glimpse-into-the-expert-outlook-on-bristol-myers-squibb-through-4-analysts-1033579081,neutral,0.8857713341712952
7/23/2024 11:25:49 AM,Hold Rating on Bristol-Myers Squibb Amid Mixed Performance and Evolving Pipeline,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-mixed-performance-and-evolving-pipeline-1033583237,negative,0.9581556916236877
7/23/2024 3:59:38 PM,Microsoft To Rally Around 10%? Here Are 10 Top Analyst Forecasts For Tuesday,Benzinga,/news/stocks/microsoft-to-rally-around-10-here-are-10-top-analyst-forecasts-for-monday-1033583172,neutral,0.9130956530570984
7/24/2024 9:25:04 PM,Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation,Benzinga,/news/stocks/newly-listed-psoriasis-focused-alumis-attracts-analysts-attention-with-promising-lead-program-and-modest-valuation-1033590627,positive,0.9513866305351257
7/25/2024 1:47:02 PM,Notable earnings before Friday's open,Seeking Alpha,https://seekingalpha.com/news/4128372-notable-earnings-before-fridays-open?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8830810189247131
7/25/2024 3:01:13 PM,Bristol-Myers Squibb earnings: here's what Wall Street expects,Markets Insider Automation,/news/stocks/bristol-myers_squibb-quarter-earnings-preview-q2-1033594625,neutral,0.9266072511672974
7/25/2024 3:13:10 PM,Bristol-Myers Squibb Q2 Earnings Preview: Strong results on the back of legacy portfolio,Seeking Alpha,https://seekingalpha.com/news/4128438-bristol-myers-squibb-q2-earnings-preview-strong-results-on-the-back-of-legacy-portfolio?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9513993859291077
7/26/2024 11:00:49 AM,"Bristol-Myers Squibb Company Non-GAAP EPS of $2.07 beats by $0.44, revenue of $12.2B beats by $680M",Seeking Alpha,https://seekingalpha.com/news/4128861-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-2_07-beats-0_44-revenue-of-12_2b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.5395187735557556
7/26/2024 11:16:19 AM,"Earnings summary: Bristol-Myers Squibb Q2 results top estimates, raises adj. EPS outlook",Seeking Alpha,https://seekingalpha.com/news/4128849-earnings-summary-bristol-myers-squibb-q2-results-top-estimates-raises-adj-eps-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8816664814949036
7/26/2024 11:34:37 AM,"Bristol-Myers Squibb in charts: Q2 revenue from Eliquis, Opdivo climb, while Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4128858-bristol-myers-squibb-in-charts-q2-revenue-from-eliquis-opdivo-climb?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.911483645439148
7/26/2024 1:08:02 PM,"Bristol-Myers Squibb Co. Q2 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q2-profit-decreases-but-beats-estimates-1033599642,negative,0.9636164903640747
7/26/2024 1:25:00 PM,"4 stocks to watch on Friday: BMY, MMM and more",Seeking Alpha,https://seekingalpha.com/news/4128974-4-stocks-to-watch-on-friday-bmy-mmm-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8903419971466064
7/26/2024 1:34:53 PM,Bristol Myers Squibb Raises 2024 Non-GAAP Guidance ,RTTNews,/news/stocks/bristol-myers-squibb-raises-2024-non-gaap-guidance-1033599730,neutral,0.8673608899116516
7/26/2024 2:26:22 PM,"Biggest stock movers today:WW, MMM, DXCM, COUR, and more",Seeking Alpha,https://seekingalpha.com/news/4128818-biggest-stock-movers-today-dxcm-cour-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.908547580242157
7/26/2024 2:45:00 PM,Bristol Myers Squibb hosts conference call for investors,Markets Insider Automation,/news/stocks/bristol-myers_squibb_conference-1030194896,neutral,0.9389457702636719
7/26/2024 3:53:36 PM,"BMY Stock Earnings: Bristol-Myers Squibb Beats EPS, Beats Revenue for Q2 2024",InvestorPlace,/news/stocks/bmy-stock-earnings-bristol-myers-squibb-for-q2-of-2024-1033601286,positive,0.8503339290618896
7/26/2024 5:00:03 PM,Bristol-Myers hits three-month high on Q2 beat and trial win (update),Seeking Alpha,https://seekingalpha.com/news/4128916-bristol-myers-stock-gains-q2-beat?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6772702932357788
7/29/2024 10:39:58 AM,Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amidst-short-term-gains-and-long-term-uncertainties-1033606431,positive,0.48719674348831177
7/29/2024 12:25:45 PM,Morgan Stanley Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-reaffirms-their-sell-rating-on-bristol-myers-squibb-bmy-1033607123,neutral,0.8409203886985779
7/29/2024 8:11:14 PM,Bristol-Myers stock snaps six days of gains,Seeking Alpha,https://seekingalpha.com/news/4129728-bristol-myers-stock-snaps-six-days-of-gains?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.674138605594635
7/29/2024 8:19:03 PM,"Barclays cuts Bristol Myers to underweight, cites recent run up",Seeking Alpha,https://seekingalpha.com/news/4129744-barclays-cuts-bristol-myers-to-underweight-cites-recent-run-up?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.8445505499839783
7/30/2024 5:55:32 AM,Bristol-Myers Squibb: A Hold Rating Amidst Short-Term Gains and Long-Term Pricing Concerns,TipRanks,/news/stocks/bristol-myers-squibb-a-hold-rating-amidst-short-term-gains-and-long-term-pricing-concerns-1033610608,negative,0.6477218270301819
7/30/2024 6:36:31 AM,Bristol-Myers Squibb: A Cautious Hold Amidst Uneven Growth Prospects,TipRanks,/news/stocks/bristol-myers-squibb-a-cautious-hold-amidst-uneven-growth-prospects-1033610772,negative,0.8037413954734802
7/30/2024 11:13:18 AM,Pfizer stock gains after raising annual earnings outlook,Seeking Alpha,https://seekingalpha.com/news/4129993-pfizer-stock-gains-after-raising-annual-outlook?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9412181973457336
7/31/2024 11:00:00 AM,Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making?,InvestorPlace,/news/stocks/kazia-therapeutics-stock-is-kzia-a-buyout-candidate-in-the-making-1033617326,neutral,0.9267992377281189
7/31/2024 11:00:00 AM,The Top 3 Healthcare Stocks to Buy Now: Summer 2024,InvestorPlace,/news/stocks/the-top-3-healthcare-stocks-to-buy-now-summer-2024-1033617324,neutral,0.9356123805046082
7/31/2024 3:16:25 PM,Argus Research Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/argus-research-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1033620407,neutral,0.8765232563018799
8/1/2024 2:00:00 PM,Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore,InvestorPlace,/news/stocks/bargain-hunters-paradise-7-value-stocks-that-are-too-cheap-to-ignore-1033627397,neutral,0.9074241518974304
8/1/2024 8:40:33 PM,"The 3 Biggest Earnings Beats for Q2 as of August 1, 2024",InvestorPlace,/news/stocks/the-3-biggest-earnings-beats-for-q2-as-of-august-1-2024-1033629095,neutral,0.9081149101257324
8/2/2024 8:43:25 PM,Bristol ends licensing agreement with Agenus on TIGIT bispecific antibody,Seeking Alpha,https://seekingalpha.com/news/4133613-bristol-ends-licensing-agreement-agenus-tigit-bispecific-antibody?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.47333309054374695
8/7/2024 5:53:29 PM,Bristol Myers cited by FDA for misleading claims on Krazati website,Seeking Alpha,https://seekingalpha.com/news/4136316-bristol-myers-cited-fda-misleading-claims-krazati-website?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6213836073875427
8/8/2024 10:40:00 AM,3 Biotech Stocks With Promising Drug Pipelines: August 2024,InvestorPlace,/news/stocks/3-biotech-stocks-with-promising-drug-pipelines-august-2024-1033659855,positive,0.567245602607727
8/9/2024 3:13:05 PM,74 S&P 500 stocks that can beat the cash yield - BofA,Seeking Alpha,https://seekingalpha.com/news/4138195-74-sp-500-stocks-that-can-beat-the-cash-yield-bofa?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6393485069274902
8/11/2024 5:20:50 PM,"Weekly Review: ANTX Downsizes, ALDX Aces Dry Eye Disease Trial, FDA Oks 1st Epinephrine Nasal Spray ",RTTNews,/news/stocks/weekly-review-antx-downsizes-aldx-aces-dry-eye-disease-trial-fda-oks-1st-epinephrine-nasal-spray-1033672016,neutral,0.5240262746810913
8/12/2024 12:21:11 AM,"Analysts’ Top Healthcare Picks: Generation Bio (GBIO), Bristol-Myers Squibb (BMY)",TipRanks,/news/stocks/analysts-top-healthcare-picks-generation-bio-gbio-bristol-myers-squibb-bmy-1033672147,positive,0.736041784286499
8/12/2024 11:00:00 AM,The 3 Best Healthcare Stocks to Buy in August 2024,InvestorPlace,/news/stocks/the-3-best-healthcare-stocks-to-buy-in-august-2024-1033676547,neutral,0.873874843120575
8/13/2024 7:52:37 AM,Evotec Secures $75 Mln In Milestone Payments From Bristol Myers Amid Pipeline Advancements ,RTTNews,/news/stocks/evotec-secures-75-mln-in-milestone-payments-from-bristol-myers-amid-pipeline-advancements-1033680319,positive,0.9481533765792847
8/14/2024 7:28:06 PM,"Tudor Investment buys/sells in Q2 feature Bristol Myers, PepsiCo, AMD, others",Seeking Alpha,https://seekingalpha.com/news/4139985-tudor-investment-buyssells-in-q2-feature-bristol-myers-pepsico-amd-others?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9041590094566345
8/15/2024 11:27:19 AM,U.S. government targets $6B in savings from first Medicare drug price negotiations,Seeking Alpha,https://seekingalpha.com/news/4140341-us-government-targets-6b-in-saving-from-first-medicare-drug-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9052250981330872
8/15/2024 11:44:07 AM,U.S. announces final drug prices after Medicare negotiations,Seeking Alpha,https://seekingalpha.com/news/4140356-us-posts-final-drug-prices-medicare-talks?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8023656606674194
8/15/2024 2:17:57 PM,"Bristol Myers, Novartis react as Medicare prices for key drugs announced",Seeking Alpha,https://seekingalpha.com/news/4140530-bristol-myers-novartis-slam-medicare-prices-key-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.3734443485736847
8/17/2024 2:09:07 PM,Trending stocks this week as U.S. equities notch their best week of 2024,Seeking Alpha,https://seekingalpha.com/news/4141247-trending-stocks-this-week-as-us-equities-notch-their-best-week-of-2024?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7283938527107239
8/19/2024 4:03:45 PM,EMA Validates Bristol Myers Squibb's Application For CAR T Cell Therapy Breyanzi ,RTTNews,/news/stocks/ema-validates-bristol-myers-squibb-s-application-for-car-t-cell-therapy-breyanzi-1033704477,positive,0.691162109375
8/19/2024 5:33:38 PM,Bristol Myers says EMA to review label expansion for Breyanzi in follicular lymphoma,Seeking Alpha,https://seekingalpha.com/news/4141548-bristol-myers-says-ema-review-label-expansion-breyanzi-follicular-lymphoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.666465163230896
8/20/2024 6:07:51 PM,"FTC says FDA biosimilar guidance would increase competition, lead to lower prices",Seeking Alpha,https://seekingalpha.com/news/4142026-ftc-says-fda-biosimilar-guidance-would-increase-competition-lead-lower-prices?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.5784043669700623
8/21/2024 11:53:20 AM,Bristol Myers bid to expand label for liver cancer drug under FDA review,Seeking Alpha,https://seekingalpha.com/news/4142249-bristol-myers-liver-cancer-drug-labeling-wins-fda-review?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8014954924583435
8/21/2024 12:06:57 PM,Jefferies Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1033711699,neutral,0.8307005167007446
8/21/2024 1:56:50 PM,Bristol Myers : FDA Accepts SBLA For First-Line Treatment Of Unresectable Hepatocellular Carcinoma ,RTTNews,/news/stocks/bristol-myers-fda-accepts-sbla-for-first-line-treatment-of-unresectable-hepatocellular-carcinoma-1033710617,positive,0.9093654751777649
8/22/2024 9:16:49 AM,Barclays Reaffirms Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-reaffirms-their-sell-rating-on-bristol-myers-squibb-bmy-1033714422,neutral,0.8251914978027344
8/23/2024 3:25:50 PM,"Merck, Bristol Myers cancer drugs included in September FDA advisory panel meeting",Seeking Alpha,https://seekingalpha.com/news/4143379-merck-bristol-myers-cancer-drugs-included-september-fda-advisory-panel-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9249929189682007
8/28/2024 12:05:22 PM,Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-patent-expirations-and-speculative-prospects-of-milvexian-1033729593,negative,0.9353027939796448
8/28/2024 12:05:51 PM,Neurocrine stock dips even as schizophrenia drug meets main goal in study,Seeking Alpha,https://seekingalpha.com/news/4144517-neurocrine-stock-dips-even-as-schizophrenia-drug-meets-main-goal-in-study?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9590901136398315
8/29/2024 10:26:46 AM,"New Medicare drug price caps could help seniors save over $1,000 a year - AARP",Seeking Alpha,https://seekingalpha.com/news/4144962-new-medicare-drug-price-caps-could-help-seniors-save-over-1000-a-year-aarp?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8434953689575195
8/29/2024 2:30:37 PM,"Neurocrine upped to overweight by Piper, sees '568 as still viable",Seeking Alpha,https://seekingalpha.com/news/4145099-piper-ups-neurocrine-to-overweight-says-568-still-in-the-game?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7126749157905579
9/1/2024 7:26:06 PM,"Weekly Biotech Buzz: BMRN Cuts Jobs, FDA Approves New Mpox Vaccine, MRK Halts 2 Keytruda Studies ",RTTNews,/news/stocks/weekly-biotech-buzz-bmrn-cuts-jobs-fda-approves-new-mpox-vaccine-mrk-halts-2-keytruda-studies-1033738673,negative,0.750618040561676
9/2/2024 4:35:44 AM,Biotech Stocks Facing FDA Decision In September 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-september-2024-1033738787,neutral,0.9196612238883972
9/3/2024 6:05:30 AM,Barclays Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1033742670,neutral,0.9151224493980408
9/3/2024 12:25:39 PM,Hold Rating on Bristol-Myers Squibb Amid Asundexian Trial Uncertainties and Milvexian Prospects,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-asundexian-trial-uncertainties-and-milvexian-prospects-1033744436,negative,0.9455410838127136
9/5/2024 2:59:46 AM,Merck's Winrevair Approved For Pulmonary Arterial Hypertension In Canada ,RTTNews,/news/stocks/merck-s-winrevair-approved-for-pulmonary-arterial-hypertension-in-canada-1033748977,positive,0.9041691422462463
9/9/2024 5:45:21 AM,Bristol-Myers Squibb (BMY): Hold Rating Justified by Mixed Growth Prospects and Pipeline Catalysts,TipRanks,/news/stocks/bristol-myers-squibb-bmy-hold-rating-justified-by-mixed-growth-prospects-and-pipeline-catalysts-1033756491,negative,0.5020385980606079
9/11/2024 5:14:26 AM,Bristol-Myers Squibb declares $0.60 dividend,Seeking Alpha,https://seekingalpha.com/news/4148533-bristol-myers-squibb-declares-060-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9295805096626282
9/11/2024 5:16:40 AM,Bristol-Myers Squibb Company PFD CONV 2 declares $0.50 dividend,Seeking Alpha,https://seekingalpha.com/news/4148534-bristol-myers-squibb-company-pfd-conv-2-declares-050-dividend?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9420519471168518
9/13/2024 6:22:24 PM,"Bicara, MBX Bio lead gainers as biotech trio makes trading debut",Seeking Alpha,https://seekingalpha.com/news/4149681-bicara-mbx-bio-lead-gainers-among-biotech-ipos?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9061312675476074
9/14/2024 12:46:29 PM,Bristol-Myers Squibb’s KarXT Faces FDA Approval Hurdles: Analyst Issues Sell Rating Amid Labeling Concerns,TipRanks,/news/stocks/bristol-myers-squibb-s-karxt-faces-fda-approval-hurdles-analyst-issues-sell-rating-amid-labeling-concerns-1033771672,negative,0.9524879455566406
9/16/2024 9:36:11 AM,Evaluating Bristol-Myers Squibb: A Balanced View Amidst NSCLC Treatment Prospects and Market Uncertainties,TipRanks,/news/stocks/evaluating-bristol-myers-squibb-a-balanced-view-amidst-nsclc-treatment-prospects-and-market-uncertainties-1033774045,neutral,0.7414190173149109
9/16/2024 11:16:05 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1033774764,neutral,0.90272456407547
9/16/2024 4:15:17 PM,Bristol unveils 10-year Opdivo + Yervoy follow-up data in melanoma,Seeking Alpha,https://seekingalpha.com/news/4150032-bristol-unveils-10-year-opdivo-yervoy-follow-up-data-melanoma?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.766292154788971
9/18/2024 7:48:22 PM,Bristol Myers Squibb Zeposia shows long-term efficacy,Seeking Alpha,https://seekingalpha.com/news/4150893-bristol-myers-squibb-zeposia-shows-long-term-efficacy?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9117668867111206
9/19/2024 6:43:06 PM,Centessa Pharmaceuticals a new buy at B Riley on sleep disorders pipeline,Seeking Alpha,https://seekingalpha.com/news/4151333-centessa-pharmaceuticals-new-buy-b-riley-sleep-disorders-pipeline?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6353678107261658
9/20/2024 7:00:55 PM,"Catalyst Watch: Spotlight on Micron, Southwest Airlines, and FOMC speakers",Seeking Alpha,https://seekingalpha.com/news/4151613-catalyst-watch-spotlight-on-micron-southwest-airlines-and-fomc-speakers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8940789103507996
9/20/2024 8:43:49 PM,Sanofi Sarclisa combo gains approval as first-line multiple myeloma treatment,Seeking Alpha,https://seekingalpha.com/news/4151719-sanofi-sarclisa-combo-gains-approval-first-line-multiple-myeloma-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.950284481048584
9/23/2024 11:15:53 AM,Bristol-Myers Squibb: Hold Rating Justified by Market-Reflected Approval of KarXT Despite Promising Clinical Data,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-justified-by-market-reflected-approval-of-karxt-despite-promising-clinical-data-1033790889,positive,0.9436721801757812
9/23/2024 7:17:40 PM,UCB gets expanded FDA approval for psoriasis drug Bimzelx,Seeking Alpha,https://seekingalpha.com/news/4152277-ucb-gets-expanded-fda-approval-for-psoriasis-drug-bimzelx?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9338515996932983
9/24/2024 9:45:22 PM,"Bristol, Merck checkpoint inhibitors focus of FDA advisory committee meeting",Seeking Alpha,https://seekingalpha.com/news/4152864-bristol-merck-checkpoint-inhibitors-focus-fda-advisory-committee-meeting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9367879033088684
9/25/2024 10:49:50 AM,"Bristol Myers, 2seventy bio halt enrollment in Abecma late-stage trial",Seeking Alpha,https://seekingalpha.com/news/4153004-bristol-myers-2seventy-bio-halt-abecma-trial?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7534781694412231
9/25/2024 1:46:53 PM,"2seventy, Bristol Myers Discontinue Enrollment In Phase 3 KarMMa-9 Study - Quick Facts ",RTTNews,/news/stocks/2seventy-bristol-myers-discontinue-enrollment-in-phase-3-karmma-9-study-quick-facts-1033796466,neutral,0.8865388631820679
9/26/2024 5:49:21 PM,"Merck, Bristol-Myers fail to convince FDA AdCom on wider Opdivo, Keytruda use",Seeking Alpha,https://seekingalpha.com/news/4153858-merck-bristol-myers-face-setback-wider-opdivo-keytruda-use?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6757486462593079
9/27/2024 2:15:55 AM,Sell Rating on Bristol-Myers Squibb Amid Competitive Pressures and Pricing Concerns,TipRanks,/news/stocks/sell-rating-on-bristol-myers-squibb-amid-competitive-pressures-and-pricing-concerns-1033802561,negative,0.9368941187858582
9/27/2024 2:25:37 AM,Bristol-Myers Squibb’s Cobenfy: A Balanced Hold Rating Amidst FDA Approval and Market Uncertainties,TipRanks,/news/stocks/bristol-myers-squibb-s-cobenfy-a-balanced-hold-rating-amidst-fda-approval-and-market-uncertainties-1033802550,positive,0.8042781352996826
9/27/2024 3:31:39 AM,Bristol Myers Squibb's COBENFY Gains FDA Approval For Adult Schizophrenia Treatment ,RTTNews,/news/stocks/bristol-myers-squibb-s-cobenfy-gains-fda-approval-for-adult-schizophrenia-treatment-1033802204,positive,0.9454361200332642
9/27/2024 4:16:00 AM,Bristol-Myers Squibb’s Cobenfy Launch Spurs ‘Buy’ Rating Amid Favorable Market Dynamics,TipRanks,/news/stocks/bristol-myers-squibb-s-cobenfy-launch-spurs-buy-rating-amid-favorable-market-dynamics-1033802729,positive,0.9448630809783936
9/27/2024 10:15:50 AM,Bristol-Myers Squibb: Sell Rating Justified by Market Challenges and Drug Uptake Concerns,TipRanks,/news/stocks/bristol-myers-squibb-sell-rating-justified-by-market-challenges-and-drug-uptake-concerns-1033803772,negative,0.6317194104194641
9/27/2024 10:52:00 AM,Bristol-Myers wins FDA nod for first-of-its-kind antipsychotic (update),Seeking Alpha,https://seekingalpha.com/news/4153957-bristol-myers-wins-fda-nod-for-first-of-its-kind-antipsychotic?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.515460193157196
9/27/2024 11:16:40 AM,Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-amid-new-schizophrenia-drug-launch-and-patent-expiries-1033804211,negative,0.955703616142273
9/27/2024 11:26:33 AM,Truist Financial Gives a Buy Rating to Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-gives-a-buy-rating-to-bristol-myers-squibb-bmy-1033804200,neutral,0.8182915449142456
9/27/2024 2:00:29 PM,"Biggest stock movers Friday: HPQ, BB, BMY, and more",Seeking Alpha,https://seekingalpha.com/news/4153990-biggest-stock-movers-friday-bb-bmy-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9132382869720459
9/27/2024 5:59:43 PM,"Bristol Cobenfy approval draws optimism from Street, though with caveats",Seeking Alpha,https://seekingalpha.com/news/4154179-bristol-cobenfy-approval-draws-optimism-from-street-though-with-caveats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8621546626091003
9/27/2024 8:42:26 PM,J&J releases encouraging data on Talvey combination therapies,Seeking Alpha,https://seekingalpha.com/news/4154260-jj-releases-encouraging-data-on-talvey-combination-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.943537712097168
9/28/2024 4:09:05 PM,Trending stocks this week as market reactions to Fed rate cut continue,Seeking Alpha,https://seekingalpha.com/news/4154316-trending-stocks-this-week-as-market-reactions-to-fed-rate-cut-continue?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6675745248794556
9/28/2024 5:06:10 PM,Here are the Medicare Part D drugs expected to face 2025 price negotiations,Seeking Alpha,https://seekingalpha.com/news/4154318-these-medicare-drugs-set-to-face-2025-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.941364049911499
9/30/2024 12:59:37 PM,Biotech Stocks Facing FDA Decision In October 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-october-2024-1033806960,neutral,0.9161741733551025
9/30/2024 2:02:03 PM,Prime Medicine Inks Strategic Research Collaboration And License Agreement With Bristol Myers Squibb ,RTTNews,/news/stocks/prime-medicine-inks-strategic-research-collaboration-and-license-agreement-with-bristol-myers-squibb-1033807165,positive,0.8675586581230164
9/30/2024 3:55:48 PM,"Bristol, Prime Medicine in deal to develop T-cell therapies",Seeking Alpha,https://seekingalpha.com/news/4154520-bristol-prime-medicine-deal-develop-t-cell-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7234774827957153
9/30/2024 8:16:49 PM,Bristol Myers gets $6.4B Celgene CVR case dismissed: report,Seeking Alpha,https://seekingalpha.com/news/4154744-bristol-myers-gets-64b-celgene-cvr-case-dismissed-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.685843825340271
10/1/2024 5:25:40 AM,Hold Rating on Bristol-Myers Squibb Amid Market Challenges and Strategic Execution Risks,TipRanks,/news/stocks/hold-rating-on-bristol-myers-squibb-amid-market-challenges-and-strategic-execution-risks-1033810156,negative,0.9535985589027405
10/1/2024 7:35:29 PM,U.S. port strike expected to have limited impact on healthcare supply chain: HHS,Seeking Alpha,https://seekingalpha.com/news/4155196-us-port-strike-have-limited-impact-medical-supplies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9400646090507507
10/2/2024 2:07:00 PM,Bristol-Myers tops growth chart among S&P 500 healthcare stocks in Q3,Seeking Alpha,https://seekingalpha.com/news/4155316-bristol-myers-tops-growth-chart-among-sp-500-healthcare-stocks-in-q3?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9400187730789185
10/3/2024 12:02:11 PM,U.S. tweaks 2025 Medicare price negotiation process,Seeking Alpha,https://seekingalpha.com/news/4155891-us-tweaks-2025-medicare-price-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7824938297271729
10/3/2024 3:32:03 PM,Bristol-Myers wins FDA nod for Opdivo lung cancer indication,Seeking Alpha,https://seekingalpha.com/news/4156093-bristol-myers-stock-up-fda-expands-opdivo-label?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7636573910713196
10/4/2024 5:00:23 PM,UMB to refile $6.4B lawsuit against Bristol-Myers by end of next week - report,Seeking Alpha,https://seekingalpha.com/news/4156523-umb-to-refile-64b-lawsuit-against-bristol-myers-by-end-of-next-week-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.752765417098999
10/4/2024 6:02:06 PM,Q3 pharma and biotech layoffs in charts: More than 1000 each in July and August,Seeking Alpha,https://seekingalpha.com/news/4156522-q3-pharma-biotech-layoffs-charts-more-than-1000-each-july-august?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9607917070388794
10/4/2024 8:34:51 PM,Bristol-Myers trades in the green for seventh straight session,Seeking Alpha,https://seekingalpha.com/news/4156562-bristol-myers-trades-in-the-green-for-seventh-straight-session?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.7383036613464355
10/7/2024 2:15:22 AM,Barclays Sticks to Their Sell Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/barclays-sticks-to-their-sell-rating-for-bristol-myers-squibb-bmy-1033823283,neutral,0.874992847442627
10/8/2024 6:03:33 PM,Harris home health care benefit likely funded through Medicare drug negotiations savings,Seeking Alpha,https://seekingalpha.com/news/4157079-harris-home-health-care-benefit-could-funded-through-medicare-drug-negotiations-savings?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8432397246360779
10/10/2024 6:04:23 PM,"Kyverna, Cabaletta started at buys by UBS on CAR T therapy potential",Seeking Alpha,https://seekingalpha.com/news/4157672-kyverna-cabaletta-started-at-buys-by-ubs-on-car-t-therapy-potential?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8460164070129395
10/11/2024 12:35:59 PM,Morgan Stanley Keeps Their Sell Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/morgan-stanley-keeps-their-sell-rating-on-bristol-myers-squibb-bmy-1033839281,neutral,0.9158970713615417
10/11/2024 2:10:42 PM,Perspective falls after data for radiopharmaceutical in skin cancer,Seeking Alpha,https://seekingalpha.com/news/4157904-perspective-stock-plunges-after-trial-data?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9549657106399536
10/14/2024 10:55:30 AM,Bristol-Myers Squibb: Hold Rating with Anticipated Revenue Outperformance Offset by Generic Competition Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-with-anticipated-revenue-outperformance-offset-by-generic-competition-concerns-1033843092,positive,0.8702739477157593
10/16/2024 9:05:09 PM,"Lilly, Gilead, Amgen started at outperform by Bernstein",Seeking Alpha,https://seekingalpha.com/news/4167588-lilly-gilead-amgen-started-at-outperform-by-bernstein?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7325482964515686
10/23/2024 6:45:27 AM,Bristol-Myers Squibb: Navigating Financial Adjustments and Competitive Pressures Amidst a Hold Rating,TipRanks,/news/stocks/bristol-myers-squibb-navigating-financial-adjustments-and-competitive-pressures-amidst-a-hold-rating-1033877222,negative,0.7268636226654053
10/23/2024 9:20:17 AM,"Evotec and Bristol Myers expand proteomics pact, triggers $50M payment",TipRanks,/news/stocks/evotec-and-bristol-myers-expand-proteomics-pact-triggers-50m-payment-1033877993,positive,0.8084769248962402
10/23/2024 11:45:20 AM,Redwire launches investigation to ISS with BMS to study drugs with PIL-BOX,TipRanks,/news/stocks/redwire-launches-investigation-to-iss-with-bms-to-study-drugs-with-pil-box-1033879611,neutral,0.5814988017082214
10/23/2024 4:40:19 PM,Evotec gains following $50M payment from Bristol for molecular glue degraders,Seeking Alpha,https://seekingalpha.com/news/4196308-evotec-gains-following-50-m-payment-bristol-molecular-glue-degraders?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9175136685371399
10/25/2024 10:12:15 AM,Bristol Myers downgraded to Neutral from Buy at Citi,TipRanks,/news/stocks/bristol-myers-downgraded-to-neutral-from-buy-at-citi-1033892615,neutral,0.4808811545372009
10/25/2024 1:46:37 PM,"Apple downgraded, Tesla upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/apple-downgraded-tesla-upgraded-wall-street-s-top-analyst-calls-1033894593,neutral,0.6842862963676453
10/28/2024 4:23:31 AM,"Earnings week ahead: MSFT, AMZN, AAPL, META, GOOG, AMD, PFE, F, MCD, SBUX, XOM, CVX and more",Seeking Alpha,https://seekingalpha.com/news/4205996-earnings-week-ahead-msft-amzn-aapl-meta-goog-amd-pfe-f-mcd-sbux-xom-cvx-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9362694025039673
10/29/2024 12:21:04 PM,Biogen appoints Quirk as Chief Medical Officer,TipRanks,/news/stocks/biogen-appoints-quirk-as-chief-medical-officer-1033910411,neutral,0.9236396551132202
10/29/2024 12:33:15 PM,Biogen names former Bristol-Myers executive as medical chief,Seeking Alpha,https://seekingalpha.com/news/4217750-biogen-names-medical-chief-from-bristol-myers?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9377938508987427
10/29/2024 4:36:07 PM,Zai Lab reports positive Chinese study data for KarXT for schizophrenia,Seeking Alpha,https://seekingalpha.com/news/4219420-zai-lab-reports-positive-chinese-study-data-for-karxt-for-schizophrenia?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9413893222808838
10/30/2024 6:00:59 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1033921038,neutral,0.9220908284187317
10/30/2024 7:07:33 PM,Bristol Myers Squibb Q3 2024 Earnings Preview: Profit decline anticipated,Seeking Alpha,https://seekingalpha.com/news/4225478-bristol-myers-squibb-q3-2024-earnings-preview-profit-decline-anticipated?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9735236763954163
10/31/2024 11:00:02 AM,"Bristol-Myers Squibb Company  Non-GAAP EPS of $1.80 beats by $0.30, revenue of $11.89B beats by $640M",Seeking Alpha,https://seekingalpha.com/news/4227809-bristol-myers-squibb-company-and-nbsp-non-gaap-eps-of-1_80-beats-0_30-revenue-of-11_89b-beats?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.472059041261673
10/31/2024 11:05:37 AM,"Bristol Myers reports Q3 EPS $1.80, consensus $1.49",TipRanks,/news/stocks/bristol-myers-reports-q3-eps-1-80-consensus-1-49-1033928687,neutral,0.6603273153305054
10/31/2024 11:45:01 AM,Bristol-Myers raises outlook ahead of consensus after Q3 beat,Seeking Alpha,https://seekingalpha.com/news/4228044-bristol-myers-stock-gains-guidance-raise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5994579195976257
10/31/2024 12:24:33 PM,"Bristol-Myers Squibb Co. Q3 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q3-profit-decreases-but-beats-estimates-1033927047,negative,0.9649553894996643
10/31/2024 12:43:52 PM,"Bristol-Myers Squibb in charts: Q3 revenue from Eliquis, Opdivo, Yervoy rises, Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4228391-bristol-myers-squibb-in-charts?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.7703050374984741
10/31/2024 12:56:50 PM,Bristol Myers Squibb Lifts FY24 Earnings View Above Market; Stock Up In Pre-market - Update ,RTTNews,/news/stocks/bristol-myers-squibb-lifts-fy24-earnings-view-above-market-stock-up-in-pre-market-update-1033927432,positive,0.9437482357025146
10/31/2024 1:01:20 PM,Morning Movers: Roblox surges and Estee Lauder sinks following earnings,TipRanks,/news/stocks/morning-movers-roblox-surges-and-estee-lauder-sinks-following-earnings-1033930078,neutral,0.5358023643493652
10/31/2024 4:01:23 PM,"Microsoft reports Q1 beat, Comcast weighs cable networks spinoff: Morning Buzz",TipRanks,/news/stocks/microsoft-reports-q1-beat-comcast-weighs-cable-networks-spinoff-morning-buzz-1033931015,neutral,0.8997287750244141
10/31/2024 8:30:29 PM,Bristol Myers presents new long-term data from EMERGENT study of COBENFY,TipRanks,/news/stocks/bristol-myers-presents-new-long-term-data-from-emergent-study-of-cobenfy-1033931793,neutral,0.6276983022689819
11/1/2024 4:33:27 AM,Bristol Myers Squibb Posts Robust Q3 2024 Growth,TipRanks,/news/stocks/bristol-myers-squibb-posts-robust-q3-2024-growth-1033934554,positive,0.9428672790527344
11/1/2024 7:30:13 AM,"Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY), 10x Genomics (TXG) and Bicycle Therapeutics (BCYC)",TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-10x-genomics-txg-and-bicycle-therapeutics-bcyc-1033935639,neutral,0.9040024876594543
11/1/2024 9:12:26 AM,Cautious Optimism: Bristol-Myers Squibb’s Hold Rating Amid Growth Prospects and Uncertainties,TipRanks,/news/stocks/cautious-optimism-bristol-myers-squibb-s-hold-rating-amid-growth-prospects-and-uncertainties-1033936174,positive,0.41250136494636536
11/1/2024 9:20:18 AM,"Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bristol-Myers Squibb (BMY), Abbott Laboratories (ABT) and Merck & Company (MRK)",TipRanks,/news/stocks/analysts-opinions-are-mixed-on-these-healthcare-stocks-bristol-myers-squibb-bmy-abbott-laboratories-abt-and-merck-company-mrk-1033936132,negative,0.7605414390563965
11/1/2024 11:16:12 AM,Bristol Myers price target raised to $60 from $55 at BofA,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-60-from-55-at-bofa-1033937020,positive,0.9456056952476501
11/1/2024 11:39:33 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1033937087,neutral,0.90272456407547
11/1/2024 11:55:43 AM,Silexion Therapeutics initiated with a Buy at Maxim,TipRanks,/news/stocks/silexion-therapeutics-initiated-with-a-buy-at-maxim-1033937192,neutral,0.8468267917633057
11/1/2024 12:01:40 PM,Analysts Offer Insights on Healthcare Companies: Select Medical (SEM) and Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-select-medical-sem-and-bristol-myers-squibb-bmy-1033937671,neutral,0.911278247833252
11/1/2024 12:09:34 PM,Bristol-Myers Squibb: Sell Rating Due to Mixed Financial Outlook and Long-Term Challenges,TipRanks,/news/stocks/bristol-myers-squibb-sell-rating-due-to-mixed-financial-outlook-and-long-term-challenges-1033937622,negative,0.9638747572898865
11/1/2024 12:15:38 PM,Bristol-Myers Squibb: Hold Rating Reflects Gradual Improvement and Strategic Caution,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-reflects-gradual-improvement-and-strategic-caution-1033937753,positive,0.9220092296600342
11/1/2024 12:36:39 PM,Jefferies Sticks to Their Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-sticks-to-their-hold-rating-for-bristol-myers-squibb-bmy-1033937861,neutral,0.8901152610778809
11/5/2024 6:35:23 AM,Bristol-Myers Squibb: Hold Rating Maintained Amid Positive Clinical Trials and Long-term EPS Concerns,TipRanks,/news/stocks/bristol-myers-squibb-hold-rating-maintained-amid-positive-clinical-trials-and-long-term-eps-concerns-1033950375,positive,0.9309133291244507
11/5/2024 6:40:47 AM,"Analysts’ Top Healthcare Picks: Bristol-Myers Squibb (BMY), Agios Pharma (AGIO)",TipRanks,/news/stocks/analysts-top-healthcare-picks-bristol-myers-squibb-bmy-agios-pharma-agio-1033950367,neutral,0.5263792872428894
11/5/2024 12:50:21 PM,Analysts Conflicted on These Healthcare Names: Bristol-Myers Squibb (BMY) and Envista Holdings (NVST),TipRanks,/news/stocks/analysts-conflicted-on-these-healthcare-names-bristol-myers-squibb-bmy-and-envista-holdings-nvst-1033953136,negative,0.5519338846206665
11/11/2024 2:32:24 PM,AbbVie declines after missing main goal in schizophrenia treatment trials,Seeking Alpha,https://seekingalpha.com/news/4274511-abbvie-declines-after-missing-main-goal-in-schizophrenia-treatment-trials?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9513046145439148
11/11/2024 2:45:15 PM,"Bristol Myers rises, AbbVie sinks after schizophrenia trials miss targets",TipRanks,/news/stocks/bristol-myers-rises-abbvie-sinks-after-schizophrenia-trials-miss-targets-1033993919,negative,0.5984252095222473
11/11/2024 2:50:11 PM,Bristol Myers rises 11.6%,TipRanks,/news/stocks/bristol-myers-rises-11-6-1033993911,positive,0.751781702041626
11/11/2024 2:50:30 PM,"Biggest stock movers Monday: Crypto stocks, TSLA, ABBV, and more",Seeking Alpha,https://seekingalpha.com/news/4272963-biggest-stock-movers-monday?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9217736124992371
11/11/2024 2:55:08 PM,Early notable gainers among liquid option names on November 11th,TipRanks,/news/stocks/early-notable-gainers-among-liquid-option-names-on-november-11th-1033993901,positive,0.8965445756912231
11/11/2024 3:05:25 PM,"AbbVie ‘pain’ is Bristol Myers ‘gain’ after emraclidine fails, says Truist",TipRanks,/news/stocks/abbvie-pain-is-bristol-myers-gain-after-emraclidine-fails-says-truist-1033993966,positive,0.6405274271965027
11/11/2024 3:15:16 PM,"JPMorgan sees AbbVie off about 10%, Bristol up 10%-15% on emraclidine news",TipRanks,/news/stocks/jpmorgan-sees-abbvie-off-about-10-bristol-up-10--15-on-emraclidine-news-1033994006,negative,0.8750485181808472
11/11/2024 3:35:15 PM,Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers,TipRanks,/news/stocks/leerink-sees-abbvie-s-trial-results-as-clear-positive-for-bristol-myers-1033994048,positive,0.9484250545501709
11/11/2024 4:10:06 PM,AbbVie under pressure as schizophrenia drug fails two trials,TipRanks,/news/stocks/abbvie-under-pressure-as-schizophrenia-drug-fails-two-trials-1033994121,negative,0.9643561244010925
11/11/2024 4:35:39 PM,Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive,TipRanks,/news/stocks/evercore-says-failure-of-emraclidine-may-be-substantial-neurocrine-positive-1033994161,negative,0.7097479104995728
11/11/2024 5:38:20 PM,How AbbVie can still benefit from Cerevel acquisition despite emraclidine setback,Seeking Alpha,https://seekingalpha.com/news/4275200-how-abbvie-can-still-benefit-cerevel-acquisition-despite-emraclidine-setback?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8106690049171448
11/12/2024 11:05:09 AM,Bristol Myers upgraded to Outperform from Market Perform at Leerink,TipRanks,/news/stocks/bristol-myers-upgraded-to-outperform-from-market-perform-at-leerink-1033999318,positive,0.9390182495117188
11/12/2024 11:05:58 AM,Bristol Myers price target raised to $60 from $55 at Citi,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-60-from-55-at-citi-1033999308,positive,0.9397873878479004
11/12/2024 11:20:30 AM,Leerink upgrades Bristol to Outperform after AbbVie schizophrenia failure,TipRanks,/news/stocks/leerink-upgrades-bristol-to-outperform-after-abbvie-schizophrenia-failure-1033999384,positive,0.7671735882759094
11/12/2024 12:31:40 PM,AbbVie price target lowered to $224 from $231 at Morgan Stanley,TipRanks,/news/stocks/abbvie-price-target-lowered-to-224-from-231-at-morgan-stanley-1034000363,negative,0.9160743355751038
11/12/2024 12:31:53 PM,Bristol Myers price target raised to $39 from $36 at Morgan Stanley,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-39-from-36-at-morgan-stanley-1034000362,positive,0.944940984249115
11/12/2024 1:22:50 PM,Bristol-Myers upgraded at Leerink after AbbVie setback,Seeking Alpha,https://seekingalpha.com/news/4279606-bristol-myers-stock-upgraded-leerink?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.789842963218689
11/12/2024 2:45:47 PM,"Nvidia initiated, Airbnb downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/nvidia-initiated-airbnb-downgraded-wall-street-s-top-analyst-calls-1034001381,negative,0.6238363981246948
11/12/2024 2:45:59 PM,Bristol Myers price target raised to $61 from $57 at BMO Capital,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-61-from-57-at-bmo-capital-1034001380,positive,0.9454479813575745
11/12/2024 5:05:59 PM,"Elliott confirms big Honeywell stake, Home Deport reports Q3 beat: Morning Buzz",TipRanks,/news/stocks/elliott-confirms-big-honeywell-stake-home-deport-reports-q3-beat-morning-buzz-1034001929,neutral,0.8393923044204712
11/13/2024 5:15:13 PM,Bristol Myers Squibb put volume heavy and directionally bearish,TipRanks,/news/stocks/bristol-myers-squibb-put-volume-heavy-and-directionally-bearish-1034011073,negative,0.839871346950531
11/14/2024 9:16:17 PM,Bristol Myers initiated with a Peer Perform at Wolfe Research,TipRanks,/news/stocks/bristol-myers-initiated-with-a-peer-perform-at-wolfe-research-1034021183,neutral,0.8661438226699829
11/14/2024 9:38:21 PM,"Tudor Investment adds Infinera, Trane, exits Disney, UnitedHealth, among top Q3 trades",Seeking Alpha,https://seekingalpha.com/news/4292366-tudor-investmentadds-infinera-traneexits-disney-united-healthamongtop-q-3-trades?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7691566944122314
11/14/2024 11:50:27 PM,"Wolfe starts Bristol Myers at Peer Perform, sees potential comeback story",TipRanks,/news/stocks/wolfe-starts-bristol-myers-at-peer-perform-sees-potential-comeback-story-1034021599,neutral,0.7593979835510254
11/15/2024 12:06:58 PM,Bristol Myers receives positive CHMP opinion for repotrectinib,TipRanks,/news/stocks/bristol-myers-receives-positive-chmp-opinion-for-repotrectinib-1034025093,positive,0.941431999206543
11/15/2024 1:30:21 PM,Bristol Myers announces CHMP opinion recommending approval of Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-announces-chmp-opinion-recommending-approval-of-opdivo-plus-yervoy-1034025634,neutral,0.8227719068527222
11/15/2024 2:59:25 PM,Bristol Myers gets positive EMA opinion for repotrectinib,Seeking Alpha,https://seekingalpha.com/news/4295034-bristol-myers-gets-positive-ema-opinion-for-repotrectinib?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9433483481407166
11/15/2024 7:29:29 PM,U.S. Pharma is largely immune from 'MAHA' impact: Wolfe,Seeking Alpha,https://seekingalpha.com/news/4296178-us-pharma-largely-immune-from-maha-impact-wolfe?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9049097299575806
11/15/2024 7:30:36 PM,"Large pharmas, biotechs down as industries grapple with RFK Jr. at HHS",Seeking Alpha,https://seekingalpha.com/news/4296140-large-pharmas-biotechs-down-industries-grapple-with-rfk-jr-hhs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9230124950408936
11/15/2024 7:40:19 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034026593,neutral,0.8970736861228943
11/17/2024 2:40:56 PM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-mimedx-group-mdxg-1034027530,neutral,0.9187651872634888
11/17/2024 2:50:40 PM,Analysts Offer Insights on Healthcare Companies: Bristol-Myers Squibb (BMY) and MiMedx Group (MDXG),TipRanks,/news/stocks/analysts-offer-insights-on-healthcare-companies-bristol-myers-squibb-bmy-and-mimedx-group-mdxg-1034027551,neutral,0.9187651872634888
11/18/2024 2:05:48 PM,Wells Fargo Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/wells-fargo-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1034032161,neutral,0.8568522334098816
11/19/2024 12:19:17 PM,Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034037419,neutral,0.7807403206825256
11/21/2024 6:45:46 PM,Optimism over global healthcare sector rises: Jefferies,Seeking Alpha,https://seekingalpha.com/news/4318258-optimism-over-global-healthcare-sector-rise?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.757529079914093
11/22/2024 1:31:12 PM,Replimune climbs after updates on lead drug,Seeking Alpha,https://seekingalpha.com/news/4320954-replimune-stock-climbs-after-updates-on-rp-1?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.4658929705619812
11/22/2024 3:40:08 PM,Health care sector had the most stocks with 4-week low and RSI below 30 since spring,Seeking Alpha,https://seekingalpha.com/news/4321978-health-care-sector-had-the-most-stocks-with-4-week-low-and-rsi-below-30-since-spring?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9638388752937317
11/23/2024 2:25:05 AM,"Trump picks surgeon Marty Makary to head FDA, Rep. Dave Weldon to lead CDC",Seeking Alpha,https://seekingalpha.com/news/4323803-trump-picks-surgeon-makary-to-head-fda-rep-dave-weldon-to-lead-cdc?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9368929862976074
11/25/2024 5:45:57 AM,Optimistic Buy Rating for Bristol-Myers Squibb Driven by Promising Cobenfy Projections and Competitive Advantages,TipRanks,/news/stocks/optimistic-buy-rating-for-bristol-myers-squibb-driven-by-promising-cobenfy-projections-and-competitive-advantages-1034058910,positive,0.948047399520874
11/25/2024 3:27:55 PM,Merck Phase 3 study of Winrevair in PAH meets primary endpoint,Seeking Alpha,https://seekingalpha.com/news/4330240-merck-phase-3-study-of-winrevair-in-pah-meets-primary-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.778440535068512
11/27/2024 11:23:42 AM,Trump taps Jay Bhattacharya to lead National Institutes of Health,Seeking Alpha,https://seekingalpha.com/news/4338432-trump-taps-jay-bhattacharya-to-lead-national-institutes-of-health?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8861560225486755
11/28/2024 3:33:22 PM,AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe,Seeking Alpha,https://seekingalpha.com/news/4344692-astrazeneca-enhertu-added-for-china-reimbursement?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8657417297363281
11/29/2024 5:00:00 PM,"Catalyst Watch: November jobs, OPEC+ meeting, Marvell, Salesforce earnings",Seeking Alpha,https://seekingalpha.com/news/4340728-catalyst-watch-november-jobs-report?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8812248110771179
12/2/2024 2:05:36 PM,"Bausch Health appoints Jonathan Sadeh as CMO, head of R&D",TipRanks,/news/stocks/bausch-health-appoints-jonathan-sadeh-as-cmo-head-of-r-d-1034087648,neutral,0.9203163385391235
12/2/2024 5:38:36 PM,Biotech Stocks Facing FDA Decision In December 2024 ,RTTNews,/news/stocks/biotech-stocks-facing-fda-decision-in-december-2024-1034087402,neutral,0.9047756791114807
12/3/2024 3:28:47 PM,Bristol in research agreement with AI Proteins on miniprotein-based therapies,Seeking Alpha,https://seekingalpha.com/news/4359654-bristol-in-research-agreement-ai-proteins-on-miniprotein-based-therapies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6907141208648682
12/10/2024 12:26:18 PM,Bristol-Myers Squibb: Balancing Stability and Competition with Cautious Optimism,TipRanks,/news/stocks/bristol-myers-squibb-balancing-stability-and-competition-with-cautious-optimism-1034119754,neutral,0.7959339618682861
12/10/2024 2:45:24 PM,"eBay downgraded, GM upgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/ebay-downgraded-gm-upgraded-wall-street-s-top-analyst-calls-1034120783,neutral,0.8453128933906555
12/10/2024 10:01:32 PM,BofA restarts coverage of 11 large-cap biopharmas,Seeking Alpha,https://seekingalpha.com/news/4384456-bofa-restarts-coverage-of-11-large-cap-biopharmas?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8290338516235352
12/11/2024 6:35:17 AM,Berenberg Bank Remains a Hold on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/berenberg-bank-remains-a-hold-on-bristol-myers-squibb-bmy-1034123133,neutral,0.8375291228294373
12/11/2024 9:20:31 PM,Bristol Myers raises quarterly dividend 3.3% to 62c per share,TipRanks,/news/stocks/bristol-myers-raises-quarterly-dividend-3-3-to-62c-per-share-1034127010,positive,0.862484872341156
12/11/2024 9:20:47 PM,Bristol-Myers Squibb Company  raises quarterly dividend by 3.3% to  $0.62/share,Seeking Alpha,https://seekingalpha.com/news/4385725-bristol-myers-squibb-company-raises-quarterly-dividend-by-33-to-062share?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.915133535861969
12/13/2024 9:20:11 PM,Bristol Myers files automatic mixed securities shelf,TipRanks,/news/stocks/bristol-myers-files-automatic-mixed-securities-shelf-1034137117,neutral,0.9501451253890991
12/16/2024 11:26:02 AM,Bristol Myers upgraded to Buy from Hold at Jefferies,TipRanks,/news/stocks/bristol-myers-upgraded-to-buy-from-hold-at-jefferies-1034140565,positive,0.6725726127624512
12/16/2024 11:30:54 AM,"Bristol Myers upgraded to Buy at Jefferies on new launch momentum, pipeline",TipRanks,/news/stocks/bristol-myers-upgraded-to-buy-at-jefferies-on-new-launch-momentum-pipeline-1034140712,positive,0.8329140543937683
12/16/2024 2:35:49 PM,"Netflix, MongoDB downgraded: Wall Street’s top analyst calls",TipRanks,/news/stocks/netflix-mongodb-downgraded-wall-street-s-top-analyst-calls-1034142189,neutral,0.7343029379844666
12/16/2024 5:01:01 PM,"Honeywell still exploring alternatives, Capri weighs Versace sale: Morning Buzz",TipRanks,/news/stocks/honeywell-still-exploring-alternatives-capri-weighs-versace-sale-morning-buzz-1034142630,neutral,0.9130474328994751
12/16/2024 5:06:51 PM,Bristol-Myers upgraded to buy by Jefferies,Seeking Alpha,https://seekingalpha.com/news/4386765-bristol-myers-upgraded-to-buy-by-jefferies?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5693292617797852
12/18/2024 2:30:47 PM,Cytokinetics price target raised to $82 from $80 at RBC Capital,TipRanks,/news/stocks/cytokinetics-price-target-raised-to-82-from-80-at-rbc-capital-1034152597,positive,0.9454621076583862
12/19/2024 12:05:39 PM,Bristol Myers added to Analyst Focus List at JPMorgan,TipRanks,/news/stocks/bristol-myers-added-to-analyst-focus-list-at-jpmorgan-1034156817,neutral,0.9119754433631897
12/19/2024 12:12:25 PM,Bristol Myers enters $100M PyroGlu-Ass license agreement with BioArctic,TipRanks,/news/stocks/bristol-myers-enters-100m-pyroglu-ass-license-agreement-with-bioarctic-1034156781,positive,0.8994864821434021
12/19/2024 6:16:03 PM,Regeneron reports positive results for two anti-coagulant drugs,Seeking Alpha,https://seekingalpha.com/news/4388091-regeneron-reports-positive-results-for-two-anti-coagulant-drugs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9454735517501831
12/19/2024 8:16:45 PM,Bristol in license agreement with BioArctic for two Alzheimer's antibody programs,Seeking Alpha,https://seekingalpha.com/news/4388608-bristol-license-agreement-bioarctic-two-alzheimers-antibody-programs?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6378671526908875
12/20/2024 8:20:32 PM,Buy/Sell: Wall Street’s top 10 stock calls this week,TipRanks,/news/stocks/buy-sell-wall-street-s-top-10-stock-calls-this-week-1034164300,neutral,0.8970736861228943
12/22/2024 9:12:14 PM,SA Asks: Which Big Pharmas are likely to announce big M&A deals?,Seeking Alpha,https://seekingalpha.com/news/4389614-sa-asks-which-big-pharmas-are-likely-to-announce-big-m-deals?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9418226480484009
12/23/2024 11:50:14 AM,Bristol Myers receives EC approval for Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-receives-ec-approval-for-opdivo-plus-yervoy-1034167773,positive,0.747272253036499
12/23/2024 12:05:43 PM,Bristol Myers announces ‘positive’ results from Phase 3 Sotyktu trials,TipRanks,/news/stocks/bristol-myers-announces-positive-results-from-phase-3-sotyktu-trials-1034168154,positive,0.8830222487449646
12/23/2024 2:03:51 PM,Bristol-Myers Squibb meets main goal in late-stage trials of its psoriatic arthritis treatment,Seeking Alpha,https://seekingalpha.com/news/4389970-bristol-myers-squibb-meets-main-goal-in-late-stage-trials-of-its-psoriatic-arthritis-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7119095325469971
12/23/2024 2:15:01 PM,Bristol Myers: Sotyktu Phase 3 Trials In Psoriatic Arthritis Meet Primary Goals ,RTTNews,/news/stocks/bristol-myers-sotyktu-phase-3-trials-in-psoriatic-arthritis-meet-primary-goals-1034167316,neutral,0.5220215320587158
12/23/2024 5:46:35 PM,Bristol-Myers gets EU okay for Opdivo/Yervoy combo,Seeking Alpha,https://seekingalpha.com/news/4390176-bristol-myers-gets-eu-okay-for-opdivoyervoy-combo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.5768056511878967
12/27/2024 4:35:14 PM,FDA approves Bristol Myers’ Opdivo Qvantig,TipRanks,/news/stocks/fda-approves-bristol-myers-opdivo-qvantig-1034177070,neutral,0.723569393157959
12/27/2024 7:43:23 PM,Bristol-Myers gets FDA okay for injectable Opdivo,Seeking Alpha,https://seekingalpha.com/news/4391265-bristol-myers-gets-fda-okay-for-injectable-opdivo?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.776333212852478
12/27/2024 10:40:09 PM,Bristol Myers announces FDA approval of Opdivo Qvantig injection,TipRanks,/news/stocks/bristol-myers-announces-fda-approval-of-opdivo-qvantig-injection-1034177307,positive,0.491689532995224
12/28/2024 4:33:24 AM,Bristol-Myers Squibb : FDA Approves Opdivo Qvantig For Subcutaneous Use In Adult Solid Tumors ,RTTNews,/news/stocks/bristol-myers-squibb-fda-approves-opdivo-qvantig-for-subcutaneous-use-in-adult-solid-tumors-1034177342,positive,0.8542175889015198
12/29/2024 5:15:05 PM,Bernstein Sticks to Its Hold Rating for Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bernstein-sticks-to-its-hold-rating-for-bristol-myers-squibb-bmy-1034177878,neutral,0.8609757423400879
12/30/2024 11:25:14 AM,Century Therapeutics price target lowered to $4 from $12 at Piper Sandler,TipRanks,/news/stocks/century-therapeutics-price-target-lowered-to-4-from-12-at-piper-sandler-1034179566,negative,0.6544280648231506
12/30/2024 11:45:06 AM,Halozyme reports FDA approval for Opdivo co-formulated with Enhanze,TipRanks,/news/stocks/halozyme-reports-fda-approval-for-opdivo-co-formulated-with-enhanze-1034179699,positive,0.9020293951034546
12/30/2024 1:03:09 PM,Halozyme Says FDA Approved Bristol Myers's Opdivo Qvantig With ENHANZE For Subcutaneous Use ,RTTNews,/news/stocks/halozyme-says-fda-approved-bristol-myers-s-opdivo-qvantig-with-enhanze-for-subcutaneous-use-1034179055,positive,0.8842207193374634
1/1/2025 2:00:28 PM,Brand prescription drugs to rise an average 4.5% in 2025,Seeking Alpha,https://seekingalpha.com/news/4391754-brand-prescription-drugs-rise-average-4_5-percent-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9456416964530945
1/2/2025 3:15:09 PM,Jefferies Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034187935,neutral,0.8419821858406067
1/2/2025 8:25:08 PM,Bristol Myers Squibb call volume above normal and directionally bullish,TipRanks,/news/stocks/bristol-myers-squibb-call-volume-above-normal-and-directionally-bullish-1034188424,positive,0.8764196038246155
1/6/2025 5:52:14 PM,"FDA issues first draft guidance on use of AI in drug, medical device development",Seeking Alpha,https://seekingalpha.com/news/4392790-fda-issues-first-draft-guidance-use-ai-drug-medical-device-development?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9278177618980408
1/6/2025 11:38:05 PM,Bristol Myers to report Q4 IPRD/licensing expense of $18M,Seeking Alpha,https://seekingalpha.com/news/4392878-bristol-myers-to-report-q4-iprdlicensing-expense-of-18m?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9495335817337036
1/7/2025 1:43:21 PM,Bristol late-stage trial of Opdivo for head and neck cancer meets endpoint,Seeking Alpha,https://seekingalpha.com/news/4392996-bristol-late-stage-trial-opdivo-head-and-neck-cancer-meets-endpoint?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6266093254089355
1/8/2025 1:10:34 AM,Bristol Myers price target raised to $65 from $62 at Truist,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-65-from-62-at-truist-1034202827,positive,0.945685088634491
1/8/2025 1:16:01 AM,Truist Financial Remains a Buy on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-remains-a-buy-on-bristol-myers-squibb-bmy-1034202849,neutral,0.90272456407547
1/9/2025 1:56:22 PM,"Novo, Eli Lilly to dominate global pharma sales in 2025: report",Seeking Alpha,https://seekingalpha.com/news/4393716-novo-eli-lilly-lead-2025-global-pharma-sales?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.691323459148407
1/9/2025 8:36:08 PM,Pharma companies welcome new year with 583 drug price hikes so far,Seeking Alpha,https://seekingalpha.com/news/4393873-2025-start-583-drug-price-hikes?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9193293452262878
1/11/2025 3:40:31 PM,Bernstein Reaffirms Their Hold Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/bernstein-reaffirms-their-hold-rating-on-bristol-myers-squibb-bmy-1034217248,neutral,0.8765362501144409
1/13/2025 12:46:00 PM,"Bristol Myers, ArsenalBio achieve milestone for AB-4000 series",TipRanks,/news/stocks/bristol-myers-arsenalbio-achieve-milestone-for-ab-4000-series-1034221570,positive,0.8286404609680176
1/13/2025 1:40:37 PM,ArsenalBios Says Bristol Myers Squibb Exercises Exclusive License Option For AB-4000 Series Programs ,RTTNews,/news/stocks/arsenalbios-says-bristol-myers-squibb-exercises-exclusive-license-option-for-ab-4000-series-programs-1034219914,neutral,0.5379636287689209
1/13/2025 2:40:15 PM,Unusually active option classes on open January 13th,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-13th-1034222275,neutral,0.7469804286956787
1/13/2025 5:53:38 PM,Bristol sees annual $1.5B in cost savings by end of 2025,Seeking Alpha,https://seekingalpha.com/news/4394642-bristol-sees-annual-1_5b-cost-savings-end-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.947330117225647
1/14/2025 2:40:39 PM,"Drugmakers to push Trump to pause price negotiations, Bloomberg reports",TipRanks,/news/stocks/drugmakers-to-push-trump-to-pause-price-negotiations-bloomberg-reports-1034226968,negative,0.7503695487976074
1/14/2025 10:55:17 PM,"Bristol Myers CEO says new drug Cobenfy effective in schizophrenia, CNBC reports",TipRanks,/news/stocks/bristol-myers-ceo-says-new-drug-cobenfy-effective-in-schizophrenia-cnbc-reports-1034227742,positive,0.4901141822338104
1/15/2025 6:56:23 AM,Positive Outlook for Bristol-Myers Squibb with Promising Market Access and Societal Benefits of Cobenfy,TipRanks,/news/stocks/positive-outlook-for-bristol-myers-squibb-with-promising-market-access-and-societal-benefits-of-cobenfy-1034229484,positive,0.9156102538108826
1/17/2025 1:19:18 PM,Wegovy included as Medicare lists 15 drugs selected for next pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4396094-wegovy-latest-medicare-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9195981025695801
1/17/2025 1:20:48 PM,"Ozempic, Xtandi among next 15 drugs selected for U.S. price talks",TipRanks,/news/stocks/ozempic-xtandi-among-next-15-drugs-selected-for-u-s-price-talks-1034240882,neutral,0.664841890335083
1/17/2025 2:39:38 PM,Chinese regulators accept Zai Lab application for KarXT,Seeking Alpha,https://seekingalpha.com/news/4396130-chinese-regulators-accept-zai-lab-application-for-karxt?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7677818536758423
1/17/2025 4:58:51 PM,"Pharma lobby slams IRA, PBMs as Medicare lists 15 more drugs for price setting",Seeking Alpha,https://seekingalpha.com/news/4396192-pharma-lobby-slams-ira-pbms-as-medicare-lists-15-more-drugs-for-price-setting?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.8260565996170044
1/17/2025 8:35:26 PM,Sector Spotlight: Big Pharma will push to pause Medicare drug price negotiations,TipRanks,/news/stocks/sector-spotlight-big-pharma-will-push-to-pause-medicare-drug-price-negotiations-1034241772,neutral,0.4902450144290924
1/24/2025 2:40:19 PM,Unusually active option classes on open January 24th,TipRanks,/news/stocks/unusually-active-option-classes-on-open-january-24th-1034267361,neutral,0.708025336265564
1/25/2025 6:11:15 PM,Bristol Myers says Opdivo + Yervoy cut risk of relapse by 38% in colorectal cancer,Seeking Alpha,https://seekingalpha.com/news/4398675-bristol-myers-colorectal-cancer-drug-cuts-relapse-risk?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9364112615585327
1/28/2025 7:26:44 AM,Buy Rating for Bristol-Myers Squibb Driven by Cobenfy’s Strong Sales Momentum and Growth Potential,TipRanks,/news/stocks/buy-rating-for-bristol-myers-squibb-driven-by-cobenfy-s-strong-sales-momentum-and-growth-potential-1034275977,positive,0.9471091032028198
1/28/2025 11:10:42 AM,"Drugmakers modestly raise price on drugs at start of year, WSJ reports",TipRanks,/news/stocks/drugmakers-modestly-raise-price-on-drugs-at-start-of-year-wsj-reports-1034276940,positive,0.9214922189712524
1/28/2025 11:18:29 AM,Cautious Outlook on Bristol-Myers Squibb: Sell Rating Maintained Amid Revenue Declines and Financial Challenges,TipRanks,/news/stocks/cautious-outlook-on-bristol-myers-squibb-sell-rating-maintained-amid-revenue-declines-and-financial-challenges-1034277072,negative,0.9661445617675781
1/28/2025 11:36:40 AM,Bristol Myers price target raised to $65 from $60 at Citi,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-65-from-60-at-citi-1034277155,positive,0.940710186958313
1/28/2025 5:10:31 PM,"GM, Boeing report quarterly results: Morning Buzz",TipRanks,/news/stocks/gm-boeing-report-quarterly-results-morning-buzz-1034278980,neutral,0.8086594939231873
1/29/2025 7:30:50 PM,CMS aiming for more transparency in drug pricing negotiations,Seeking Alpha,https://seekingalpha.com/news/4400241-cms-aiming-for-more-transparency-in-drug-pricing-negotiations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.7420772314071655
1/30/2025 1:52:59 PM,Merck to stop late-stage HYPERION trial evaluating WINREVAIR,Seeking Alpha,https://seekingalpha.com/news/4400749-merck-to-stop-late-stage-hyperion-trial-evaluating-winrevair?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.6311899423599243
1/31/2025 11:55:16 AM,Bristol Myers’ Breyanzi receives positive CHMP opinion in follicular lymphoma,TipRanks,/news/stocks/bristol-myers-breyanzi-receives-positive-chmp-opinion-in-follicular-lymphoma-1034294927,positive,0.933695375919342
1/31/2025 12:07:26 PM,Bristol Myers gets positive CHMP opinion for Opdivo plus Yervoy,TipRanks,/news/stocks/bristol-myers-gets-positive-chmp-opinion-for-opdivo-plus-yervoy-1034295061,positive,0.9270156025886536
1/31/2025 2:05:25 PM,Bristol Myers Squibb receives positive CHMP opinion for hepatocellular carcinoma treatment,Seeking Alpha,https://seekingalpha.com/news/4401412-bristol-myers-squibb-receives-positive-chmp-opinion-for-hepatocellular-carcinoma-treatment?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9388362765312195
1/31/2025 8:00:55 PM,"Catalyst Watch: Tariff drama, OPEC+, Alphabet and Amazon earnings, Lennar spinoff",Seeking Alpha,https://seekingalpha.com/news/4401505-catalyst-watch-tariff-drama-opec-alphabet-and-amazon-earnings-lennar-spinoff?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.929256021976471
2/2/2025 1:00:00 PM,"Earnings week ahead: PLTR, AMZN, GOOG, AMD, LLY, PEP, F, PFE, MRK, PYPL and more",Seeking Alpha,https://seekingalpha.com/news/4401431-earnings-week-ahead-pltr-amzn-goog-amd-lly-pep-f-pfe-mrk-pypl-qcom-and-more?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.9316384792327881
2/4/2025 1:27:30 PM,Pfizer's 2025 guidance falls short of expectations,Seeking Alpha,https://seekingalpha.com/news/4402612-pfizer-2025-guidance-falls-short-expectations?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9602089524269104
2/5/2025 1:35:33 PM,Jefferies Keeps Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/jefferies-keeps-their-buy-rating-on-bristol-myers-squibb-bmy-1034315683,neutral,0.9174307584762573
2/5/2025 5:30:13 PM,Bristol Myers Squibb call volume above normal and directionally bullish,TipRanks,/news/stocks/bristol-myers-squibb-call-volume-above-normal-and-directionally-bullish-1034317214,positive,0.8764196038246155
2/5/2025 6:40:19 PM,Notable companies reporting before tomorrow’s open,TipRanks,/news/stocks/notable-companies-reporting-before-tomorrow-s-open-1034317367,neutral,0.9220908284187317
2/5/2025 6:42:25 PM,Bristol-Myers Squibb Q4 2024 Earnings Preview: Strong product sales to continue into 2025,Seeking Alpha,https://seekingalpha.com/news/4403814-bristol-myers-squibb-q4-2024-earnings-preview-strong-product-sales-to-continue-into-2025?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9486438632011414
2/6/2025 12:04:16 PM,Bristol-Myers Squibb beats Q4 estimates,Seeking Alpha,https://seekingalpha.com/news/4404314-bristol-myers-squibb-beats-q4-estimates?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.6027758121490479
2/6/2025 12:05:36 PM,"Options Volatility and Implied Earnings Moves Today, February 06, 2025",TipRanks,/news/stocks/options-volatility-and-implied-earnings-moves-today-february-06-2025-1034322024,neutral,0.9175546765327454
2/6/2025 12:07:06 PM,"Bristol Myers sees FY25 adjusted EPS $6.55-$6.85, consensus $6.92",TipRanks,/news/stocks/bristol-myers-sees-fy25-adjusted-eps-6-55--6-85-consensus-6-92-1034322009,neutral,0.7716426253318787
2/6/2025 12:10:39 PM,Bristol Myers expects to deliver additional ~$2B in cost savings by 2027-end,TipRanks,/news/stocks/bristol-myers-expects-to-deliver-additional-~-2b-in-cost-savings-by-2027-end-1034321965,positive,0.944657027721405
2/6/2025 12:41:04 PM,"Bristol Myers Squibb in charts: Q4 revenue from Eliquis, Opdivo, Yervoy rises; Sprycel falls",Seeking Alpha,https://seekingalpha.com/news/4404353-bristol-myers-squibb-in-charts-q4-revenue-from-eliquis-opdivo-yervoy-rises-sprycel-falls?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.9386494755744934
2/6/2025 12:47:26 PM,Bristol-Myers Squibb slips as 2025 outlook disappoints,Seeking Alpha,https://seekingalpha.com/news/4404333-bristol-myers-stock-slips-amid-outlook-concerns?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,negative,0.9675890207290649
2/6/2025 1:06:14 PM,"Bristol-Myers Squibb Co. Q4 Profit Decreases, But Beats Estimates ",RTTNews,/news/stocks/bristol-myers-squibb-co-q4-profit-decreases-but-beats-estimates-1034321923,negative,0.9638311266899109
2/6/2025 1:26:52 PM,Bristol-Myers Squibb Guides FY25 Below Estimates - Update ,RTTNews,/news/stocks/bristol-myers-squibb-guides-fy25-below-estimates-update-1034322212,neutral,0.9063441753387451
2/6/2025 1:57:03 PM,Morning Movers: Roblox sinks following fourth quarter results and guidance,TipRanks,/news/stocks/morning-movers-roblox-sinks-following-fourth-quarter-results-and-guidance-1034322920,neutral,0.9285986423492432
2/6/2025 3:50:07 PM,"Cytokinetics share weakness on updated Camzyos REMS overdone, says Truist",TipRanks,/news/stocks/cytokinetics-share-weakness-on-updated-camzyos-rems-overdone-says-truist-1034323842,negative,0.954731285572052
2/6/2025 5:06:03 PM,"Qualcomm, Eli Lilly report quarterly earnings beats: Morning Buzz",TipRanks,/news/stocks/qualcomm-eli-lilly-report-quarterly-earnings-beats-morning-buzz-1034324189,neutral,0.8575504422187805
2/6/2025 5:55:07 PM,"Camzyos news has negative readthroughs for Cytokinetics, says BofA",TipRanks,/news/stocks/camzyos-news-has-negative-readthroughs-for-cytokinetics-says-bofa-1034324349,negative,0.959589421749115
2/6/2025 6:35:50 PM,"White House readying order to fire thousands of federal health workers, WSJ says",TipRanks,/news/stocks/white-house-readying-order-to-fire-thousands-of-federal-health-workers-wsj-says-1034324421,negative,0.9388384819030762
2/7/2025 11:38:22 AM,Bristol-Myers Squibb (BMY) Gets a Hold from Citi,TipRanks,/news/stocks/bristol-myers-squibb-bmy-gets-a-hold-from-citi-1034326736,positive,0.5170348882675171
2/7/2025 12:01:15 PM,Cytokinetics initiated with a Buy at Citi,TipRanks,/news/stocks/cytokinetics-initiated-with-a-buy-at-citi-1034327003,neutral,0.7300235033035278
2/7/2025 12:55:35 PM,Bristol Myers price target raised to $62 from $60 at Wells Fargo,TipRanks,/news/stocks/bristol-myers-price-target-raised-to-62-from-60-at-wells-fargo-1034327270,positive,0.9438547492027283
2/7/2025 12:58:20 PM,Truist Financial Reaffirms Their Buy Rating on Bristol-Myers Squibb (BMY),TipRanks,/news/stocks/truist-financial-reaffirms-their-buy-rating-on-bristol-myers-squibb-bmy-1034327241,neutral,0.7807403206825256
2/7/2025 3:21:13 PM,Trump Trade: President advocates to close carried interest tax loophole,TipRanks,/news/stocks/trump-trade-president-advocates-to-close-carried-interest-tax-loophole-1034328479,neutral,0.6031151413917542
2/7/2025 3:41:01 PM,Cytokinetics draws new Buy from Citi on aficamten potential,Seeking Alpha,https://seekingalpha.com/news/4405175-cytokinetics-stock-draws-new-buy-citi?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,neutral,0.6829383373260498
2/8/2025 9:04:00 PM,18 out of 21 healthcare companies beat profit estimates this week- Earnings scorecard,Seeking Alpha,https://seekingalpha.com/news/4405247-18-out-of-21-healthcare-companies-beat-profit-estimates-this-week-earnings-scorecard?utm_source=businessinsider&utm_medium=referral&feed_item_type=news,positive,0.8692340850830078
